{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ok\n"
     ]
    }
   ],
   "source": [
    "print(\"ok\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: ctransformers==0.2.5 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from -r requirements.txt (line 1)) (0.2.5)\n",
      "Requirement already satisfied: sentence-transformers==2.2.2 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from -r requirements.txt (line 2)) (2.2.2)\n",
      "Requirement already satisfied: pinecone-client in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from -r requirements.txt (line 3)) (3.2.0)\n",
      "Requirement already satisfied: langchain==0.0.225 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from -r requirements.txt (line 4)) (0.0.225)\n",
      "Requirement already satisfied: flask in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from -r requirements.txt (line 5)) (3.0.2)\n",
      "Requirement already satisfied: huggingface-hub in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from ctransformers==0.2.5->-r requirements.txt (line 1)) (0.21.4)\n",
      "Requirement already satisfied: transformers<5.0.0,>=4.6.0 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from sentence-transformers==2.2.2->-r requirements.txt (line 2)) (4.39.1)\n",
      "Requirement already satisfied: tqdm in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from sentence-transformers==2.2.2->-r requirements.txt (line 2)) (4.66.2)\n",
      "Requirement already satisfied: torch>=1.6.0 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from sentence-transformers==2.2.2->-r requirements.txt (line 2)) (2.2.1)\n",
      "Requirement already satisfied: torchvision in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from sentence-transformers==2.2.2->-r requirements.txt (line 2)) (0.17.1)\n",
      "Requirement already satisfied: numpy in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from sentence-transformers==2.2.2->-r requirements.txt (line 2)) (1.26.4)\n",
      "Requirement already satisfied: scikit-learn in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from sentence-transformers==2.2.2->-r requirements.txt (line 2)) (1.4.1.post1)\n",
      "Requirement already satisfied: scipy in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from sentence-transformers==2.2.2->-r requirements.txt (line 2)) (1.12.0)\n",
      "Requirement already satisfied: nltk in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from sentence-transformers==2.2.2->-r requirements.txt (line 2)) (3.8.1)\n",
      "Requirement already satisfied: sentencepiece in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from sentence-transformers==2.2.2->-r requirements.txt (line 2)) (0.2.0)\n",
      "Requirement already satisfied: PyYAML>=5.4.1 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from langchain==0.0.225->-r requirements.txt (line 4)) (6.0.1)\n",
      "Requirement already satisfied: SQLAlchemy<3,>=1.4 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from langchain==0.0.225->-r requirements.txt (line 4)) (2.0.28)\n",
      "Requirement already satisfied: aiohttp<4.0.0,>=3.8.3 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from langchain==0.0.225->-r requirements.txt (line 4)) (3.9.3)\n",
      "Requirement already satisfied: dataclasses-json<0.6.0,>=0.5.7 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from langchain==0.0.225->-r requirements.txt (line 4)) (0.5.14)\n",
      "Requirement already satisfied: langchainplus-sdk<0.0.21,>=0.0.20 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from langchain==0.0.225->-r requirements.txt (line 4)) (0.0.20)\n",
      "Requirement already satisfied: numexpr<3.0.0,>=2.8.4 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from langchain==0.0.225->-r requirements.txt (line 4)) (2.9.0)\n",
      "Requirement already satisfied: openapi-schema-pydantic<2.0,>=1.2 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from langchain==0.0.225->-r requirements.txt (line 4)) (1.2.4)\n",
      "Requirement already satisfied: pydantic<2,>=1 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from langchain==0.0.225->-r requirements.txt (line 4)) (1.10.14)\n",
      "Requirement already satisfied: requests<3,>=2 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from langchain==0.0.225->-r requirements.txt (line 4)) (2.31.0)\n",
      "Requirement already satisfied: tenacity<9.0.0,>=8.1.0 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from langchain==0.0.225->-r requirements.txt (line 4)) (8.2.3)\n",
      "Requirement already satisfied: certifi>=2019.11.17 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from pinecone-client->-r requirements.txt (line 3)) (2024.2.2)\n",
      "Requirement already satisfied: typing-extensions>=3.7.4 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from pinecone-client->-r requirements.txt (line 3)) (4.10.0)\n",
      "Requirement already satisfied: urllib3>=1.26.5 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from pinecone-client->-r requirements.txt (line 3)) (2.2.1)\n",
      "Requirement already satisfied: Werkzeug>=3.0.0 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from flask->-r requirements.txt (line 5)) (3.0.1)\n",
      "Requirement already satisfied: Jinja2>=3.1.2 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from flask->-r requirements.txt (line 5)) (3.1.3)\n",
      "Requirement already satisfied: itsdangerous>=2.1.2 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from flask->-r requirements.txt (line 5)) (2.1.2)\n",
      "Requirement already satisfied: click>=8.1.3 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from flask->-r requirements.txt (line 5)) (8.1.7)\n",
      "Requirement already satisfied: blinker>=1.6.2 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from flask->-r requirements.txt (line 5)) (1.7.0)\n",
      "Requirement already satisfied: aiosignal>=1.1.2 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from aiohttp<4.0.0,>=3.8.3->langchain==0.0.225->-r requirements.txt (line 4)) (1.3.1)\n",
      "Requirement already satisfied: attrs>=17.3.0 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from aiohttp<4.0.0,>=3.8.3->langchain==0.0.225->-r requirements.txt (line 4)) (23.2.0)\n",
      "Requirement already satisfied: frozenlist>=1.1.1 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from aiohttp<4.0.0,>=3.8.3->langchain==0.0.225->-r requirements.txt (line 4)) (1.4.1)\n",
      "Requirement already satisfied: multidict<7.0,>=4.5 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from aiohttp<4.0.0,>=3.8.3->langchain==0.0.225->-r requirements.txt (line 4)) (6.0.5)\n",
      "Requirement already satisfied: yarl<2.0,>=1.0 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from aiohttp<4.0.0,>=3.8.3->langchain==0.0.225->-r requirements.txt (line 4)) (1.9.4)\n",
      "Requirement already satisfied: colorama in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from click>=8.1.3->flask->-r requirements.txt (line 5)) (0.4.6)\n",
      "Requirement already satisfied: marshmallow<4.0.0,>=3.18.0 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from dataclasses-json<0.6.0,>=0.5.7->langchain==0.0.225->-r requirements.txt (line 4)) (3.21.1)\n",
      "Requirement already satisfied: typing-inspect<1,>=0.4.0 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from dataclasses-json<0.6.0,>=0.5.7->langchain==0.0.225->-r requirements.txt (line 4)) (0.9.0)\n",
      "Requirement already satisfied: filelock in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from huggingface-hub->ctransformers==0.2.5->-r requirements.txt (line 1)) (3.13.1)\n",
      "Requirement already satisfied: fsspec>=2023.5.0 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from huggingface-hub->ctransformers==0.2.5->-r requirements.txt (line 1)) (2024.3.1)\n",
      "Requirement already satisfied: packaging>=20.9 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from huggingface-hub->ctransformers==0.2.5->-r requirements.txt (line 1)) (23.2)\n",
      "Requirement already satisfied: MarkupSafe>=2.0 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from Jinja2>=3.1.2->flask->-r requirements.txt (line 5)) (2.1.5)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from requests<3,>=2->langchain==0.0.225->-r requirements.txt (line 4)) (3.3.2)\n",
      "Requirement already satisfied: idna<4,>=2.5 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from requests<3,>=2->langchain==0.0.225->-r requirements.txt (line 4)) (3.6)\n",
      "Requirement already satisfied: greenlet!=0.4.17 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from SQLAlchemy<3,>=1.4->langchain==0.0.225->-r requirements.txt (line 4)) (3.0.3)\n",
      "Requirement already satisfied: sympy in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from torch>=1.6.0->sentence-transformers==2.2.2->-r requirements.txt (line 2)) (1.12)\n",
      "Requirement already satisfied: networkx in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from torch>=1.6.0->sentence-transformers==2.2.2->-r requirements.txt (line 2)) (3.2.1)\n",
      "Requirement already satisfied: regex!=2019.12.17 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from transformers<5.0.0,>=4.6.0->sentence-transformers==2.2.2->-r requirements.txt (line 2)) (2023.12.25)\n",
      "Requirement already satisfied: tokenizers<0.19,>=0.14 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from transformers<5.0.0,>=4.6.0->sentence-transformers==2.2.2->-r requirements.txt (line 2)) (0.15.2)\n",
      "Requirement already satisfied: safetensors>=0.4.1 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from transformers<5.0.0,>=4.6.0->sentence-transformers==2.2.2->-r requirements.txt (line 2)) (0.4.2)\n",
      "Requirement already satisfied: joblib in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from nltk->sentence-transformers==2.2.2->-r requirements.txt (line 2)) (1.3.2)\n",
      "Requirement already satisfied: threadpoolctl>=2.0.0 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from scikit-learn->sentence-transformers==2.2.2->-r requirements.txt (line 2)) (3.4.0)\n",
      "Requirement already satisfied: pillow!=8.3.*,>=5.3.0 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from torchvision->sentence-transformers==2.2.2->-r requirements.txt (line 2)) (10.2.0)\n",
      "Requirement already satisfied: mypy-extensions>=0.3.0 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from typing-inspect<1,>=0.4.0->dataclasses-json<0.6.0,>=0.5.7->langchain==0.0.225->-r requirements.txt (line 4)) (1.0.0)\n",
      "Requirement already satisfied: mpmath>=0.19 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from sympy->torch>=1.6.0->sentence-transformers==2.2.2->-r requirements.txt (line 2)) (1.3.0)\n",
      "Note: you may need to restart the kernel to use updated packages.\n"
     ]
    }
   ],
   "source": [
    "pip install -r requirements.txt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: pymupdf in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (1.24.0)\n",
      "Requirement already satisfied: PyMuPDFb==1.24.0 in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from pymupdf) (1.24.0)\n",
      "Note: you may need to restart the kernel to use updated packages.\n"
     ]
    }
   ],
   "source": [
    "pip install pymupdf"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\ASUS\\anaconda3\\envs\\adhdchatBot\\Lib\\site-packages\\pinecone\\data\\index.py:1: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from tqdm.autonotebook import tqdm\n"
     ]
    }
   ],
   "source": [
    "from langchain import PromptTemplate\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain.embeddings import HuggingFaceEmbeddings\n",
    "from langchain.vectorstores import pinecone\n",
    "import pinecone\n",
    "from langchain.document_loaders import PyMuPDFLoader,DirectoryLoader\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain.prompts import PromptTemplate\n",
    "from langchain.llms import CTransformers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "PINECONE_API_KEY=\"80ffeaf1-be81-4e81-99ae-5ee13bf3e1fc\"\n",
    "PINECONE_API_ENV=\"gcp-starter\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Extract data from pdf\n",
    "def load_pdf(data):\n",
    "    loader=DirectoryLoader(data,glob='*.pdf',loader_cls=PyMuPDFLoader)\n",
    "    documents=loader.load()\n",
    "    return documents\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "extractedData=load_pdf(\"dataSet/\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Create text chunks\n",
    "def text_split(extractedData):\n",
    "    textSplitter=RecursiveCharacterTextSplitter(chunk_size=500,chunk_overlap=20)\n",
    "    textChunks=textSplitter.split_documents(extractedData)\n",
    "    return textChunks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "textChunks=text_split(extractedData)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content='Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist \\nInstructions \\n \\nThe questions on the back page are designed to stimulate dialogue between you and your patients and to help \\nconfirm if they may be suffering from the symptoms of attention-deficit/hyperactivity disorder (ADHD). \\n \\nDescription:  The Symptom Checklist is an instrument consisting of the eighteen DSM-IV-TR criteria.  \\nSix of the eighteen questions were found to be the most predictive of symptoms consistent with', metadata={'source': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'file_path': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'page': 0, 'total_pages': 3, 'format': 'PDF 1.5', 'title': '10852_elto_question_fhp2.PDF', 'author': 'shelbyw', 'subject': '', 'keywords': '', 'creator': 'QuarkXPress (tm) - [10852_elto_question_fhp2.qxd : 10852_elto_question_fhp2.qxd]', 'producer': 'Acrobat PDFWriter 4.0 for Windows NT', 'creationDate': 'D:20031003160125Z', 'modDate': \"D:20110916085029-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='ADHD.  These six questions are the basis for the ASRS v1.1 Screener and are also Part A of the \\nSymptom Checklist.  Part B of the Symptom Checklist contains the remaining twelve questions. \\n \\nInstructions: \\n \\nSymptoms \\n \\n1. Ask the patient to complete both Part A and Part B of the Symptom Checklist by marking an X \\nin the box that most closely represents the frequency of occurrence of each of the symptoms.', metadata={'source': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'file_path': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'page': 0, 'total_pages': 3, 'format': 'PDF 1.5', 'title': '10852_elto_question_fhp2.PDF', 'author': 'shelbyw', 'subject': '', 'keywords': '', 'creator': 'QuarkXPress (tm) - [10852_elto_question_fhp2.qxd : 10852_elto_question_fhp2.qxd]', 'producer': 'Acrobat PDFWriter 4.0 for Windows NT', 'creationDate': 'D:20031003160125Z', 'modDate': \"D:20110916085029-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='2. Score Part A.  If four or more marks appear in the darkly shaded boxes within Part A then the \\npatient has symptoms highly consistent with ADHD in adults and further investigation is \\nwarranted.  \\n \\n \\n3. The frequency scores on Part B provide additional cues and can serve as further probes into the \\npatient’s symptoms.  Pay particular attention to marks appearing in the dark shaded boxes.  The', metadata={'source': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'file_path': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'page': 0, 'total_pages': 3, 'format': 'PDF 1.5', 'title': '10852_elto_question_fhp2.PDF', 'author': 'shelbyw', 'subject': '', 'keywords': '', 'creator': 'QuarkXPress (tm) - [10852_elto_question_fhp2.qxd : 10852_elto_question_fhp2.qxd]', 'producer': 'Acrobat PDFWriter 4.0 for Windows NT', 'creationDate': 'D:20031003160125Z', 'modDate': \"D:20110916085029-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='frequency-based response is more sensitive with certain questions.  No total score or diagnostic \\nlikelihood is utilized for the twelve questions. It has been found that the six questions in Part A \\nare the most predictive of the disorder and are best for use as a screening instrument. \\n \\nImpairments \\n \\n1. Review the entire Symptom Checklist with your patients and evaluate the level of impairment \\nassociated with the symptom.   \\n \\n \\n2. Consider work/school, social and family settings.', metadata={'source': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'file_path': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'page': 0, 'total_pages': 3, 'format': 'PDF 1.5', 'title': '10852_elto_question_fhp2.PDF', 'author': 'shelbyw', 'subject': '', 'keywords': '', 'creator': 'QuarkXPress (tm) - [10852_elto_question_fhp2.qxd : 10852_elto_question_fhp2.qxd]', 'producer': 'Acrobat PDFWriter 4.0 for Windows NT', 'creationDate': 'D:20031003160125Z', 'modDate': \"D:20110916085029-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='3. Symptom frequency is often associated with symptom severity, therefore the Symptom \\nChecklist may also aid in the assessment of impairments.  If your patients have frequent \\nsymptoms, you may want to ask them to describe how these problems have affected the ability \\nto work, take care of things at home, or get along with other people such as their \\nspouse/significant other.   \\n \\nHistory \\n \\n1. Assess the presence of these symptoms or similar symptoms in childhood.  Adults who have', metadata={'source': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'file_path': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'page': 0, 'total_pages': 3, 'format': 'PDF 1.5', 'title': '10852_elto_question_fhp2.PDF', 'author': 'shelbyw', 'subject': '', 'keywords': '', 'creator': 'QuarkXPress (tm) - [10852_elto_question_fhp2.qxd : 10852_elto_question_fhp2.qxd]', 'producer': 'Acrobat PDFWriter 4.0 for Windows NT', 'creationDate': 'D:20031003160125Z', 'modDate': \"D:20110916085029-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='ADHD need not have been formally diagnosed in childhood.  In evaluating a patient’s history, \\nlook for evidence of early-appearing and long-standing problems with attention or self-control.  \\nSome significant symptoms should have been present in childhood, but full symptomology is not \\nnecessary.', metadata={'source': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'file_path': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'page': 0, 'total_pages': 3, 'format': 'PDF 1.5', 'title': '10852_elto_question_fhp2.PDF', 'author': 'shelbyw', 'subject': '', 'keywords': '', 'creator': 'QuarkXPress (tm) - [10852_elto_question_fhp2.qxd : 10852_elto_question_fhp2.qxd]', 'producer': 'Acrobat PDFWriter 4.0 for Windows NT', 'creationDate': 'D:20031003160125Z', 'modDate': \"D:20110916085029-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='Never\\nRarely\\nSometimes\\nOften\\nVery Often\\nAdult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist\\nPlease answer the questions below, rating yourself on each of the criteria shown using the\\nscale on the right side of the page. As you answer each question, place an X in the box that\\nbest describes how you have felt and conducted yourself over the past 6 months. Please give\\nthis completed checklist to your healthcare professional to discuss during today’s\\nappointment.\\nPatient Name\\nToday’s Date', metadata={'source': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'file_path': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'page': 1, 'total_pages': 3, 'format': 'PDF 1.5', 'title': '10852_elto_question_fhp2.PDF', 'author': 'shelbyw', 'subject': '', 'keywords': '', 'creator': 'QuarkXPress (tm) - [10852_elto_question_fhp2.qxd : 10852_elto_question_fhp2.qxd]', 'producer': 'Acrobat PDFWriter 4.0 for Windows NT', 'creationDate': 'D:20031003160125Z', 'modDate': \"D:20110916085029-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='Today’s Date\\n1. How often do you have trouble wrapping up the final details of a project, \\nonce the challenging parts have been done?\\n2. How often do you have difficulty getting things in order when you have to do \\na task that requires organization?\\n3. How often do you have problems remembering appointments or obligations?\\n4. \\n5. How often do you fidget or squirm with your hands or feet when you have \\nto sit down for a long time?', metadata={'source': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'file_path': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'page': 1, 'total_pages': 3, 'format': 'PDF 1.5', 'title': '10852_elto_question_fhp2.PDF', 'author': 'shelbyw', 'subject': '', 'keywords': '', 'creator': 'QuarkXPress (tm) - [10852_elto_question_fhp2.qxd : 10852_elto_question_fhp2.qxd]', 'producer': 'Acrobat PDFWriter 4.0 for Windows NT', 'creationDate': 'D:20031003160125Z', 'modDate': \"D:20110916085029-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='6. How often do you feel overly active and compelled to do things, like you \\nwere driven by a motor?\\n7. How often do you make careless mistakes when you have to work on a boring or\\ndifficult project?\\n8. How often do you have difficulty keeping your attention when you are doing boring\\nor repetitive work?\\n9. How often do you have difficulty concentrating on what people say to you, \\neven when they are speaking to you directly?', metadata={'source': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'file_path': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'page': 1, 'total_pages': 3, 'format': 'PDF 1.5', 'title': '10852_elto_question_fhp2.PDF', 'author': 'shelbyw', 'subject': '', 'keywords': '', 'creator': 'QuarkXPress (tm) - [10852_elto_question_fhp2.qxd : 10852_elto_question_fhp2.qxd]', 'producer': 'Acrobat PDFWriter 4.0 for Windows NT', 'creationDate': 'D:20031003160125Z', 'modDate': \"D:20110916085029-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='10. How often do you misplace or have difficulty finding things at home or at work?\\n11. How often are you distracted by activity or noise around you?\\n12. How often do you leave your seat in meetings or other situations in which \\nyou are expected to remain seated?\\n13. How often do you feel restless or fidgety?\\n14. How often do you have difficulty unwinding and relaxing when you have time \\nto yourself?\\n15. How often do you find yourself talking too much when you are in social situations?', metadata={'source': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'file_path': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'page': 1, 'total_pages': 3, 'format': 'PDF 1.5', 'title': '10852_elto_question_fhp2.PDF', 'author': 'shelbyw', 'subject': '', 'keywords': '', 'creator': 'QuarkXPress (tm) - [10852_elto_question_fhp2.qxd : 10852_elto_question_fhp2.qxd]', 'producer': 'Acrobat PDFWriter 4.0 for Windows NT', 'creationDate': 'D:20031003160125Z', 'modDate': \"D:20110916085029-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='16. When you’re in a conversation, how often do you find yourself finishing \\nthe sentences of the people you are talking to, before they can finish \\nthem themselves?\\n17. How often do you have difficulty waiting your turn in situations when \\nturn taking is required?\\n18. How often do you interrupt others when they are busy?\\nPart B \\nPart A \\n   When you have a task that requires a lot of thought, how often do you avoid \\nor delay getting started?', metadata={'source': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'file_path': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'page': 1, 'total_pages': 3, 'format': 'PDF 1.5', 'title': '10852_elto_question_fhp2.PDF', 'author': 'shelbyw', 'subject': '', 'keywords': '', 'creator': 'QuarkXPress (tm) - [10852_elto_question_fhp2.qxd : 10852_elto_question_fhp2.qxd]', 'producer': 'Acrobat PDFWriter 4.0 for Windows NT', 'creationDate': 'D:20031003160125Z', 'modDate': \"D:20110916085029-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='The Value of Screening for Adults With ADHD \\n \\n \\n \\nResearch suggests that the symptoms of ADHD can persist into adulthood, having a significant \\nimpact on the relationships, careers, and even the personal safety of your patients who may \\nsuffer from it.1-4 Because this disorder is often misunderstood, many people who have it do not \\nreceive appropriate treatment and, as a result, may never reach their full potential. Part of the', metadata={'source': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'file_path': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'page': 2, 'total_pages': 3, 'format': 'PDF 1.5', 'title': '10852_elto_question_fhp2.PDF', 'author': 'shelbyw', 'subject': '', 'keywords': '', 'creator': 'QuarkXPress (tm) - [10852_elto_question_fhp2.qxd : 10852_elto_question_fhp2.qxd]', 'producer': 'Acrobat PDFWriter 4.0 for Windows NT', 'creationDate': 'D:20031003160125Z', 'modDate': \"D:20110916085029-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='problem is that it can be difficult to diagnose, particularly in adults.  \\n \\nThe Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist was developed \\nin conjunction with the World Health Organization (WHO), and the Workgroup on Adult \\nADHD that included the following team of psychiatrists and researchers: \\n \\n•  Lenard Adler, MD  \\nAssociate Professor of Psychiatry and Neurology \\nNew York University Medical School \\n \\n•  Ronald C. Kessler, PhD \\nProfessor, Department of Health Care Policy', metadata={'source': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'file_path': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'page': 2, 'total_pages': 3, 'format': 'PDF 1.5', 'title': '10852_elto_question_fhp2.PDF', 'author': 'shelbyw', 'subject': '', 'keywords': '', 'creator': 'QuarkXPress (tm) - [10852_elto_question_fhp2.qxd : 10852_elto_question_fhp2.qxd]', 'producer': 'Acrobat PDFWriter 4.0 for Windows NT', 'creationDate': 'D:20031003160125Z', 'modDate': \"D:20110916085029-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='Harvard Medical School \\n \\n•  Thomas Spencer, MD \\nAssociate Professor of Psychiatry \\nHarvard Medical School \\n  \\nAs a healthcare professional, you can use the ASRS v1.1 as a tool to help screen for ADHD in \\nadult patients. Insights gained through this screening may suggest the need for a more in-depth \\nclinician interview. The questions in the ASRS v1.1 are consistent with DSM-IV criteria and \\naddress the manifestations of ADHD symptoms in adults. Content of the questionnaire also', metadata={'source': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'file_path': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'page': 2, 'total_pages': 3, 'format': 'PDF 1.5', 'title': '10852_elto_question_fhp2.PDF', 'author': 'shelbyw', 'subject': '', 'keywords': '', 'creator': 'QuarkXPress (tm) - [10852_elto_question_fhp2.qxd : 10852_elto_question_fhp2.qxd]', 'producer': 'Acrobat PDFWriter 4.0 for Windows NT', 'creationDate': 'D:20031003160125Z', 'modDate': \"D:20110916085029-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='reflects the importance that DSM-IV places on symptoms, impairments, and history for a correct \\ndiagnosis.4 \\n \\nThe checklist takes about 5 minutes to complete and can provide information that is critical  \\nto supplement the diagnostic process. \\n \\n \\n \\n \\n \\n \\n \\n \\nReferences: \\n1. \\nSchweitzer JB, et al. Med Clin North Am. 2001;85(3):10-11, 757-777. \\n2. \\nBarkley RA. Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 2nd ed. 1998. \\n3.', metadata={'source': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'file_path': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'page': 2, 'total_pages': 3, 'format': 'PDF 1.5', 'title': '10852_elto_question_fhp2.PDF', 'author': 'shelbyw', 'subject': '', 'keywords': '', 'creator': 'QuarkXPress (tm) - [10852_elto_question_fhp2.qxd : 10852_elto_question_fhp2.qxd]', 'producer': 'Acrobat PDFWriter 4.0 for Windows NT', 'creationDate': 'D:20031003160125Z', 'modDate': \"D:20110916085029-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='3. \\nBiederman J, et al. Am J Psychiatry.1993;150:1792-1798. \\n4. \\nAmerican Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. \\nWashington, DC, American Psychiatric Association. 2000: 85-93.', metadata={'source': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'file_path': 'dataSet\\\\adhd-questionnaire-ASRS111.pdf', 'page': 2, 'total_pages': 3, 'format': 'PDF 1.5', 'title': '10852_elto_question_fhp2.PDF', 'author': 'shelbyw', 'subject': '', 'keywords': '', 'creator': 'QuarkXPress (tm) - [10852_elto_question_fhp2.qxd : 10852_elto_question_fhp2.qxd]', 'producer': 'Acrobat PDFWriter 4.0 for Windows NT', 'creationDate': 'D:20031003160125Z', 'modDate': \"D:20110916085029-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='CLINICAL PRACTICE GUIDELINES FOR ASSESSMENT AND MANAGEMENT OF ATTENTION-\\nDEFICIT/ HYPERACTIVITY DISORDER \\n \\nAuthors: Ruchita Shah, Sandeep Grover, Ajit Avasthi \\nDepartment of Psychiatry, Postgraduate Institute of Medical Education and Research, \\nChandigarh, India \\nCorrespondence: drruchitashah@gmail.com  \\n \\nINTRODUCTION \\nAttention-deficit/ hyperactivity disorder (ADHD) is one of the most common childhood \\npsychiatric disorders. ADHD affects around 5%- 7% of school-aged children. It is a neuro-', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 0, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='developmental disorder that runs a chronic course and causes significant impairments across \\nvarious domains of everyday functioning, such as peer and social functioning, academic and \\noccupational functioning across the lifespan. Besides the patient, ADHD also has significant \\nnegative impact on the caregivers. This Guideline seeks to lay out guidelines for effective and \\ncomprehensive assessment, diagnosis and management of ADHD. It attempts to update the', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 0, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='previous guidelines taking into account current state of evidence that can inform clinical \\npractice. These guidelines ought to be read in conjunction with the earlier version of the \\ntreatment guidelines on ADHD as developed and published by the Indian Psychiatric Society in \\nthe year 2007. \\nSCOPE OF THIS DOCUMENT \\nThis Guideline provides a frame work for diagnosis and management of ADHD in children and', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 0, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='adolescents aged upto 18 years. In this document, the terms ‘child’ and ‘children’ represent all \\nindividuals below 18 years of age, unless specified otherwise. The term ‘adolescent’ represents \\nindividuals between 13 to 18 years of age. The term ‘pre-schoolers’ is used to indicate individuals \\nwho are below 6 years of age. These guidelines may not be applicable to adult patients suffering \\nfrom ADHD, as their treatment needs may be different. Finally, it is expected that', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 0, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='recommendations made will have to be tailored to suit the needs of individual patients.   \\nASSESSMENT AND EVALUATION \\nA comprehensive assessment including detailed history, mental state and physical examination is \\nneeded to reach the diagnosis and estimate the severity and impact of the disorder on the \\npatient and caregivers. Co-morbid developmental, psychiatric and medical disorders; and \\npsycho-social or environmental factors such as family discord, parenting and parental substance', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 0, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='abuse that are directly relevant to the management should be assessed as far as possible. Table-\\n1 presents the components of a comprehensive assessment and Table 2 shows the clinical \\nquestions that need to be answered while undertaking the process of assessment. \\nTable 1 here \\nTable 2 here \\nThe assessment of pre-schoolers, children and adolescents for ADHD comprise of clinical \\ninterviews with parents and the patient, as well as obtaining information directly or indirectly', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 0, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='(through parent accounts) from other relevant sources and settings including pre-school, day', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 0, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='care and school. Information from teachers may be obtained by requesting for teacher \\nobservation reports (unstructured) or teacher ratings on a structured rating scale (see section on \\nrating scales). Such requests should be sent through parents after explaining to them the need \\nfor such information, and seeking their and the child’s explicit consent and assent. Parents or the \\nchild may be reluctant to initiate such a communication for several reasons; the most important', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 1, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='being fear of the child being stigmatized. Clinicians must as far as possible explain to the parents \\nthe need of teacher report and how this can aid in assessment, diagnosis and management. If \\nthe child and parents are still reluctant, then the clinicians may satisfy themselves through \\nparent and child accounts of symptoms and functioning in the school setting, and review of \\nschool work and report cards. Further, in Indian context, the clinician may involve other family', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 1, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='members such as grandparents; especially if the child resides in a joint or an extended family. \\nThis will provide additional important information, opportunities to understand methods the \\nfamily uses to handle the problematic behaviors; and expectations and perceptions regarding, \\nand treatment of these behaviours.  \\nIt is important to remember that the histories may vary considerably depending upon the', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 1, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='informants’ own perceptions regarding and tolerance towards such behaviors, their awareness \\nand opportunities for observations. The histories from different sources may complement each \\nother to provide a more complete and realistic picture; hence multi-informant interviews \\nseeking information across various domains of functioning and in various settings is the key. \\nThe process of assessment may require more than one visit.  It is an ongoing process, which as', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 1, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='far as possible must be continued to be based on multi-informant accounts across multiple \\nsettings as for the initial assessment and it should focus on changing needs of the patient and \\nthe family.  \\nThe diagnosis should preferably be based on the diagnostic criteria as per prevailing nosological \\nsystems for the symptoms of inattention, hyperactivity and impulsivity. While establishing the \\ndiagnostic criteria age of onset, persistence and duration of the symptoms must be taken into', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 1, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='account. When symptoms are of relatively recent onset, other psychiatric disorders, such as \\nmood or psychotic disorders that may mimic ADHD must be considered. The symptoms must be \\ndevelopmentally inappropriate; it is suggested that the clinician assess the developmental \\nhistory thoroughly and make a working clinical impression of the mental age of the child or \\nadolescent. When intellectual sub-normality is known or suspected, the rule of thumb is that the', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 1, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='symptoms should be inappropriate for the mental age to consider ADHD. Another related \\nconsideration is that as a child grows symptom manifestations may change. Pre-schoolers with \\nADHD are highly overactive (described as ‘whirlwind’), do not listen to when called, have no \\nsense of danger, and have short play sequences (of less than 3 minutes), and often leave \\nactivities incomplete. As a child reaches primary school, he is found to have difficulty remaining', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 1, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='still or calm in situations where he is expected to remain so; for example, in assembly halls and \\nclassrooms. Inattention is manifested by brief activities of less than 10 minutes, being forgetful, \\ndisorganised and easily distractible. Impulsivity is seen in the form of acting out of turn, \\ninterrupting other children, thoughtless rule breaking, intrusions on peers and getting into \\naccidents. During adolescence, the over-activity presents more as inner restlessness and some', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 1, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='fidgetiness instead of the manifest over-activity seen during pre-school and early childhood \\nyears. Inattention on the other hand, may manifest as difficulties in organising tasks, \\nprocrastinations and frequent missing of deadlines. Impulsivity may manifest as risk taking and \\nsubstance use. Thus, adolescents may present with problems mainly related to inattention and \\nimpulsivity; and a thorough developmental history that traces the symptoms from their onset', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 2, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='during childhood may help clarify the diagnosis. Several symptoms are present in two or more \\nsettings such as at home, school or pre-school, family and friends, etc. It may be borne in mind \\nthat the symptomatic manifestations can vary considerably depending on the context in a given \\nsetting. See Table 3 for factors that can affect symptoms of ADHD. \\nTable 3 here \\nNext, it is important to assess the impairment caused by the symptoms in different domains of', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 2, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='functioning including social and inter-personal, academic or occupational and legal domains. In \\nfact for the diagnosis, it is required that the symptoms should cause impairment in at least one \\ndomain. The clinician must attempt to make an overall impression of the severity of ADHD based \\non the severity and number of symptoms and severity of impairments caused by the symptoms. \\nAdditionally, there may be some associated problems that should not by themselves be used as', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 2, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='an evidence for ADHD, but if present alongside need to be taken into account while planning \\nmanagement. These problems include defiant or non-compliant behaviors, irritability, mood \\nswings, aggression, temper tantrums, sleep difficulties, clumsiness, mild delays in speech and \\nlanguage and substance abuse or high risk behaviors. \\nThe clinician must as far as possible also assess for the potential effects that ADHD symptoms', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 2, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='can have on development. Such effects are seen in cognitive development and academic \\nachievements (for example, chronic inattentiveness leads to years of inadequate learning and \\nhence, affects adversely further learning), social development (children with ADHD may be \\ninattentive to social cues, are impulsive during their interactions with peers and occasionally \\nhave lesser opportunities needed for peer interactions due to peer rejection; these all lead to', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 2, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='inadequate social development, manifesting as social immaturity), development of self-esteem \\nand self-identity (peer rejection, rejection by adults, constant criticism may all affect the \\ndevelopment of self-esteem and identity; though many of these children may appear \\nboisterous). \\nDifferential diagnosis and co-morbidities \\nIt is important to note that the same disorder may be a differential diagnosis or may even be a', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 2, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='co-morbid disorder.  See Table 4 for co-morbidites seen with ADHD. Table 5 presents clinical \\npoints to differentiate ADHD from other developmental and psychiatric disorders. The clinician \\nmust as far as possible enquire into developmental and, current and past psychiatric history. \\nTable 4 here \\nTable 5 here \\nIn case of pre-schoolers, clinicians must also bear in mind that the so-called symptoms may be', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 2, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='developmentally normal or may represent the temperamental characteristics of the child. In the \\nlatter case, the clinician should refrain from diagnosing ADHD, but offer parent training for \\nmanaging difficult behaviors (See section on management; formulating treatment plan for pre-', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 2, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='schoolers). Substance use history should be enquired into, especially while assessing older \\nchildren and adolescents. This history may be taken from the adolescent by ensuring privacy \\n(Also see section on mental state examination). \\nIt is suggested that the clinician be aware of the problem of diagnostic overshadowing, i.e. \\nsymptoms of another disorder are mistakenly subsumed as manifestations of the primary', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 3, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='disorder. For example, in a child with hyperactivity and impulsivity with mild intellectual \\ndisability, the symptoms are considered to be due to the latter though they are clearly \\ndevelopmentally inappropriate. The clinicians must also recognize the problem of over-diagnosis \\nin presence of other disorders. For example, a child with autism spectrum disorder (ASD) is \\ndiagnosed with ADHD, when the symptoms of inattention and hyperactivity are mainly related to', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 3, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='social communication and sensory issues of ASD. Detailed and focused clinical interviewing and \\ncollecting information across various situations and domains will help the clinician in such \\ncircumstances. \\nTable 6 presents the key clinical points to guide the process of establishing the diagnosis. \\nTable 6 here \\nMedical history \\nRarely medical disorders may present with behaviors resembling ADHD. Such ADHD like', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 3, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='problems may be secondary to head injury, wherein inattention is prominent, thyroid disorders \\nand absence seizures. Rarely ADHD like symptoms may be present in genetic syndromes such as \\nFragile X or may be secondary to certain medications such as bronchodilators, thyroxine, \\nneuroleptics (causing akathisia) and isoniazid. Epilepsy may be co-morbid especially in children \\nwith co-morbid neuro-developmental disorders such as intellectual disability. The clinician must', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 3, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='also take specific medical history before prescribing any drug. This should include history of \\nsyncope or fainting episodes, exercise intolerance, congenital cardiac malformations or any \\ncardiac surgery. \\nMental state examination \\nMental state examination of a pre-schooler or a young child may be carried out concurrently \\nwith parent interview. It is important that the clinicians equip themselves with age appropriate', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 3, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='play and work materials that would help in building rapport as well as engaging the child in an \\nage appropriate activity. During such observations and interactions, it is suggested clinicians \\nattempt to gauge the general intellectual capacity of the child, language development and verbal \\nand non-verbal communication. The clinician may or may not find evidence of over-activity, \\nimpulsivity and inattention during the time of interview as children may perform better when', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 3, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='they find tasks interesting or the situation is structured with one-to-one adult interaction as in \\nthe clinic. This should not be taken as evidence of absence of ADHD. Also, younger children \\nmight not be aware of their problems. Clinicians therefore, should not rely solely on their \\nobservations and interview with younger children for diagnosing ADHD. Rather, clinicians may \\nuse this opportunity to observe for co-existing disorders including intellectual sub-normality, as', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 3, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='well as to observe child-parent interactions. It may reveal over-protective, hostile and critical \\nparent-child interactions, and parents’ styles of responding to defiance.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 3, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='It is desirable that older children and adolescents also be interviewed separately from their \\nparents; this acknowledges their need for autonomy and confidentiality. Adolescents may down \\nplay their problems and its impact on their functioning. So, clinician need not focus on ADHD \\nsymptoms, but may rather interview the child/ adolescent regarding depressive symptoms and \\nsuicidal ideation, peer relations and bullying. Mental state examination should include a formal', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 4, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='assessment of form and content of thought, presence of delusions, hallucinations, depressive \\ncognitions, worries, ruminations and obsessive symptoms as far as possible. There may be \\nevidence of low self esteem despite apparent boisterousness. Substance use history should be \\nelicited and history related to other high risk behaviors may be elicited if overall history is \\nindicative of the same. However, such assessments should preferably not be done before a', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 4, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='working therapeutic relation has been established with the adolescent or child. \\nRating scales \\nRating scales and screening instruments may assist in the diagnostic process, but these are \\nneither necessary nor can these replace a good clinical assessment. These include Conner’s \\nparent and teacher rating scales; Vanderbilt parent and teacher rating scales and ADHD rating \\nscale – fourth edition. These can be helpful in acquiring structured information from other', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 4, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='sources such as teachers. Besides, the rating scales may assist in monitoring treatment response. \\nThe scales may over or under diagnose ADHD when co-morbid intellectual disability or ASD is \\npresent. Most of the rating scales are expensive and do not have Indian norms, hence, it might \\nbe difficult to use these in routine clinical practice. However, more generic instruments such as \\nStrengths and Difficulties Questionnaire and Achenbach’s Child Behavior Checklist may be more', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 4, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='easily accessible. The clinical global impression (CGI) scales and children’s global assessment of \\nfunctioning scale (CGAS) may be used for baseline assessments and further monitoring. \\nPsychological testing \\nRoutine psychological testing is not indicated. If intellectual disability is suspected, IQ testing \\nmay be conducted. However, in case of severe symptoms, the scores may be erroneously low, \\nand hence, test must be repeated after adequate symptom control. Similarly if specific learning', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 4, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='disorder is suspected, the psychological assessment for the same should be carried out after \\nadequate control of ADHD symptom. Play room observation may be assistive when carried out \\nby an experienced clinician. However, it is neither mandatory nor replaces a thorough clinical \\nevaluation. Similarly, neuro-psychological tests such as continuous performance tests are not \\nindicated in routine clinical practice.  \\nPhysical investigations', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 4, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='No specific physical investigations are needed or indicated to diagnose ADHD. Neuro-imaging (CT \\nscan, MRI, PET and SPECT scans) and EEG should not be carried out without any specific clinical \\nindication. In cases where lead toxicity is suspected, i.e. when history reveals exposure to lead \\nplumbing or high lead levels in the environment, lead levels should be checked. Thyroid profile \\nshould be tested only when clinical features are suggestive of a thyroid disorder.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 4, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='FORMULATING A TREATMENT PLAN \\nFor a comprehensive treatment plan, factors that need to be taken into account are age and \\ndevelopmental stage of the child, severity of symptoms, domains of functioning affected, how \\nsymptoms affect or may affect everyday life, co-morbid developmental, psychiatric and medical \\ndisorders, psycho-social risk factors and protective factors, and goals and resources or assets \\nwithin the child and family. The plan must address as far as possible the child’s current', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 5, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='psychological, behavioral and educational needs. It is suggested that needs assessment be an \\nongoing process as needs may change over time. Regular discussions with the children and their \\nfamily must be carried out to the extent possible regarding the same. Table-7 presents the \\nguiding principles for a comprehensive treatment plan. \\nTable 7 here \\nBefore starting any treatment for ADHD, it is important to build a working therapeutic alliance', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 5, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='with the child and family, take their accounts of perceptions and preferences regarding \\ntreatment and offer them information regarding diagnosis and treatment. \\nTherapeutic alliance \\nThe first step towards management is building a good therapeutic alliance with the child or \\nadolescent and the family. Positive regard for the family’s perceptions and concerns is needed. \\nParents’ perceptions regarding diagnosis and treatment may be influenced by other family', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 5, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='members, friends, teachers, media and other physicians; and may differ from the clinician’s \\nopinion. These perceptions may influence treatment preferences as well as adherence to \\ntreatment. For example, parents who consider the behaviors diagnosed as ADHD to be ‘normal \\nnaughty behavior’ or due to the child ‘being lazy’ may request for only ‘counseling’ to the child \\nand may not consider medication or parent training as necessary. Family’s concerns regarding', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 5, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='side effects, and weighing of risk-benefit may not match with that of the clinician’s. Inadequate \\nadherence on the prescribed treatment may occur due to any of these reasons, leading to non-\\nresponse and potentially a breach in alliance and treatment drop-out. Parental expectations \\nfrom treatment also vary. For example, parents of children with ADHD and co-morbid conduct \\ndisorder may expect complete resolution of all the symptoms with a medication and may find', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 5, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='the treatment ineffective when such expectations are not realized, again leading to treatment \\ndrop-out. The clinician may take into account that the needs identified by the parents and the \\npatient may be often different. For example, the parents may be more concerned about \\nacademic performance, while the child may not identify this as an area of concern. Hence, the \\nclinician must as far as possible make an effort to establish alliance with both the child, and his', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 5, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='parents, and take into account their perceptions, preferences and expectations. Parents have \\noften been blamed by family, friends or teachers for their child’s behaviors or difficulties. They \\nare often emotionally drained and experience burn-out by the time the child is brought to the \\nclinic. The clinician must not blame the parents, must validate their positive and negative \\nexperiences with the school, extended family and professional agencies including doctors and', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 5, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='offer support. A good therapeutic alliance coupled with psycho-education will help the child and \\nparents take informed treatment decisions. Factors which can enhance therapeutic alliance are \\nshown in Table-8.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 5, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Table 8 here \\nCommunication of diagnosis \\nBefore communicating the diagnosis, the clinician may as a minimum ask the parents and other \\nsignificant family members about their perceptions regarding the causation of the problem \\nbehaviours. The clinician may present the diagnosis as a ‘brain disorder’ or a ‘neuro-\\ndevelopmental disorder’ with both genetic and environmental influences. The clinician may also', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 6, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='briefly present the psycho-social factors that can potentially influence the course and outcome \\nof the disorder (e.g. highly inconsistent parenting, severe family discord). Further, the clinician \\nmust as far as possible address guilt and blame amongst the parents, and address the \\nmisconceptions regarding ADHD. It may be followed by detailed psycho-education. Also, the \\nclinician must communicate any co-morbid diagnosis, if present. This is essential as treatment', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 6, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='considerations and overall course and prognosis may vary depending upon such co-morbidities. \\nIt is not uncommon in clinical practice, for parents to feel stigmatized that their child has been \\ngiven a diagnostic label, and these parents and patients are often apprehensive of and reluctant \\nto liaise with the school, fearing that the child will be labeled by the teachers. Such anticipations \\nare often true in the child’s given circumstances. The clinician must acknowledge the same while', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 6, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='communicating the diagnosis and educating the child and parents. The clinician must preferably \\nnot communicate the diagnosis to the school without the consent of the patient and parents, \\neven if the child was referred to the clinic by the school.  \\nPsycho-education \\nPsycho-education may be carried out over 2-3 sessions, and should as far as possible be tailored \\nfor a given child and the family. The clinician may involve any other significant family members', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 6, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='during these sessions or may conduct psycho-education later with them as and when such need \\nis identified. Table 9 presents the rationale for involving extended family members in our \\ncontext. \\nTable 9 here \\nPsycho-education may begin by asking the patient and his family regarding their own \\nunderstanding of symptoms, their causation and their beliefs regarding treatments. Psycho-\\neducation may cover detailed description of core symptoms of hyperactivity/ impulsivity; and', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 6, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='inattention and organizational difficulties, including difficulties keeping track of time, poor \\nplanning and time management, associated genetic and environmental factors such as pre or \\nperinatal factors, misconceptions regarding ADHD, including that the symptoms are merely due \\nto child’s laziness or lack of motivation and available treatment modalities; both pharmacological \\nand non-pharmacological with  benefits and risks of each modality. The basic components that', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 6, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='may be covered in psychoeducation sessions are given in table-10. \\nTable 10 here \\nTREATMENT OPTIONS FOR MANAGEMENT OF ADHD \\nAs with other psychiatric disorders, the treatment options are broadly categorized as non-\\npharmacological measures, pharmacological interventions and other treatments. See table-11.  \\nTable 11 here', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 6, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='PSYCHO-SOCIAL INTERVENTIONS \\nDespite the evidence for short term eficacy of medications, treatment with medications has \\nsome limitations; partial or no response in a proportion of cases, side effects, not well proven \\nlong term efficacy and cost effectiveness, poor adherence and negative perceptions of family \\nand professionals towards medications. Non-pharmacological interventions, on the other hand, \\nif implemented properly and adherently may produce benefits in symptoms as well as', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 7, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='functioning in different domains. \\nEnvironmental modifications \\nEnvironmental modifications include changes made in the environment in one or preferably \\nmore settings to either decrease the symptom manifestations or importantly, to decrease the \\nimpact of the symptoms. Such modifications should help enhance the performance and \\nfunctioning of the child. \\nSuch modifications include introducing structure and routine in the child’s life. The daily routines', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 7, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='such as those related to getting up and getting ready for school, on returning from school, \\nmealtimes and bedtime must be made regular and predictable. The child must be informed in \\nadvance of any change in the schedule as well as given reminders during transition. The physical \\nenvironment must also be structured with ‘a place for everything’. Allot a fixed place for almost \\neverything in the house, and particularly for belongings of the patient.Use of verbal prompts and', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 7, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='visual cues may be necessary for effective implementation. Parents can help the child in planning \\nand managing theirtime through use of daily and weekly planners; sticking planners in prominent \\nplaces such as in the bedroom or near the study table; labelling ‘places where things go’ (e.g. on \\nbookshelfs) and by giving verbal or visual (or both)reminders 3-5 minutes before a transition in \\nroutine. For example, the parent may say “5 minutes are left for playing your game”, or “after 5', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 7, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='minutes we will start with Maths”. Classrooms are ordinarily more structured as compared to \\nhome, and the routines are better defined. The teachers can use visual and verbal reminders; \\nand praise to re-inforce the same. \\nAdult supervision may help the child, especially when on boring or mentally demanding tasks \\nsuch as homework. The parent or teacher may give a simple reminder to the child when he goes', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 7, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='off task. Such reminder may be verbal or physical or both; for e.g., a tap on the shoulder and \\ntelling him, “Read the fifth question” or asking him, “so, where were we?” \\nWhile studying, minimise distractions around; for e.g. make the child sit away from traffic, away \\nfrom the TV room. The study table may be in the corner of the room, away from the windows \\nand doors (preferably child’s back facing the door), with only the books, which the child is', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 7, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='suppose to read at that time with no other distraction on the table, with no distraction on the \\nwalls which are being faced by the child and no other child in the room to distract the child. The \\nhouse should be as quiet as possible. The parent/supervisor should preferably sit with the child. \\nPresence of toys and other screen media around should be avioded.Parents may increase \\nstimulation of the material related to task to improve attention through use of highlighters, i.e.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 7, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='use colours to highlight important points. If listening to any genre of instrumental music helps \\nthe child improve his on-task attention, it may be tried.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 7, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Children may be provided with break times in middle of lengthy or boring tasks. The break may \\nbe of around 5 minutes after every 15-20 minutes of being on-task or lesser in younger children \\nor when the adult senses increase in fidgetiness. The parent may request the child to carry out a \\nhousehold chore like fetching water or shovelling or any task that helps the child use his physical \\nenergy. In school, the teacher may ask the child to distribute copies or fetching something from', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 8, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='the other classroom.Children may also be allowed to stand and work, if that helps them to \\nremain on-task. The child must be given adequate opportunities to channelise theirexcessive \\nenergy, for example, by participating in physical sports such as cycling, running, swimming or \\nfootball. \\nFor some children, extra time to complete work, decreasing work loads (these children take \\nmuch more time in completing their work as compared to peers, not because they do not know,', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 8, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='but because of their problem of inattention), giving smaller assignments focusing on must-knows \\nand use of word processors may help improve their performance and their self esteem. Some \\nschools may be open to use of these strategies. Only the Indian Certificate of Secondary \\nEducation (ICSE) Board allows for some of these accomodations, but these must be \\nrecommended only in conjunction with other treatments and must not be used as a sole \\nmeasure.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 8, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='measure.  \\nIn any case, every attempt should be made after obtaining consent, to liaise with the school. As a \\nminimum, it should be conveyed to the school teachers that ADHD is a valid diagnosis and use of \\ncertain environmentalmodifications and strategies will help the child. Every effort should be \\nmade to enlist their support.See the section on ‘Liasing with the school’ for detailed discussion. \\nTable 12 summarises the environmental modifications that can be instituted at home and \\nschool.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 8, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='school. \\nTable 12 here \\nParent training intervention \\nIndividual or group parent training programs are generally skills based andaim at imparting such \\nskills to parents that they are able to implement behavioral strategies effectively. Parents must \\nbe explicitly told that referral for parent training does not mean that their parenting is faulty; \\nrather the training would help them in learning strategies for particularly difficult and extra-', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 8, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='ordinary situation that they are facing. Other significant members of the family may be involved \\nin such programs, if needed.  \\nThe clinician must remember while dealing with the parents and family, that a parent might \\nhimself or herself have ADHD with its resultant attentional and organisational difficulties and \\nimpulsivity, or may have other psychopathology (e.g. depression) that may hinder the effective', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 8, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='implementation of the strategies. Also, some families may be better suited for individual \\ntraining. The indications for individual parental training include co-morbid conduct problems or \\ndisorder, family psychopathology, intellectual disability in parent, language difficulties or \\ndifficulties in therapeutic engagement due to any reason. \\nMost parent training programs are carried out over 8-10 weekly sessions if indivudal and 10-20', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 8, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='sessions if group training. It must cover psycho-education, environmental modifications, \\neffective communication methods, behavioural management strategies (may include token', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 8, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='economy), anticipating and preparing for unstructured situations, taking care of self and may \\ninclude liaising with teachers.Environmental modifications specific to ADHD have been \\npresented in detail in the earlier section. Effective communication includes effective ways of \\ninstructing (clear, short, long instructions simplified into steps), re-phrasing statements, focusing \\non postives while communicating, decreasing critical comments and establishing consistency', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 9, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='between what is said and what is done (no empty promises or warnings regarding \\nconsequences).The behavioral principles usedare: setting of clear rules, consistency, use of \\nimmediate rewards, followed by use of delayed rewards contigent upon desirable behaviors, \\nwithdrawal of rewards or response cost contigent upon undesriable behaviors; rewards and cost \\nbeing proportionate to the behavior. Consistency should be employed across time (i.e. a parent', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 9, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='being consistent over time across situations) and across individuals (i.e. there must be \\nconsistency between both the parents; and also grandparents if applicable). Above all, parents \\nmust be encouraged to focus on their child’s and their own strengths and inculcate healthy \\nparent-child interactions. Parents must also be encouraged to appreciate their own and the \\nchild’s efforts through regular positive feedback. Feedback should also be sought regularly from', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 9, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='the parents and difficulties faced by them in implementing the strategies must be addressed \\nregularly. Table-13 presents the components of a parent training intervention manualised at \\nPGIMER, Chandigarh. \\nTable-13 here \\nCognitive behavior therapy \\nIn case of older children and adolescents, who have benefited from environmental \\nmodificationsand parent training and/or use of medications, but still have significant', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 9, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='impairments  in specific domains,cognitive behavior therapy may be considered. For example, \\nthere may be problems in peer functioning or social functioning, or problems in academics due \\nto poor time management. For example, the cognitive behavior therapy may focus on enhancing \\nsocial skills in dealing with peers, time management, problem solving, dealing with and \\nexpressing feelings and self-control and anger management. \\nCognitive training', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 9, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Cognitive training \\nCognitive training may improve working memeory, but it is not yet well researched if this \\ntranslates into improved academic functioning. \\nPHARMACOLOGICAL INTERVENTIONS \\nBasic considerations \\nThe treatment should as far as possible be tailored to the individual needs based on current level \\nof symptom severity and impairment, and improvements, if any gained by the non-\\npharmacological measures. Factors that may need to be taken into account include variations in', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 9, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='bioavailability and pharmacokinetic profiles of different preparations so as to avoid reduced \\neffects or excessive side effects, co-existing neuro-developmental or psychiatric or physical \\ndisorders, specific treatment needs, and risk of drug misuse or diversion. Diversion occurs when \\nsomeone in the patient’s circle who has access to the medication uses it without prescription, \\nusually for recreational purposes or to enhance performance.  \\nBaseline assessment before starting a medication', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 9, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Weight and height should be measured and plotted on the World Healh Organization (WHO) or \\nIndian Association of Paediatrics (IAP) weight for age and height for age growth charts \\nrespectively along with Body mass Index (BMI). Baseline assessment of appetite, diet and sleep \\nshould be done and recorded.  \\nSpecific medical and family history that takes into account contra-indications for specific \\nmedications should be reviewed. This history must include that of exercise intolerance or', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 10, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='shortness of breath during exercise that is excessive as compared to peers, or syncope or fainting \\nepisodes on exertion or in response to sudden noise or fright, congenital heart disease or \\nprevious cardiac surgery, rapid, regular palpitations that stop and start suddenly, or chest pain \\nsuggestive of cardiac origin. Family history of sudden young (less than 40 years of age) cardiac \\ndeath should be specifically enquired into. A cardiologist’s opinion should be sought before', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 10, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='starting the medication if any of these are present. Heart rate and blood pressure must be \\nmeasured in the patient at rest. The blood pressure must be measured using age-appropriate \\ncuffsand plotted on age adjusted percentile charts. Alternately, heart rate and blood pressure \\nmay be compared with the normal range for age. If the baseline heart rate is more than 100 \\nbeats per minute or systolic or diastolic blood pressure is more than the 95th percentile, or more', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 10, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='than normal for age, it should be repeated twice within 10 minutes. If there is persistent \\ntachycardia (> 100 beats per minute) or systolic or diastolic blood pressure is> 95th percentileor \\nthere are signs of heart failure or a murmur is heard on auscultation, an electrocardiogram (ECG) \\nshould be done and a cardiologist opinion should be sought. There is no recommendation for \\nroutine baseline ECG, except when a triccylic antidepressant (TCA) is considered. TCAs are', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 10, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='however, third line drugs and should be avoided due to their side effect profile. \\nHistory of seizures of any kind and of tics must be specifically looked for. \\nLiver enzymes, i.e.,  alanine trasferase (ALT) and aspartate trasferase (AST) levels should be done \\nat baseline if atomoxetine is to be prsecribed.  \\nParents must be explained about the effect of medications on the symptoms, i.e., which \\nsymptoms will improve with medications and which will not improve with medications. Parents', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 10, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='also must be explained about the available options,  possible side effects with different \\nmedications and given the choice to select a specific agent.  \\nMedications \\nStimulants \\nThe stimulant medications with maximum evidence for ADHD include methylphenidate, \\ndexamphetamine and lisdexamphetamine. Methylphenidate is the only stimulant available in \\nIndia. There are several different formulations of methylphenidate available in the Indian', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 10, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='market.These include immediate release (short acting), sustained / extended release \\n(intermediate acting) and osmotic-controlled release oral delivery system, i.e. OROS (long acting) \\npreparations (Table-14). Methylphenidate - immediate release (IR) has a relatively short half life, \\nwith a duration of action of about 1-4 hours. Maximum drug concentration occurs at about 1-2 \\nhours after oral adminstration, and this is the time of maximum effect also. Due to short half life,', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 10, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='IR preparations need twice or thrice daily dosing. Sustained/ extended release preparations have \\na duration of action of about 6-8 hours, while the OROS preparation has duration of action of 12', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 10, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='hours. Due to their longer half lives, the intermediate acting (sustained preparations) and long \\nacting (OROS) need single dosing in the morning and may improve adherence as compared to IR \\npreparation. There is marked individual variability in dose response relation, and optimal dose \\ntitration aiming at maximum response with minimal or acceptable level of side effects must be \\ndone for each individual patient. \\nNon-stimulants', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 11, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Non-stimulants \\nThe non-stimulants that have evidence for ADHD in children and adolescents include \\natomoxetine, clonidine, guanfacine, tricyclic anti-depressants, modafinil and bupropion and \\ndesipramine. Out of these, clonidine extended release and guanfacine are not available in India. \\nAtomoxetine is a selective noradrenaline reuptake inhibitor, taken as once daily dose in the \\nmorning. Some individuals may benefit by dividing the daily dose and taking it twice daily, once', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 11, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='in morning and second doseat late afternoon or early evening. Atomoxetine is metabolised by \\nCYP2D6 enzyme, hence, poor metabolisers may have more side effects and there are chances of \\ndrug-drug interactions. Atomoxetine has evidence of greater efficacy than other non-stimulant \\ndrugs. Clonidine is an alpha 2 noradrenergic agonist taken in 3-4 divided daily doses as extended \\nrelease clonidine is not available currently in India.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 11, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='TCAs, modafinil and bupropion are considered third line drugs. TCAs are generally not \\nrecommended due to their side effect profile.  \\nTable-14 here \\nInitiating medication \\nIf a medication has to be started, the child and parents must again be apprised of the specific \\nside effects, monitoring and any precautions, as the case may be. In case of stimulants and \\natomoxetine, appetite suppression and sleep difficulties may become a concern in the initial part', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 11, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='of the treatment itself. Hence, specific advice regarding meals and sleep hygiene may be given. \\nIn case of clonidine, parents must be specifically advised regarding the risk of rebound \\nhypertension with abrupt discontiuation of the drug; so doses of clonidine should not be missed. \\nMedications should be started at a low dose (as indicated in Table 14); and side effects and \\nimprovement must be montiored after each increment. Stimulants are Schedule X drugs;', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 11, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='retailers cannot sell without a license and except on and in accordance with the prescription of a \\nRegistered Medical Practitioner; and are supposed to retain a copy of the prescription for a \\nperiod of two years. The clinician must mention clearly the exact number of days for which the \\nprescription is given.  \\nInitial monitoring  \\nDuring the phase of dose titration, the child should preferably be seen every week/ once in 2', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 11, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='weeks. The clinician must guage improvement vis-a-vis side effects. Improvement may be rated \\non a structured scale or on a simple instrument such as CGI If possible, ratings may be obtained \\nfrom the teachers at 2-4 weekly intervals. Specific enquiries should be made regarding the onset \\nof improvement noted after intake of medication (for example about 60 minutes after the \\nmorning dose) and duration of such improvement (for example, till 11am). Parents and teachers', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 11, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='may report that the child is disruptive in the class during afternoons. This may be due to', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 11, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='tiredness or wearing off of the drug’s effects. Such reporting will aid the clinician to titrate the \\ndose or change the dosing pattern.  \\nSpecific enquiries should be made regarding side effects. This should be done both from parents \\nand the child. Some older children and adolescents report that they do not like the drug effect, \\nand feel they are not themselves. Such concerns may affect adherence to the medication and', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 12, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='should be addressed. The child’s sleep patterns and food intake should be asked about. Appetite \\nsuppression and reduced food intake may be a major concern for the parents. Weight should be \\nmeasured on every visit during titration and plotted on the for-age charts. \\nContinued monitoring \\nResponse to medications must be reviewed across different settings and domains of functioning. \\nSpecific enquiries should be made regarding side effects. The child’s sleep patterns and food', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 12, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='intake should be asked about. Weight should be measured on every visit during titration, and \\nthereafter every 3 months. Height should be measured every 3-6 months. Both weight and \\nheight should be plotted on the for-age charts and monitored over time. Heart rate and blood \\npressure should be measured on every visit. Stimulants may increase the pulse rate and blood \\npressure, while clonidine can cause orthostatic hypotension. Liver enzymes should be montiored', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 12, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='periodically if atomoxetine has been started. \\nAdequate trial \\nA 6 week trial of methylphenidate at an adequate dose if taken with good adherence may be \\nconsidered as adequate. Time to response for atomoxetine is longer than that for stimulants. \\nHence, it may be continued at an adequate dose for at least 12 weeks with good adherence for \\nan adequate trial.  \\nImproving medication adherence \\nBesides response to the medication and its tolerability, other important factors that may affect', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 12, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='adherence are multiple dosing, stigma especially if the child needs to take a dose during the \\nschool hours, perceptions of patients and families regarding medications and cost. Cost of the \\nmedication and that of multiple visits to the hospital during drug titration and for later follow \\nups may be a major practical hindrance.  \\nIn case of inadequate adherence due to multiple dosing, sustained release or OROS preparations', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 12, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='may be prescribed. OROS preparations are relatively more expensive. A sustained release \\npreparation with additional immediate release doses as required may be another option. \\nOngoing discussions related to efficacy, side effects and patient and family preferences are \\nnecessary and should be carried out regularly as far as possible. \\nDrug Holidays \\nDrug holidays are planned breaks in taking medications, usually during periods when the child is', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 12, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='expected to have lesser demands for performance. These can be short, over weekends, or \\nlonger, during summer vacations. Drug holidays may reduce adverse events and give \\nopportunities for improvement in appetite and catch up growth. During drug holidays, the \\nsymptoms may or may not worsen. Longer drug holidays also provide with opportunties to \\nassess for ongoing need for medications. Weekend drug holidays are more appropriate for', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 12, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='stimulant drugs, where such holidays do not cause any advertent effect such as rebound', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 12, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='hypertension with clonidine. However, drug holidays increase the chances of non-adherence  \\n(unplanned discontinuation or missing of doses) during non ‘holiday’ periods.  \\nDiscontinuation of medication \\nThe need for continued medication should be reviewed at least once a year. The benefits, impact \\non functioning including academics, side effects, effects of missed doses, planned dose \\nreductions and periods of no treatment and any psycho-social treatment in place and its effects', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 13, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='as well as patient and family preferences are the factors to be taken into account. A few clinical \\nsigns that indicate that ADHD has remitted include, lack of any need to adjust dose despite \\nrobust growth, lack of deterioration when a dose of stimulant medication is missed or able to \\nconcentrate during drug holidays. Consider trial periods of stopping or reducing the medication \\ndose if benefit-risk analysis suggests that it may be appropriate. Vacations are probably a good', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 13, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='time to attempt withdrawal of medications. However, parents should be advised to assign the \\nchild in some cognitively demanding tasks (such as solving math problems, reading a book) to \\nconfirm that improvements persist despite being medication free. \\nManaging drug side effects \\nTable 15 presents the side effects of ADHD medications, along with guidance on monitoring for \\nand management of these side effects. \\nTable 15 here \\nManaging sleep problems asociated with ADHD', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 13, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Behavioral problems such as bedtime resistance, sleep onset delay, effect of psychiatric \\ncomorbidity and sleep disorders may contribute to sleep difficulties in children with ADHD. It is \\nsuggested that pre-treatment or baseline sleep patterns, including behavioral patterns around \\nbedtime routines be evaulated. Bedtime resistance include behaviors such as the child refusing \\nto get ready for bed, refusing to remain in bed or requiring a parent to be present at bedtime is', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 13, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='often the result of parental difficulties in limit setting and managing behaviors. It is suggested \\nthat sleep hygiene measures and behavioral interventions for healthier bedtime routines be \\ninstituted. These may include avoiding evening naps, having a regular bedtime, calming bedtime \\nroutine, darkened room, comfortable bed and no loud noises that promote sleep, and avoiding \\nelctronic media or screen use in the evening and adults also not using screens in the bedroom. In', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 13, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='individual cases, low dose clonidine or melatonin (3 mg in children and 3-6 mg in adolescents) \\nmay be used for sleep onset delay. Sleep studies including polysomnography are only indicated \\nfor specific sleep related disorders, and not routinely.  \\nEVIDENCE \\nMedications \\nIn pre-schoolers, there is some evidence of short term efficacy of stimulants, however, there are \\nserious concerns regarding side effects, especially related to appetite and growth suppression. In', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 13, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='children > 6 years and adolescents, stimulants, atomoxetine and clonidine have been shown to \\nbe significantly more efficacious than placebo. Stimulants have been shown to be superior to \\nnon-stimulants and have good short term efficacy, though evidence for long term efficacy is \\ninadequate. There is not adequate evidence of differences in efficacy or side effects between the \\ndifferent formulations of methylphenidate. The main advantage of longer acting formulations', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 13, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='over the short acting is in single versus multiple dosing that may result in lesser stigma \\nassociated with taking a dose in school and better adherence. Amongst non-stimulants, \\natomoxetine has greater evidence of efficacy with effect sizes though lower than stimulants, \\nbetter than the other non-stimulants. There is evidence of efficacy for clonidine, though effect \\nsizes are smaller than that for atomoxetine. Amongst tricyclic antidepressants, desipramine has', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 14, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='the largest evidence of efficacy but the medication has considerable cardiac side effects.  \\nPsychosocial interventions \\nIn pre-schoolers, there is enough evidence for group and individual parent training interventions. \\nIn children > 6 years and adolescents, there is evidence of efficacy for parent training \\ninterventions; and in older children and adolescents for other psycho-social interventions also.   \\nComparing medication and psychosocial interventions', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 14, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='There is no robust evidence directly comparing medications with psycho-social interventions. In \\npre-schoolers, there is evidence of efficacy for both medications and psycho-social interventions, \\nwith more concerns about side effects with the medications. In children > 6 years of age and \\nadolescents, there is evidence of efficacy for both medications and psycho-social interventions. \\nThere is some evidence of possibly differential effects of the two modalities; with the drug more', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 14, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='efficacious for the core symptoms whereas non-pharmacological interventions more efficacious \\nin improving associated behavioral problems and functioning. Though the effect sizes for \\nmedications, especially stimulants are greater than those for psycho-social interventions, it is \\nprobable that this is because of the outcome measures studied; ADHD symptom specific \\noutcomes versus more generic outcomes regarding behavioral problems and functioning. \\nCombination Treatments', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 14, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='There is no evidence that combination of two medications offers any advantage over a single \\nmedication. Additionally, there are more side effects; and hence should be avoided. \\nCombination of medication with psycho-social intervention has been found to be more \\nefficacious than psycho-social intervention alone. Adding psycho-social intervention to the \\nmedication treatment may offer specific benefits and so, must be instituted when indicated.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 14, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Besides evidence of possibly differential effects of the two modalities; there is also some \\nevidence that addition of psycho-social interventions may facilitate dose reduction and \\ndiscontinuation of medication on follow up.  \\nOTHER INTERVENTIONS \\nDiet and exercise \\nIt is suggested that all children and adolescents be advised regarding need for nutritious and \\nbalanced diet; and physical exercise. \\nExclusion of food preservatives and additives and Elimination or oligoanitgenic (few foods)', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 14, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='diets \\nThere is not enough evidence for special diets such as exclsuion of food additives and \\npreservatives, or elimination of several potential antigens as in the oligo-antigenic diets as stand \\nalone treatments in the management of ADHD. There is limited evidence of short-term benefits; \\nand not enough evidence of long-term effectiveness or harms of elimination diets. If it is \\nsuspected that specific foods increase the symptoms, it is suggested that parents  be advised to', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 14, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='maintain detailed diet diaries and any elimination of specific food be attempted only in \\nconsultation with an expert dietician. It may take weeks to months for tailoring an oligoantigenic \\ndiet through series of re-introduction of foods; and requires close collaboration between the \\ndietician, clinician and the family anfd patient. IgG blood tests are not helpful in selecting foods \\nfor elimination. The clinical utility of dietary interventions may be explored in individual cases,', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='bearing in mind difficulties in practical implementation such as preparation of special foods in a \\nhousehold with several members, parents‘ control over child’s diet, motivation of child and \\nfamily as well as expenses towards preparation of additive-free or anitgen free foods.  \\nOmega fatty acids and nutritional supplements \\nThere is inconclusive evidence for use of omega fatty acids or any micronutrient or nutritional', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='supplements for treatment of ADHD, and hence, it is suggested that such dietary supplements \\nmay not be prescribed for this purpose routinely till further good quality evidence emerges. \\nNeurofeedback \\nThough small studies indicate that neurofeedback may have some positive effects on core \\nsymptoms and neuropsychological functions, well designed studies and meta-analysis have  have \\nfailed to show the same. Overall, there is not adequate evidence to support neurofeedback for', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='treatment of ADHD. \\nLIAISON WITH SCHOOL \\nIt is suggested that liaison with the school be a continual activity. First and all subsequent \\ncontacts with the school should be after parental and patient’s consent and as far as possible \\ncontact should be made through the parents. It is sound clinical practice to acknowledge the \\nschool’s strengths while dealing with the index child, taking teacher’s observational report and', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='follow up feedbacks. Teacher reports and parent reports may give insights into different areas of \\nimpairment and in different settings. A good alliance with the teachers will set the stage to \\ncommunicate the diagnosis and that it is a valid disorder; and suggest environmental \\nmodifications that a teacher can easily implement in the classroom. Efficient and sensitive \\nteachers do encourage these children to exploit their other potentials and use verbal re-', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='inforcements effectively, while minimally using punishment. These children often are bullied or \\nare bullies themselves, and school intervention can be very helpful in either case. Besides \\nclinicians liaising with the school, parents may be advised to liaise with the child’s teachers and \\nuse the parent-teacher daily report cards. These report cards aid in implementing the behavior \\nprinciples more consistently and across the two settings. \\nSTEPS IN MANAGING ADHD', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Factors determining the steps in management of ADHD \\nThe evidence for medications is limited in pre-schoolers; whereas there are genuine concerns \\nregarding the side effects of the medications. There is enough evidence for group and individual \\nparent training interventions. Keeping these in mind, pre-schoolers must first be offered psycho-\\nsocial interventions. \\nIn children > 6 years of age and adolescents, there is evidence of efficacy for both medications', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='and psycho-social interventions. Medications appear to be more efficacious in improving the \\ncore symptoms of ADHD and psycho-social interventions in improving associated behavioral', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='problems and functioning in specific domains. In mild ADHD, environmental modifications \\nusually suffice alone; while in severe ADHD, medications may be necessary. In the latter case, \\nfollowing some response with the medication, psycho-social interventions may be indicated for \\nspecific problems or impairments in specific domains. In case of moderate ADHD, parent training \\nwhere available must be offered first.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 16, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Besides the evidence for efficacy and side effects, and severity of ADHD, the other important \\nfactors that determine the strategies in managing ADHD include co-morbidities, current needs, \\npatient and family’s preferences, affordability and availability. Table 16 lists the factors \\ndetermining the steps in management of ADHD. \\nTable-16 here \\nSteps in management of ADHD \\nFigure 1 presents the algorithm for managing ADHD. It is expected that the plan and steps may', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 16, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='have to be tailored to suit the needs of an individual patient. Psycho-education and support to \\nthe child and family must as far as possible be provided to all individuals. Medication is not the \\nfirst line of management in pre-schoolers and those aged less than 6 years as there are concerns \\nregarding tolerability and safety. Also, it is often difficult to differentiate a difficult temperament \\nfrom ADHD in toddlers. Parent training interventions that include environmental modifications', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 16, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='as well as behavioral management may be offered instead. The training may be given as group \\ntraining or individual training. The clinician must consider addressing any factors that may hinder \\nthe effective implementation of the parent training intervention.  \\nFor school aged children and adolescents, it is suggested that environmental modifications be \\nadvised first. Despite the implementation of environmental modifications or in cases where the', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 16, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='severity is so marked that such implementation is quite difficult, choose the next line of \\nmanagement based on the severity. In children with mild to moderate level of severity, offer \\nparent training and school interventions. If the response is not good or parent training \\nintervention is not available and severity is at least of moderate level, offer medications. If ADHD \\nis severe, medications must be offered. The sequencing of medications considering response,', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 16, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='contra-indications, side effects affordability and availability is preferably stimulant followed by \\natomoxetine followed by clonidine.  \\nFor all individuals who respond on a given treatment, continue with the same, along with \\nperiodic review and monitoring. In children and adolescents who have responded on a \\nmedication, but still have impairments in a specific domain, offer additional focused psycho-', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 16, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='social intervention. For example, an adolescent having impairments in peer functioning, offer \\nsocial skills training. In case of response to a psycho-social intervention, continue with periodic \\nbooster sessions and monitoring. \\nIn case of inadequate response on a medication, check for non-adherence. Ensure adherence \\nafter addressing the child and family’s concerns regarding the medication; these may include', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 16, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='side effects, cost and stigma. If child is adherent on the medication, optimize the dose while \\nmonitoring for side effects. If despite an adequate trial, there is inadequate response, consider \\nchanging the drug. Family may prefer psycho-social intervention following a failed medication \\ntrial; in that case, it must be offered, if available after again discussing the benefits and risks of', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 16, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='each modality of treatment. If there is inadequate response after adequate medication trials, \\nreview the diagnosis, manage co-morbidities (for example, conduct disorder), may add parent \\ntraining intervention. In case of inadequate response following parent training intervention, first \\ncheck for and address adherence to the interventions. If despite this, there is inadequate \\nresponse, offer medication alone or in combination with the psycho-social intervention. Table-17', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 17, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='lists out the factors related to inadequate response to pharmacological or non-pharmacological \\nintervention. \\nBesides the medication or parent training and other child focused psycho-social interventions, \\nongoing liaison with the school must be carried out with consent of child and parents. School \\nliaison strategies must be attempted. Review of teacher-implemented environmental \\nmodifications and behavioral management strategies must be made periodically, along with', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 17, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='teacher reports regarding child’s problems and progress.  \\nFigure 1 here \\nTable-17 here \\nReview and discontinuation of treatment \\nThe clinician must perform ongoing reviews regarding improvement, tolerability and needs of \\nthe child and family. The management plan may be altered in accordance with changing needs as \\noutlined in earlier sections.  \\nFurther, the clinician must review the need for ongoing treatment at least once a year. For this,', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 17, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='response to treatment, functioning in various domains and maintenance of response despite \\nperiods of planned or unplanned discontinuation of treatment must be considered. As during \\ninitial assessment, assessment of symptoms and functioning at this stage must involve multiple \\ninformants (preferably, must involve teachers) and must be done across settings. The child and \\nfamily must be involved in discussions regarding possibility of discontinuation and risks and', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 17, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='benefits thereof, including chances of relapse, though definitely not inevitable and improvement \\nin side effects. Discontinuation must be attempted during low stress periods such as during \\nvacations. Discontinuation of medications has been dealt with in detail in an earlier section. In \\ncase of psycho-social intervention, it is expected that some benefits may persist beyond the \\ntraining programs. However, booster sessions may be required or focused strategies such as life', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 17, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='skills or time management may be required. In case a child is on drug and non-drug treatment, \\nthe former may be discontinued first. The children and adolescents and their families must be \\nadvised ongoing reviews despite discontinuation of treatment. The clinician must monitor for \\nrelapse of symptoms or any impairments in functioning that need to be addressed. \\nSPECIAL CIRCUMSTANCES \\nIn case of co-morbid tic disorder, anxiety disorders, obsessive compulsive disorder and ASD, the', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 17, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='same medication may be started as for children and adolescents without any co-\\nmorbidity.However, drug titration must be slower and special attention should be paid to side \\neffects.Clonidine or atomoxetine may be a good choice in case of co-morbid tic disorder; while \\natomoxetine may be a good choice in case of co-morbid anxiety disorder although there is no \\ngood evidence for avoiding methylphenidate.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 17, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='In case of children with co-morbid intellectual disability or ASD, tolerability is an important \\nconsideration. Some children with developmental disabilities experience irritability, withdrawal \\nor agitation and apparent worsening of symptoms. In such children, the diagnosis of ADHD \\nshould be re-visited and the medication should be stopped. A non-stimulant medication may be \\nstarted. \\nIn case of psychosis or bipolar disorder co-existing with ADHD, the psychosis or mood disorder', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 18, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='should be treated first, and after resolution of the symptoms, a review of diagnosis of ADHD \\nshould be made. The clinician should assess the need for medication and then may start a \\nstimulant or a non-stimulant drug weighing the risks and benefits in the individual case and \\nconsidering drug interactions.  \\nIn case of co-morbid depression, the clinician must assess the severity of depression, presence of', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 18, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='suicidal attempts or strong suicidal intent, and contribution of depressive symptoms to the \\noverall global clinical severity. If the any of these are present, depression should be treated first. \\nIn case of severe depression or suicidal ideas or attempts, inpatient management may be \\nwarranted depending on the individual circumstances. On the other hand, if depression is not \\nsevere with mild neuro-vegetative symptoms, suicidal ideas but without strong intent and ADHD', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 18, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='sympotms are thought to contribute more than depressive symptoms to overall clinical severity, \\nADHD must be treated first. Often, the depressive symptoms and dysphoria may be related to \\nthe ADHD and resolve with effective treatment of ADHD. \\nIn case of co-morbid substance dependence, treatment of ADHD and substance dependence \\nshould be instituted simultaneously. The clinician must assess the risk of medicalion misuse and \\ndiversion. If this risk is high, a non-stimulant may be used.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 18, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='If  co-morbid conduct disorder or oppositional defiant disorder are present, parent training \\ndirected towards the behavioural problems in addition to ADHD focused parent training should \\nbe commenced. Also, risk of medication misuse and diversion should be assessed and a non-\\nstimulant drug may be started. Risperidone in low doses may be started particularly for \\naggression. Refer to CPG on Conduct Disorder for its management. \\n \\nREFERENCES', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 18, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='REFERENCES \\n1. American Academy of Child and Adolescent Psychiatry. Practice Parameter for the \\nAssessment and Treatment of Children and Adolescents with Attention-Deficit/ \\nHyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2007; 46(7):894-921. \\n2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders \\n(5th ed.). 2013; APA, Washington DC. \\n3. Barkley RA. Taking charge of ADHD: the complete, authoritative guide for parents. 2005;', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 18, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Guilford Press, New York. \\n4. Bolea-Alamañac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the \\npharmacological management of attention deficit hyperactivity disorder: update on \\nrecommendations \\nfrom \\nthe \\nBritish \\nAssociation \\nfor \\nPsychopharmacology. \\nJ \\nPsychopharmacol. 2014; 28: 179-203.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 18, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='5. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA): Canadian \\nADHD Practice Guidelines, Third Edition, 2011; CADDRA, Toronto ON. \\n6. Catalá-López F, Hutton B, Núñez-Beltrán A, et al. The pharmacological and non-\\npharmacological treatment of attention deficit hyperactivity disorder in children and \\nadolescents: A systematic review with network meta-analyses of randomised trials. Gluud \\nC, ed. PLoS ONE. 2017;12(7):e0180355. doi:10.1371/journal.pone.0180355.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 19, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='7. Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M,, et \\nal. Practitioner Review: Current best practice in the management of adverse events \\nduring treatment with ADHD medications in children and adolescents. J Child Psychol \\nPsychiatry. 2013;54: 227–246 \\n8. Cortese S, Vincenzi B, Angriman M. Identifying and managing sleep disorders associated \\nwith ADHD. Neuropsychiatry. 2012; 2:393–405', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 19, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='9. Cortese S, Ferrin M, Brandeis D, Holtmann M, Aggensteiner P, Daley D, et al. \\nNeurofeedback for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and \\nNeuropsychological Outcomes From Randomized Controlled Trials. J Am Acad Child \\nAdolesc Psychiatry. 2016; 55: 444 - 455 \\n10. Daniel F, Guan C, Wong CJM, Ng KH, Cheok CCS, Kiing JSH, et al. Academy of Medicine-\\nMinistry of Health Clinical Practice Guidelines: Attention Deficit Hyperactivity Disorder.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 19, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Singapore Med J. 2014; 55(8): 411-415doi: 10.11622/smedj.2014098 \\n11. Ferrin M, SonugaBarke E, Daley D, Danckaerts M, van der Oord S, Buitelaar JK. Non-\\npharmacologic treatments for Attention deficit hyperactivity disorder. In Eds. Zepf FD. \\nIACAPAP Textbook of Child and Adolescent Mental Health. 2015 Available at: \\nhttp://iacapap.org/iacapap-textbook-of-child-and-adolescent-mental-health \\n12. Gautam S, Batra L, Gaur N, Meena PS. Clinical Practice Guidelines for the Assessment and', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 19, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Treatment of Attention- Deficit/Hyperactivity Disorder. Indian Psychiatric Society, 2007. \\n13. Gillies D, Sinn JKH, Lad  SS, Leach  MJ, Ross  MJ. Polyunsaturated fatty acids (PUFA) for \\nattention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane \\nDatabase of Systematic Reviews 2012, Issue 7. Art. No.: CD007986. DOI: \\n10.1002/14651858.CD007986.pub2 \\n14. Maia CRM, Samuele C, Arthur C, Deakin TK, Polanczyk GV, et al. Long-Term Efficacy of', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 19, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Methylphenidate Immediate-Release for the Treatment of Childhood ADHD: A Systematic \\nReview and Meta-Analysis. J AttenDisord. 2017, Vol. 21(1) 3– 13 \\n15. Moriyama TS, Cho AJM, Verin RE, Fuentes J, Polanczyk GV. Attention deficit hyperactivity \\ndisorder. In Eds. Zepf FD. IACAPAP Textbook of Child and Adolescent Mental Health. \\n2015. Available at: http://iacapap.org/iacapap-textbook-of-child-and-adolescent-mental-\\nhealth', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 19, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='health \\n16. National Institute for Health and Care Excellence.Antisocial behaviour and conduct \\ndisorders in children and young people: recognition and management. London: NICE; \\n2013 \\n17. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: \\ndiagnosis and management. London: NICE; 2018', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 19, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='18. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder \\nin children and young people: clonidine. London: NICE; 2013 \\n19. National Institute for Health and Care Excellence.Attention deficit hyperactivity disorder \\n(update). [B] Evidence reviews for information and support for people with ADHD. \\nEvidence review. London: NICE;2018 \\n20. National Institute for Health and Care Excellence.Attention deficit hyperactivity disorder', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 20, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='(update). [C] Evidence reviews for pharmacological efficacy and sequencing \\npharmacological treatment. Evidence review. London: NICE; 2018 \\n21. National Institute for Health and Care Excellence.Attention deficit hyperactivity disorder \\n(update). [D] Evidence reviews for safety of pharmacological treatment. Evidence review. \\nLondon: NICE; 2018 \\n22. National Institute for Health and Care Excellence.Attention deficit hyperactivity disorder', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 20, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='(update). [E] Evidence reviews for efficacy of non-pharmacological treatment and the \\nimpact of adverse events associated with non-pharmacological treatments of ADHD. \\nIntervention evidence review. London: NICE; 2018 \\n23. National Institute for Health and Care Excellence.Attention deficit hyperactivity disorder \\n(update). [F] Evidence reviews for combined pharmacological and non-pharmacological \\ntreatments review. Intervention evidence review. London: NICE; 2018', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 20, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='24. National Institute for Health and Care Excellence.Attention deficit hyperactivity disorder \\n(update). [G] Evidence reviews for adherence to treatment (pharmacological and non-\\npharmacological). Evidence review. London: NICE;2018 \\n25. National Institute for Health and Care Excellence.Attention deficit hyperactivity disorder \\n(update). [H] Evidence reviews for the principles for discussion when starting, adjusting', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 20, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='and discontinuing pharmacological treatment for ADHD. Evidence review. London: NICE; \\n2018 \\n26. National Institute for Health and Care Excellence.Attention deficit hyperactivity disorder \\n(update). [I] Withdrawal from pharmacological treatment and drug holidays. Evidence \\nreview. 2018 \\n27. National Institute for Health and Care Excellence.Sleep disorders in children and young \\npeople with attention deficit hyperactivity disorder melatonin. Evidence summary. \\nLondon: NICE; 2013', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 20, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='London: NICE; 2013 \\n28. National Institute for Health and Care Excellence. The NICE guideline on diagnosis and \\nmanagement of ADHD in children, young people and adults. London: NICE; 2009 \\n29. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder \\nClinical Guideline Addendum 72.1 Methods, evidence and recommendations. London: \\nNICE; 2016 \\n30. Osland ST, Steeves TDL, Pringsheim T. Pharmacological treatment for attention deficit', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 20, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database \\nof \\nSystematic \\nReviews \\n2018, \\n6. \\nArt. \\nNo.: \\nCD007990. \\nDOI: \\n10.1002/14651858.CD007990.pub3.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 20, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='31. Osland ST, Steeves TDL, Pringsheim T. Pharmacological treatment for attention deficit \\nhyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database \\nof \\nSystematic \\nReviews \\n2018, \\nIssue \\n6. \\nArt. \\nNo.: \\nCD007990. \\nDOI: \\n10.1002/14651858.CD007990.pub3. \\n32. Otasowie J, Castells X, Ehimare UP, Smith CH. Tricyclic antidepressants for attention \\ndeficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of \\nSystematic \\nReviews \\n2014, \\nIssue', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 21, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='2014, \\nIssue \\n9. \\nArt. \\nNo.: \\nCD006997. \\nDOI: \\n10.1002/14651858.CD006997.pub2. \\n33. Pelsser LM, Frankena K, Toorman J, Rodrigues Pereira R (2017) Diet and ADHD, Reviewing \\nthe Evidence: A Systematic Review of Meta-Analyses of Double-Blind Placebo-Controlled \\nTrials Evaluating the Efficacy of Diet Interventions on the Behavior of Children with \\nADHD. PLoS ONE 12(1): e0169277.  \\n34. Shah R, Sharma A, Grover S, Sachdeva D, Chakrabarti S, Avasthi A. PGIMER Manual Parent', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 21, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='training for families of children with attention deficit/ hyperactivity disorder. \\n35. Sonuga-Barke E, Brandeis D, Ferrin M, Holtmann, M, Stevenson J.  Nonpharmacological \\nInterventions for ADHD: Systematic Review and Meta-Analyses of Randomized Controlled \\nTrials of Dietary and Psychological Treatments. Am J Psychiatry 2013; 170:275–289 \\n36. Sonuga-Barke E, Taylor E. ADHD and hyperkinetic disorder. In EdsThaparA et al. Rutter’s', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 21, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Child and Adolescent Psychiatry. Sixth edition. Blackwell Publishing Limited. USA, 2015 \\n37. Taylor E, Döpfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic \\ndisorder — first upgrade. Eur Child Adolesc Psychiatry 2004; 13(Suppl 1): I/7-I/30. \\n38. Taylor E, Sonuga-Barke E. Disorders of attention and activity. In EdsRutter M et al. \\nRutter’s Child and Adolescent Psychiatry. Fifth edition. Blackwell Publishing Limited. USA, \\n2008.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 21, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='2008. \\n39. World Health Organisation. The 11th Revision of the International Classification of \\nDiseases \\n(ICD-11) \\nBeta \\ndraft. \\nAvailable \\nat: \\nhttp://www.who.int/classifications/icd/revision/en \\n40. World Health Organisation.The ICD‐10 classification of mental and behavioural disorders: \\nclinical descriptions and diagnostic guidelines. Geneva, 1992 \\n41. Young S, Amarasinghe JM. Practitioner Review: Non-pharmacological treatments for', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 21, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='ADHD: A lifespan approach. Journal of Child Psychology and Psychiatry 2010;51:116–33', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 21, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Table 1: Components of a comprehensive assessment and evaluation (text in parenthesis may \\nbe used as a guide for assessment) \\n Core components \\n1. \\nEstablishing diagnosis through detailed history from multiple informants \\n2. \\nDevelopmental and psychiatric history (for differential diagnosis and co-morbidities) \\n3. \\nMedical history (for co-morbidities and contra-indications for medications) \\na. Comorbid physical disorders: Include tics, seizures, malnutrition, thyroid \\nabnormalities', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 22, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='abnormalities \\nb. Contra-indications: Syncope, exercise intolerance \\n4. \\nSubstance use history \\n5. \\nFamily history (Family h/o ADHD, other developmental, psychiatric and physical \\ndisorders; family history of young, i.e. <40 years age sudden cardiac deaths if \\nplanning to prescribe a drug) \\n6. Treatment history (past treatment contacts and experiences, type of treatment, drug \\ndose, formulation, dosing schedule, adherence, response, side  effects and', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 22, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='perceptions, use of drug holidays, treatment adherence, premature termination of \\ntreatment, etc.)   \\n7. \\nSleep patterns and appetite (pre-treatment baseline night sleep and day time naps; \\nbaseline history of appetite and food intake) \\n8. Psycho-social history (environmental factors, perceptions and expectations \\nregarding diagnosis and treatment, family psychopathology and family resources)  \\n9. \\nDysfunction: domains involved (academic, family, social, interpersonal,  legal, peer', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 22, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='relationship, occupational), severity of illness \\n10. \\nImpact of illness on the patient: secondary depression, perpetuator of bullying, or a \\nbully victim , stigma, parental abuse (psychological, physical and neglect) \\n11. \\nImpact of illness on the life of caregivers: burden, distress, burnout, \\npsychiatric/psychological burden, stigma \\n12. \\nStrengths (physical, psychological, cognitive or creative attributes of the child that', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 22, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='can be considered as assets; e.g. good in a sport, coloring or sketching, obedient and \\nrespectful of elders) \\n13. \\nAssessment of current needs (to be assessed across various domains such as \\npsychological, social and academic) \\n14. \\nPhysical examination (for co-morbidities and contra-indications; pre-treatment \\nbaseline assessments) \\n15. \\nMental state examination (to assess for any other psychopathology such as \\ndepressive cognitions, suicidal ideas, delusions and hallucinations)', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 22, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Supportive or only if indicated \\n1. \\nRating scales (baseline assessment and monitoring treatment response) \\n2. \\nPsychological testing (e.g. IQ assessment, only if indicated) \\n3. \\nPhysical investigations (e.g. Lead levels; only if indicated)', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 22, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content=\"Table 2: Clinical questions to be answered in the process of assessment \\n1. \\nIs there presence of symptoms of inattention/ overactivity / impulsivity? \\n2. \\nWhat has been the onset and course of these complaints? \\n3. \\nAre the symptoms age-appropriate?  \\n4. \\nAre there global developmental delays? If so, are the symptoms appropriate to the level \\nof   ‘mental-age' or stage of development  \\n5. \\nAre the symptoms persistent (present more often than not)? \\n6.\", metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 23, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='6. \\nAre the symptoms causing impairment in more than one setting (e.g. home, school)? \\n7. \\nHow severe are the symptoms and the impairment? \\n8. \\nAre there associated developmental and/or other psychiatric problems?  \\n9. \\nAre there any associated medical problems? \\n10. \\nWhat are the genetic and environmental risk factors? \\n11. \\nRelevant psychosocial factors, parenting, parenting stress & parents’ perceptions and \\nexperiences regarding diagnosis and treatment \\n12.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 23, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='12. \\nStrengths or assets of the child and family and any protective or positive environmental \\nfactors (e.g. supportive school environment) \\n \\nTable 3: factors that may affect symptom manifestations of ADHD \\nSigns of ADHD may be minimal or absent if \\n\\uf0b7 child is engaged in a one to one interaction (as with the clinician),  \\n\\uf0b7 in a novel setting (such a clinic),  \\n\\uf0b7 under close supervision (as in private tuitions),  \\n\\uf0b7 is being frequently rewarded for appropriate behaviors,', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 23, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='\\uf0b7 is engaged in especially interesting activity or  \\n\\uf0b7 getting consistent external stimulation, often with rewards (as while watching TV or \\nplaying video games).  \\nInattention is more evident when  \\n\\uf0b7 tasks are lengthy, boring or monotonous  \\n\\uf0b7 depends on the demands for attention that the tasks/ environment make \\nThe symptoms can vary with both internal and external motivation, type of activity (interesting', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 23, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='versus boring), demands that the task makes for attention, adult supervision, one to one \\ninteraction as well as with fatigue and time of the day. \\nTable 4: Co-morbidities seen with ADHD \\nDevelopmental: Intellectual disability, speech and language disorders, learning disorders, motor \\nco-ordination disorders, autism spectrum disorders, tic disorders \\nPsychiatric: Oppositional defiant disorder, conduct disorder, mood and anxiety disorders, \\npsychotic disorders, substance use disorders', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 23, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Medical: Epilepsy, tics, seizures, malnutrition, thyroid abnormalities', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 23, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Table 5: Clinical features for differentiating ADHD from other disorders \\nDifferential diagnosis \\nClinical features that help in differentiating \\nOppositional defiant disorder \\nand conduct disorder \\n\\uf0b7 Symptoms of ADHD usually pre-date the symptoms of \\ndefiant disorders \\n\\uf0b7 However, in extremely severe cases of ADHD, defiance \\nmay seem to start very soon after the onset of ADHD.  \\n\\uf0b7 It may at times be clinically difficult to separate out the \\ntwo; though a good chronological history may help.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 24, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='\\uf0b7 However, a diagnosis of ADHD should not be made \\nwhen there is presence of defiance in absence of the \\ncore symptoms of ADHD. \\nIntellectual disability (ID) \\n\\uf0b7 In children with ID, apparent inattentiveness and \\ndifficulty to follow instructions can be better explained \\nby a lack of comprehension  \\n\\uf0b7 In case of suspected co-morbidity, symptoms suggestive \\nof ADHD must be clearly developmentally inappropriate. \\nSpecific \\nlearning \\ndisorders \\n(SLD)', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 24, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='disorders \\n(SLD) \\n\\uf0b7 Academic difficulties in SLD are quite persistent while in \\nADHD the performance can be strikingly variable \\n\\uf0b7 Children with ADHD may engage in reading or writing as \\nleisure activities (e.g. reading fiction) in contrast to \\nthose with specific learning disorders \\n\\uf0b7 It is clinically a good practice to first treat ADHD and \\nthen assess for specific learning disorders if these \\nappear to be co-existent. \\nAutism \\nspectrum \\ndisorders \\n(ASDs)', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 24, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='disorders \\n(ASDs) \\n\\uf0b7 increased motor activity of ASDs is characterized by \\nrepetitive, stereotyped movements as against the \\nhyperactivity of ADHD \\n\\uf0b7 Several behaviors mimicking ADHD may be due to \\nsensory issues and deviant socio-emotional reciprocity  \\nTic disorders \\n\\uf0b7 Prolonged observation helps in differentiating complex \\nmotor tics seen in Tourette’s disorder from the \\nincreased motor activity and fidgetiness seen in ADHD. \\nMania \\n\\uf0b7 Symptoms are of a relatively recent onset', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 24, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='\\uf0b7 Definite change from pre-morbid state \\n\\uf0b7 Increased activity in mania is goal directed; that of \\nADHD is not \\n\\uf0b7 Presence of symptoms such as inflated self-esteem and \\ngrandiosity \\nDepression \\n\\uf0b7 Symptoms are of a relatively recent onset \\n\\uf0b7 Definite change from pre-morbid state', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 24, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='\\uf0b7 Symptoms other than irritability and agitation, such as \\ndecreased interest in pleasurable activities \\nPsychosis \\n\\uf0b7 Symptoms are of a relatively recent onset \\n\\uf0b7 Definite change from pre-morbid state \\n\\uf0b7 Presence of delusions and hallucinations \\nAnxiety disorders \\n\\uf0b7 Inattentiviness, lack of concentration and generalized \\nhyperarousal may be seen in anxiety disorders; but \\npresence of other cognitive (e.g. worry) and behavioral \\nsymptoms (e.g. autonomic arousal) may be present', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 25, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Obsessive compulsive disorder \\n\\uf0b7 Compulsive behaviors are repetitive, goal directed and \\noften ritualistic \\n\\uf0b7 Concurrent obsessions may be present \\n \\nTable 6: Key clinical points to guide the process of establishing the diagnosis \\n1. Multi-informant; each informant may add a different dimension to the history \\n2. Assess symptoms across multiple settings \\n3. Compare the reported symptoms to developmentally normal levels of inattention, activity \\nand impulsivity', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 25, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='and impulsivity \\n4. Symptom manifestation may change with development \\n5. Symptoms may vary with internal and external motivation, re-inforcers, close supervision, \\none to one interaction, time of the day, and fatigue \\n6. Symptoms are not due to merely defiance or lack of comprehension or are specific to a \\nparticular task or due to another psychiatric disorder \\n7. Assess impairment in multiple domains \\n8. Assess effects on development in various domains', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 25, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='9. Make an impression of overall severity of the disorder \\n \\nTable 7: Principles to guide formulation of a comprehensive treatment plan \\n1. The main objectives of a treatment plan must be to alleviate symptoms as well as \\nimprove functioning in various domains of functioning \\n2. It should be needs-based, individualised and may change over time \\n3. Consider the level of symptoms and impairments in functioning across settings and \\ndomains of functioning', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 25, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='4. Consider co-morbid developmental, psychiatric and medical disorders \\n5. Consider psycho-social and environmental protective and risk factors \\n6. Consider patient’s and family’s perceptions regarding treatment and their treatment \\npreferences \\n7. Consider family’s resources including financial resources', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 25, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Table 8: Important points to remember while building therapeutic alliance \\n1. Positive regard for all involved in the care of the child  \\n2. Parental (and family’s) perceptions regarding diagnosis and treatment may differ \\nfrom that of the clinician’s. \\n3. Parental expectations may differ from realistic goals that can be achieved. \\n4. Parents have often experienced blame and guilt before reaching the clinic. Validate \\ntheir experiences and feelings; offer support.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 26, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='5. Child or adolescent’s needs may be different from those identified by the parents. \\nEstablish a working therapeutic alliance with both the parties.  \\n \\nTable 9: Rationale for involving extended family members in the Indian context \\n1. Parental perceptions regarding diagnosis and treatment may be influenced by the \\nextended family.  \\n2. It is common for parents to take treatment decisions jointly with grandparents and \\nmembers of extended family, even when residing as nuclear families.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 26, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='3. Treatment adherence; both for pharmacological and non-pharmacological modalities will \\nbe affected at least partially by other significant elders in the family. For example, much \\nof the behavioural management is dependent upon the consistency shown in \\nimplementing the strategies by all the significant adults in the child’s life. Behavioral \\nmanagement through parent training may fail, if grandparents who stay in the same \\nhousehold are not involved pro-actively.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 26, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='4. Involving other members may mitigate blame and conflict amongst them. For example, \\nfamily members often hold each other responsible for ineffective or punitive or \\nexcessively liberal disciplining, and hence, the child’s ‘misbehaviors’.   \\n \\n \\nTable 10: Components of psycho-education \\n1. Take feedback about their understanding about the symptoms/diagnosis and \\nexpectation from treatment \\n2. Information about prevalence: ADHD is seen world-wide with global estimates of 5%', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 26, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='-7% in school aged children. Higher prevalence rate in clinic population \\n3. Possible etiological factors:  \\na. ADHD is a neuro-developmental disorder; i.e. a state arising out of problems \\nin development of the brain. \\nb. Like many other psychiatric and developmental problems, the problems are \\nat the level of neuro-chemicals and neural connections between different \\nregions of the brain.  \\nc. Genetic and environmental factors (such as low birth weight and pre-', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 26, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='maturity) are associated with ADHD. \\nd. Symptoms are neither child’s fault nor parents’ fault. \\n4. Discuss how parental factors can contribute in manifestation of symptoms, \\ncontinuation, and influence the course of the disorder  \\n5. Symptoms of the disorder: The core symptoms are inattention (difficulty in sustained \\nattention), hyperactivity (problem of too much behavior) and impulsivity (problem of \\nacting without thinking or controlling impulses), with a likely central problem in self-', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 27, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='control (behavior) or response inhibition). Core symptoms must be described with \\nexamples. \\n6. Symptoms are usually present since early childhood; manifestations may change \\nover time with age. \\n7. Symptoms cause impairments in different domains of functioning; may increase \\nprobability of high risk behaviors and substance use. \\n8. Co-morbid developmental, psychiatric and physical disorders may be present. \\n9. Long term course is variable; ADHD may be a life-long disorder in a significant', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 27, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='proportion of individuals \\n10. Long term outcomes including risk of substance use are known to improve with \\ntreatment; while co-morbid disorders, drug or alcohol use in family, other \\npsychological or socio-environmental risk factors may lead to worse outcomes.  \\n11. No specific investigations needed to diagnose; ADHD is a clinical diagnosis. \\n12. Treatment consists of medications and non-medication interventions including \\nbehaviour training programs.', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 27, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='13. Discuss evidence for, and benefits and risks of each modality of treatment (For e.g. \\nbenefits of drug on the core symptoms of ADHD, along with side effects of the \\nmedication may be explained; benefits of parent training programs but the risk of \\nineffective implementation due to factors such as parental psychopathology and \\npreferences that may lead to unresponsiveness may be explained). \\n14. If a child has co-morbid disorder, include discussion on how it may affect the course', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 27, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='and treatment choices in that child. \\n  \\nTable 11: Modalities of intervention for ADHD \\nPSYCHO-SOCIAL INTERVENTIONS \\nA. Environmental modifications \\nB. Parent training intervention \\nC. Cognitive behavior therapy \\nD. Cognitive training \\nPHARMACOLOGICAL INTERVENTIONS \\nA. Stimulants \\nB. Non-stimulants \\nOTHER MEASURES', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 27, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='A. Diet and exercise \\nB. Exclusion and Elimination / few food diets \\nC. Omega fatty acid and nutritional supplements \\nD. Neuro-feedback \\n \\nTable 12: Environmental modifications to minimse distraction, improve attention and \\nchannelize energy \\n\\uf0b7 Structured routine \\n\\uf0b7 Structure the physical environment \\n\\uf0b7 Assist the child in learning time management \\n\\uf0b7 Use reminders and planners \\n\\uf0b7 Increase supervision by adults  \\n\\uf0b7 Minimize distraction in the environment while studying', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 28, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='\\uf0b7 Improve attention on the task by using highlighters \\n\\uf0b7 Listening to instrument music: can help in improving attention insome patients  \\n\\uf0b7 Short breaks at regular intervals \\n\\uf0b7 Allow activity during breaks to channelize the excessive energy \\n\\uf0b7 Providing extra time to complete work, decreasing the work load, giving small assignments \\n\\uf0b7 If feasible, informing the teacher through parents about the problem and thier role in the \\nmanagement', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 28, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='management \\n \\nTable 13: Components of PGIMER Manual: ‘Parent training for families of children with \\nattention deficit/ hyperactivity disorder’ \\n1. Psycho-education \\n2. Parenting and communication: 3 Ps (Patience, Persistence, Special Play Time) and \\n4Cs of communication (Clear, specific and short instructions, Consistency between \\nwhat is said and done, across adults, over time and in different situations); Catch \\nthem good and Cut down critical comments)', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 28, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='3. Dealing with Inattention – disorganisation through structure and routines \\na. Helping him to make sense of time: Structuring the day \\nb. Helping in organising: Structure the physical environment (Home and \\nroom) \\nc. Helping in organising: Use of visual cues and prompts \\nd. Preparing in advance for daily routines \\ne. Helping in sustaining attention: Decrease off task distractibility, \\nincrease on task stimulation \\nf. Helping in sustaining attention: External motivators; and immediate', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 28, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='and powerful rewards \\n4. Attention enhancing tasks \\n5. Managing hyperactivity through environmental modifications', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 28, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='6. Home point (token economy) system (setting the rules) \\n7. Home point system (to reinforce desirable behaviours) \\n8. Home point system (Response cost/ penalty) and time outs \\n9. Anticipating and preparing in advance \\n10. Liaising with the School; Teacher-parent note \\n \\n \\nTable 14: Medications available in India for management of ADHD \\n \\nFormulation \\nStarting doses \\nMaximum \\nrecommended dose \\nSTIMULANTS \\nMethylphenidate \\nImmediate \\nrelease \\n(Duration of action: 1-4 \\nhours) \\nTablets,10 mg', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 29, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Tablets,10 mg \\n5mg once or b.i.d \\nMax. 60 mg \\nMethylphenidate \\nIntermediate \\nrelease \\n(Duration of action: 6-8 \\nhours \\nTablets, 10 mg, 18mg, \\n20 mg \\n10mg q.a.m. \\nMax 60 mg \\nMethylphenidate \\nLong \\nacting (OROS) (Duration \\nof action: 12 hours) \\nTablets, 18 mg, 36 mg, \\n54 mg \\n18 mg q.a.m. \\n72 mg \\nNON-STIMULANTS \\nAtomoxetine \\nTablet, capsule, 10mg, \\n18 mg, 25 mg, 40 mg \\n<70 \\nkg; \\n0.5 \\nmg/kg/day \\n>70 Kg; 40 mg/day \\nLesser \\nof \\n1.2 \\nmg/kg/day or 80 mg \\nClonidine \\nTablet 0.1 mg \\n< 45 kg, 0.05 mg', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 29, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='< 45 kg, 0.05 mg \\nq.h.s., titrate in \\n0.05 \\nmg \\nincrements b.i.d., \\nt.i.d., q.i.d \\n>45 kg 0.1 mg \\nq.h.s., titrate in 0.1 \\nmg \\nincrements \\nb.i.d., t.i.d., q.i.d \\n27-40.5 kg; 0.2 mg, \\n40.5-45 kg; 0.3 kg; \\n>45kg; 0.4 mg \\n \\n \\nTable 15: Side effects with medications and their management \\n \\nCommonly seen with  \\nMonitoring \\nInitial management \\nManagement if side effects \\npersist despite initial', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 29, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='management \\nAppetite \\nsuppression \\nMethylphenidate \\nAtomoxetine \\nWeight \\nevery visit \\nduring \\ntitration and \\nonce every 3 \\nmonths \\nthereafter;  \\nheight every \\n3-6 months \\n\\uf0b7 \\nDifferentiate \\nbetween pre-\\ntreatment eating \\nproblems from \\nmedication induced \\n\\uf0b7 \\nMedication should \\nbe taken either with \\nor after meals and \\nnot before meals \\n\\uf0b7 \\nBreakfast and late \\nevening meal should \\nbe high on calories \\nand nutrition \\n\\uf0b7 \\nDose reduction \\n\\uf0b7 \\nDiscontinuing \\nmedication on \\nweekends to prevent', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 30, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='weight loss \\n\\uf0b7 \\nChanging to another \\nclass of medication \\n \\nGrowth \\nretardation \\nMethylphenidate \\nPossibly with \\natomoxetine \\nSame as \\nabove \\n\\uf0b7 \\nIf the trajectory of \\ngrowth is \\nsuppressed and the \\nchild lags behind \\npeers significantly \\n(on for age charts) \\non weight or height, \\nrisk-benefit ratio \\nshould be weighed. \\n\\uf0b7 \\nDosage reduction \\n\\uf0b7 \\nInstitute weekend \\nand longer drug \\nholidays for catch up \\ngrowth \\n\\uf0b7 \\n Changing the class \\nof medication \\n\\uf0b7 \\nStop the drug  \\n\\uf0b7 \\nIf growth suppression', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 30, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='persists or growth \\nparameters are below \\nthe critical thresholds \\neven after stopping the \\ndrug (roughly below \\nthe third percentile \\nand growth velocity \\nfalling 2 centile lines \\nover 1 year), refer to a \\npediatric \\nendocrinologist \\nTachycardia \\nand rise in \\nblood pressure \\nMethylphenidate \\nAtomoxetine \\nMeasure \\nheart rate \\nand blood \\npressure \\nevery visit \\nduring \\ntitration, \\nand once \\nevery 3 \\nmonths \\n\\uf0b7 \\nIf there is sustained \\ntachycardia of more \\nthan 120 beats per \\nminute or systolic', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 30, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='minute or systolic \\nblood pressure or \\ndiastolic blood \\npressure more than \\n95th percentile \\nmeasured on 2 \\noccasions, reduce \\nthe dose and refer \\nto a cardiologist. \\n \\n\\uf0b7 \\nECG and \\nechocardiography may \\nbe needed to assess \\nfor arterial \\nhypertension and \\nruling out secondary \\ncauses of the same. If \\nthe BP > 95th \\npercentile even after \\ninstitution of \\ntreatment for \\nhypertension, then \\nstop  the medication \\nOrthostatic \\nhypotension  \\n(Fall in systolic \\nblood pressure \\nof at least 20', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 30, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='of at least 20 \\nmm HG or in \\ndiastolic blood \\npressure of 10 \\nmm Hg within 3 \\nminutes of \\nstanding) \\nClonidine  \\nSame as \\nabove. \\nMeasure \\nblood \\npressure for \\northostatic \\nfall \\n\\uf0b7 \\nGeneral measures to \\nprevent fall  \\n\\uf0b7 \\nDose reduction \\n\\uf0b7 \\nDivide the doses \\nwith frequent \\nmonitoring \\n \\n\\uf0b7 \\nChange of medication \\n\\uf0b7 \\nStop the medication \\nInsomnia \\nMethylphenidate \\nSleep onset, \\n\\uf0b7 \\nDifferentiate \\n\\uf0b7 \\nAdd low dose clonidine', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 30, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='duration and \\nquality \\nbetween pre-\\nexisting sleep \\nproblems and post-\\nmedication. \\n\\uf0b7 \\nSleep hygiene \\nmeasures  and \\nhealthy bedtime \\nroutines \\n\\uf0b7 \\nTake stimulant \\nmedications prior to \\n3.00 pm \\n\\uf0b7 \\nReduce dose, \\nespecially evening \\ndose of stimulant \\nor melatonin at night \\n\\uf0b7 \\nChange medication \\n \\nSedation  \\nClonidine  \\nSleep onset, \\nduration and \\nquality; \\ndaytime \\nsedation \\n\\uf0b7 \\nShift higher dose to \\nnight time  \\n\\uf0b7 \\nReduce dose \\nStop or change medication \\nTics (New \\nonset) \\nMethylphenidate', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 31, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Methylphenidate \\nMontior for \\ntics \\n\\uf0b7 \\nFirst consider if tics \\nare related to the \\nmedication or not; \\nbecause tics \\nnaturally wax and \\nwane and may be \\ncoincidental; if \\npossible observe for \\na prolonged period, \\ne.g. 3 months \\n\\uf0b7 \\nWeigh the risk-\\nbenefits,    \\nimpairment due to \\ntics vis-a-vis \\nimpairment due to \\nADHD symptoms \\nand discuss same \\nwith child and \\nparents \\n\\uf0b7 \\nDose reduction  \\n\\uf0b7 \\nPlanned \\ndiscontinuation of \\nstimulant \\n\\uf0b7 \\nChange to \\natomoxetine or \\nclonidine', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 31, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='clonidine \\nIf tics persist, start \\nclonidine or low dose \\nantipsychotic \\nMania/Psychosi\\ns  \\nMethylphenidate \\nMonitor for \\nside effects \\n\\uf0b7 \\nStop the medication  \\n \\n\\uf0b7 \\nIf symptoms persist, \\ntreat psychosis/ mania. \\n\\uf0b7 \\nAfter symptom \\nresolution, start \\nanother ADHD \\nmedication if there is \\nneed for \\npharmacological \\ntreatment  \\n\\uf0b7 \\nStimulants may be best \\navoided, especially if', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 31, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Footnote: If a medication is stopped due to side effects, monitor ADHD symptoms and the side effects; review \\nagain the need for medication for ADHD; and if there is need, then start with a medication from a different class \\n \\nTable 16: Factors determining the steps in management of ADHD \\nAge of the child \\nSeverity of ADHD (consider symptoms and impairments in various domains) \\nCo-morbidities and contra-indications  \\nSide effect profile and tolerability \\nCurrent needs of child and family', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 32, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Preferences of child and family \\nthe episode was \\nstimulant induced. \\nSeizures (New \\nonset) \\nMethylphenidate \\nSame as \\nabove \\n\\uf0b7 \\nStop the medication \\n\\uf0b7 \\nNeurologist referral \\nand assessment for \\ncause of seizure \\n\\uf0b7 \\nIf the drug seems to \\nbe innocuous it may \\nbe gradually re-\\nintroduced with \\ncontinued \\nmonitoring. \\n\\uf0b7 \\nIf seizures appear to \\nbe drug induced, \\nstart another \\nmedication after \\nreviewing the need \\nfor medication \\n \\nSuicidal \\nbehaviour \\nAtomoxetine \\nAsk patients \\nabout \\nsuicidal or', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 32, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='about \\nsuicidal or \\naggressive \\nideas or \\nimpulses \\n\\uf0b7 \\nStop the medication \\n\\uf0b7 \\nHigh risk \\nmanagement  \\n\\uf0b7 \\nNew onset \\nsymptoms must be \\nclosely monitored – \\npatient may need \\nadmission \\n\\uf0b7 \\nADHD medication \\nfrom a different \\nclass may be \\nstarted; do not start \\natomoxetine \\n \\nMood lability \\nand aggression \\nAtomoxetine \\nSame as \\nabove \\nSame as above \\n \\nHepatotoxicity \\n(If suspected \\neither clinically \\nor on \\ninvestigations) \\nAtomoxetine \\nMonitor \\nliver \\nenzymes  \\n\\uf0b7 \\nStop medication \\n\\uf0b7', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 32, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Stop medication \\n\\uf0b7 \\nMedical referral and \\nmanagement  \\n\\uf0b7 \\nADHD medication \\nfrom a different \\nclass may be \\nstarted; do not start \\natomoxetine', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 32, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Availability \\nAffordability \\n \\nTable 17: Factors related to inadequate response to pharmacological or non-pharmacological \\ninterventions \\nPoor adherence  \\nSub-optimal dosing \\nCo-morbidities (for example, conduct disorder) \\nMismatch between needs and target goals of treatment \\nMis-diagnosis', metadata={'source': 'dataSet\\\\ADHD.pdf', 'file_path': 'dataSet\\\\ADHD.pdf', 'page': 33, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='DSM-5 Diagnostic Criteria for ADHD \\n \\nSymptoms and/or behaviors that have persisted ≥ 6 months in ≥ 2 settings (e.g., school, home, \\nchurch). Symptoms have negatively impacted academic, social, and/or occupational functioning. In \\npatients aged < 17 years, ≥ 6 symptoms are necessary; in those aged ≥ 17 years, ≥ 5 symptoms are \\nnecessary. \\nInattentive  \\nType  \\nDiagnosis  \\nCriteria \\n• \\nDisplays poor listening skills \\n• \\nLoses and/or misplaces items needed to complete activities or tasks \\n•', metadata={'source': 'dataSet\\\\adhd19-assessment-table1.pdf', 'file_path': 'dataSet\\\\adhd19-assessment-table1.pdf', 'page': 0, 'total_pages': 1, 'format': 'PDF 1.6', 'title': 'DSM-5 Diagnostic Criteria for ADHD', 'author': 'American Academy of Family Physicians', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 19 for Word', 'producer': 'Adobe PDF Library 19.12.68', 'creationDate': \"D:20190916121323-05'00'\", 'modDate': \"D:20191001132907-05'00'\", 'trapped': ''}),\n",
       " Document(page_content='• \\nSidetracked by external or unimportant stimuli \\n• \\nForgets daily activities \\n• \\nDiminished attention span \\n• \\nLacks ability to complete schoolwork and other assignments or to follow \\ninstructions \\n• \\nAvoids or is disinclined to begin homework or activities requiring concentration \\n• \\nFails to focus on details and/or makes thoughtless mistakes in schoolwork or \\nassignments \\nHyperactive/ \\nImpulsive  \\nType \\nDiagnosis \\nCriteria \\nHyperactive Symptoms: \\n•', metadata={'source': 'dataSet\\\\adhd19-assessment-table1.pdf', 'file_path': 'dataSet\\\\adhd19-assessment-table1.pdf', 'page': 0, 'total_pages': 1, 'format': 'PDF 1.6', 'title': 'DSM-5 Diagnostic Criteria for ADHD', 'author': 'American Academy of Family Physicians', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 19 for Word', 'producer': 'Adobe PDF Library 19.12.68', 'creationDate': \"D:20190916121323-05'00'\", 'modDate': \"D:20191001132907-05'00'\", 'trapped': ''}),\n",
       " Document(page_content='• \\nSquirms when seated or fidgets with feet/hands \\n• \\nMarked restlessness that is difficult to control \\n• \\nAppears to be driven by “a motor” or is often “on the go” \\n• \\nLacks ability to play and engage in leisure activities in a quiet manner \\n• \\nIncapable of staying seated in class \\n• \\nOverly talkative \\nImpulsive Symptoms: \\n• \\nDifficulty waiting turn \\n• \\nInterrupts or intrudes into conversations and activities of others \\n• \\nImpulsively blurts out answers before questions completed \\nAdditional', metadata={'source': 'dataSet\\\\adhd19-assessment-table1.pdf', 'file_path': 'dataSet\\\\adhd19-assessment-table1.pdf', 'page': 0, 'total_pages': 1, 'format': 'PDF 1.6', 'title': 'DSM-5 Diagnostic Criteria for ADHD', 'author': 'American Academy of Family Physicians', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 19 for Word', 'producer': 'Adobe PDF Library 19.12.68', 'creationDate': \"D:20190916121323-05'00'\", 'modDate': \"D:20191001132907-05'00'\", 'trapped': ''}),\n",
       " Document(page_content='Additional \\nRequirements  \\nfor Diagnosis \\n• \\nSymptoms present prior to age 12 years \\n• \\nSymptoms not better accounted for by a different psychiatric disorder (e.g., mood \\ndisorder, anxiety disorder) and do not occur exclusively during a psychotic disorder \\n(e.g., schizophrenia) \\n• \\nSymptoms not exclusively a manifestation of oppositional behavior \\nClassification \\nCombined Type: \\n• \\nPatient meets both inattentive and hyperactive/impulsive criteria for the past 6 \\nmonths', metadata={'source': 'dataSet\\\\adhd19-assessment-table1.pdf', 'file_path': 'dataSet\\\\adhd19-assessment-table1.pdf', 'page': 0, 'total_pages': 1, 'format': 'PDF 1.6', 'title': 'DSM-5 Diagnostic Criteria for ADHD', 'author': 'American Academy of Family Physicians', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 19 for Word', 'producer': 'Adobe PDF Library 19.12.68', 'creationDate': \"D:20190916121323-05'00'\", 'modDate': \"D:20191001132907-05'00'\", 'trapped': ''}),\n",
       " Document(page_content='months \\nPredominantly Inattentive Type: \\n• \\nPatient meets inattentive criterion, but not hyperactive/impulse criterion, for the \\npast 6 months \\nPredominantly Hyperactive/Impulsive Type: \\n• \\nPatient meets hyperactive/impulse criterion, but not inattentive criterion, for the \\npast 6 months \\n \\nSymptoms may be classified as mild, moderate, or severe based on symptom severity \\nSource: DSM-5 Diagnostic and Statistical Manual of Mental Disorders, 5th edition; ADHD: attention deficit', metadata={'source': 'dataSet\\\\adhd19-assessment-table1.pdf', 'file_path': 'dataSet\\\\adhd19-assessment-table1.pdf', 'page': 0, 'total_pages': 1, 'format': 'PDF 1.6', 'title': 'DSM-5 Diagnostic Criteria for ADHD', 'author': 'American Academy of Family Physicians', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 19 for Word', 'producer': 'Adobe PDF Library 19.12.68', 'creationDate': \"D:20190916121323-05'00'\", 'modDate': \"D:20191001132907-05'00'\", 'trapped': ''}),\n",
       " Document(page_content='hyperactivity disorder', metadata={'source': 'dataSet\\\\adhd19-assessment-table1.pdf', 'file_path': 'dataSet\\\\adhd19-assessment-table1.pdf', 'page': 0, 'total_pages': 1, 'format': 'PDF 1.6', 'title': 'DSM-5 Diagnostic Criteria for ADHD', 'author': 'American Academy of Family Physicians', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 19 for Word', 'producer': 'Adobe PDF Library 19.12.68', 'creationDate': \"D:20190916121323-05'00'\", 'modDate': \"D:20191001132907-05'00'\", 'trapped': ''}),\n",
       " Document(page_content='CLINICAL PRACTICE GUIDELINES FOR ASSESSMENT AND MANAGEMENT OF ATTENTION-\\nDEFICIT/ HYPERACTIVITY DISORDER \\n \\nAuthors: Ruchita Shah, Sandeep Grover, Ajit Avasthi \\nDepartment of Psychiatry, Postgraduate Institute of Medical Education and Research, \\nChandigarh, India \\nCorrespondence: drruchitashah@gmail.com  \\n \\nINTRODUCTION \\nAttention-deficit/ hyperactivity disorder (ADHD) is one of the most common childhood \\npsychiatric disorders. ADHD affects around 5%- 7% of school-aged children. It is a neuro-', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 0, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='developmental disorder that runs a chronic course and causes significant impairments across \\nvarious domains of everyday functioning, such as peer and social functioning, academic and \\noccupational functioning across the lifespan. Besides the patient, ADHD also has significant \\nnegative impact on the caregivers. This Guideline seeks to lay out guidelines for effective and \\ncomprehensive assessment, diagnosis and management of ADHD. It attempts to update the', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 0, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='previous guidelines taking into account current state of evidence that can inform clinical \\npractice. These guidelines ought to be read in conjunction with the earlier version of the \\ntreatment guidelines on ADHD as developed and published by the Indian Psychiatric Society in \\nthe year 2007. \\nSCOPE OF THIS DOCUMENT \\nThis Guideline provides a frame work for diagnosis and management of ADHD in children and', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 0, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='adolescents aged upto 18 years. In this document, the terms ‘child’ and ‘children’ represent all \\nindividuals below 18 years of age, unless specified otherwise. The term ‘adolescent’ represents \\nindividuals between 13 to 18 years of age. The term ‘pre-schoolers’ is used to indicate individuals \\nwho are below 6 years of age. These guidelines may not be applicable to adult patients suffering \\nfrom ADHD, as their treatment needs may be different. Finally, it is expected that', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 0, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='recommendations made will have to be tailored to suit the needs of individual patients.   \\nASSESSMENT AND EVALUATION \\nA comprehensive assessment including detailed history, mental state and physical examination is \\nneeded to reach the diagnosis and estimate the severity and impact of the disorder on the \\npatient and caregivers. Co-morbid developmental, psychiatric and medical disorders; and \\npsycho-social or environmental factors such as family discord, parenting and parental substance', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 0, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='abuse that are directly relevant to the management should be assessed as far as possible. Table-\\n1 presents the components of a comprehensive assessment and Table 2 shows the clinical \\nquestions that need to be answered while undertaking the process of assessment. \\nTable 1 here \\nTable 2 here \\nThe assessment of pre-schoolers, children and adolescents for ADHD comprise of clinical \\ninterviews with parents and the patient, as well as obtaining information directly or indirectly', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 0, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='(through parent accounts) from other relevant sources and settings including pre-school, day', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 0, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='care and school. Information from teachers may be obtained by requesting for teacher \\nobservation reports (unstructured) or teacher ratings on a structured rating scale (see section on \\nrating scales). Such requests should be sent through parents after explaining to them the need \\nfor such information, and seeking their and the child’s explicit consent and assent. Parents or the \\nchild may be reluctant to initiate such a communication for several reasons; the most important', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 1, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='being fear of the child being stigmatized. Clinicians must as far as possible explain to the parents \\nthe need of teacher report and how this can aid in assessment, diagnosis and management. If \\nthe child and parents are still reluctant, then the clinicians may satisfy themselves through \\nparent and child accounts of symptoms and functioning in the school setting, and review of \\nschool work and report cards. Further, in Indian context, the clinician may involve other family', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 1, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='members such as grandparents; especially if the child resides in a joint or an extended family. \\nThis will provide additional important information, opportunities to understand methods the \\nfamily uses to handle the problematic behaviors; and expectations and perceptions regarding, \\nand treatment of these behaviours.  \\nIt is important to remember that the histories may vary considerably depending upon the', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 1, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='informants’ own perceptions regarding and tolerance towards such behaviors, their awareness \\nand opportunities for observations. The histories from different sources may complement each \\nother to provide a more complete and realistic picture; hence multi-informant interviews \\nseeking information across various domains of functioning and in various settings is the key. \\nThe process of assessment may require more than one visit.  It is an ongoing process, which as', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 1, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='far as possible must be continued to be based on multi-informant accounts across multiple \\nsettings as for the initial assessment and it should focus on changing needs of the patient and \\nthe family.  \\nThe diagnosis should preferably be based on the diagnostic criteria as per prevailing nosological \\nsystems for the symptoms of inattention, hyperactivity and impulsivity. While establishing the \\ndiagnostic criteria age of onset, persistence and duration of the symptoms must be taken into', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 1, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='account. When symptoms are of relatively recent onset, other psychiatric disorders, such as \\nmood or psychotic disorders that may mimic ADHD must be considered. The symptoms must be \\ndevelopmentally inappropriate; it is suggested that the clinician assess the developmental \\nhistory thoroughly and make a working clinical impression of the mental age of the child or \\nadolescent. When intellectual sub-normality is known or suspected, the rule of thumb is that the', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 1, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='symptoms should be inappropriate for the mental age to consider ADHD. Another related \\nconsideration is that as a child grows symptom manifestations may change. Pre-schoolers with \\nADHD are highly overactive (described as ‘whirlwind’), do not listen to when called, have no \\nsense of danger, and have short play sequences (of less than 3 minutes), and often leave \\nactivities incomplete. As a child reaches primary school, he is found to have difficulty remaining', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 1, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='still or calm in situations where he is expected to remain so; for example, in assembly halls and \\nclassrooms. Inattention is manifested by brief activities of less than 10 minutes, being forgetful, \\ndisorganised and easily distractible. Impulsivity is seen in the form of acting out of turn, \\ninterrupting other children, thoughtless rule breaking, intrusions on peers and getting into \\naccidents. During adolescence, the over-activity presents more as inner restlessness and some', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 1, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='fidgetiness instead of the manifest over-activity seen during pre-school and early childhood \\nyears. Inattention on the other hand, may manifest as difficulties in organising tasks, \\nprocrastinations and frequent missing of deadlines. Impulsivity may manifest as risk taking and \\nsubstance use. Thus, adolescents may present with problems mainly related to inattention and \\nimpulsivity; and a thorough developmental history that traces the symptoms from their onset', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 2, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='during childhood may help clarify the diagnosis. Several symptoms are present in two or more \\nsettings such as at home, school or pre-school, family and friends, etc. It may be borne in mind \\nthat the symptomatic manifestations can vary considerably depending on the context in a given \\nsetting. See Table 3 for factors that can affect symptoms of ADHD. \\nTable 3 here \\nNext, it is important to assess the impairment caused by the symptoms in different domains of', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 2, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='functioning including social and inter-personal, academic or occupational and legal domains. In \\nfact for the diagnosis, it is required that the symptoms should cause impairment in at least one \\ndomain. The clinician must attempt to make an overall impression of the severity of ADHD based \\non the severity and number of symptoms and severity of impairments caused by the symptoms. \\nAdditionally, there may be some associated problems that should not by themselves be used as', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 2, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='an evidence for ADHD, but if present alongside need to be taken into account while planning \\nmanagement. These problems include defiant or non-compliant behaviors, irritability, mood \\nswings, aggression, temper tantrums, sleep difficulties, clumsiness, mild delays in speech and \\nlanguage and substance abuse or high risk behaviors. \\nThe clinician must as far as possible also assess for the potential effects that ADHD symptoms', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 2, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='can have on development. Such effects are seen in cognitive development and academic \\nachievements (for example, chronic inattentiveness leads to years of inadequate learning and \\nhence, affects adversely further learning), social development (children with ADHD may be \\ninattentive to social cues, are impulsive during their interactions with peers and occasionally \\nhave lesser opportunities needed for peer interactions due to peer rejection; these all lead to', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 2, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='inadequate social development, manifesting as social immaturity), development of self-esteem \\nand self-identity (peer rejection, rejection by adults, constant criticism may all affect the \\ndevelopment of self-esteem and identity; though many of these children may appear \\nboisterous). \\nDifferential diagnosis and co-morbidities \\nIt is important to note that the same disorder may be a differential diagnosis or may even be a', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 2, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='co-morbid disorder.  See Table 4 for co-morbidites seen with ADHD. Table 5 presents clinical \\npoints to differentiate ADHD from other developmental and psychiatric disorders. The clinician \\nmust as far as possible enquire into developmental and, current and past psychiatric history. \\nTable 4 here \\nTable 5 here \\nIn case of pre-schoolers, clinicians must also bear in mind that the so-called symptoms may be', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 2, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='developmentally normal or may represent the temperamental characteristics of the child. In the \\nlatter case, the clinician should refrain from diagnosing ADHD, but offer parent training for \\nmanaging difficult behaviors (See section on management; formulating treatment plan for pre-', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 2, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='schoolers). Substance use history should be enquired into, especially while assessing older \\nchildren and adolescents. This history may be taken from the adolescent by ensuring privacy \\n(Also see section on mental state examination). \\nIt is suggested that the clinician be aware of the problem of diagnostic overshadowing, i.e. \\nsymptoms of another disorder are mistakenly subsumed as manifestations of the primary', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 3, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='disorder. For example, in a child with hyperactivity and impulsivity with mild intellectual \\ndisability, the symptoms are considered to be due to the latter though they are clearly \\ndevelopmentally inappropriate. The clinicians must also recognize the problem of over-diagnosis \\nin presence of other disorders. For example, a child with autism spectrum disorder (ASD) is \\ndiagnosed with ADHD, when the symptoms of inattention and hyperactivity are mainly related to', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 3, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='social communication and sensory issues of ASD. Detailed and focused clinical interviewing and \\ncollecting information across various situations and domains will help the clinician in such \\ncircumstances. \\nTable 6 presents the key clinical points to guide the process of establishing the diagnosis. \\nTable 6 here \\nMedical history \\nRarely medical disorders may present with behaviors resembling ADHD. Such ADHD like', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 3, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='problems may be secondary to head injury, wherein inattention is prominent, thyroid disorders \\nand absence seizures. Rarely ADHD like symptoms may be present in genetic syndromes such as \\nFragile X or may be secondary to certain medications such as bronchodilators, thyroxine, \\nneuroleptics (causing akathisia) and isoniazid. Epilepsy may be co-morbid especially in children \\nwith co-morbid neuro-developmental disorders such as intellectual disability. The clinician must', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 3, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='also take specific medical history before prescribing any drug. This should include history of \\nsyncope or fainting episodes, exercise intolerance, congenital cardiac malformations or any \\ncardiac surgery. \\nMental state examination \\nMental state examination of a pre-schooler or a young child may be carried out concurrently \\nwith parent interview. It is important that the clinicians equip themselves with age appropriate', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 3, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='play and work materials that would help in building rapport as well as engaging the child in an \\nage appropriate activity. During such observations and interactions, it is suggested clinicians \\nattempt to gauge the general intellectual capacity of the child, language development and verbal \\nand non-verbal communication. The clinician may or may not find evidence of over-activity, \\nimpulsivity and inattention during the time of interview as children may perform better when', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 3, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='they find tasks interesting or the situation is structured with one-to-one adult interaction as in \\nthe clinic. This should not be taken as evidence of absence of ADHD. Also, younger children \\nmight not be aware of their problems. Clinicians therefore, should not rely solely on their \\nobservations and interview with younger children for diagnosing ADHD. Rather, clinicians may \\nuse this opportunity to observe for co-existing disorders including intellectual sub-normality, as', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 3, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='well as to observe child-parent interactions. It may reveal over-protective, hostile and critical \\nparent-child interactions, and parents’ styles of responding to defiance.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 3, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='It is desirable that older children and adolescents also be interviewed separately from their \\nparents; this acknowledges their need for autonomy and confidentiality. Adolescents may down \\nplay their problems and its impact on their functioning. So, clinician need not focus on ADHD \\nsymptoms, but may rather interview the child/ adolescent regarding depressive symptoms and \\nsuicidal ideation, peer relations and bullying. Mental state examination should include a formal', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 4, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='assessment of form and content of thought, presence of delusions, hallucinations, depressive \\ncognitions, worries, ruminations and obsessive symptoms as far as possible. There may be \\nevidence of low self esteem despite apparent boisterousness. Substance use history should be \\nelicited and history related to other high risk behaviors may be elicited if overall history is \\nindicative of the same. However, such assessments should preferably not be done before a', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 4, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='working therapeutic relation has been established with the adolescent or child. \\nRating scales \\nRating scales and screening instruments may assist in the diagnostic process, but these are \\nneither necessary nor can these replace a good clinical assessment. These include Conner’s \\nparent and teacher rating scales; Vanderbilt parent and teacher rating scales and ADHD rating \\nscale – fourth edition. These can be helpful in acquiring structured information from other', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 4, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='sources such as teachers. Besides, the rating scales may assist in monitoring treatment response. \\nThe scales may over or under diagnose ADHD when co-morbid intellectual disability or ASD is \\npresent. Most of the rating scales are expensive and do not have Indian norms, hence, it might \\nbe difficult to use these in routine clinical practice. However, more generic instruments such as \\nStrengths and Difficulties Questionnaire and Achenbach’s Child Behavior Checklist may be more', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 4, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='easily accessible. The clinical global impression (CGI) scales and children’s global assessment of \\nfunctioning scale (CGAS) may be used for baseline assessments and further monitoring. \\nPsychological testing \\nRoutine psychological testing is not indicated. If intellectual disability is suspected, IQ testing \\nmay be conducted. However, in case of severe symptoms, the scores may be erroneously low, \\nand hence, test must be repeated after adequate symptom control. Similarly if specific learning', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 4, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='disorder is suspected, the psychological assessment for the same should be carried out after \\nadequate control of ADHD symptom. Play room observation may be assistive when carried out \\nby an experienced clinician. However, it is neither mandatory nor replaces a thorough clinical \\nevaluation. Similarly, neuro-psychological tests such as continuous performance tests are not \\nindicated in routine clinical practice.  \\nPhysical investigations', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 4, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='No specific physical investigations are needed or indicated to diagnose ADHD. Neuro-imaging (CT \\nscan, MRI, PET and SPECT scans) and EEG should not be carried out without any specific clinical \\nindication. In cases where lead toxicity is suspected, i.e. when history reveals exposure to lead \\nplumbing or high lead levels in the environment, lead levels should be checked. Thyroid profile \\nshould be tested only when clinical features are suggestive of a thyroid disorder.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 4, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='FORMULATING A TREATMENT PLAN \\nFor a comprehensive treatment plan, factors that need to be taken into account are age and \\ndevelopmental stage of the child, severity of symptoms, domains of functioning affected, how \\nsymptoms affect or may affect everyday life, co-morbid developmental, psychiatric and medical \\ndisorders, psycho-social risk factors and protective factors, and goals and resources or assets \\nwithin the child and family. The plan must address as far as possible the child’s current', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 5, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='psychological, behavioral and educational needs. It is suggested that needs assessment be an \\nongoing process as needs may change over time. Regular discussions with the children and their \\nfamily must be carried out to the extent possible regarding the same. Table-7 presents the \\nguiding principles for a comprehensive treatment plan. \\nTable 7 here \\nBefore starting any treatment for ADHD, it is important to build a working therapeutic alliance', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 5, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='with the child and family, take their accounts of perceptions and preferences regarding \\ntreatment and offer them information regarding diagnosis and treatment. \\nTherapeutic alliance \\nThe first step towards management is building a good therapeutic alliance with the child or \\nadolescent and the family. Positive regard for the family’s perceptions and concerns is needed. \\nParents’ perceptions regarding diagnosis and treatment may be influenced by other family', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 5, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='members, friends, teachers, media and other physicians; and may differ from the clinician’s \\nopinion. These perceptions may influence treatment preferences as well as adherence to \\ntreatment. For example, parents who consider the behaviors diagnosed as ADHD to be ‘normal \\nnaughty behavior’ or due to the child ‘being lazy’ may request for only ‘counseling’ to the child \\nand may not consider medication or parent training as necessary. Family’s concerns regarding', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 5, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='side effects, and weighing of risk-benefit may not match with that of the clinician’s. Inadequate \\nadherence on the prescribed treatment may occur due to any of these reasons, leading to non-\\nresponse and potentially a breach in alliance and treatment drop-out. Parental expectations \\nfrom treatment also vary. For example, parents of children with ADHD and co-morbid conduct \\ndisorder may expect complete resolution of all the symptoms with a medication and may find', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 5, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='the treatment ineffective when such expectations are not realized, again leading to treatment \\ndrop-out. The clinician may take into account that the needs identified by the parents and the \\npatient may be often different. For example, the parents may be more concerned about \\nacademic performance, while the child may not identify this as an area of concern. Hence, the \\nclinician must as far as possible make an effort to establish alliance with both the child, and his', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 5, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='parents, and take into account their perceptions, preferences and expectations. Parents have \\noften been blamed by family, friends or teachers for their child’s behaviors or difficulties. They \\nare often emotionally drained and experience burn-out by the time the child is brought to the \\nclinic. The clinician must not blame the parents, must validate their positive and negative \\nexperiences with the school, extended family and professional agencies including doctors and', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 5, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='offer support. A good therapeutic alliance coupled with psycho-education will help the child and \\nparents take informed treatment decisions. Factors which can enhance therapeutic alliance are \\nshown in Table-8.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 5, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Table 8 here \\nCommunication of diagnosis \\nBefore communicating the diagnosis, the clinician may as a minimum ask the parents and other \\nsignificant family members about their perceptions regarding the causation of the problem \\nbehaviours. The clinician may present the diagnosis as a ‘brain disorder’ or a ‘neuro-\\ndevelopmental disorder’ with both genetic and environmental influences. The clinician may also', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 6, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='briefly present the psycho-social factors that can potentially influence the course and outcome \\nof the disorder (e.g. highly inconsistent parenting, severe family discord). Further, the clinician \\nmust as far as possible address guilt and blame amongst the parents, and address the \\nmisconceptions regarding ADHD. It may be followed by detailed psycho-education. Also, the \\nclinician must communicate any co-morbid diagnosis, if present. This is essential as treatment', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 6, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='considerations and overall course and prognosis may vary depending upon such co-morbidities. \\nIt is not uncommon in clinical practice, for parents to feel stigmatized that their child has been \\ngiven a diagnostic label, and these parents and patients are often apprehensive of and reluctant \\nto liaise with the school, fearing that the child will be labeled by the teachers. Such anticipations \\nare often true in the child’s given circumstances. The clinician must acknowledge the same while', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 6, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='communicating the diagnosis and educating the child and parents. The clinician must preferably \\nnot communicate the diagnosis to the school without the consent of the patient and parents, \\neven if the child was referred to the clinic by the school.  \\nPsycho-education \\nPsycho-education may be carried out over 2-3 sessions, and should as far as possible be tailored \\nfor a given child and the family. The clinician may involve any other significant family members', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 6, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='during these sessions or may conduct psycho-education later with them as and when such need \\nis identified. Table 9 presents the rationale for involving extended family members in our \\ncontext. \\nTable 9 here \\nPsycho-education may begin by asking the patient and his family regarding their own \\nunderstanding of symptoms, their causation and their beliefs regarding treatments. Psycho-\\neducation may cover detailed description of core symptoms of hyperactivity/ impulsivity; and', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 6, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='inattention and organizational difficulties, including difficulties keeping track of time, poor \\nplanning and time management, associated genetic and environmental factors such as pre or \\nperinatal factors, misconceptions regarding ADHD, including that the symptoms are merely due \\nto child’s laziness or lack of motivation and available treatment modalities; both pharmacological \\nand non-pharmacological with  benefits and risks of each modality. The basic components that', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 6, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='may be covered in psychoeducation sessions are given in table-10. \\nTable 10 here \\nTREATMENT OPTIONS FOR MANAGEMENT OF ADHD \\nAs with other psychiatric disorders, the treatment options are broadly categorized as non-\\npharmacological measures, pharmacological interventions and other treatments. See table-11.  \\nTable 11 here', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 6, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='PSYCHO-SOCIAL INTERVENTIONS \\nDespite the evidence for short term eficacy of medications, treatment with medications has \\nsome limitations; partial or no response in a proportion of cases, side effects, not well proven \\nlong term efficacy and cost effectiveness, poor adherence and negative perceptions of family \\nand professionals towards medications. Non-pharmacological interventions, on the other hand, \\nif implemented properly and adherently may produce benefits in symptoms as well as', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 7, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='functioning in different domains. \\nEnvironmental modifications \\nEnvironmental modifications include changes made in the environment in one or preferably \\nmore settings to either decrease the symptom manifestations or importantly, to decrease the \\nimpact of the symptoms. Such modifications should help enhance the performance and \\nfunctioning of the child. \\nSuch modifications include introducing structure and routine in the child’s life. The daily routines', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 7, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='such as those related to getting up and getting ready for school, on returning from school, \\nmealtimes and bedtime must be made regular and predictable. The child must be informed in \\nadvance of any change in the schedule as well as given reminders during transition. The physical \\nenvironment must also be structured with ‘a place for everything’. Allot a fixed place for almost \\neverything in the house, and particularly for belongings of the patient.Use of verbal prompts and', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 7, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='visual cues may be necessary for effective implementation. Parents can help the child in planning \\nand managing theirtime through use of daily and weekly planners; sticking planners in prominent \\nplaces such as in the bedroom or near the study table; labelling ‘places where things go’ (e.g. on \\nbookshelfs) and by giving verbal or visual (or both)reminders 3-5 minutes before a transition in \\nroutine. For example, the parent may say “5 minutes are left for playing your game”, or “after 5', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 7, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='minutes we will start with Maths”. Classrooms are ordinarily more structured as compared to \\nhome, and the routines are better defined. The teachers can use visual and verbal reminders; \\nand praise to re-inforce the same. \\nAdult supervision may help the child, especially when on boring or mentally demanding tasks \\nsuch as homework. The parent or teacher may give a simple reminder to the child when he goes', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 7, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='off task. Such reminder may be verbal or physical or both; for e.g., a tap on the shoulder and \\ntelling him, “Read the fifth question” or asking him, “so, where were we?” \\nWhile studying, minimise distractions around; for e.g. make the child sit away from traffic, away \\nfrom the TV room. The study table may be in the corner of the room, away from the windows \\nand doors (preferably child’s back facing the door), with only the books, which the child is', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 7, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='suppose to read at that time with no other distraction on the table, with no distraction on the \\nwalls which are being faced by the child and no other child in the room to distract the child. The \\nhouse should be as quiet as possible. The parent/supervisor should preferably sit with the child. \\nPresence of toys and other screen media around should be avioded.Parents may increase \\nstimulation of the material related to task to improve attention through use of highlighters, i.e.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 7, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='use colours to highlight important points. If listening to any genre of instrumental music helps \\nthe child improve his on-task attention, it may be tried.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 7, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Children may be provided with break times in middle of lengthy or boring tasks. The break may \\nbe of around 5 minutes after every 15-20 minutes of being on-task or lesser in younger children \\nor when the adult senses increase in fidgetiness. The parent may request the child to carry out a \\nhousehold chore like fetching water or shovelling or any task that helps the child use his physical \\nenergy. In school, the teacher may ask the child to distribute copies or fetching something from', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 8, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='the other classroom.Children may also be allowed to stand and work, if that helps them to \\nremain on-task. The child must be given adequate opportunities to channelise theirexcessive \\nenergy, for example, by participating in physical sports such as cycling, running, swimming or \\nfootball. \\nFor some children, extra time to complete work, decreasing work loads (these children take \\nmuch more time in completing their work as compared to peers, not because they do not know,', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 8, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='but because of their problem of inattention), giving smaller assignments focusing on must-knows \\nand use of word processors may help improve their performance and their self esteem. Some \\nschools may be open to use of these strategies. Only the Indian Certificate of Secondary \\nEducation (ICSE) Board allows for some of these accomodations, but these must be \\nrecommended only in conjunction with other treatments and must not be used as a sole \\nmeasure.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 8, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='measure.  \\nIn any case, every attempt should be made after obtaining consent, to liaise with the school. As a \\nminimum, it should be conveyed to the school teachers that ADHD is a valid diagnosis and use of \\ncertain environmentalmodifications and strategies will help the child. Every effort should be \\nmade to enlist their support.See the section on ‘Liasing with the school’ for detailed discussion. \\nTable 12 summarises the environmental modifications that can be instituted at home and \\nschool.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 8, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='school. \\nTable 12 here \\nParent training intervention \\nIndividual or group parent training programs are generally skills based andaim at imparting such \\nskills to parents that they are able to implement behavioral strategies effectively. Parents must \\nbe explicitly told that referral for parent training does not mean that their parenting is faulty; \\nrather the training would help them in learning strategies for particularly difficult and extra-', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 8, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='ordinary situation that they are facing. Other significant members of the family may be involved \\nin such programs, if needed.  \\nThe clinician must remember while dealing with the parents and family, that a parent might \\nhimself or herself have ADHD with its resultant attentional and organisational difficulties and \\nimpulsivity, or may have other psychopathology (e.g. depression) that may hinder the effective', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 8, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='implementation of the strategies. Also, some families may be better suited for individual \\ntraining. The indications for individual parental training include co-morbid conduct problems or \\ndisorder, family psychopathology, intellectual disability in parent, language difficulties or \\ndifficulties in therapeutic engagement due to any reason. \\nMost parent training programs are carried out over 8-10 weekly sessions if indivudal and 10-20', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 8, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='sessions if group training. It must cover psycho-education, environmental modifications, \\neffective communication methods, behavioural management strategies (may include token', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 8, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='economy), anticipating and preparing for unstructured situations, taking care of self and may \\ninclude liaising with teachers.Environmental modifications specific to ADHD have been \\npresented in detail in the earlier section. Effective communication includes effective ways of \\ninstructing (clear, short, long instructions simplified into steps), re-phrasing statements, focusing \\non postives while communicating, decreasing critical comments and establishing consistency', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 9, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='between what is said and what is done (no empty promises or warnings regarding \\nconsequences).The behavioral principles usedare: setting of clear rules, consistency, use of \\nimmediate rewards, followed by use of delayed rewards contigent upon desirable behaviors, \\nwithdrawal of rewards or response cost contigent upon undesriable behaviors; rewards and cost \\nbeing proportionate to the behavior. Consistency should be employed across time (i.e. a parent', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 9, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='being consistent over time across situations) and across individuals (i.e. there must be \\nconsistency between both the parents; and also grandparents if applicable). Above all, parents \\nmust be encouraged to focus on their child’s and their own strengths and inculcate healthy \\nparent-child interactions. Parents must also be encouraged to appreciate their own and the \\nchild’s efforts through regular positive feedback. Feedback should also be sought regularly from', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 9, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='the parents and difficulties faced by them in implementing the strategies must be addressed \\nregularly. Table-13 presents the components of a parent training intervention manualised at \\nPGIMER, Chandigarh. \\nTable-13 here \\nCognitive behavior therapy \\nIn case of older children and adolescents, who have benefited from environmental \\nmodificationsand parent training and/or use of medications, but still have significant', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 9, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='impairments  in specific domains,cognitive behavior therapy may be considered. For example, \\nthere may be problems in peer functioning or social functioning, or problems in academics due \\nto poor time management. For example, the cognitive behavior therapy may focus on enhancing \\nsocial skills in dealing with peers, time management, problem solving, dealing with and \\nexpressing feelings and self-control and anger management. \\nCognitive training', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 9, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Cognitive training \\nCognitive training may improve working memeory, but it is not yet well researched if this \\ntranslates into improved academic functioning. \\nPHARMACOLOGICAL INTERVENTIONS \\nBasic considerations \\nThe treatment should as far as possible be tailored to the individual needs based on current level \\nof symptom severity and impairment, and improvements, if any gained by the non-\\npharmacological measures. Factors that may need to be taken into account include variations in', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 9, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='bioavailability and pharmacokinetic profiles of different preparations so as to avoid reduced \\neffects or excessive side effects, co-existing neuro-developmental or psychiatric or physical \\ndisorders, specific treatment needs, and risk of drug misuse or diversion. Diversion occurs when \\nsomeone in the patient’s circle who has access to the medication uses it without prescription, \\nusually for recreational purposes or to enhance performance.  \\nBaseline assessment before starting a medication', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 9, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Weight and height should be measured and plotted on the World Healh Organization (WHO) or \\nIndian Association of Paediatrics (IAP) weight for age and height for age growth charts \\nrespectively along with Body mass Index (BMI). Baseline assessment of appetite, diet and sleep \\nshould be done and recorded.  \\nSpecific medical and family history that takes into account contra-indications for specific \\nmedications should be reviewed. This history must include that of exercise intolerance or', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 10, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='shortness of breath during exercise that is excessive as compared to peers, or syncope or fainting \\nepisodes on exertion or in response to sudden noise or fright, congenital heart disease or \\nprevious cardiac surgery, rapid, regular palpitations that stop and start suddenly, or chest pain \\nsuggestive of cardiac origin. Family history of sudden young (less than 40 years of age) cardiac \\ndeath should be specifically enquired into. A cardiologist’s opinion should be sought before', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 10, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='starting the medication if any of these are present. Heart rate and blood pressure must be \\nmeasured in the patient at rest. The blood pressure must be measured using age-appropriate \\ncuffsand plotted on age adjusted percentile charts. Alternately, heart rate and blood pressure \\nmay be compared with the normal range for age. If the baseline heart rate is more than 100 \\nbeats per minute or systolic or diastolic blood pressure is more than the 95th percentile, or more', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 10, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='than normal for age, it should be repeated twice within 10 minutes. If there is persistent \\ntachycardia (> 100 beats per minute) or systolic or diastolic blood pressure is> 95th percentileor \\nthere are signs of heart failure or a murmur is heard on auscultation, an electrocardiogram (ECG) \\nshould be done and a cardiologist opinion should be sought. There is no recommendation for \\nroutine baseline ECG, except when a triccylic antidepressant (TCA) is considered. TCAs are', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 10, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='however, third line drugs and should be avoided due to their side effect profile. \\nHistory of seizures of any kind and of tics must be specifically looked for. \\nLiver enzymes, i.e.,  alanine trasferase (ALT) and aspartate trasferase (AST) levels should be done \\nat baseline if atomoxetine is to be prsecribed.  \\nParents must be explained about the effect of medications on the symptoms, i.e., which \\nsymptoms will improve with medications and which will not improve with medications. Parents', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 10, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='also must be explained about the available options,  possible side effects with different \\nmedications and given the choice to select a specific agent.  \\nMedications \\nStimulants \\nThe stimulant medications with maximum evidence for ADHD include methylphenidate, \\ndexamphetamine and lisdexamphetamine. Methylphenidate is the only stimulant available in \\nIndia. There are several different formulations of methylphenidate available in the Indian', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 10, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='market.These include immediate release (short acting), sustained / extended release \\n(intermediate acting) and osmotic-controlled release oral delivery system, i.e. OROS (long acting) \\npreparations (Table-14). Methylphenidate - immediate release (IR) has a relatively short half life, \\nwith a duration of action of about 1-4 hours. Maximum drug concentration occurs at about 1-2 \\nhours after oral adminstration, and this is the time of maximum effect also. Due to short half life,', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 10, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='IR preparations need twice or thrice daily dosing. Sustained/ extended release preparations have \\na duration of action of about 6-8 hours, while the OROS preparation has duration of action of 12', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 10, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='hours. Due to their longer half lives, the intermediate acting (sustained preparations) and long \\nacting (OROS) need single dosing in the morning and may improve adherence as compared to IR \\npreparation. There is marked individual variability in dose response relation, and optimal dose \\ntitration aiming at maximum response with minimal or acceptable level of side effects must be \\ndone for each individual patient. \\nNon-stimulants', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 11, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Non-stimulants \\nThe non-stimulants that have evidence for ADHD in children and adolescents include \\natomoxetine, clonidine, guanfacine, tricyclic anti-depressants, modafinil and bupropion and \\ndesipramine. Out of these, clonidine extended release and guanfacine are not available in India. \\nAtomoxetine is a selective noradrenaline reuptake inhibitor, taken as once daily dose in the \\nmorning. Some individuals may benefit by dividing the daily dose and taking it twice daily, once', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 11, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='in morning and second doseat late afternoon or early evening. Atomoxetine is metabolised by \\nCYP2D6 enzyme, hence, poor metabolisers may have more side effects and there are chances of \\ndrug-drug interactions. Atomoxetine has evidence of greater efficacy than other non-stimulant \\ndrugs. Clonidine is an alpha 2 noradrenergic agonist taken in 3-4 divided daily doses as extended \\nrelease clonidine is not available currently in India.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 11, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='TCAs, modafinil and bupropion are considered third line drugs. TCAs are generally not \\nrecommended due to their side effect profile.  \\nTable-14 here \\nInitiating medication \\nIf a medication has to be started, the child and parents must again be apprised of the specific \\nside effects, monitoring and any precautions, as the case may be. In case of stimulants and \\natomoxetine, appetite suppression and sleep difficulties may become a concern in the initial part', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 11, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='of the treatment itself. Hence, specific advice regarding meals and sleep hygiene may be given. \\nIn case of clonidine, parents must be specifically advised regarding the risk of rebound \\nhypertension with abrupt discontiuation of the drug; so doses of clonidine should not be missed. \\nMedications should be started at a low dose (as indicated in Table 14); and side effects and \\nimprovement must be montiored after each increment. Stimulants are Schedule X drugs;', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 11, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='retailers cannot sell without a license and except on and in accordance with the prescription of a \\nRegistered Medical Practitioner; and are supposed to retain a copy of the prescription for a \\nperiod of two years. The clinician must mention clearly the exact number of days for which the \\nprescription is given.  \\nInitial monitoring  \\nDuring the phase of dose titration, the child should preferably be seen every week/ once in 2', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 11, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='weeks. The clinician must guage improvement vis-a-vis side effects. Improvement may be rated \\non a structured scale or on a simple instrument such as CGI If possible, ratings may be obtained \\nfrom the teachers at 2-4 weekly intervals. Specific enquiries should be made regarding the onset \\nof improvement noted after intake of medication (for example about 60 minutes after the \\nmorning dose) and duration of such improvement (for example, till 11am). Parents and teachers', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 11, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='may report that the child is disruptive in the class during afternoons. This may be due to', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 11, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='tiredness or wearing off of the drug’s effects. Such reporting will aid the clinician to titrate the \\ndose or change the dosing pattern.  \\nSpecific enquiries should be made regarding side effects. This should be done both from parents \\nand the child. Some older children and adolescents report that they do not like the drug effect, \\nand feel they are not themselves. Such concerns may affect adherence to the medication and', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 12, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='should be addressed. The child’s sleep patterns and food intake should be asked about. Appetite \\nsuppression and reduced food intake may be a major concern for the parents. Weight should be \\nmeasured on every visit during titration and plotted on the for-age charts. \\nContinued monitoring \\nResponse to medications must be reviewed across different settings and domains of functioning. \\nSpecific enquiries should be made regarding side effects. The child’s sleep patterns and food', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 12, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='intake should be asked about. Weight should be measured on every visit during titration, and \\nthereafter every 3 months. Height should be measured every 3-6 months. Both weight and \\nheight should be plotted on the for-age charts and monitored over time. Heart rate and blood \\npressure should be measured on every visit. Stimulants may increase the pulse rate and blood \\npressure, while clonidine can cause orthostatic hypotension. Liver enzymes should be montiored', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 12, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='periodically if atomoxetine has been started. \\nAdequate trial \\nA 6 week trial of methylphenidate at an adequate dose if taken with good adherence may be \\nconsidered as adequate. Time to response for atomoxetine is longer than that for stimulants. \\nHence, it may be continued at an adequate dose for at least 12 weeks with good adherence for \\nan adequate trial.  \\nImproving medication adherence \\nBesides response to the medication and its tolerability, other important factors that may affect', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 12, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='adherence are multiple dosing, stigma especially if the child needs to take a dose during the \\nschool hours, perceptions of patients and families regarding medications and cost. Cost of the \\nmedication and that of multiple visits to the hospital during drug titration and for later follow \\nups may be a major practical hindrance.  \\nIn case of inadequate adherence due to multiple dosing, sustained release or OROS preparations', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 12, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='may be prescribed. OROS preparations are relatively more expensive. A sustained release \\npreparation with additional immediate release doses as required may be another option. \\nOngoing discussions related to efficacy, side effects and patient and family preferences are \\nnecessary and should be carried out regularly as far as possible. \\nDrug Holidays \\nDrug holidays are planned breaks in taking medications, usually during periods when the child is', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 12, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='expected to have lesser demands for performance. These can be short, over weekends, or \\nlonger, during summer vacations. Drug holidays may reduce adverse events and give \\nopportunities for improvement in appetite and catch up growth. During drug holidays, the \\nsymptoms may or may not worsen. Longer drug holidays also provide with opportunties to \\nassess for ongoing need for medications. Weekend drug holidays are more appropriate for', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 12, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='stimulant drugs, where such holidays do not cause any advertent effect such as rebound', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 12, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='hypertension with clonidine. However, drug holidays increase the chances of non-adherence  \\n(unplanned discontinuation or missing of doses) during non ‘holiday’ periods.  \\nDiscontinuation of medication \\nThe need for continued medication should be reviewed at least once a year. The benefits, impact \\non functioning including academics, side effects, effects of missed doses, planned dose \\nreductions and periods of no treatment and any psycho-social treatment in place and its effects', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 13, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='as well as patient and family preferences are the factors to be taken into account. A few clinical \\nsigns that indicate that ADHD has remitted include, lack of any need to adjust dose despite \\nrobust growth, lack of deterioration when a dose of stimulant medication is missed or able to \\nconcentrate during drug holidays. Consider trial periods of stopping or reducing the medication \\ndose if benefit-risk analysis suggests that it may be appropriate. Vacations are probably a good', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 13, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='time to attempt withdrawal of medications. However, parents should be advised to assign the \\nchild in some cognitively demanding tasks (such as solving math problems, reading a book) to \\nconfirm that improvements persist despite being medication free. \\nManaging drug side effects \\nTable 15 presents the side effects of ADHD medications, along with guidance on monitoring for \\nand management of these side effects. \\nTable 15 here \\nManaging sleep problems asociated with ADHD', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 13, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Behavioral problems such as bedtime resistance, sleep onset delay, effect of psychiatric \\ncomorbidity and sleep disorders may contribute to sleep difficulties in children with ADHD. It is \\nsuggested that pre-treatment or baseline sleep patterns, including behavioral patterns around \\nbedtime routines be evaulated. Bedtime resistance include behaviors such as the child refusing \\nto get ready for bed, refusing to remain in bed or requiring a parent to be present at bedtime is', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 13, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='often the result of parental difficulties in limit setting and managing behaviors. It is suggested \\nthat sleep hygiene measures and behavioral interventions for healthier bedtime routines be \\ninstituted. These may include avoiding evening naps, having a regular bedtime, calming bedtime \\nroutine, darkened room, comfortable bed and no loud noises that promote sleep, and avoiding \\nelctronic media or screen use in the evening and adults also not using screens in the bedroom. In', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 13, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='individual cases, low dose clonidine or melatonin (3 mg in children and 3-6 mg in adolescents) \\nmay be used for sleep onset delay. Sleep studies including polysomnography are only indicated \\nfor specific sleep related disorders, and not routinely.  \\nEVIDENCE \\nMedications \\nIn pre-schoolers, there is some evidence of short term efficacy of stimulants, however, there are \\nserious concerns regarding side effects, especially related to appetite and growth suppression. In', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 13, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='children > 6 years and adolescents, stimulants, atomoxetine and clonidine have been shown to \\nbe significantly more efficacious than placebo. Stimulants have been shown to be superior to \\nnon-stimulants and have good short term efficacy, though evidence for long term efficacy is \\ninadequate. There is not adequate evidence of differences in efficacy or side effects between the \\ndifferent formulations of methylphenidate. The main advantage of longer acting formulations', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 13, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='over the short acting is in single versus multiple dosing that may result in lesser stigma \\nassociated with taking a dose in school and better adherence. Amongst non-stimulants, \\natomoxetine has greater evidence of efficacy with effect sizes though lower than stimulants, \\nbetter than the other non-stimulants. There is evidence of efficacy for clonidine, though effect \\nsizes are smaller than that for atomoxetine. Amongst tricyclic antidepressants, desipramine has', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 14, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='the largest evidence of efficacy but the medication has considerable cardiac side effects.  \\nPsychosocial interventions \\nIn pre-schoolers, there is enough evidence for group and individual parent training interventions. \\nIn children > 6 years and adolescents, there is evidence of efficacy for parent training \\ninterventions; and in older children and adolescents for other psycho-social interventions also.   \\nComparing medication and psychosocial interventions', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 14, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='There is no robust evidence directly comparing medications with psycho-social interventions. In \\npre-schoolers, there is evidence of efficacy for both medications and psycho-social interventions, \\nwith more concerns about side effects with the medications. In children > 6 years of age and \\nadolescents, there is evidence of efficacy for both medications and psycho-social interventions. \\nThere is some evidence of possibly differential effects of the two modalities; with the drug more', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 14, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='efficacious for the core symptoms whereas non-pharmacological interventions more efficacious \\nin improving associated behavioral problems and functioning. Though the effect sizes for \\nmedications, especially stimulants are greater than those for psycho-social interventions, it is \\nprobable that this is because of the outcome measures studied; ADHD symptom specific \\noutcomes versus more generic outcomes regarding behavioral problems and functioning. \\nCombination Treatments', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 14, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='There is no evidence that combination of two medications offers any advantage over a single \\nmedication. Additionally, there are more side effects; and hence should be avoided. \\nCombination of medication with psycho-social intervention has been found to be more \\nefficacious than psycho-social intervention alone. Adding psycho-social intervention to the \\nmedication treatment may offer specific benefits and so, must be instituted when indicated.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 14, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Besides evidence of possibly differential effects of the two modalities; there is also some \\nevidence that addition of psycho-social interventions may facilitate dose reduction and \\ndiscontinuation of medication on follow up.  \\nOTHER INTERVENTIONS \\nDiet and exercise \\nIt is suggested that all children and adolescents be advised regarding need for nutritious and \\nbalanced diet; and physical exercise. \\nExclusion of food preservatives and additives and Elimination or oligoanitgenic (few foods)', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 14, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='diets \\nThere is not enough evidence for special diets such as exclsuion of food additives and \\npreservatives, or elimination of several potential antigens as in the oligo-antigenic diets as stand \\nalone treatments in the management of ADHD. There is limited evidence of short-term benefits; \\nand not enough evidence of long-term effectiveness or harms of elimination diets. If it is \\nsuspected that specific foods increase the symptoms, it is suggested that parents  be advised to', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 14, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='maintain detailed diet diaries and any elimination of specific food be attempted only in \\nconsultation with an expert dietician. It may take weeks to months for tailoring an oligoantigenic \\ndiet through series of re-introduction of foods; and requires close collaboration between the \\ndietician, clinician and the family anfd patient. IgG blood tests are not helpful in selecting foods \\nfor elimination. The clinical utility of dietary interventions may be explored in individual cases,', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='bearing in mind difficulties in practical implementation such as preparation of special foods in a \\nhousehold with several members, parents‘ control over child’s diet, motivation of child and \\nfamily as well as expenses towards preparation of additive-free or anitgen free foods.  \\nOmega fatty acids and nutritional supplements \\nThere is inconclusive evidence for use of omega fatty acids or any micronutrient or nutritional', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='supplements for treatment of ADHD, and hence, it is suggested that such dietary supplements \\nmay not be prescribed for this purpose routinely till further good quality evidence emerges. \\nNeurofeedback \\nThough small studies indicate that neurofeedback may have some positive effects on core \\nsymptoms and neuropsychological functions, well designed studies and meta-analysis have  have \\nfailed to show the same. Overall, there is not adequate evidence to support neurofeedback for', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='treatment of ADHD. \\nLIAISON WITH SCHOOL \\nIt is suggested that liaison with the school be a continual activity. First and all subsequent \\ncontacts with the school should be after parental and patient’s consent and as far as possible \\ncontact should be made through the parents. It is sound clinical practice to acknowledge the \\nschool’s strengths while dealing with the index child, taking teacher’s observational report and', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='follow up feedbacks. Teacher reports and parent reports may give insights into different areas of \\nimpairment and in different settings. A good alliance with the teachers will set the stage to \\ncommunicate the diagnosis and that it is a valid disorder; and suggest environmental \\nmodifications that a teacher can easily implement in the classroom. Efficient and sensitive \\nteachers do encourage these children to exploit their other potentials and use verbal re-', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='inforcements effectively, while minimally using punishment. These children often are bullied or \\nare bullies themselves, and school intervention can be very helpful in either case. Besides \\nclinicians liaising with the school, parents may be advised to liaise with the child’s teachers and \\nuse the parent-teacher daily report cards. These report cards aid in implementing the behavior \\nprinciples more consistently and across the two settings. \\nSTEPS IN MANAGING ADHD', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Factors determining the steps in management of ADHD \\nThe evidence for medications is limited in pre-schoolers; whereas there are genuine concerns \\nregarding the side effects of the medications. There is enough evidence for group and individual \\nparent training interventions. Keeping these in mind, pre-schoolers must first be offered psycho-\\nsocial interventions. \\nIn children > 6 years of age and adolescents, there is evidence of efficacy for both medications', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='and psycho-social interventions. Medications appear to be more efficacious in improving the \\ncore symptoms of ADHD and psycho-social interventions in improving associated behavioral', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='problems and functioning in specific domains. In mild ADHD, environmental modifications \\nusually suffice alone; while in severe ADHD, medications may be necessary. In the latter case, \\nfollowing some response with the medication, psycho-social interventions may be indicated for \\nspecific problems or impairments in specific domains. In case of moderate ADHD, parent training \\nwhere available must be offered first.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 16, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Besides the evidence for efficacy and side effects, and severity of ADHD, the other important \\nfactors that determine the strategies in managing ADHD include co-morbidities, current needs, \\npatient and family’s preferences, affordability and availability. Table 16 lists the factors \\ndetermining the steps in management of ADHD. \\nTable-16 here \\nSteps in management of ADHD \\nFigure 1 presents the algorithm for managing ADHD. It is expected that the plan and steps may', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 16, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='have to be tailored to suit the needs of an individual patient. Psycho-education and support to \\nthe child and family must as far as possible be provided to all individuals. Medication is not the \\nfirst line of management in pre-schoolers and those aged less than 6 years as there are concerns \\nregarding tolerability and safety. Also, it is often difficult to differentiate a difficult temperament \\nfrom ADHD in toddlers. Parent training interventions that include environmental modifications', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 16, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='as well as behavioral management may be offered instead. The training may be given as group \\ntraining or individual training. The clinician must consider addressing any factors that may hinder \\nthe effective implementation of the parent training intervention.  \\nFor school aged children and adolescents, it is suggested that environmental modifications be \\nadvised first. Despite the implementation of environmental modifications or in cases where the', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 16, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='severity is so marked that such implementation is quite difficult, choose the next line of \\nmanagement based on the severity. In children with mild to moderate level of severity, offer \\nparent training and school interventions. If the response is not good or parent training \\nintervention is not available and severity is at least of moderate level, offer medications. If ADHD \\nis severe, medications must be offered. The sequencing of medications considering response,', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 16, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='contra-indications, side effects affordability and availability is preferably stimulant followed by \\natomoxetine followed by clonidine.  \\nFor all individuals who respond on a given treatment, continue with the same, along with \\nperiodic review and monitoring. In children and adolescents who have responded on a \\nmedication, but still have impairments in a specific domain, offer additional focused psycho-', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 16, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='social intervention. For example, an adolescent having impairments in peer functioning, offer \\nsocial skills training. In case of response to a psycho-social intervention, continue with periodic \\nbooster sessions and monitoring. \\nIn case of inadequate response on a medication, check for non-adherence. Ensure adherence \\nafter addressing the child and family’s concerns regarding the medication; these may include', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 16, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='side effects, cost and stigma. If child is adherent on the medication, optimize the dose while \\nmonitoring for side effects. If despite an adequate trial, there is inadequate response, consider \\nchanging the drug. Family may prefer psycho-social intervention following a failed medication \\ntrial; in that case, it must be offered, if available after again discussing the benefits and risks of', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 16, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='each modality of treatment. If there is inadequate response after adequate medication trials, \\nreview the diagnosis, manage co-morbidities (for example, conduct disorder), may add parent \\ntraining intervention. In case of inadequate response following parent training intervention, first \\ncheck for and address adherence to the interventions. If despite this, there is inadequate \\nresponse, offer medication alone or in combination with the psycho-social intervention. Table-17', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 17, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='lists out the factors related to inadequate response to pharmacological or non-pharmacological \\nintervention. \\nBesides the medication or parent training and other child focused psycho-social interventions, \\nongoing liaison with the school must be carried out with consent of child and parents. School \\nliaison strategies must be attempted. Review of teacher-implemented environmental \\nmodifications and behavioral management strategies must be made periodically, along with', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 17, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='teacher reports regarding child’s problems and progress.  \\nFigure 1 here \\nTable-17 here \\nReview and discontinuation of treatment \\nThe clinician must perform ongoing reviews regarding improvement, tolerability and needs of \\nthe child and family. The management plan may be altered in accordance with changing needs as \\noutlined in earlier sections.  \\nFurther, the clinician must review the need for ongoing treatment at least once a year. For this,', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 17, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='response to treatment, functioning in various domains and maintenance of response despite \\nperiods of planned or unplanned discontinuation of treatment must be considered. As during \\ninitial assessment, assessment of symptoms and functioning at this stage must involve multiple \\ninformants (preferably, must involve teachers) and must be done across settings. The child and \\nfamily must be involved in discussions regarding possibility of discontinuation and risks and', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 17, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='benefits thereof, including chances of relapse, though definitely not inevitable and improvement \\nin side effects. Discontinuation must be attempted during low stress periods such as during \\nvacations. Discontinuation of medications has been dealt with in detail in an earlier section. In \\ncase of psycho-social intervention, it is expected that some benefits may persist beyond the \\ntraining programs. However, booster sessions may be required or focused strategies such as life', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 17, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='skills or time management may be required. In case a child is on drug and non-drug treatment, \\nthe former may be discontinued first. The children and adolescents and their families must be \\nadvised ongoing reviews despite discontinuation of treatment. The clinician must monitor for \\nrelapse of symptoms or any impairments in functioning that need to be addressed. \\nSPECIAL CIRCUMSTANCES \\nIn case of co-morbid tic disorder, anxiety disorders, obsessive compulsive disorder and ASD, the', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 17, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='same medication may be started as for children and adolescents without any co-\\nmorbidity.However, drug titration must be slower and special attention should be paid to side \\neffects.Clonidine or atomoxetine may be a good choice in case of co-morbid tic disorder; while \\natomoxetine may be a good choice in case of co-morbid anxiety disorder although there is no \\ngood evidence for avoiding methylphenidate.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 17, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='In case of children with co-morbid intellectual disability or ASD, tolerability is an important \\nconsideration. Some children with developmental disabilities experience irritability, withdrawal \\nor agitation and apparent worsening of symptoms. In such children, the diagnosis of ADHD \\nshould be re-visited and the medication should be stopped. A non-stimulant medication may be \\nstarted. \\nIn case of psychosis or bipolar disorder co-existing with ADHD, the psychosis or mood disorder', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 18, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='should be treated first, and after resolution of the symptoms, a review of diagnosis of ADHD \\nshould be made. The clinician should assess the need for medication and then may start a \\nstimulant or a non-stimulant drug weighing the risks and benefits in the individual case and \\nconsidering drug interactions.  \\nIn case of co-morbid depression, the clinician must assess the severity of depression, presence of', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 18, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='suicidal attempts or strong suicidal intent, and contribution of depressive symptoms to the \\noverall global clinical severity. If the any of these are present, depression should be treated first. \\nIn case of severe depression or suicidal ideas or attempts, inpatient management may be \\nwarranted depending on the individual circumstances. On the other hand, if depression is not \\nsevere with mild neuro-vegetative symptoms, suicidal ideas but without strong intent and ADHD', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 18, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='sympotms are thought to contribute more than depressive symptoms to overall clinical severity, \\nADHD must be treated first. Often, the depressive symptoms and dysphoria may be related to \\nthe ADHD and resolve with effective treatment of ADHD. \\nIn case of co-morbid substance dependence, treatment of ADHD and substance dependence \\nshould be instituted simultaneously. The clinician must assess the risk of medicalion misuse and \\ndiversion. If this risk is high, a non-stimulant may be used.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 18, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='If  co-morbid conduct disorder or oppositional defiant disorder are present, parent training \\ndirected towards the behavioural problems in addition to ADHD focused parent training should \\nbe commenced. Also, risk of medication misuse and diversion should be assessed and a non-\\nstimulant drug may be started. Risperidone in low doses may be started particularly for \\naggression. Refer to CPG on Conduct Disorder for its management. \\n \\nREFERENCES', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 18, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='REFERENCES \\n1. American Academy of Child and Adolescent Psychiatry. Practice Parameter for the \\nAssessment and Treatment of Children and Adolescents with Attention-Deficit/ \\nHyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2007; 46(7):894-921. \\n2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders \\n(5th ed.). 2013; APA, Washington DC. \\n3. Barkley RA. Taking charge of ADHD: the complete, authoritative guide for parents. 2005;', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 18, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Guilford Press, New York. \\n4. Bolea-Alamañac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the \\npharmacological management of attention deficit hyperactivity disorder: update on \\nrecommendations \\nfrom \\nthe \\nBritish \\nAssociation \\nfor \\nPsychopharmacology. \\nJ \\nPsychopharmacol. 2014; 28: 179-203.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 18, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='5. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA): Canadian \\nADHD Practice Guidelines, Third Edition, 2011; CADDRA, Toronto ON. \\n6. Catalá-López F, Hutton B, Núñez-Beltrán A, et al. The pharmacological and non-\\npharmacological treatment of attention deficit hyperactivity disorder in children and \\nadolescents: A systematic review with network meta-analyses of randomised trials. Gluud \\nC, ed. PLoS ONE. 2017;12(7):e0180355. doi:10.1371/journal.pone.0180355.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 19, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='7. Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M,, et \\nal. Practitioner Review: Current best practice in the management of adverse events \\nduring treatment with ADHD medications in children and adolescents. J Child Psychol \\nPsychiatry. 2013;54: 227–246 \\n8. Cortese S, Vincenzi B, Angriman M. Identifying and managing sleep disorders associated \\nwith ADHD. Neuropsychiatry. 2012; 2:393–405', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 19, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='9. Cortese S, Ferrin M, Brandeis D, Holtmann M, Aggensteiner P, Daley D, et al. \\nNeurofeedback for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and \\nNeuropsychological Outcomes From Randomized Controlled Trials. J Am Acad Child \\nAdolesc Psychiatry. 2016; 55: 444 - 455 \\n10. Daniel F, Guan C, Wong CJM, Ng KH, Cheok CCS, Kiing JSH, et al. Academy of Medicine-\\nMinistry of Health Clinical Practice Guidelines: Attention Deficit Hyperactivity Disorder.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 19, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Singapore Med J. 2014; 55(8): 411-415doi: 10.11622/smedj.2014098 \\n11. Ferrin M, SonugaBarke E, Daley D, Danckaerts M, van der Oord S, Buitelaar JK. Non-\\npharmacologic treatments for Attention deficit hyperactivity disorder. In Eds. Zepf FD. \\nIACAPAP Textbook of Child and Adolescent Mental Health. 2015 Available at: \\nhttp://iacapap.org/iacapap-textbook-of-child-and-adolescent-mental-health \\n12. Gautam S, Batra L, Gaur N, Meena PS. Clinical Practice Guidelines for the Assessment and', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 19, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Treatment of Attention- Deficit/Hyperactivity Disorder. Indian Psychiatric Society, 2007. \\n13. Gillies D, Sinn JKH, Lad  SS, Leach  MJ, Ross  MJ. Polyunsaturated fatty acids (PUFA) for \\nattention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane \\nDatabase of Systematic Reviews 2012, Issue 7. Art. No.: CD007986. DOI: \\n10.1002/14651858.CD007986.pub2 \\n14. Maia CRM, Samuele C, Arthur C, Deakin TK, Polanczyk GV, et al. Long-Term Efficacy of', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 19, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Methylphenidate Immediate-Release for the Treatment of Childhood ADHD: A Systematic \\nReview and Meta-Analysis. J AttenDisord. 2017, Vol. 21(1) 3– 13 \\n15. Moriyama TS, Cho AJM, Verin RE, Fuentes J, Polanczyk GV. Attention deficit hyperactivity \\ndisorder. In Eds. Zepf FD. IACAPAP Textbook of Child and Adolescent Mental Health. \\n2015. Available at: http://iacapap.org/iacapap-textbook-of-child-and-adolescent-mental-\\nhealth', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 19, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='health \\n16. National Institute for Health and Care Excellence.Antisocial behaviour and conduct \\ndisorders in children and young people: recognition and management. London: NICE; \\n2013 \\n17. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: \\ndiagnosis and management. London: NICE; 2018', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 19, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='18. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder \\nin children and young people: clonidine. London: NICE; 2013 \\n19. National Institute for Health and Care Excellence.Attention deficit hyperactivity disorder \\n(update). [B] Evidence reviews for information and support for people with ADHD. \\nEvidence review. London: NICE;2018 \\n20. National Institute for Health and Care Excellence.Attention deficit hyperactivity disorder', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 20, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='(update). [C] Evidence reviews for pharmacological efficacy and sequencing \\npharmacological treatment. Evidence review. London: NICE; 2018 \\n21. National Institute for Health and Care Excellence.Attention deficit hyperactivity disorder \\n(update). [D] Evidence reviews for safety of pharmacological treatment. Evidence review. \\nLondon: NICE; 2018 \\n22. National Institute for Health and Care Excellence.Attention deficit hyperactivity disorder', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 20, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='(update). [E] Evidence reviews for efficacy of non-pharmacological treatment and the \\nimpact of adverse events associated with non-pharmacological treatments of ADHD. \\nIntervention evidence review. London: NICE; 2018 \\n23. National Institute for Health and Care Excellence.Attention deficit hyperactivity disorder \\n(update). [F] Evidence reviews for combined pharmacological and non-pharmacological \\ntreatments review. Intervention evidence review. London: NICE; 2018', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 20, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='24. National Institute for Health and Care Excellence.Attention deficit hyperactivity disorder \\n(update). [G] Evidence reviews for adherence to treatment (pharmacological and non-\\npharmacological). Evidence review. London: NICE;2018 \\n25. National Institute for Health and Care Excellence.Attention deficit hyperactivity disorder \\n(update). [H] Evidence reviews for the principles for discussion when starting, adjusting', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 20, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='and discontinuing pharmacological treatment for ADHD. Evidence review. London: NICE; \\n2018 \\n26. National Institute for Health and Care Excellence.Attention deficit hyperactivity disorder \\n(update). [I] Withdrawal from pharmacological treatment and drug holidays. Evidence \\nreview. 2018 \\n27. National Institute for Health and Care Excellence.Sleep disorders in children and young \\npeople with attention deficit hyperactivity disorder melatonin. Evidence summary. \\nLondon: NICE; 2013', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 20, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='London: NICE; 2013 \\n28. National Institute for Health and Care Excellence. The NICE guideline on diagnosis and \\nmanagement of ADHD in children, young people and adults. London: NICE; 2009 \\n29. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder \\nClinical Guideline Addendum 72.1 Methods, evidence and recommendations. London: \\nNICE; 2016 \\n30. Osland ST, Steeves TDL, Pringsheim T. Pharmacological treatment for attention deficit', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 20, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database \\nof \\nSystematic \\nReviews \\n2018, \\n6. \\nArt. \\nNo.: \\nCD007990. \\nDOI: \\n10.1002/14651858.CD007990.pub3.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 20, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='31. Osland ST, Steeves TDL, Pringsheim T. Pharmacological treatment for attention deficit \\nhyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database \\nof \\nSystematic \\nReviews \\n2018, \\nIssue \\n6. \\nArt. \\nNo.: \\nCD007990. \\nDOI: \\n10.1002/14651858.CD007990.pub3. \\n32. Otasowie J, Castells X, Ehimare UP, Smith CH. Tricyclic antidepressants for attention \\ndeficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of \\nSystematic \\nReviews \\n2014, \\nIssue', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 21, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='2014, \\nIssue \\n9. \\nArt. \\nNo.: \\nCD006997. \\nDOI: \\n10.1002/14651858.CD006997.pub2. \\n33. Pelsser LM, Frankena K, Toorman J, Rodrigues Pereira R (2017) Diet and ADHD, Reviewing \\nthe Evidence: A Systematic Review of Meta-Analyses of Double-Blind Placebo-Controlled \\nTrials Evaluating the Efficacy of Diet Interventions on the Behavior of Children with \\nADHD. PLoS ONE 12(1): e0169277.  \\n34. Shah R, Sharma A, Grover S, Sachdeva D, Chakrabarti S, Avasthi A. PGIMER Manual Parent', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 21, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='training for families of children with attention deficit/ hyperactivity disorder. \\n35. Sonuga-Barke E, Brandeis D, Ferrin M, Holtmann, M, Stevenson J.  Nonpharmacological \\nInterventions for ADHD: Systematic Review and Meta-Analyses of Randomized Controlled \\nTrials of Dietary and Psychological Treatments. Am J Psychiatry 2013; 170:275–289 \\n36. Sonuga-Barke E, Taylor E. ADHD and hyperkinetic disorder. In EdsThaparA et al. Rutter’s', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 21, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Child and Adolescent Psychiatry. Sixth edition. Blackwell Publishing Limited. USA, 2015 \\n37. Taylor E, Döpfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic \\ndisorder — first upgrade. Eur Child Adolesc Psychiatry 2004; 13(Suppl 1): I/7-I/30. \\n38. Taylor E, Sonuga-Barke E. Disorders of attention and activity. In EdsRutter M et al. \\nRutter’s Child and Adolescent Psychiatry. Fifth edition. Blackwell Publishing Limited. USA, \\n2008.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 21, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='2008. \\n39. World Health Organisation. The 11th Revision of the International Classification of \\nDiseases \\n(ICD-11) \\nBeta \\ndraft. \\nAvailable \\nat: \\nhttp://www.who.int/classifications/icd/revision/en \\n40. World Health Organisation.The ICD‐10 classification of mental and behavioural disorders: \\nclinical descriptions and diagnostic guidelines. Geneva, 1992 \\n41. Young S, Amarasinghe JM. Practitioner Review: Non-pharmacological treatments for', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 21, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='ADHD: A lifespan approach. Journal of Child Psychology and Psychiatry 2010;51:116–33', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 21, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Table 1: Components of a comprehensive assessment and evaluation (text in parenthesis may \\nbe used as a guide for assessment) \\n Core components \\n1. \\nEstablishing diagnosis through detailed history from multiple informants \\n2. \\nDevelopmental and psychiatric history (for differential diagnosis and co-morbidities) \\n3. \\nMedical history (for co-morbidities and contra-indications for medications) \\na. Comorbid physical disorders: Include tics, seizures, malnutrition, thyroid \\nabnormalities', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 22, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='abnormalities \\nb. Contra-indications: Syncope, exercise intolerance \\n4. \\nSubstance use history \\n5. \\nFamily history (Family h/o ADHD, other developmental, psychiatric and physical \\ndisorders; family history of young, i.e. <40 years age sudden cardiac deaths if \\nplanning to prescribe a drug) \\n6. Treatment history (past treatment contacts and experiences, type of treatment, drug \\ndose, formulation, dosing schedule, adherence, response, side  effects and', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 22, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='perceptions, use of drug holidays, treatment adherence, premature termination of \\ntreatment, etc.)   \\n7. \\nSleep patterns and appetite (pre-treatment baseline night sleep and day time naps; \\nbaseline history of appetite and food intake) \\n8. Psycho-social history (environmental factors, perceptions and expectations \\nregarding diagnosis and treatment, family psychopathology and family resources)  \\n9. \\nDysfunction: domains involved (academic, family, social, interpersonal,  legal, peer', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 22, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='relationship, occupational), severity of illness \\n10. \\nImpact of illness on the patient: secondary depression, perpetuator of bullying, or a \\nbully victim , stigma, parental abuse (psychological, physical and neglect) \\n11. \\nImpact of illness on the life of caregivers: burden, distress, burnout, \\npsychiatric/psychological burden, stigma \\n12. \\nStrengths (physical, psychological, cognitive or creative attributes of the child that', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 22, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='can be considered as assets; e.g. good in a sport, coloring or sketching, obedient and \\nrespectful of elders) \\n13. \\nAssessment of current needs (to be assessed across various domains such as \\npsychological, social and academic) \\n14. \\nPhysical examination (for co-morbidities and contra-indications; pre-treatment \\nbaseline assessments) \\n15. \\nMental state examination (to assess for any other psychopathology such as \\ndepressive cognitions, suicidal ideas, delusions and hallucinations)', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 22, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Supportive or only if indicated \\n1. \\nRating scales (baseline assessment and monitoring treatment response) \\n2. \\nPsychological testing (e.g. IQ assessment, only if indicated) \\n3. \\nPhysical investigations (e.g. Lead levels; only if indicated)', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 22, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content=\"Table 2: Clinical questions to be answered in the process of assessment \\n1. \\nIs there presence of symptoms of inattention/ overactivity / impulsivity? \\n2. \\nWhat has been the onset and course of these complaints? \\n3. \\nAre the symptoms age-appropriate?  \\n4. \\nAre there global developmental delays? If so, are the symptoms appropriate to the level \\nof   ‘mental-age' or stage of development  \\n5. \\nAre the symptoms persistent (present more often than not)? \\n6.\", metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 23, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='6. \\nAre the symptoms causing impairment in more than one setting (e.g. home, school)? \\n7. \\nHow severe are the symptoms and the impairment? \\n8. \\nAre there associated developmental and/or other psychiatric problems?  \\n9. \\nAre there any associated medical problems? \\n10. \\nWhat are the genetic and environmental risk factors? \\n11. \\nRelevant psychosocial factors, parenting, parenting stress & parents’ perceptions and \\nexperiences regarding diagnosis and treatment \\n12.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 23, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='12. \\nStrengths or assets of the child and family and any protective or positive environmental \\nfactors (e.g. supportive school environment) \\n \\nTable 3: factors that may affect symptom manifestations of ADHD \\nSigns of ADHD may be minimal or absent if \\n\\uf0b7 child is engaged in a one to one interaction (as with the clinician),  \\n\\uf0b7 in a novel setting (such a clinic),  \\n\\uf0b7 under close supervision (as in private tuitions),  \\n\\uf0b7 is being frequently rewarded for appropriate behaviors,', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 23, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='\\uf0b7 is engaged in especially interesting activity or  \\n\\uf0b7 getting consistent external stimulation, often with rewards (as while watching TV or \\nplaying video games).  \\nInattention is more evident when  \\n\\uf0b7 tasks are lengthy, boring or monotonous  \\n\\uf0b7 depends on the demands for attention that the tasks/ environment make \\nThe symptoms can vary with both internal and external motivation, type of activity (interesting', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 23, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='versus boring), demands that the task makes for attention, adult supervision, one to one \\ninteraction as well as with fatigue and time of the day. \\nTable 4: Co-morbidities seen with ADHD \\nDevelopmental: Intellectual disability, speech and language disorders, learning disorders, motor \\nco-ordination disorders, autism spectrum disorders, tic disorders \\nPsychiatric: Oppositional defiant disorder, conduct disorder, mood and anxiety disorders, \\npsychotic disorders, substance use disorders', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 23, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Medical: Epilepsy, tics, seizures, malnutrition, thyroid abnormalities', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 23, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Table 5: Clinical features for differentiating ADHD from other disorders \\nDifferential diagnosis \\nClinical features that help in differentiating \\nOppositional defiant disorder \\nand conduct disorder \\n\\uf0b7 Symptoms of ADHD usually pre-date the symptoms of \\ndefiant disorders \\n\\uf0b7 However, in extremely severe cases of ADHD, defiance \\nmay seem to start very soon after the onset of ADHD.  \\n\\uf0b7 It may at times be clinically difficult to separate out the \\ntwo; though a good chronological history may help.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 24, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='\\uf0b7 However, a diagnosis of ADHD should not be made \\nwhen there is presence of defiance in absence of the \\ncore symptoms of ADHD. \\nIntellectual disability (ID) \\n\\uf0b7 In children with ID, apparent inattentiveness and \\ndifficulty to follow instructions can be better explained \\nby a lack of comprehension  \\n\\uf0b7 In case of suspected co-morbidity, symptoms suggestive \\nof ADHD must be clearly developmentally inappropriate. \\nSpecific \\nlearning \\ndisorders \\n(SLD)', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 24, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='disorders \\n(SLD) \\n\\uf0b7 Academic difficulties in SLD are quite persistent while in \\nADHD the performance can be strikingly variable \\n\\uf0b7 Children with ADHD may engage in reading or writing as \\nleisure activities (e.g. reading fiction) in contrast to \\nthose with specific learning disorders \\n\\uf0b7 It is clinically a good practice to first treat ADHD and \\nthen assess for specific learning disorders if these \\nappear to be co-existent. \\nAutism \\nspectrum \\ndisorders \\n(ASDs)', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 24, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='disorders \\n(ASDs) \\n\\uf0b7 increased motor activity of ASDs is characterized by \\nrepetitive, stereotyped movements as against the \\nhyperactivity of ADHD \\n\\uf0b7 Several behaviors mimicking ADHD may be due to \\nsensory issues and deviant socio-emotional reciprocity  \\nTic disorders \\n\\uf0b7 Prolonged observation helps in differentiating complex \\nmotor tics seen in Tourette’s disorder from the \\nincreased motor activity and fidgetiness seen in ADHD. \\nMania \\n\\uf0b7 Symptoms are of a relatively recent onset', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 24, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='\\uf0b7 Definite change from pre-morbid state \\n\\uf0b7 Increased activity in mania is goal directed; that of \\nADHD is not \\n\\uf0b7 Presence of symptoms such as inflated self-esteem and \\ngrandiosity \\nDepression \\n\\uf0b7 Symptoms are of a relatively recent onset \\n\\uf0b7 Definite change from pre-morbid state', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 24, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='\\uf0b7 Symptoms other than irritability and agitation, such as \\ndecreased interest in pleasurable activities \\nPsychosis \\n\\uf0b7 Symptoms are of a relatively recent onset \\n\\uf0b7 Definite change from pre-morbid state \\n\\uf0b7 Presence of delusions and hallucinations \\nAnxiety disorders \\n\\uf0b7 Inattentiviness, lack of concentration and generalized \\nhyperarousal may be seen in anxiety disorders; but \\npresence of other cognitive (e.g. worry) and behavioral \\nsymptoms (e.g. autonomic arousal) may be present', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 25, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Obsessive compulsive disorder \\n\\uf0b7 Compulsive behaviors are repetitive, goal directed and \\noften ritualistic \\n\\uf0b7 Concurrent obsessions may be present \\n \\nTable 6: Key clinical points to guide the process of establishing the diagnosis \\n1. Multi-informant; each informant may add a different dimension to the history \\n2. Assess symptoms across multiple settings \\n3. Compare the reported symptoms to developmentally normal levels of inattention, activity \\nand impulsivity', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 25, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='and impulsivity \\n4. Symptom manifestation may change with development \\n5. Symptoms may vary with internal and external motivation, re-inforcers, close supervision, \\none to one interaction, time of the day, and fatigue \\n6. Symptoms are not due to merely defiance or lack of comprehension or are specific to a \\nparticular task or due to another psychiatric disorder \\n7. Assess impairment in multiple domains \\n8. Assess effects on development in various domains', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 25, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='9. Make an impression of overall severity of the disorder \\n \\nTable 7: Principles to guide formulation of a comprehensive treatment plan \\n1. The main objectives of a treatment plan must be to alleviate symptoms as well as \\nimprove functioning in various domains of functioning \\n2. It should be needs-based, individualised and may change over time \\n3. Consider the level of symptoms and impairments in functioning across settings and \\ndomains of functioning', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 25, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='4. Consider co-morbid developmental, psychiatric and medical disorders \\n5. Consider psycho-social and environmental protective and risk factors \\n6. Consider patient’s and family’s perceptions regarding treatment and their treatment \\npreferences \\n7. Consider family’s resources including financial resources', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 25, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Table 8: Important points to remember while building therapeutic alliance \\n1. Positive regard for all involved in the care of the child  \\n2. Parental (and family’s) perceptions regarding diagnosis and treatment may differ \\nfrom that of the clinician’s. \\n3. Parental expectations may differ from realistic goals that can be achieved. \\n4. Parents have often experienced blame and guilt before reaching the clinic. Validate \\ntheir experiences and feelings; offer support.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 26, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='5. Child or adolescent’s needs may be different from those identified by the parents. \\nEstablish a working therapeutic alliance with both the parties.  \\n \\nTable 9: Rationale for involving extended family members in the Indian context \\n1. Parental perceptions regarding diagnosis and treatment may be influenced by the \\nextended family.  \\n2. It is common for parents to take treatment decisions jointly with grandparents and \\nmembers of extended family, even when residing as nuclear families.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 26, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='3. Treatment adherence; both for pharmacological and non-pharmacological modalities will \\nbe affected at least partially by other significant elders in the family. For example, much \\nof the behavioural management is dependent upon the consistency shown in \\nimplementing the strategies by all the significant adults in the child’s life. Behavioral \\nmanagement through parent training may fail, if grandparents who stay in the same \\nhousehold are not involved pro-actively.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 26, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='4. Involving other members may mitigate blame and conflict amongst them. For example, \\nfamily members often hold each other responsible for ineffective or punitive or \\nexcessively liberal disciplining, and hence, the child’s ‘misbehaviors’.   \\n \\n \\nTable 10: Components of psycho-education \\n1. Take feedback about their understanding about the symptoms/diagnosis and \\nexpectation from treatment \\n2. Information about prevalence: ADHD is seen world-wide with global estimates of 5%', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 26, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='-7% in school aged children. Higher prevalence rate in clinic population \\n3. Possible etiological factors:  \\na. ADHD is a neuro-developmental disorder; i.e. a state arising out of problems \\nin development of the brain. \\nb. Like many other psychiatric and developmental problems, the problems are \\nat the level of neuro-chemicals and neural connections between different \\nregions of the brain.  \\nc. Genetic and environmental factors (such as low birth weight and pre-', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 26, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='maturity) are associated with ADHD. \\nd. Symptoms are neither child’s fault nor parents’ fault. \\n4. Discuss how parental factors can contribute in manifestation of symptoms, \\ncontinuation, and influence the course of the disorder  \\n5. Symptoms of the disorder: The core symptoms are inattention (difficulty in sustained \\nattention), hyperactivity (problem of too much behavior) and impulsivity (problem of \\nacting without thinking or controlling impulses), with a likely central problem in self-', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 27, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='control (behavior) or response inhibition). Core symptoms must be described with \\nexamples. \\n6. Symptoms are usually present since early childhood; manifestations may change \\nover time with age. \\n7. Symptoms cause impairments in different domains of functioning; may increase \\nprobability of high risk behaviors and substance use. \\n8. Co-morbid developmental, psychiatric and physical disorders may be present. \\n9. Long term course is variable; ADHD may be a life-long disorder in a significant', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 27, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='proportion of individuals \\n10. Long term outcomes including risk of substance use are known to improve with \\ntreatment; while co-morbid disorders, drug or alcohol use in family, other \\npsychological or socio-environmental risk factors may lead to worse outcomes.  \\n11. No specific investigations needed to diagnose; ADHD is a clinical diagnosis. \\n12. Treatment consists of medications and non-medication interventions including \\nbehaviour training programs.', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 27, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='13. Discuss evidence for, and benefits and risks of each modality of treatment (For e.g. \\nbenefits of drug on the core symptoms of ADHD, along with side effects of the \\nmedication may be explained; benefits of parent training programs but the risk of \\nineffective implementation due to factors such as parental psychopathology and \\npreferences that may lead to unresponsiveness may be explained). \\n14. If a child has co-morbid disorder, include discussion on how it may affect the course', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 27, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='and treatment choices in that child. \\n  \\nTable 11: Modalities of intervention for ADHD \\nPSYCHO-SOCIAL INTERVENTIONS \\nA. Environmental modifications \\nB. Parent training intervention \\nC. Cognitive behavior therapy \\nD. Cognitive training \\nPHARMACOLOGICAL INTERVENTIONS \\nA. Stimulants \\nB. Non-stimulants \\nOTHER MEASURES', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 27, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='A. Diet and exercise \\nB. Exclusion and Elimination / few food diets \\nC. Omega fatty acid and nutritional supplements \\nD. Neuro-feedback \\n \\nTable 12: Environmental modifications to minimse distraction, improve attention and \\nchannelize energy \\n\\uf0b7 Structured routine \\n\\uf0b7 Structure the physical environment \\n\\uf0b7 Assist the child in learning time management \\n\\uf0b7 Use reminders and planners \\n\\uf0b7 Increase supervision by adults  \\n\\uf0b7 Minimize distraction in the environment while studying', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 28, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='\\uf0b7 Improve attention on the task by using highlighters \\n\\uf0b7 Listening to instrument music: can help in improving attention insome patients  \\n\\uf0b7 Short breaks at regular intervals \\n\\uf0b7 Allow activity during breaks to channelize the excessive energy \\n\\uf0b7 Providing extra time to complete work, decreasing the work load, giving small assignments \\n\\uf0b7 If feasible, informing the teacher through parents about the problem and thier role in the \\nmanagement', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 28, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='management \\n \\nTable 13: Components of PGIMER Manual: ‘Parent training for families of children with \\nattention deficit/ hyperactivity disorder’ \\n1. Psycho-education \\n2. Parenting and communication: 3 Ps (Patience, Persistence, Special Play Time) and \\n4Cs of communication (Clear, specific and short instructions, Consistency between \\nwhat is said and done, across adults, over time and in different situations); Catch \\nthem good and Cut down critical comments)', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 28, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='3. Dealing with Inattention – disorganisation through structure and routines \\na. Helping him to make sense of time: Structuring the day \\nb. Helping in organising: Structure the physical environment (Home and \\nroom) \\nc. Helping in organising: Use of visual cues and prompts \\nd. Preparing in advance for daily routines \\ne. Helping in sustaining attention: Decrease off task distractibility, \\nincrease on task stimulation \\nf. Helping in sustaining attention: External motivators; and immediate', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 28, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='and powerful rewards \\n4. Attention enhancing tasks \\n5. Managing hyperactivity through environmental modifications', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 28, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='6. Home point (token economy) system (setting the rules) \\n7. Home point system (to reinforce desirable behaviours) \\n8. Home point system (Response cost/ penalty) and time outs \\n9. Anticipating and preparing in advance \\n10. Liaising with the School; Teacher-parent note \\n \\n \\nTable 14: Medications available in India for management of ADHD \\n \\nFormulation \\nStarting doses \\nMaximum \\nrecommended dose \\nSTIMULANTS \\nMethylphenidate \\nImmediate \\nrelease \\n(Duration of action: 1-4 \\nhours) \\nTablets,10 mg', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 29, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Tablets,10 mg \\n5mg once or b.i.d \\nMax. 60 mg \\nMethylphenidate \\nIntermediate \\nrelease \\n(Duration of action: 6-8 \\nhours \\nTablets, 10 mg, 18mg, \\n20 mg \\n10mg q.a.m. \\nMax 60 mg \\nMethylphenidate \\nLong \\nacting (OROS) (Duration \\nof action: 12 hours) \\nTablets, 18 mg, 36 mg, \\n54 mg \\n18 mg q.a.m. \\n72 mg \\nNON-STIMULANTS \\nAtomoxetine \\nTablet, capsule, 10mg, \\n18 mg, 25 mg, 40 mg \\n<70 \\nkg; \\n0.5 \\nmg/kg/day \\n>70 Kg; 40 mg/day \\nLesser \\nof \\n1.2 \\nmg/kg/day or 80 mg \\nClonidine \\nTablet 0.1 mg \\n< 45 kg, 0.05 mg', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 29, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='< 45 kg, 0.05 mg \\nq.h.s., titrate in \\n0.05 \\nmg \\nincrements b.i.d., \\nt.i.d., q.i.d \\n>45 kg 0.1 mg \\nq.h.s., titrate in 0.1 \\nmg \\nincrements \\nb.i.d., t.i.d., q.i.d \\n27-40.5 kg; 0.2 mg, \\n40.5-45 kg; 0.3 kg; \\n>45kg; 0.4 mg \\n \\n \\nTable 15: Side effects with medications and their management \\n \\nCommonly seen with  \\nMonitoring \\nInitial management \\nManagement if side effects \\npersist despite initial', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 29, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='management \\nAppetite \\nsuppression \\nMethylphenidate \\nAtomoxetine \\nWeight \\nevery visit \\nduring \\ntitration and \\nonce every 3 \\nmonths \\nthereafter;  \\nheight every \\n3-6 months \\n\\uf0b7 \\nDifferentiate \\nbetween pre-\\ntreatment eating \\nproblems from \\nmedication induced \\n\\uf0b7 \\nMedication should \\nbe taken either with \\nor after meals and \\nnot before meals \\n\\uf0b7 \\nBreakfast and late \\nevening meal should \\nbe high on calories \\nand nutrition \\n\\uf0b7 \\nDose reduction \\n\\uf0b7 \\nDiscontinuing \\nmedication on \\nweekends to prevent', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 30, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='weight loss \\n\\uf0b7 \\nChanging to another \\nclass of medication \\n \\nGrowth \\nretardation \\nMethylphenidate \\nPossibly with \\natomoxetine \\nSame as \\nabove \\n\\uf0b7 \\nIf the trajectory of \\ngrowth is \\nsuppressed and the \\nchild lags behind \\npeers significantly \\n(on for age charts) \\non weight or height, \\nrisk-benefit ratio \\nshould be weighed. \\n\\uf0b7 \\nDosage reduction \\n\\uf0b7 \\nInstitute weekend \\nand longer drug \\nholidays for catch up \\ngrowth \\n\\uf0b7 \\n Changing the class \\nof medication \\n\\uf0b7 \\nStop the drug  \\n\\uf0b7 \\nIf growth suppression', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 30, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='persists or growth \\nparameters are below \\nthe critical thresholds \\neven after stopping the \\ndrug (roughly below \\nthe third percentile \\nand growth velocity \\nfalling 2 centile lines \\nover 1 year), refer to a \\npediatric \\nendocrinologist \\nTachycardia \\nand rise in \\nblood pressure \\nMethylphenidate \\nAtomoxetine \\nMeasure \\nheart rate \\nand blood \\npressure \\nevery visit \\nduring \\ntitration, \\nand once \\nevery 3 \\nmonths \\n\\uf0b7 \\nIf there is sustained \\ntachycardia of more \\nthan 120 beats per \\nminute or systolic', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 30, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='minute or systolic \\nblood pressure or \\ndiastolic blood \\npressure more than \\n95th percentile \\nmeasured on 2 \\noccasions, reduce \\nthe dose and refer \\nto a cardiologist. \\n \\n\\uf0b7 \\nECG and \\nechocardiography may \\nbe needed to assess \\nfor arterial \\nhypertension and \\nruling out secondary \\ncauses of the same. If \\nthe BP > 95th \\npercentile even after \\ninstitution of \\ntreatment for \\nhypertension, then \\nstop  the medication \\nOrthostatic \\nhypotension  \\n(Fall in systolic \\nblood pressure \\nof at least 20', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 30, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='of at least 20 \\nmm HG or in \\ndiastolic blood \\npressure of 10 \\nmm Hg within 3 \\nminutes of \\nstanding) \\nClonidine  \\nSame as \\nabove. \\nMeasure \\nblood \\npressure for \\northostatic \\nfall \\n\\uf0b7 \\nGeneral measures to \\nprevent fall  \\n\\uf0b7 \\nDose reduction \\n\\uf0b7 \\nDivide the doses \\nwith frequent \\nmonitoring \\n \\n\\uf0b7 \\nChange of medication \\n\\uf0b7 \\nStop the medication \\nInsomnia \\nMethylphenidate \\nSleep onset, \\n\\uf0b7 \\nDifferentiate \\n\\uf0b7 \\nAdd low dose clonidine', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 30, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='duration and \\nquality \\nbetween pre-\\nexisting sleep \\nproblems and post-\\nmedication. \\n\\uf0b7 \\nSleep hygiene \\nmeasures  and \\nhealthy bedtime \\nroutines \\n\\uf0b7 \\nTake stimulant \\nmedications prior to \\n3.00 pm \\n\\uf0b7 \\nReduce dose, \\nespecially evening \\ndose of stimulant \\nor melatonin at night \\n\\uf0b7 \\nChange medication \\n \\nSedation  \\nClonidine  \\nSleep onset, \\nduration and \\nquality; \\ndaytime \\nsedation \\n\\uf0b7 \\nShift higher dose to \\nnight time  \\n\\uf0b7 \\nReduce dose \\nStop or change medication \\nTics (New \\nonset) \\nMethylphenidate', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 31, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Methylphenidate \\nMontior for \\ntics \\n\\uf0b7 \\nFirst consider if tics \\nare related to the \\nmedication or not; \\nbecause tics \\nnaturally wax and \\nwane and may be \\ncoincidental; if \\npossible observe for \\na prolonged period, \\ne.g. 3 months \\n\\uf0b7 \\nWeigh the risk-\\nbenefits,    \\nimpairment due to \\ntics vis-a-vis \\nimpairment due to \\nADHD symptoms \\nand discuss same \\nwith child and \\nparents \\n\\uf0b7 \\nDose reduction  \\n\\uf0b7 \\nPlanned \\ndiscontinuation of \\nstimulant \\n\\uf0b7 \\nChange to \\natomoxetine or \\nclonidine', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 31, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='clonidine \\nIf tics persist, start \\nclonidine or low dose \\nantipsychotic \\nMania/Psychosi\\ns  \\nMethylphenidate \\nMonitor for \\nside effects \\n\\uf0b7 \\nStop the medication  \\n \\n\\uf0b7 \\nIf symptoms persist, \\ntreat psychosis/ mania. \\n\\uf0b7 \\nAfter symptom \\nresolution, start \\nanother ADHD \\nmedication if there is \\nneed for \\npharmacological \\ntreatment  \\n\\uf0b7 \\nStimulants may be best \\navoided, especially if', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 31, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Footnote: If a medication is stopped due to side effects, monitor ADHD symptoms and the side effects; review \\nagain the need for medication for ADHD; and if there is need, then start with a medication from a different class \\n \\nTable 16: Factors determining the steps in management of ADHD \\nAge of the child \\nSeverity of ADHD (consider symptoms and impairments in various domains) \\nCo-morbidities and contra-indications  \\nSide effect profile and tolerability \\nCurrent needs of child and family', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 32, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Preferences of child and family \\nthe episode was \\nstimulant induced. \\nSeizures (New \\nonset) \\nMethylphenidate \\nSame as \\nabove \\n\\uf0b7 \\nStop the medication \\n\\uf0b7 \\nNeurologist referral \\nand assessment for \\ncause of seizure \\n\\uf0b7 \\nIf the drug seems to \\nbe innocuous it may \\nbe gradually re-\\nintroduced with \\ncontinued \\nmonitoring. \\n\\uf0b7 \\nIf seizures appear to \\nbe drug induced, \\nstart another \\nmedication after \\nreviewing the need \\nfor medication \\n \\nSuicidal \\nbehaviour \\nAtomoxetine \\nAsk patients \\nabout \\nsuicidal or', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 32, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='about \\nsuicidal or \\naggressive \\nideas or \\nimpulses \\n\\uf0b7 \\nStop the medication \\n\\uf0b7 \\nHigh risk \\nmanagement  \\n\\uf0b7 \\nNew onset \\nsymptoms must be \\nclosely monitored – \\npatient may need \\nadmission \\n\\uf0b7 \\nADHD medication \\nfrom a different \\nclass may be \\nstarted; do not start \\natomoxetine \\n \\nMood lability \\nand aggression \\nAtomoxetine \\nSame as \\nabove \\nSame as above \\n \\nHepatotoxicity \\n(If suspected \\neither clinically \\nor on \\ninvestigations) \\nAtomoxetine \\nMonitor \\nliver \\nenzymes  \\n\\uf0b7 \\nStop medication \\n\\uf0b7', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 32, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Stop medication \\n\\uf0b7 \\nMedical referral and \\nmanagement  \\n\\uf0b7 \\nADHD medication \\nfrom a different \\nclass may be \\nstarted; do not start \\natomoxetine', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 32, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='Availability \\nAffordability \\n \\nTable 17: Factors related to inadequate response to pharmacological or non-pharmacological \\ninterventions \\nPoor adherence  \\nSub-optimal dosing \\nCo-morbidities (for example, conduct disorder) \\nMismatch between needs and target goals of treatment \\nMis-diagnosis', metadata={'source': 'dataSet\\\\adhd_childadol.pdf', 'file_path': 'dataSet\\\\adhd_childadol.pdf', 'page': 33, 'total_pages': 39, 'format': 'PDF 1.4', 'title': '', 'author': 'PC2', 'subject': '', 'keywords': '', 'creator': 'Microsoft® Word 2010', 'producer': 'GPL Ghostscript 9.27', 'creationDate': \"D:20200601205221+02'00'\", 'modDate': \"D:20200601205221+02'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nUW PACC \\nPsychiatry and Addictions Case Conference \\nUW Medicine | Psychiatry and Behavioral Sciences \\n \\nADHD: SCREENING, ASSESSMENT, \\nAND TREATMENT MONITORING \\nWILLIAM P. FRENCH, MD \\nUW DEPARTMENT OF PSYCHIATRY AND \\nBEHAVIORAL SCIENCES \\nSEATTLE CHILDREN’S HOSPITAL', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 0, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nGENERAL DISCLOSURES \\nThe University of Washington School of \\nMedicine also gratefully acknowledges receipt of \\neducational grant support for this activity from \\nthe Washington State Legislature through the \\nSafety-Net Hospital Assessment, working to \\nexpand access to psychiatric services throughout \\nWashington State.', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 1, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nDISCLOSURE OF POTENTIAL CONFLICTS \\nSource \\nDisclosure \\nResearch Funding \\nPfizer, Shire \\nBooks, Intellectual Property \\nnone \\nAdvisor/ Consultant \\nnone \\nSpeakers’ Bureau \\nnone \\nEmployee \\nnone \\nIn-kind Services (example: travel) \\nnone \\nStock or Equity \\nnone \\nHonorarium or expenses for this \\npresentation or meeting \\nnone', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 2, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nOBJECTIVES \\n1. At participating in this program, learners will be \\nable to describe the strengths and limitations of \\nscreening tools to identify ADHD \\n2. At participating in this program, learners will be \\nable to describe the general components of a \\ncomprehensive assessment for ADHD \\n3. At participating in this program, learners will be \\nable several key aspects to successfully \\nmonitoring ADHD treatment response', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 3, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nADHD AS A SOURCE OF CONTROVERSY…\\n \\n \\n• NY Times search of “ADHD”: \\n– Thousands of Toddlers are Medicated for \\nADHD (May 2014) \\n– Reports Says Medications Use is Rising for \\nAdults with ADHD (May 2014) \\n– Expand Pre-K, Not ADHD (February 2014) \\n– Untangling the Myths About Attention \\nDisorder (March 2016) \\n \\nOther media:  \\nLast Child in the Woods: Saving Our Children From \\nNature-Deficit Disorder by Richard Louv (2008)', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 4, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nCAN OVER-STIMULATION (E.G., EXPOSURE TO RAPIDLY PACED TELEVISION \\nPROGRAMS IN THE FIRST 3 YEARS OF LIFE) INCREASE THE RISK OF \\nATTENTIONAL DEFICITS AT SCHOOL AGE?', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 5, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nShould We Be Thinking of Adult ADHD By Comparing It to \\nType-2 Diabetes?', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 6, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nPREVALENCE AND PROGNOSIS \\n• Prevalence 6-9% (2x boys); 4-5% in adults  \\n• Adult prevalence approximately ½ of youth prevalence \\n• Many will have symptoms persisting into adulthood. \\n– As many as 90% will still have some symptoms of ADHD, \\nnot necessarily meeting strict diagnostic criteria. \\n• Long-term consequences of ADHD:  \\n– Higher rates of traffic and other accidents, marital \\ndifficulties, unemployment, antisocial and criminal', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 7, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='behavior, and obesity. \\n– Lower household income attained \\n– Higher rates of attempted and \\n  completed suicide \\n \\nPliszka S. AACAP Work Group on \\nQuality Issues. Practice Parameter. J. \\nAm. Acad. Child Adolesc. Psychiatry \\n2007; 46(7):894-921. \\nFliers et al. ADHD Is a Risk Factor for \\nOverweight and Obesity in Children; J \\nDevelop & Behavior Peds 2013; \\n34:566-574. Ljung et al.  ADHD and \\nSuicidal Behavior; JAMA Psychiatry \\n2014; 71(8):958-964.', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 7, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nDSM-5 DIAGNOSTIC CRITERIA AND THE \\nFUNCTION OF SCREENING TOOLS', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 8, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nDIAGNOSIS \\n• Before 12 yo (versus prior to age 7 in DSM-IV) \\n• 6 months duration \\n• 2 or more settings \\n• Clinically significant impairment \\n• Not explained by other disorder \\n• 6 symptoms of inattention or hyperactivity or both \\n– Other DSM-5 updates: 5 symptoms for adults, examples included to \\nfacilitate diagnoses across the life span, cross-situational requirement \\nstrengthened to include several symptoms in each setting, subtypes', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 9, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='replaced with specifiers (which map to previous subtypes), autism is \\nno longer an exclusionary comorbid diagnosis \\n \\n \\nhttp://www.dsm5.org/ProposedRevision/Pag\\nes/proposedrevision.aspx?rid=383#.  \\nAccessed 4/25/12.', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 9, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nINATTENTION \\n•\\nLacks attention to detail/careless mistakes \\n•\\nDifficulty sustaining attention \\n•\\nDoes not seem to listen when spoken to \\n•\\nPoor follow through \\n•\\nDifficulty with organization \\n•\\nAvoids tasks requiring sustained mental effort \\n•\\nLoses things \\n•\\nEasily distracted \\n•\\nForgetful \\nhttp://www.dsm5.org/ProposedRevision/P\\nages/proposedrevision.aspx?rid=383#.  \\nAccessed 4/25/12.', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 10, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nHYPERACTIVITY/IMPULSIVITY \\n•\\nBlurts out answers before question completed \\n•\\nRuns/climbs excessively (restless in adolescents) \\n•\\nDifficulty staying in seat \\n•\\nDifficulty engaging in quiet activities \\n•\\n“On the go” \\n•\\nTalks excessively \\n•\\nInterrupts \\n•\\nDifficulty awaiting turn \\n•\\nFidgets \\n \\nhttp://www.dsm5.org/ProposedRevision/\\nPages/proposedrevision.aspx?rid=383#.  \\nAccessed 4/25/12.', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 11, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nSCHOOL-AGE VERSUS ADOLESCENT ADHD', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 12, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nTOOLS TO DISTINGUISH ADULT ADHD FROM OTHER DISORDERS \\nDiagnosis \\nKey Questions \\nDifferentiating Symptom \\nBehavioral Heath Measure \\nADHD \\nDo you struggle with impulsivity, hyperactivity, or \\nproblems with attention? \\nPoor focus \\nASRS v1.1 \\nMajor Depressive \\nDisorder \\nHave you been feeling depressed or having \\ndifficulty enjoying things in your life? \\nLow mood or anhedonia \\nPHQ-9 \\nBipolar Disorder:  \\nHypomania or Mania', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 13, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='Hypomania or Mania \\nDo you have periods of time with much less sleep \\nthan usual and not really missing it the next day? \\nDecreased need for sleep \\nMDQ \\nCIDI-3 \\n  \\nGeneralized Anxiety \\nDisorder \\nHave you been worrying excessively for greater \\nthan six months? Are you a worrier? \\nWorry \\nGAD-7 \\nObsessive Compulsive \\nDisorder \\nDo you have any repetitive thoughts or behaviors \\nthat bother you? \\nRepetitive thoughts or \\nbehaviors \\nYale Obsessive Compulsive Checklist \\n(Y-BOC) \\nLearning Disabilities', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 13, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='Do you have a history of poor academic \\nperformance in any specific domain?  \\nFailure to acquire reading, \\nwriting or math skills at age \\nexpected levels \\nNo measure available (consider \\npsychometric or neuropsychological \\ntesting) \\nAnti-social Personality \\nDisorder \\nDo you have a history of frequent fights, stealing, \\nvandalism or other legal problems? \\nGeneral disregard for and \\nviolation of the rights of \\nothers \\nNo measure available   \\nTrauma and PTSD', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 13, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='Trauma and PTSD \\nDo you have a history of trauma or abuse with \\nnightmares and flashbacks? \\nRecurring traumatic \\nmemories, hyperarousal, and \\navoidance behaviors \\nPCL-C \\nOther disorders to consider:  Mental retardation, Traumatic Brain Injury, Delirium, Dementia, Malingering', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 13, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nTOOLS TO DISTINGUISH CHILDHOOD ONSET ADHD \\nFROM OTHER DISORDERS \\nDiagnosis \\nKey Questions \\nDifferentiating Symptom \\nBehavioral Health Measure \\nADHD \\nDoes your child struggle with impulsivity, \\nhyperactivity, or problems with attention? \\nPoor focus \\nConnors Early Childhood (ages 2-6) \\nConnors 3 (ages 6-18); Vanderbilt \\n(non-proprietary, ages 6-12) \\nOppositional Defiant \\nDisorder \\nDoes your child often lose his or her temper,', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 14, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='argue or behave defiantly with adults, or become \\nresentful or vindictive when things do not go his \\nor her way? \\nContext dependent \\nemotional and behavioral \\nreactivity  \\nChild Behavior Check List (CBCL) \\nConduct Disorder  \\nDoes your child have a history of being aggression \\nto people or animals, destroying property, \\nstealing, or staying out all night? \\nGeneral disregard for and \\nviolation of the rights of \\nothers \\nCBCL \\nTrauma and PTSD \\nDoes your child have a history of severe neglect,', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 14, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='maltreatment, trauma or prolonged exposure to \\npsychosocial adversity? \\nRecurring traumatic \\nmemories, hyperarousal, \\nand avoidance behaviors \\nUCLA PTSD Index Trauma Screen,  \\nPCL-C \\nAutism Spectrum \\nDisorders \\nDoes your child have poor social skills and a \\nnarrow range of interests? \\nImpaired social \\ncommunication along with \\nrestricted interests  and \\nrepetitive behaviors \\nSocial Communication \\nQuestionnaire (SCQ) \\nOther disorders to consider:  Mental retardation, Traumatic Brain Injury', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 14, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nSYMPTOM ASSESSMENT SCALES \\nScale \\nDescription/ Features/ Comments \\nScale available from: \\nAdult Self-Report Scale  \\n \\nADHD DSM items reworded for adults; \\nscreener + 18 item;  frequency rating \\nwww.med.nyu.edu/Psych/training/adhd.\\nhtml and the WHO website \\nConners Adult ADHD \\nRating Scale (CAARS) \\nLarge item set of developmentally relevant \\nitems; DSM subscale maps onto \\ndiagnosis; self- and other-report forms \\nMulti Health Systems, Inc.', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='Wender-Reimherr Adult \\nAttention Deficit \\nDisorder Scale \\nRetrospective symptom scales provide age \\nof onset data; less clearly tied to DSM-\\nIV ADHD.  \\nFred W. Reimherr, MD, Salt Lake City,  \\nBarkley Adult ADHD Rating \\nScale-IV (BAARS-IV)  \\n \\nDimensional scale; uses actual DSM items \\nbut not re-worked for adults; behavior \\nin past 6 mos; self and other informant.   \\nrussellbarkley.org \\nBrown ADD Scale \\nRates inattention/executive dysfunction; \\nitems extend beyond DSM definition of', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='ADHD; good for high functioning \\nadults with inattentive subtype  \\nThe Psychological Corporation \\nAdult Investigator Symptom \\nReport Scale (AISRS) \\nInterviewer administered scale; 18 DSM-IV \\nADHD criteria worded for adults with \\nprompts. \\nLenard Adler, MD \\nadultADHD@med.nyu.edu  \\nAdult Symptom and Role \\nImpairment \\nInventories \\nSelf, Informant, & Clinician Inventories with \\nprompts for DSM diagnosis. \\nwww.DrSurman.org \\nSurman, Editor: ADHD in Adults in  \\nAdults: A Practical Guide to', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='Evaluation and Management', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 15, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nADULT SCREENING TOOL EXAMPLE', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 16, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nACCURATE DIAGNOSES AND THE ROLE OF RATING \\nSCALES \\n \\n• Over-reliance on parent- and teacher-completed rating \\nscales during the assessment process may lead to \\ninaccurate diagnoses \\n• ADHD rating scales have only moderate sensitivity \\nwhile their specificity ranges from low to moderate.   \\n• Additionally, there is often poor agreement between \\nparent and teacher responses. With these limitations in \\nmind, it is important to remember that rating scales', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 17, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='are best used as screening tools and to measure \\ntreatment response.  \\n• Rating scales are best used as screening tools and to \\nmeasure treatment response', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 17, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nCENTRAL ROLE OF IMPAIRMENT IN ASSESSMENT \\nAND TREATMENT \\n \\n• Impairment--that is, problems in daily life functioning that \\nresult from symptoms (rather than symptoms themselves) are  \\nwhat should be targeted in treatment \\n• Assessment of impairment in daily life functioning is a \\nfundamental aspect of initial evaluation \\n• Ongoing assessment of impairment in critical domains is \\nnecessary to determine the impact of and need for', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 18, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='modifications in treatment \\n• Normalization or minimization of impairment in daily life \\nfunctioning is the goal of treatment', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 18, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nQUESTIONS TO HELP ELICIT IMPAIRMENT \\n• Evaluate the burden of symptoms \\n•\\nDoes it show up differently in roles or contexts? \\n•\\nIs it an effort to compensate for?  \\n•   Consider impairment relative to potential \\n•\\nHow would individual function if symptoms resolved? \\n•\\n  Is there mismatch with role/environment? \\n•\\nWould change in role or environment remedy? \\n•\\n  Is concern exaggerated? \\n•\\nUnrealistic parental or individual expectations /', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 19, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='perfectionistic / inaccurate self-evaluation', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 19, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nSUMMARY OF KEY ADHD SCREENING \\nPOINTS \\n• ADHD is both underdiagnosed and over-diagnosed in different \\npopulations and should be routinely screened for during \\nregular office visits, especially if there are concerns for poor \\nconcentration and functional achievement below expected \\npotential \\n• Adults with concerns for ADHD may not have been diagnosed \\nas children and may present with different \\ncomplaints/symptoms', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 20, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='• Often exists with other co-morbid illnesses but symptoms may \\nalso represent a ADHD “mimic;” both should be screened for  \\n• Secondary gain may play a part in diagnostic picture \\n• Determining level of functional impairment is critical', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 20, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nBEYOND SCREENING TOOLS: ADDITIONAL \\nWORKUP CONSIDERATIONS', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 21, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nWORK-UP \\n• In general, no testing or imaging is indicated. \\n• Clinical diagnosis \\n– But some soft physical signs may be present, such as motor overflow \\nand clumsiness. \\n• Rating scales can help elicit symptoms. \\n• Comparison to peers \\n– Inattention/hyperactivity common in preschoolers.   \\n• Response to stimulants is not unique to individuals with \\nADHD. \\n• Consider psychological or neuropsychological testing if low', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 22, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='cognitive ability or achievement relative to ability. \\n \\nPliszka S. AACAP Work Group on Quality \\nIssues. Practice Parameter. J. Am. Acad. \\nChild Adolesc. Psychiatry 2007; \\n46(7):894-921.', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 22, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nWORK-UP  \\n•\\nIf other symptoms present, consider \\n– Lead \\n– Thyroid and other endocrine (eg, low testosterone in adults) \\n– Seizures \\n– OSA \\n– Anemia \\n– Trauma \\n– Substance abuse \\n– Sensory impairment \\n– Brain injury \\n– Genetic syndrome \\n \\n•\\nMedication side effects may mimic ADHD. \\n– Bronchodilators \\n– Corticosteroids \\n– Antihistamines \\n– Antipsychotics', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 23, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nCOMORBIDITY VS. ADHD MIMICS', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 24, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nPSYCHIATRIC MIMICS   \\n– Autism Spectrum  Disorder \\n– Intellectual Disability (not obvious) \\n– Depression (not comorbid) \\n– Anxiety and OCD \\n– Bipolar disorder (especially in adults) \\n– Eating Disorder \\n– Adjustment disorders \\n– ADHD personality (symptoms without impairment) \\n– Stimulant seeking (abuse, anorexia) \\n– Other substance abuse', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 25, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nOTHER FACTORS \\n– Poor fit between temperament, environment, and \\nexpectations \\n– Mercer Island ADHD  \\n– Marital dissatisfaction and other stressors \\n– Chaotic environments \\n– Fad? \\n– Excuse?', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 26, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nCOMMON CHILDHOOD COMORBIDITIES  \\n• Language or Learning problem (25-35%) \\n• ODD (55-85%) \\n• Substance abuse (20-40%) \\n• Conduct (10-20%) \\n• Anxiety (33%) \\n• Tic disorder (50%) \\n• Mood disorders \\n• Sleep problems \\n \\nPliszka S. AACAP Work Group on Quality Issues. \\nPractice Parameter. J. Am. Acad. Child Adolesc. \\nPsychiatry 2007; 46(7):894-921.', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 27, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nADULT COMORBIDITIES ARE COMMON AS WELL', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 28, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nADHD AND COMPLETED SUICIDE IN SCHOOL-AGED CHILDREN: \\nA CONNECTION?', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 29, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nADHD AND SUBSTANCE ABUSE \\n• ADHD diagnosis increases the risk of substance use and \\nnicotine dependence. \\n• Early stimulant treatment may reduce or delay the onset \\nof substance use disorder. \\n– Recent follow up data from the MTA revealed no harm or \\nbenefit from medication treatment in regard to rates of \\nadolescent substance abuse. \\nCharach A, et al. Childhood attention-deficit/hyperactivity \\ndisorder and future substance use disorders: comparative', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 30, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='meta-analyses. J Am Acad Child Adolesc Psychiatry 2011; 50:9–\\n21.  Wilens TE et al. Effect of prior stimulant treatment for \\nattention-deficit/hyperactivity disorder on subsequent risk for \\ncigarette smoking and alcohol and drug use disorders in \\nadolescents. Arch Pediatr Adolesc Med 2008; 162:916–921; \\nMolina Et al. Adolescent Substance Use in the Multimodal \\nTreatment Study of Attention-Deficit/Hyperactivity Disorder. J \\nAm Acad Child Adolesc Psychiatry 2013; 52: 251-263.', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 30, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nADHD AND SUBSTANCE ABUSE \\n• Stimulant misuse rates of 5-9% for grade school and high \\nschool (and 5-35% in college-age individuals) \\n• Consider longer-acting formulations, lisdexamfetamine, \\nand atomoxetine. \\n• ADHD medications used for adolescents with active \\nsubstance abuse are not as effective. \\n \\nWilens TE, Adler LA, Adamson J, et al. Misuse \\nand diversion of stimulants prescribed for \\nADHD: a systematic review of the literature. J', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 31, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='Am Acad Child Adolesc Psychiatry 2008; 47:21–\\n31.', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 31, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nTREATMENT MONITORING', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 32, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nTREATMENT MONITORING  \\n•\\nSymptoms may improve over time but oftentimes impairment \\npersists even if attenuated \\n•\\nMedication non-compliance is common; monitor for abuse and/or \\ndiversion \\n•\\nConsider use of long-acting stimulants and/or non-stimulants for \\npatients with substance abuse histories. \\n•\\nImportant to follow consensus guidelines, including frequent use of \\nfollow-up rating scales \\n•', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 33, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='•\\nHelp patients develop clear treatment goals so that expectations \\nare reasonable and functional improvement can be measured \\n•\\nCollect collateral data both during diagnostic phase and during \\noutcome monitoring', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 33, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nAGE-DEPENDENT DECLINE  \\nOF ADHD SYMPTOMS \\nBiederman J et al. Age-dependent decline of symptoms of attention deficit hyperactivity disorder:  \\nimpact of remission definition and symptom type. Am J Psychiatry. 2000 May;157(5):816-8. \\n0\\n20\\n40\\n60\\n80\\n100\\n<6\\n6-8\\n9-11\\n12-14\\n15-17\\n18-20\\nSyndromatic remission\\nSymptomatic remission\\nFunctional remission\\nAge (years) \\nAge-specific prevalence of remission from ADHD among 138 boys,', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 34, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='according to definition of remission and symptom type \\nn=138', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 34, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nVARIABILITY IN ADHD CARE IN  \\nCOMMUNITY-BASED PEDIATRICS \\n•\\n93% received medication, 13% received \\npsychosocial treatment \\n•\\nHalf using rating scales during assessment \\n•\\nVariability at patient but also practice level \\n•\\n“Almost no ADHD care follows ADHD \\nconsensus guideline recommendations for \\ntreatment” \\n•\\n“the proportion of children receiving \\npsychosocial treatment was miniscule” \\nEpstein et al. Pediatrics. 2014;134:1-8.', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 35, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nMEDICATION ADHERENCE AND \\nCONTINUITY \\n• ½ of the children experienced their first 30-day gap in \\nmedication supply within the first 3 months of treatment \\n• Fewer than ½ of the parents had contact with their physicians \\nwithin the first month of medication initiation with the \\naverage time being greater than 2 months \\n• The average time to the first medication change was over \\n3 months.   \\n• Results indicated that early physician contact and', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 36, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='titration were related to greater continuity and \\nmedication supply over a period of 1 year \\nBrinkman WB, Baum R, Kelleher KJ, Peugh J, Gardner W, Lichtenstein \\nP, Langberg J, Epstein JN. Relationship Between Attention-\\nDeficit/Hyperactivity Disorder Care and Medication Continuity. J Am \\nAcad Child Adolesc Psychiatry. 2016 Apr;55(4):289-94.', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 36, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nSUMMARY OF KEY POINTS \\n• ADHD is: \\n– Highly prevalent (8%-10% of children and adolescents; 4% \\n- 5% of adults) \\n– Familial  \\n– Neurobiologically-based but environmentally influenced \\n– Range of severity, mild to chronic and debilitating \\n(substantial comorbidity; severe academic, occupational, \\npersonal consequences)  \\n– Often chronic but symptoms may decline but impairments \\nremain or even increase over time due to cumulative \\neffect of illness', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 37, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='UW PACC \\n©2017 University of Washington \\nDIAGNOSIS \\n– Complicated by  heterogeneity, age, method, and practice \\nissues \\n– Absence of biomarker does not equate with subjectivity \\n– Rating scales are diagnostic tools but do not meet the \\nstandard of a laboratory test, especially in terms of \\nspecificity \\n– Further workup (eg, neuropsych testing, specialty referrals) \\nmay can be helpful for mimics and comorbidity \\n– Impairment is central and guides treatment', metadata={'source': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'file_path': 'dataSet\\\\ADHD_Screening_Diagnosis_and_Treatment_Monitoring_William_French_MD_01-04-2017.pdf', 'page': 38, 'total_pages': 39, 'format': 'PDF 1.5', 'title': 'PowerPoint Presentation', 'author': 'Towle, Cara B', 'subject': '', 'keywords': '', 'creator': 'Acrobat PDFMaker 15 for PowerPoint', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20170105152053-08'00'\", 'modDate': \"D:20170105152057-08'00'\", 'trapped': ''}),\n",
       " Document(page_content='May 2020\\ncep.health/ADHD\\nPage 1 of 7 \\nSections:        A        B        C        D        E        F        Resources        References\\nTABLE OF CONTENTS\\nThis tool is designed to support primary care providers in screening, diagnosing and implementing treatment for adult patients (≥ 18 years) \\nwith attention deficit hyperactivity disorder (ADHD). ADHD in adulthood can be associated with significant impairment in occupational,', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 0, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='academic, social and emotional functioning.1,2 The treatment of ADHD involves pharmacological and non-pharmacological interventions. \\nAttention Deficit Hyperactivity \\nDisorder in Adults\\nSection A: Screening and diagnosis\\nSection B: Initiating treatment\\nSection C: Pharmacological management\\nSection D: Non-pharmacological treatment options\\nSection E: Treatment for patients with comorbid \\nconditions and differential diagnosis\\nSection F: Maintenance and monitoring\\nResources\\npg.1\\npg.2\\npg.2\\npg.4', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 0, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='pg.1\\npg.2\\npg.2\\npg.4\\npg.5 \\npg.5\\npg.6\\nSECTION A: Screening and diagnosis \\nConsider screening for ADHD in primary care in adults who present with executive function difficulties, including those who do not have a childhood \\ndiagnosis of ADHD. Recent studies have shown that a substantial proportion of individuals with adult ADHD were not diagnosed or recognized in childhood.3\\nUse the Adult ADHD self-report scale (ASRS-V1.1) symptom checklist to screen patients for ADHD.6', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 0, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='The ASRS-V1.1 is designed to encourage dialogue between you and your patient to identify if they \\nhave symptoms of ADHD.3  If the patient has symptoms highly consistent with ADHD in adults, then \\ninvestigation is warranted using the diagnostic criteria below.6\\nConsider screening your patient who has:2\\n•\\tA hard time adjusting to structure and\\ntransitions in their life\\n•\\tBinge eating issues/fluctuating weight\\n•\\tEmotional dysregulation\\n•\\tFamily dysfunction\\n•\\tOccupational instability', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 0, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='•\\tPersistent perceived underachievement\\n•\\tPoor adherence to healthy lifestyle\\n•\\tRisk taking behaviour\\n•\\tTreatment resistant anxiety and/or\\ndepression\\nIn order to diagnose for ADHD, symptom manifestations of hyperactivity/impulsivity and/or \\ninattention should:7\\nThe following are examples of impairment that patients with ADHD may experience. \\nIf possible, ask the patient for permission to consult a third-party (a friend or family member) who is', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 0, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content=\"close to the patient and can offer further insight into their symptoms.\\nScreening\\nSome opportunities for screening\\nDiagnosis\\nCategories of impairment \\nLook for signs of ADHD and address it \\nwith your patient\\n“Were you diagnosed with ADHD as a child? \\nYou seem to have some symptoms of \\nADHD.  Let's do an assessment to check.”\\nTalk to your patient without judgment,\\nstigma or bias\\n“Many people don’t know that they have \\nbeen living with ADHD until adulthood.\", metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 0, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='It is a treatable and common condition, \\naffecting 3.4% of adults worldwide.\"3\\nTalking Points\\nEducational\\nProblems with:\\n•\\tFocusing\\n•\\tCompleting\\nassignments\\n•\\tMeeting\\ndeadlines\\nFamily\\nProblems with:\\n•\\t Family members\\n•\\tParenting\\n•\\tBalancing their\\nneeds against \\nthose of their \\nfamily\\nLife skills\\nProblems with:\\n•\\t Weight control\\n•\\t Sleeping\\n•\\t Perceived\\nunderachievement\\n•\\t Time management\\nOccupational\\nProblems with:\\n•\\t Performing\\nrequired duties\\n•\\t Keeping a job\\n•\\t Supervisors\\nSelf-concept', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 0, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='Self-concept\\nFeels:\\n•\\t Bad about\\nthemselves\\n•\\t Frustrated with\\nthemselves\\n•\\t Discouraged\\nSocial\\nProblems with:\\n•\\t Avoiding\\narguments\\n•\\t Getting along\\nwith people\\n•\\t Regulating\\nemotions\\nRisk\\nProblems with:\\n•\\t Aggressive\\ndriving\\n•\\t Substance use\\n•\\t Physical\\naggression\\nTable adapted from the Weiss functional impairment rating scale (WFIRS-S)10\\n\\uf06f\\nMeet the diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders \\n5th edition (DSM-5) for ADHD8,9\\n\\uf06f', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 0, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='\\uf06f\\nBe pervasive, occurring in two or more of the categories in the Categories of impairment \\ntable below\\n\\uf06f\\nCause at least moderate impairment in one category in the Categories of impairment table \\nbelow as identified in the initial assessment\\nDue to the barriers to accessing \\nspecialty care, this tool aims to \\nempower and guide primary care \\nproviders to manage adult ADHD \\nwithin the primary care setting. \\nFor additional support consult \\nspecialists across the province', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 0, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content=\"at OTN eConsult4 and find \\nmentors at the Ontario College \\nof Family Physician's (OCFP) \\nCollaborative Mental Health \\nNetwork.5\", metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 0, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='May 2020\\ncep.health/ADHD\\nPage 2 of 7 \\nSections:        A        B        C        D        E        F        Resources        References\\nSECTION B: Initiating treatment\\nDevelop a treatment plan with your patient that addresses their psychological, behavioural, \\noccupational and educational needs.7\\nTake into account:7\\n•\\thow symptoms and impairments affect the patient’s daily life activities, including sleep7', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 1, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='•\\tthe patient’s resilience and protective factors (positive self-esteem, success at school, steady \\nemployment, supportive family)7,11\\nDiscuss the following with your patient:7\\n•\\thow to use the Specific, Measurable, Achievable, Realistic, and Timely (S.M.A.R.T.) goals \\nframework to create S.M.A.R.T. methods for monitoring treatment effect (e.g. if a patient wants to focus more on their studies, be more \\nfinancially responsible, manage their time better)12', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 1, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='•\\thow other diagnosed mental health or neurodevelopmental conditions might affect their treatment decisions\\n•\\tthe benefits and risks of non-pharmacological and pharmacological treatments\\n•\\tthe importance of adherence to their treatment plan\\nReassure patients that their treatment \\nplan can be changed \\n“Nothing is set in stone. Your treatment \\noptions are negotiable, and we can always \\nrevisit at the next appointment.”\\nTalking Point\\nDiscuss the following when starting pharmacological treatment', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 1, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='\"When starting at a low dose it\\'s not uncommon to feel like the same dose is no longer \\nsupportive. This is normal and expected and we can increase the dose based on your needs.\"\\n\"It is important to maintain a routine and to take your medications at the same time  \\nevery day.\"\\n\"Avoid drinking excessive alcohol and caffeinated beverages while taking stimulants.\"\\nTalking Points\\nSECTION C: Pharmacological management', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 1, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='If a patient has a diagnosis of ADHD, pharmacological and non-pharmacological treatment should be used in parallel.\\n•\\tRevisit the patient’s S.M.A.R.T. goal methods to determine when their medication needs to be effective over an extended period of time (this can help \\ndetermine if medication is losing effect during the day)2\\n•\\tRule out contraindications to medication (e.g. uncontrolled hypertension, cardiovascular disease, uncontrolled epilepsy)2', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 1, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content=\"•\\tWhen prescribing stimulants for ADHD, use extended-release once-daily preparations (see SECTION C: First-line treatment options)7\\n•\\tPrescribe medication for no more than three months and have patient come back for review of medication (see SECTION F: Maintenance and monitoring)2\\n•\\tDocument the patient's blood pressure, pulse rate, BMI/weight and ASRS-V1.1 score at baseline and all subsequent visits to measure the effect of \\ntreatment for monitoring purposes2,4\\nConsiderations when prescribing\", metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 1, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='•\\t Choose extended-release stimulants \\nbecause of the higher risk of \\ndiversion and misuse affiliated with \\nimmediate-release medications2\\n•\\t Be aware of possible diversion by \\nsome patients who may request \\nthese medications for cognitive \\nenhancement or appetite suppression2\\nPT NAME\\nDATE\\nBLOOD PRESSURE\\nPULSE RATE\\nBMI/WEIGHT\\nASRS-V1.1 SCORE', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 1, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='May 2020\\ncep.health/ADHD\\nPage 3 of 7 \\nSections:        A        B        C        D        E        F        Resources        References\\nSECTION C: Pharmacological management (Continued)\\nThe medication list below is recommended for adult patients ≥ 18 years. It does not address patient populations <18 years of age. For a more \\ncomprehensive list of medication information such as adverse effects, consult each individual product monograph.', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 2, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content=\"Evidence supports the efficacy of the stimulants lisdexamfetamine or methylphenidate as first-line pharmacological treatment for adult patients \\nliving with ADHD.2,15\\n•\\tIf one stimulant doesn't work consider conducting a trial with another stimulant in the table2\\nFirst-line treatment options\\nMedication\\nFormulation\\nDosage\\nDuration \\nof action\\nAdverse effects 16, 35\\nODB  \\ncoverage\\nCost*\\nLisdexamfetamine \\n(Vyvanse ®)16,17,18\\n10 mg, 20 mg, \\n30 mg, 40 mg, \\n50 mg, 60 mg \\nand 70 mg \\ncapsules18\", metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 2, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='capsules18\\n10 mg, 20 mg, \\n30 mg, 40 mg, \\n50 mg and 60 \\nmg tablets18\\nInitial: 20-30 mg19 once daily in \\nthe morning; may increase in \\nincrements of 10 mg or 20 mg \\nat weekly intervals until optimal \\nresponse is obtained \\nMaximum: 60 mg/day19,20\\n13–14 \\nhours16\\nCommon adverse effects:  \\nRestlessness, irritability, anxiety, insomnia or \\nanorexia, worsening of aggressive behaviour or \\nhostility at the start of treatment\\n•\\tParadoxical psychiatric effects such as', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 2, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='rebound, restlessness, irritability, and \\nincreased aggression may be observed\\n•\\tSomatic effects such as insomnia, decreased \\nappetite, tics, stomach ache, and headache \\nare all common, especially at the beginning \\nof therapy\\n•\\tThe slower the rate of titration, the less \\nsevere the initial side effects\\n•\\tMany of these psychiatric and somatic side \\neffects will endure throughout treatment, \\nmaking drug holidays useful to assess impact \\nof relative risk vs. benefit, and necessitating', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 2, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='the regular monitoring of growth\\nDiscontinuation syndrome: \\nAbrupt withdrawal after prolonged use may result \\nin dysphoria, irritability or rebound in symptoms \\nof ADHD, increase in sleep and appetite reported. \\nConsider tapering over several weeks in patients \\nwho poorly tolerate discontinuation or have been \\non medication for longer than 3 months.\\nIf stimulants are taken in conjunction with an \\nantipsychotic, sudden discontinuation may result \\nin the emergence of extrapyramidal symptoms', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 2, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='previously masked by the stimulant.\\nNote:  \\nMonitor patient for suicidal thoughts/ideation; \\nconsider a change in treatment if concerns arise.\\nYes\\n$$$$$\\nMethylphenidate \\ncontrolled-\\nrelease capsules \\n(Biphentin®)16,21,22\\n10 mg, 15 mg, \\n20 mg, 30 mg, \\n40 mg, 50 mg, \\n60 mg and 80 \\nmg capsules22\\nInitial: 10–20 mg QAM PO; may \\nincrease by 5–10 mg Q 7 days16\\nMaximum: 80 mg/day16\\n10–12 \\nhours16\\nYes\\n$$$$\\nMethylphenidate \\ncontrolled-release \\ncapsules  \\n(Foquest ®)16,21,23\\n25 mg, 35 mg, \\n45 mg, 55 mg,', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 2, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='45 mg, 55 mg, \\n70 mg, 85 mg \\nand 100 mg \\ncapsules23\\nInitial: 25 QAM PO; may increase by \\n10–15 mg Q 5 days16\\nMaximum: 100 mg/day16\\nPatients who are already taking \\nmethylphenidate can convert to the \\nnext lower strength of Foquest® \\nbased on the total methylphenidate \\ndaily dose16\\n16 hours16\\nNo\\n$$$$$\\nMethylphenidate \\nbilayer controlled-\\nrelease tablets \\n(Concerta ®)16,21,24\\n18 mg, 27 mg, \\n36 mg, and 54 \\nmg tablets24\\nInitial: 18 mg QAM PO; may increase \\nby 9–18 mg Q 7 days16', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 2, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='Maximum: 72 mg/day16,19\\nConsult product monograph \\nfor dose conversion from other \\nmethylphenidate formulations16\\nNote: When possible, use the brand \\nname product of this medication as \\nthe generic brand version does not \\nhave the same bioequivalence and \\ndoes not work the same2\\n12 hours16\\nPartially \\ncovered\\n$$\\nCost of 30-day supply of mean dosage: $< $30 $$=$30–60 $$$=$60–90 $$$$=$90–120 $$$$$=$120–150\\n*Please note that dispensing fees have not been included', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 2, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='Note: reference to brand names does not imply endorsement of any of these products', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 2, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='May 2020\\ncep.health/ADHD\\nPage 4 of 7 \\nSections:        A        B        C        D        E        F        Resources        References\\nSECTION C: Pharmacological management (Continued)\\n•\\tMost patients will notice initial improvement but it may also take a number of months to get the choice of medication and dosage into the range \\nwhere the patient has the optimum benefit2\\n•\\tProgress should be reviewed regularly - initially at one month and then less frequently as the patient stabilizes', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 3, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='•\\tReview of ADHD symptoms, impairments and side effects should be discussed. The ASRS-V1.1 can also be used as a scale to follow changes in the \\npatient’s executive function. Inquiry as to how patients are managing with their S.M.A.R.T. methods are also important2,7\\n•\\tDose titration must be slower and monitored more carefully in patients with co-morbid conditions, neurodevelopment disorders and medical', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 3, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='conditions as outlined in SECTION E: Treatment for patients with comorbid conditions and differential diagnosis\\nTitrate starting at the lowest appropriate dose according to the product monograph, the patient’s symptoms and adverse effects until dose \\noptimisation is achieved (i.e. the patient experiences reduced symptoms; a positive behaviour change; or, improvements in education, employment and \\nrelationships, while reporting potential tolerable adverse effects).\\nTitration', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 3, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='Titration\\nSECTION D: Non-pharmacological treatment options\\nNon-pharmacological treatment should always be discussed when prescribing medication for ADHD in order to optimize the effects of the patients \\ntreatment.2 When available, the following maybe helpful:\\nFor additional support consider consulting the Canadian ADHD Resource Alliance (CADDRA) Guide to ADHD psychoeducation for tips on engaging \\nin pyschosocial treatment with your patient.28\\nConsider offering a print out of', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 3, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='the Patient resources section \\nfor more information on ADHD \\ncoaches, counselling, food \\nand nutrition, healthy lifestyle \\nmodifications, vocational advice, \\nfinancial resources and other tips\\nConsider a structured, supportive \\npsychological intervention focused \\non ADHD, such as cognitive \\nbehavioural therapy (CBT)7\\nOffer atomoxetine to adults if:7\\n• they cannot tolerate lisdexamfetamine or methylphenidate or', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 3, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='• their symptoms have not responded to separate six-week trials of lisdexamfetamine and methylphenidate, having considered alternative \\npreparations and adequate doses\\nCost of 30-day supply of mean dosage: $< $30 $$=$30–60 $$$=$60–90 $$$$=$90–120 $$$$$=$120–150\\n*Please note that dispensing fees have not been included\\nNote: reference to brand names does not imply endorsement of any of these products\\nSecond-line treatment options\\nMedication\\nFormulation\\nDosage\\nDuration of \\naction\\nAdverse effects', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 3, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='Adverse effects\\nODB  \\ncoverage\\nCost*\\nAtomoxetine \\n(Strattera ®)16,25,26\\n10 mg, 18 mg, 25 \\nmg, 40 mg, 60 mg, \\n80 mg and 100 mg \\ncapsules26\\nInitial: 60 mg then 80 \\nmg/day\\nMaintain dose for a \\nminimum of 7-14 days \\nbefore adjusting \\nMaximum: 100 mg/\\nday 19,27\\nNote: Generic versions \\nof this medication work \\nwell2\\n24 hours19\\nCommon adverse effects:  \\nRhinitis, upper abdominal pain, nausea, vomiting, \\ndecreased appetite, weight loss (seen initially, especially', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 3, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='if dose titrated too rapidly but levels off with time), \\ndizziness, headache, fatigue, emotional liability, \\ninsomnia (more common in adults), sexual dysfunction.\\nDiscontinuation syndrome:  \\nNo evidence to date that suggests a drug discontinuation \\nor withdrawal syndrome exists.\\nNote: Monitor patient for suicidal thoughts/ideation; \\nconsider a change in treatment if concerns arise.\\nPartially \\ncovered\\n$$$$$', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 3, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='May 2020\\ncep.health/ADHD\\nPage 5 of 7 \\nSections:        A        B        C        D        E        F        Resources        References\\nAbout 75% of adults with ADHD will have at least one other mental health condition (e.g. anxiety, a \\nmood disorder, personality disorder or substance use disorder) or a comorbid neurodevelopmental \\ncondition (e.g. autism spectrum disorder or a learning/intellectual disability).7,29 Consultation with', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 4, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='a psychiatrist or psychologist may be required for complex cases (see Provider resources).2 The \\ncomorbid conditions in this section are common in adults with ADHD, but it is not an exhaustive list.\\nSECTION E: Treatment for patients with comorbid conditions and differential diagnosis \\n\"We will need to treat your other \\nconditions for you to start feeling better. \\nIn order to do this, we will address the \\nmost important issues first.”\\nTalking Point\\nAcute psychotic or manic episodes', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 4, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='•\\tFor adults with ADHD experiencing an acute psychotic (e.g. hallucinations, \\ndelusions and disorganized thinking) or manic episode (e.g. abnormally \\nupbeat, jumpy or wired, increased activity, energy or agitation, decreased \\nneed for sleep)7,30,34\\n•\\tstop stimulant medication for ADHD7\\n•\\tconsider resuming or starting new ADHD medication after the episode \\nhas been treated2,7\\nAnxiety disorders\\n•\\tConsider the same medication choices to patients who have ADHD comorbid to', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 4, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='an anxiety disorder as offered to patients who have ADHD without a comorbid \\ncondition7\\n•\\tIn situations where anxiety is exacerbated by the ADHD, treat the anxiety first2\\n•\\tNote: anxiety is often secondary to unsupported ADHD2\\nSubstance use disorder (SUD)\\n•\\tIn adults with ADHD and an active SUD, the SUD is to be acknowledged and \\nideally stabilized before starting pharmacotherapy for ADHD1\\n•\\tTreatment with atomoxetine may be recommended as it has limited \\nabuse potential1', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 4, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='abuse potential1\\n•\\tLisdexamfetamine is also recommended because of its unique chemical \\nproperties that makes it difficult to abuse2\\n•\\tPatients with SUD benefit from additional structure in dispensation and \\nmonitoring for their safety:\\n•\\tConsider daily observed doses at the pharmacy2\\nBipolar disorder\\n•\\tPatients with co-occurring bipolar disorder and ADHD should be stabilized \\non a therapeutic dose of a mood-stabilizing medication before treating ADHD \\nwith a stimulant1\\nCardiovascular disease', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 4, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='•\\tAll patients should be monitored with regular blood pressure and pulse rate checks\\n•\\tIf a patient has significant cardiovascular disease or a family history of sudden \\ncardiac death in young family members, referral to a cardiologist should be \\nundertaken prior to treatment 2\\nDepression\\n•\\tFor patients with ADHD and co-occurring depression, consider combining \\nADHD treatment with an antidepressant \\n•\\tIf a patient has treatment-resistant depression, then the primary concern', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 4, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='may be the undiagnosed ADHD. When the ADHD is treated, the continued \\nuse of antidepressants may not be required1,2\\nGuidance for conducting follow-up visits with patients\\nThe recommended time frame after initiating treatment should be at three months, unless clinical indicators warrant the need for an earlier visit. See  \\nbelow on considerations to address during the follow-up visit.', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 4, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='•\\t Ongoing maintenance of the following is recommended: appetite, weight, sleep, cardiovascular, and wellness, including sexual performance2\\n•\\t Revisit the patient’s S.M.A.R.T goal methods for monitoring treatment effect from before treatment onset to assess the patient’s areas  \\nof improvement and change2\\n•\\t Ask patient if they notice the medication wearing off during the day (avoid adding a top-up medication)', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 4, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='•\\t Monitor and record the effectiveness of the patient’s medication for ADHD by conducting the ASRS-V1.1 at each visit to monitor for improvement7\\n•\\t Encourage the patient to monitor and record the effects associated with their medication, both positive and negative7,31\\nReview of medication and discontinuation\\n•\\t Review ADHD medication at least once a year and discuss with the patient whether medication should be continued7\\n•\\t Atomoxetine can be stopped at anytime without tapering2,20,35', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 4, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content=\"•\\t When tapering is warranted for lisdexamfetamine or methylphenidate, please decide based on patient's medical history and needs (i.e. if they have prolonged \\nuse of a stimulant and/or they are taking another medication in conjunction such as antipsychotics)35\\n•\\t Continue to document patient factors to monitor treatment effects at follow-up visits\\nPT NAME\\nDATE\\nBLOOD PRESSURE\\nPULSE RATE\\nBMI/WEIGHT\\nASRS-V1.1 SCORE\\nSECTION F: Maintenance and monitoring\", metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 4, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='May 2020\\ncep.health/ADHD\\nPage 6 of 7 \\nSections:        A        B        C        D        E        F        Resources        References\\nResources\\nProvider resources\\n[I]\\t\\nAdult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist Instructions: https://add.org/wp-content/uploads/2015/03/adhd-questionnaire-\\nASRS111.pdf\\n[II]\\t\\nCanadian ADHD Resource Alliance (CADDRA): https://www.caddra.ca/\\n[III]', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 5, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='[III]\\t\\nCanadian ADHD Resource Alliance (CADDRA) guide to ADHD psychosocial interventions: https://caddra.ca/pdfs/Psychosocial_October2016.pdf\\n[IV]\\t\\nCentre for ADHD awareness Canada (CADDAC): https://caddac.ca/adhd/\\n[V]\\t\\nDSM-5 diagnostic criteria for ADHD: https://images.pearsonclinical.com/images/assets/basc-3/basc3resources/DSM5_DiagnosticCriteria_ADHD.pdf\\n[VI]\\t\\nOTN eConsult: https://otn.ca/providers/ \\n \\nPatient resources\\nCognitive behavioural therapy, oaches, counselling and support groups', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 5, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='•\\tBig White Wall: https://www.bigwhitewall.com/\\n•\\tADHD coaches: https://caddac.ca/adhd/resources/clinicsagencies/\\n•\\tMindShift™ CBT app: https://www.anxietycanada.com/resources/\\nmindshift-cbt/ \\n•\\tOccupational therapy: https://www.caot.ca/site/findot\\n•\\tSupport groups: https://caddac.ca/adhd/resources/support-groups/\\nGeneral information, fact sheets, and recommended reading\\n•\\tCADDRA recommended reading list: https://www.caddra.ca/public-\\ninformation/adults/recommended-reading/', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 5, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='•\\tFact sheets for patients: https://chadd.org/understanding-adhd/adhd-\\nfact-sheets/\\n•\\tRed flags for adult ADHD: https://caddac.ca/adhd/wp-content/\\nuploads/2016/10/Red-Flags-for-Adult-ADHD.pdf\\n•\\tWhat you need to know about ADHD: https://caddac.ca/adhd/wp-content/\\nuploads/2019/02/What-You-Need-to-Know-About-ADHD_Final.pdf\\nFinancial aid, managing money and scholarships\\n•\\tFinancial aid and scholarships: https://caddac.ca/adhd/resources/\\nscholarships/', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 5, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='scholarships/\\n•\\tManaging money & ADHD: https://chadd.org/wp-content/\\nuploads/2019/08/ManageMoneyInfographic.pdf\\n•\\tMint app: https://www.mint.com/\\n•\\tSpending Tracker app: https://apps.apple.com/ca/app/spending-tracker/\\nid548615579\\nMental health \\n•\\tCanadian Mental Health Association (CMHA) resources:  \\nhttps://cmha.ca/\\nManaging social media \\n•\\tFreedom app:* https://freedom.to/\\n•\\tScreen Time (Apple products): https://support.apple.com/en-ca/\\nHT208982', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 5, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content=\"HT208982  \\n•\\tQuality Time (Android products): https://play.google.com/store/apps/\\ndetails?id=com.zerodesktop.appdetox.qualitytime&hl=en_CA\\nFood and nutrition\\n•\\tCanada's food guide:\\n•\\thttps://food-guide.canada.ca/en/\\n•\\thttps://food-guide.canada.ca/static/assets/pdf/CDG-EN-2018.pdf\\n•\\tChildren and Adults with Attention-Deficit/Hyperactivity Disorder \\n(CHADD) resource for nutrition and ADHD:  \\nhttps://chadd.org/about-adhd/nutrition-and-adhd/\\nRecreation programs, tutors, schools, and camps\", metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 5, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='•\\tRecreation programs, tutors, schools, and camps: https://caddac.ca/\\nadhd/resources/tutoring/\\nSetting routines and reminders\\n•\\tRoutinist app:* http://morningroutineapp.com/\\n•\\tRemember the Milk:* https://www.rememberthemilk.com/\\n•\\tEpicWin app:* https://apps.apple.com/ca/app/epicwin/id372927221\\nYouTube Videos\\n•\\tVideos from CADDAC: https://www.youtube.com/user/adhdvid/featured\\nOrganization and task management\\n•\\tEvernote app:* https://evernote.com/', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 5, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='•\\tOmniFocus:* https://www.omnigroup.com/omnifocus/\\n•\\tTodoist:* https://todoist.com/\\n•\\tEngross app:* https://engrossapp.com/\\nPodcasts\\n•\\tCADDAC Club ADHD the Podcast: https://caddac.ca/adhd/resources/\\npodcast/\\n*Costs may be associated', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 5, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='May 2020\\ncep.health/ADHD\\nPage 7 of 7 \\nSections:        A        B        C        D        E        F        Resources        References\\n[1]\\t UpToDate. Approach to treating attention deficit hyperactivity disorder in adults. 2019. \\n[cited 2019 November 13].\\n[2]\\t Expert opinion\\n[3]\\t UpToDate. Attention deficit hyperactivity disorder in adults: Epidemiology, pathogenesis, \\nclinical features, course, assessment, and diagnosis. 2018. [cited 2020 March 4].', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='[4]\\t Ontario Telemedicine Network. eConsult. [cited 2020 January 13]. Available from: https://\\notn.ca/providers/\\n[5]\\t Ontario College of Family Physicians. Collaborative Mental Health Network. [cited \\n2020 January 13]. Available from: https://www.ontariofamilyphysicians.ca/education/\\ncollaborative-mentoring-networks/collaborative-mental-health-network\\n[6]\\t Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist Instructions. [cited', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='2019 November 15]. Available from: https://add.org/wp-content/uploads/2015/03/\\nadhdquestionnaire-ASRS111.pdf\\n[7]\\t National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity \\ndisorder: diagnosis and management. 2018. [cited 2019 November 1]. Available from \\nhttps://www.nice.org.uk/guidance/ng87\\n[8]\\t American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='(DSM-5 ). 5th ed. Washington: American Psychiatric Publishing; 2013. Section II: Attention-\\nDeficit/HyperactivityDisorder; p.59-66. [cited 2019 December 1].\\n[9]\\t Attention-Deficit/Hyperactivity Disorder (ADHD). [cited 2019 December 1]. Available \\nfrom https://images.pearsonclinical.com/images/assets/basc-3/basc3resources/DSM5_\\nDiagnosticCriteria_ADHD.pdf\\n[10]\\t Weiss functional impairment rating scale-self report (WFIRS-S). [cited 2020 January 18].', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='Available from https://www.caddra.ca/wp-content/uploads/WFIRS-S.pdf\\n[11]\\t Government of Canada. Risk and protective factors. 2015. [cited 2020 February 20].\\nAvailable from https://www.publicsafety.gc.ca/cnt/cntrng-crm/crm-prvntn/fndng-prgrms/\\nrsk-fctrs-en.aspx\\n[12]\\t SMART goal worksheet. [cited 2020 January 18]. Available from https://www.mcckc.edu/\\ncounseling/goal-setting/docs/SMARTGoalWorksheet.pdf', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='[13]\\t Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD). Nutrition and ADHD. \\n[cited 2020 February 28]. Available from https://chadd.org/about-adhd/nutritionand-adhd/\\n[14]\\t Sample Patient Agreement Forms. [cited 2019 December 3]. Available from https://www.\\ndrugabuse.gov/sites/default/files/files/SamplePatientAgreementForms.pdf\\n[15]\\t UpToDate. Pharmacotherapy for attention deficit hyperactivity disorder in adults. 2019. [cited \\n2020 February 19].', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='2020 February 19].\\n[16]\\t RxTx. Attention-Deficit Hyperactivity Disorder. 2019. [cited 2019 November 12].\\n[17]\\t Ontario Drug Benefit Formulary/Comparative Drug Index. Lisdexamfetamine. [cited \\n2019 December 4]. Available from https://www.formulary.health.gov.on.ca/formulary/\\nresults.xhtml?q=Lisdexamfetamine%2B&type=1\\n[18]\\t Shire Pharma Canada ULC. Vyvanse®. [cited 2019 December 4]. Available from https://pdf.\\nhres.ca/dpd_pm/00052075.PDF', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='[19]\\t Canadian ADHD Resource Alliance (CADDRA). CADDRA Guide to ADHD Pharmacological \\nTreatments in Canada - January 2020. 2020. [cited 2020 February 14]. Available from \\nhttps://www.caddra.ca/wp-content/uploads/Medication_Chart_English_CANADA-1.pdf\\n[20]\\t Lexicomp. Lisdexamfetamine (Lexi-Drugs). [cited 2019 December 3].\\n[21]\\t Ontario Drug Benefit Formulary/Comparative Drug Index. Methylphenidate. [cited 2019 \\nDecember 4]. Available from https://www.formulary.health.gov.on.ca/formulary/results.', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='xhtml?q=methylphenidate%2B&type=1\\n[22]\\t Purdue Pharma. Biphentin®. [cited 2019 December 4]. Available from https://pdf.hres.ca/\\ndpd_pm/00049365.PDF\\n[23]\\t Purdue Pharma. Foquest®. [cited 2019 December 3]. Available from https://pdf.hres.ca/\\ndpd_pm/00049955.PDF\\n[24]\\t Janssen Inc. Concerta®. [cited 2019 December 4]. Available from https://pdf.hres.ca/\\ndpd_pm/00050777.PDF\\n[25]\\t Ontario Drug Benefit Formulary/Comparative Drug Index. Atomoxetine. [cited 2019', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='December 3]. Available from https://www.formulary.health.gov.on.ca/formulary/results.\\nxhtml?q=atomoxetine&type=1\\n[26]\\t Eli Lilly Canada Inc. Strattera®. [cited 2019 December 3]. Available from https://pdf.hres.ca/\\ndpd_pm/00032230.PDF\\n[27]\\t Lexicomp. AtoMOXetine (Lexi-Drugs). [cited 2019 December 4].\\n[28]\\t Canadian ADHD Resource Alliance. CADDRA Guide to ADHD Psychosocial \\nInterventions.2016. [cited 2020 February 19]. Available from https://caddra.ca/pdfs/\\nPsychosocial_October2016.pdf', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='[29]\\t BMJ Best Practice. Attention deficit hyperactivity disorder in adults. 2018. [cited 2019 \\nDecember 4].\\n[30]\\t Centre for Addiction and Mental Health (CAMH). First episode psychosis An \\ninformation guide. 2015. [cited 2020 February 20]. Available from https://www.\\ncamh.ca/-/media/files/guides-and-publications/first-episode-psychosis-guide-en.\\npdf?la=en&hash=E217B7A693F6AE0E4242A6535F922C50A1E24F78\\n[31]\\t Canadian ADHD Resource Alliance (CADDRA). CADDRA Patient ADHD Medication Form.', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='[cited 2020 February 28]. Available from https://www.caddra.ca/wp-content/uploads/\\nCADDRA-Patient-ADHD-Medication-Form.pdf\\n[32]\\t ConnexOntario. Intensive Case Management Program. [cited 2020 February 27]. Available \\nfrom https://www.connexontario.ca/\\n[33]\\t National Sleep Foundation. Sleep Diary. [cited 2020 February 27]. Available from https://\\nwww.sleepfoundation.org/sites/default/files/inline-files/SleepDiaryv6.pdf', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='[34]\\t Mayo Clinic. Bipolar disorder. 2018. [cited 2020 February 21]. Available from https://www.\\nmayoclinic.org/diseasesconditions/bipolar-disorder/symptoms-causes/syc-20355955\\n[35]\\t Virani AS, Bezchlibnyk-Butler KZ, Jeffries JJ, Procyshyn RM, editors. Clinical Handbook of \\nPsychotropic Drugs. 19th ed. Boston: Hogrefe Publishing Corp; 2012.\\nReferences', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='References\\nThe Attention Deficit Hyperactivity Disorder in Adults tool is a product of the Centre for Effective Practice. Permission to use, copy, and distribute this material is for all non-commercial and \\nresearch purposes is granted, provided the above disclaimer, this paragraph and the following paragraphs, and appropriate citations appear in all copies, modifications, and distributions. Use', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='of the Attention Deficit Hyperactivity Disorder in Adults Tool Tool for commercial purposes or any modifications of the Tool are subject to charge and must be negotiated with the Centre for \\nEffective Practice (Email: info@cep.health).\\nIn collaboration with:\\nFor statistical and bibliographic purposes, please notify the Centre for Effective Practice (info@cep.health) of any use or reprinting of the Tool.  \\nPlease use the below citation when referencing the Tool:', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='Reprinted with Permission from Centre for Effective Practice. (May 2020). Attention Deficit Hyperactivity Disorder (ADHD) in Adults: Ontario. Toronto: Centre for Effective \\nPractice.\\nThis Tool was developed as part of the Knowledge Translation in Primary Care Initiative, led by the Centre for Effective Practice in collaboration with the Ontario College of Family Physicians and the Nurse Practitioners’', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='Association of Ontario. Clinical leadership for the development of the Tool was provided by Ainslie Gray MD, MCFP and was subject to external review by health care providers and other relevant stakeholders. This Tool \\nwas funded by the Government of Ontario as part of the Knowledge Translation in Primary Care Initiative.', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='This Tool was developed for licensed health care professionals in Ontario as a guide only and does not constitute medical or other professional advice. Health care professionals are required to exercise their \\nown clinical judgement in using this Tool. Neither the Centre for Effective Practice (“CEP”), Ontario College of Family Physicians, Nurse Practitioners’ Association of Ontario, Government of Ontario, nor any of', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='their respective agents, appointees, directors, officers, employees, contractors, members or volunteers: (i) are providing medical, diagnostic or treatment services through this Tool; (ii) to the extent permitted by \\napplicable law, accept any responsibility for the use or misuse of this Tool by any individual including, but not limited to, primary care providers or entity, including for any loss, damage or injury (including death)', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='arising from or in connection with the use of this Tool, in whole or in part; or (iii) give or make any representation, warranty or endorsement of any external sources referenced in this Tool (whether specifically \\nnamed or not) that are owned or operated by third parties, including any information or advice contained therein.\\nDeveloped by:', metadata={'source': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'file_path': 'dataSet\\\\CEP_AdultADHD_2020.pdf', 'page': 6, 'total_pages': 7, 'format': 'PDF 1.7', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.0 (Macintosh)', 'producer': 'Adobe PDF Library 15.0', 'creationDate': \"D:20200420132210-04'00'\", 'modDate': \"D:20200420132701-04'00'\", 'trapped': ''}),\n",
       " Document(page_content='CLINICAL PRACTICE GUIDELINE\\nClinical Practice Guideline for the\\nDiagnosis, Evaluation, and Treatment of\\nAttention-Deﬁcit/Hyperactivity\\nDisorder in Children and Adolescents\\nMark L. Wolraich, MD, FAAP,a Joseph F. Hagan, Jr, MD, FAAP,b,c Carla Allan, PhD,d,e Eugenia Chan, MD, MPH, FAAP,f,g\\nDale Davison, MSpEd, PCC,h,i Marian Earls, MD, MTS, FAAP,j,k Steven W. Evans, PhD,l,m Susan K. Flinn, MA,n\\nTanya Froehlich, MD, MS, FAAP,o,p Jennifer Frost, MD, FAAFP,q,r Joseph R. Holbrook, PhD, MPH,s', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 0, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Christoph Ulrich Lehmann, MD, FAAP,t Herschel Robert Lessin, MD, FAAP,u Kymika Okechukwu, MPA,v\\nKaren L. Pierce, MD, DFAACAP,w,x Jonathan D. Winner, MD, FAAP,y William Zurhellen, MD, FAAP,z SUBCOMMITTEE ON CHILDREN AND\\nADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVE DISORDER\\nabstract\\nAttention-deﬁcit/hyperactivity disorder (ADHD) is one of the most common\\nneurobehavioral disorders of childhood and can profoundly affect children’s', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 0, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='academic achievement, well-being, and social interactions. The American Academy\\nof Pediatrics ﬁrst published clinical recommendations for evaluation and\\ndiagnosis of pediatric ADHD in 2000; recommendations for treatment followed\\nin 2001. The guidelines were revised in 2011 and published with an accompanying\\nprocess of care algorithm (PoCA) providing discrete and manageable steps by\\nwhich clinicians could fulﬁll the clinical guideline’s recommendations. Since the', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 0, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='release of the 2011 guideline, the Diagnostic and Statistical Manual of Mental\\nDisorders has been revised to the ﬁfth edition, and new ADHD-related research\\nhas been published. These publications do not support dramatic changes to\\nthe previous recommendations. Therefore, only incremental updates have been\\nmade in this guideline revision, including the addition of a key action statement\\nrelated to diagnosis and treatment of comorbid conditions in children and', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 0, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='adolescents with ADHD. The accompanying process of care algorithm has also\\nbeen updated to assist in implementing the guideline recommendations.\\nThroughout the process of revising the guideline and algorithm, numerous\\nsystemic barriers were identiﬁed that restrict and/or hamper pediatric clinicians’\\nability to adopt their recommendations. Therefore, the subcommittee created\\na companion article (available in the Supplemental Information) on systemic', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 0, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='barriers to the care of children and adolescents with ADHD, which identiﬁes the\\nmajor systemic-level barriers and presents recommendations to address those\\nbarriers; in this article, we support the recommendations of the clinical practice\\nguideline and accompanying process of care algorithm.\\naSection of Developmental and Behavioral Pediatrics, University of\\nOklahoma, Oklahoma City, Oklahoma; bDepartment of Pediatrics, The\\nRobert Larner, MD, College of Medicine, The University of Vermont,', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 0, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Burlington, Vermont; cHagan, Rinehart, and Connolly Pediatricians,\\nPLLC, Burlington, Vermont; dDivision of Developmental and Behavioral\\nHealth, Department of Pediatrics, Children’s Mercy Kansas City, Kansas\\nCity, Missouri; eSchool of Medicine, University of Missouri-Kansas City,\\nKansas City, Missouri; fDivision of Developmental Medicine, Boston\\nChildren’s Hospital, Boston, Massachusetts; gHarvard Medical School,\\nHarvard University, Boston, Massachusetts; hChildren and Adults with', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 0, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Attention-Deﬁcit/Hyperactivity Disorder, Lanham, Maryland; iDale\\nDavison, LLC, Skokie, Illinois; jCommunity Care of North Carolina,\\nRaleigh, North Carolina; kSchool of Medicine, University of North\\nCarolina, Chapel Hill, North Carolina; lDepartment of Psychology, Ohio\\nUniversity, Athens, Ohio; mCenter for Intervention Research in Schools,\\nOhio University, Athens, Ohio; nAmerican Academy of Pediatrics,\\nAlexandria, Virginia; oDepartment of Pediatrics, University of', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 0, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Cincinnati, Cincinnati, Ohio; pCincinnati Children’s Hospital Medical\\nCenter, Cincinnati, Ohio; qSwope Health Services, Kansas City, Kansas;\\nrAmerican Academy of Family Physicians, Leawood, Kansas; sNational\\nCenter on Birth Defects and Developmental Disabilities, Centers for\\nDisease Control and Prevention, Atlanta, Georgia; tDepartments of\\nBiomedical Informatics and Pediatrics, Vanderbilt University, Nashville,\\nTennessee; uThe Children’s Medical Group, Poughkeepsie, New York;', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 0, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='To cite: Wolraich ML, Hagan JF, Allan C, et al. AAP\\nSUBCOMMITTEE ON CHILDREN AND ADOLESCENTS WITH\\nATTENTION-DEFICIT/HYPERACTIVE DISORDER. Clinical Practice\\nGuideline for the Diagnosis, Evaluation, and Treatment of\\nAttention-Deﬁcit/Hyperactivity Disorder in Children and\\nAdolescents. Pediatrics. 2019;144(4):e20192528\\nPEDIATRICS Volume 144, number 4, October 2019:e20192528\\nFROM THE AMERICAN ACADEMY OF PEDIATRICS', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 0, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Downloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 0, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='INTRODUCTION\\nThis article updates and replaces the\\n2011 clinical practice guideline\\nrevision published by the American\\nAcademy of Pediatrics (AAP), “Clinical\\nPractice Guideline: Diagnosis and\\nEvaluation of the Child with\\nAttention-Deﬁcit/Hyperactivity\\nDisorder.”1 This guideline, like the\\nprevious document, addresses the\\nevaluation, diagnosis, and treatment\\nof attention-deﬁcit/hyperactivity\\ndisorder (ADHD) in children from age\\n4 years to their 18th birthday, with', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 1, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='special guidance provided for ADHD\\ncare for preschool-aged children and\\nadolescents. (Note that for the\\npurposes of this document,\\n“preschool-aged” refers to children\\nfrom age 4 years to the sixth\\nbirthday.) Pediatricians and other\\nprimary care clinicians (PCCs) may\\ncontinue to provide care after\\n18 years of age, but care beyond this\\nage was not studied for this guideline.\\nSince 2011, much research has\\noccurred, and the Diagnostic and\\nStatistical Manual of Mental Disorders,', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 1, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Fifth Edition (DSM-5), has been\\nreleased. The new research and DSM-\\n5 do not, however, support dramatic\\nchanges to the previous\\nrecommendations. Hence, this new\\nguideline includes only incremental\\nupdates to the previous guideline.\\nOne such update is the addition of\\na key action statement (KAS) about\\nthe diagnosis and treatment of\\ncoexisting or comorbid conditions in\\nchildren and adolescents with ADHD.\\nThe subcommittee uses the term\\n“comorbid,” to be consistent with the\\nDSM-5.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 1, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='DSM-5.\\nSince 2011, the release of new\\nresearch reﬂects an increased\\nunderstanding and recognition of\\nADHD’s prevalence and\\nepidemiology; the challenges it raises\\nfor children and families; the need for\\na comprehensive clinical resource for\\nthe evaluation, diagnosis, and\\ntreatment of pediatric ADHD; and the\\nbarriers that impede the\\nimplementation of such a resource. In\\nresponse, this guideline is supported\\nby 2 accompanying documents,\\navailable in the Supplemental', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 1, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Information: (1) a process of care\\nalgorithm (PoCA) for the diagnosis\\nand treatment of children and\\nadolescents with ADHD and (2) an\\narticle on systemic barriers to the\\ncare of children and adolescents with\\nADHD. These supplemental\\ndocuments are designed to aid PCCs\\nin implementing the formal\\nrecommendations for the evaluation,\\ndiagnosis, and treatment of children\\nand adolescents with ADHD. Although\\nthis document is speciﬁc to children\\nand adolescents in the United States', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 1, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='in some of its recommendations,\\ninternational stakeholders can modify\\nspeciﬁc content (ie, educational laws\\nabout accommodations, etc) as\\nneeded. (Prevention is addressed in\\nthe Mental Health Task Force\\nrecommendations.2)\\nPoCA for the Diagnosis and\\nTreatment of Children and\\nAdolescents With ADHD\\nIn this revised guideline and\\naccompanying PoCA, we recognize\\nthat evaluation, diagnosis, and\\ntreatment are a continuous process.\\nThe PoCA provides recommendations\\nfor implementing the guideline steps,', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 1, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='although there is less evidence for the\\nPoCA than for the guidelines. The\\nsection on evaluating and treating\\ncomorbidities has also been expanded\\nin the PoCA document.\\nSystems Barriers to the Care of\\nChildren and Adolescents With ADHD\\nThere are many system-level barriers\\nthat hamper the adoption of the best-\\npractice recommendations contained\\nin the clinical practice guideline and\\nthe PoCA. The procedures\\nrecommended in this guideline\\nnecessitate spending more time with', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 1, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='patients and their families,\\ndeveloping a care management\\nsystem of contacts with school and\\nother community stakeholders, and\\nproviding continuous, coordinated\\ncare to the patient and his or her\\nfamily. There is some evidence that\\nAfrican American and Latino children\\nare less likely to have ADHD\\ndiagnosed and are less likely to be\\ntreated for ADHD. Special attention\\nshould be given to these populations\\nwhen assessing comorbidities as they\\nrelate to ADHD and when treating for', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 1, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='ADHD symptoms.3 Given the\\nnationwide problem of limited access\\nto mental health clinicians,4\\npediatricians and other PCCs are\\nincreasingly called on to provide\\nservices to patients with ADHD and to\\ntheir families. In addition, the AAP\\nholds that primary care pediatricians\\nshould be prepared to diagnose and\\nmanage mild-to-moderate ADHD,\\nanxiety, depression, and problematic\\nsubstance use, as well as co-manage\\npatients who have more severe\\nconditions with mental health', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 1, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='professionals. Unfortunately, third-\\nparty payers seldom pay\\nappropriately for these time-\\nconsuming services.5,6\\nTo assist pediatricians and other\\nPCCs in overcoming such obstacles,\\nthe companion article on systemic\\nbarriers to the care of children and\\nadolescents with ADHD reviews the\\nbarriers and makes recommendations\\nto address them to enhance care for\\nchildren and adolescents with ADHD.\\nADHD EPIDEMIOLOGY AND SCOPE\\nPrevalence estimates of ADHD vary\\non the basis of differences in research', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 1, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='methodologies, the various age\\ngroups being described, and changes\\nin diagnostic criteria over time.7\\nAuthors of a recent meta-analysis\\ncalculated a pooled worldwide ADHD\\nprevalence of 7.2% among children8;\\nestimates from some community-\\nbased samples are somewhat higher,\\nat 8.7% to 15.5%.9,10 National survey\\ndata from 2016 indicate that 9.4% of\\nchildren in the United States 2 to\\n17 years of age have ever had an\\nADHD diagnosis, including 2.4% of\\nchildren 2 to 5 years of age.11 In that\\n2', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 1, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='2\\nFROM THE AMERICAN ACADEMY OF PEDIATRICS\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 1, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='national survey, 8.4% of children 2 to\\n17 years of age currently had ADHD,\\nrepresenting 5.4 million children.11\\nAmong children and adolescents with\\ncurrent ADHD, almost two-thirds\\nwere taking medication, and\\napproximately half had received\\nbehavioral treatment of ADHD in the\\npast year. Nearly one quarter had\\nreceived neither type of treatment of\\nADHD.11\\nSymptoms of ADHD occur in\\nchildhood, and most children with\\nADHD will continue to have\\nsymptoms and impairment through', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 2, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='adolescence and into adulthood.\\nAccording to a 2014 national survey,\\nthe median age of diagnosis was\\n7 years; approximately one-third of\\nchildren were diagnosed before\\n6 years of age.12 More than half of\\nthese children were ﬁrst diagnosed\\nby a PCC, often a pediatrician.12 As\\nindividuals with ADHD enter\\nadolescence, their overt hyperactive\\nand impulsive symptoms tend to\\ndecline, whereas their inattentive\\nsymptoms tend to persist.13,14\\nLearning and language problems are', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 2, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='common comorbid conditions with\\nADHD.15\\nBoys are more than twice as likely as\\ngirls to receive a diagnosis of\\nADHD,9,11,16 possibly because\\nhyperactive behaviors, which are\\neasily observable and potentially\\ndisruptive, are seen more frequently\\nin boys. The majority of both boys\\nand girls with ADHD also meet\\ndiagnostic criteria for another mental\\ndisorder.17,18 Boys are more likely to\\nexhibit externalizing conditions like\\noppositional deﬁant disorder or\\nconduct disorder.17,19,20 Recent', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 2, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='research has established that girls\\nwith ADHD are more likely than boys\\nto have a comorbid internalizing\\ncondition like anxiety or\\ndepression.21\\nAlthough there is a greater risk of\\nreceiving a diagnosis of ADHD for\\nchildren who are the youngest in\\ntheir class (who are therefore less\\ndevelopmentally capable of\\ncompensating for their weaknesses),\\nfor most children, retention is not\\nbeneﬁcial.22\\nMETHODOLOGY\\nAs with the original 2000 clinical\\npractice guideline and the 2011', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 2, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='revision, the AAP collaborated with\\nseveral organizations to form\\na subcommittee on ADHD (the\\nsubcommittee) under the oversight of\\nthe AAP Council on Quality\\nImprovement and Patient Safety.\\nThe subcommittee’s membership\\nincluded representation of a wide\\nrange of primary care and\\nsubspecialty groups, including\\nprimary care pediatricians,\\ndevelopmental-behavioral\\npediatricians, an epidemiologist from\\nthe Centers for Disease Control and\\nPrevention; and representatives from', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 2, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='the American Academy of Child and\\nAdolescent Psychiatry, the Society for\\nPediatric Psychology, the National\\nAssociation of School Psychologists,\\nthe Society for Developmental and\\nBehavioral Pediatrics (SDBP), the\\nAmerican Academy of Family\\nPhysicians, and Children and Adults\\nwith Attention-Deﬁcit/Hyperactivity\\nDisorder (CHADD) to provide\\nfeedback on the patient/parent\\nperspective.\\nThis subcommittee met over a 3.5-\\nyear period from 2015 to 2018 to\\nreview practice changes and newly', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 2, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='identiﬁed issues that have arisen\\nsince the publication of the 2011\\nguidelines. The subcommittee\\nmembers’ potential conﬂicts were\\nidentiﬁed and taken into\\nconsideration in the group’s\\ndeliberations. No conﬂicts prevented\\nsubcommittee member participation\\non the guidelines.\\nResearch Questions\\nThe subcommittee developed a series\\nof research questions to direct an\\nevidence-based review sponsored by\\n1 of the Evidence-based Practice\\nCenters of the US Agency for\\nHealthcare Research and Quality', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 2, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='(AHRQ).23 These questions assessed\\n4 diagnostic areas and 3 treatment\\nareas on the basis of research\\npublished in 2011 through 2016.\\nThe AHRQ’s framework was guided\\nby key clinical questions addressing\\ndiagnosis as well as treatment\\ninterventions for children and\\nadolescents 4 to 18 years of age.\\nThe ﬁrst clinical questions pertaining\\nto ADHD diagnosis were as follows:\\n1. What is the comparative\\ndiagnostic accuracy of approaches\\nthat can be used in the primary\\ncare practice setting or by', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 2, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='specialists to diagnose ADHD\\namong children younger than\\n7 years of age?\\n2. What is the comparative\\ndiagnostic accuracy of EEG,\\nimaging, or executive function\\napproaches that can be used in the\\nprimary care practice setting or by\\nspecialists to diagnose ADHD\\namong individuals aged 7 to their\\n18th birthday?\\n3. What are the adverse effects\\nassociated with being labeled\\ncorrectly or incorrectly as having\\nADHD?\\n4. Are there more formal\\nneuropsychological, imaging, or\\ngenetic tests that improve the', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 2, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='diagnostic process?\\nThe treatment questions were as\\nfollows:\\n1. What are the comparative safety\\nand effectiveness of pharmacologic\\nand/or nonpharmacologic\\ntreatments of ADHD in improving\\noutcomes associated with ADHD?\\n2. What is the risk of diversion of\\npharmacologic treatment?\\n3. What are the comparative safety\\nand effectiveness of different\\nmonitoring strategies to evaluate\\nthe effectiveness of treatment or\\nchanges in ADHD status (eg,\\nworsening or resolving\\nsymptoms)?', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 2, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='symptoms)?\\nPEDIATRICS Volume 144, number 4, October 2019\\n3\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 2, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='In addition to this review of the\\nresearch questions, the subcommittee\\nconsidered information from a review\\nof evidence-based psychosocial\\ntreatments for children and\\nadolescents with ADHD24 (which, in\\nsome cases, affected the evidence\\ngrade) as well as updated information\\non prevalence from the Centers for\\nDisease Control and Prevention.\\nEvidence Review\\nThis article followed the latest\\nversion of the evidence base update\\nformat used to develop the previous 3\\nclinical practice guidelines.24–26', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 3, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Under this format, studies were only\\nincluded in the review when they met\\na variety of criteria designed to\\nensure the research was based on\\na strong methodology that yielded\\nconﬁdence in its conclusions.\\nThe level of efﬁcacy for each\\ntreatment was deﬁned on the basis of\\nchild-focused outcomes related to\\nboth symptoms and impairment.\\nHence, improvements in behaviors on\\nthe part of parents or teachers, such\\nas the use of communication or\\npraise, were not considered in the', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 3, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='review. Although these outcomes are\\nimportant, they address how\\ntreatment reaches the child or\\nadolescent with ADHD and are,\\ntherefore, secondary to changes in the\\nchild’s behavior. Focusing on\\nimprovements in the child or\\nadolescent’s symptoms and\\nimpairment emphasizes the\\ndisorder’s characteristics and\\nmanifestations that affect children\\nand their families.\\nThe treatment-related evidence relied\\non a recent review of literature from\\n2011 through 2016 by the AHRQ of', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 3, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='citations from Medline, Embase,\\nPsycINFO, and the Cochrane Database\\nof Systematic Reviews.\\nThe original methodology and report,\\nincluding the evidence search and\\nreview, are available in their entirety\\nand as an executive summary at\\nhttps://effectivehealthcare.ahrq.gov/\\nsites/default/ﬁles/pdf/cer-203-adhd-\\nﬁnal_0.pdf.\\nThe evidence is discussed in more\\ndetail in published reports and\\narticles.25\\nGuideline Recommendations and Key\\nAction Statements\\nThe AAP policy statement,', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 3, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='“Classifying Recommendations for\\nClinical Practice Guidelines,” was\\nfollowed in designating aggregate\\nevidence quality levels for the\\navailable evidence (see Fig 1).27 The\\nAAP policy statement is consistent\\nwith the grading recommendations\\nadvanced by the University of\\nOxford Centre for Evidence Based\\nMedicine.\\nThe subcommittee reached consensus\\non the evidence, which was then used\\nto develop the clinical practice\\nguideline’s KASs.\\nWhen the scientiﬁc evidence was at\\nleast “good” in quality and', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 3, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='demonstrated a preponderance of\\nbeneﬁts over harms, the KAS provides\\na “strong recommendation” or\\n“recommendation.”27 Clinicians\\nshould follow a “strong\\nrecommendation” unless a clear and\\ncompelling rationale for an\\nalternative approach is present;\\nclinicians are prudent to follow\\na “recommendation” but are advised\\nto remain alert to new information\\nand be sensitive to patient\\npreferences27 (see Fig 1).\\nWhen the scientiﬁc evidence\\ncomprised lower-quality or limited', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 3, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='data and expert consensus or high-\\nquality evidence with a balance\\nbetween beneﬁts and harms, the KAS\\nprovides an “option” level of\\nrecommendation. Options are clinical\\ninterventions that a reasonable\\nhealth care provider might or might\\nnot wish to implement in the\\npractice.27 Where the evidence\\nwas lacking, a combination of\\nevidence and expert consensus\\nFIGURE 1\\nAAP rating of evidence and recommendations.\\n4\\nFROM THE AMERICAN ACADEMY OF PEDIATRICS', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 3, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Downloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 3, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='would be used, although this\\ndid not occur in these\\nguidelines, and all KASs\\nachieved a “strong\\nrecommendation” level except\\nfor KAS 7, on comorbidities,\\nwhich received a recommendation\\nlevel (see Fig 1).\\nAs shown in Fig 1, integrating\\nevidence quality appraisal with an\\nassessment of the anticipated balance\\nbetween beneﬁts and harms leads to\\na designation of a strong\\nrecommendation, recommendation,\\noption, or no recommendation.\\nOnce the evidence level was\\ndetermined, an evidence grade was', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 4, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='assigned. AAP policy stipulates that\\nthe evidence supporting each KAS be\\nprospectively identiﬁed, appraised,\\nand summarized, and an explicit link\\nbetween quality levels and the grade\\nof recommendation must be deﬁned.\\nPossible grades of recommendations\\nrange from “A” to “D,” with “A” being\\nthe highest:\\n• grade A: consistent level A studies;\\n• grade B: consistent level B or\\nextrapolations from level A studies;\\n• grade C: level C studies or\\nextrapolations from level B or level\\nC studies;', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 4, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='C studies;\\n• grade D: level D evidence or\\ntroublingly inconsistent or\\ninconclusive studies of any level;\\nand\\n• level X: not an explicit level of\\nevidence as outlined by the Centre\\nfor Evidence-Based Medicine. This\\nlevel is reserved for interventions\\nthat are unethical or impossible to\\ntest in a controlled or scientiﬁc\\nfashion and for which the\\npreponderance of beneﬁt or harm\\nis overwhelming, precluding\\nrigorous investigation.\\nGuided by the evidence quality and', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 4, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='grade, the subcommittee developed 7\\nKASs for the evaluation, diagnosis,\\nand treatment of ADHD in children\\nand adolescents (see Table 1).\\nThese KASs provide for consistent\\nand high-quality care for children and\\nadolescents who may have symptoms\\nsuggesting attention disorders or\\nproblems as well as for their families.\\nIn developing the 7 KASs, the\\nsubcommittee considered the\\nrequirements for establishing the\\ndiagnosis; the prevalence of ADHD;\\nthe effect of untreated ADHD; the', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 4, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='efﬁcacy and adverse effects of\\ntreatment; various long-term\\noutcomes; the importance of\\ncoordination between pediatric and\\nmental health service providers; the\\nvalue of the medical home; and the\\ncommon occurrence of comorbid\\nconditions, the importance of\\naddressing them, and the effects of\\nnot treating them.\\nThe subcommittee members with the\\nmost epidemiological experience\\nassessed the strength of each\\nrecommendation and the quality of\\nevidence supporting each draft KAS.\\nPeer Review', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 4, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Peer Review\\nThe guidelines and PoCA underwent\\nextensive peer review by more than\\n30 internal stakeholders (eg, AAP\\ncommittees, sections, councils, and\\ntask forces) and external stakeholder\\ngroups identiﬁed by the\\nsubcommittee. The resulting\\ncomments were compiled and\\nreviewed by the chair and vice chair;\\nrelevant changes were incorporated\\ninto the draft, which was then\\nreviewed by the full subcommittee.\\nKASS FOR THE EVALUATION,\\nDIAGNOSIS, TREATMENT, AND\\nMONITORING OF CHILDREN AND', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 4, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='ADOLESCENTS WITH ADHD\\nKAS 1\\nThe pediatrician or other PCC should\\ninitiate an evaluation for ADHD for\\nany child or adolescent age 4 years to\\nthe 18th birthday who presents with\\nacademic or behavioral problems and\\nsymptoms of inattention,\\nhyperactivity, or impulsivity\\n(Table 2). (Grade B: strong\\nrecommendation.)\\nThe basis for this recommendation is\\nessentially unchanged from the\\nprevious guideline. As noted, ADHD is\\nthe most common neurobehavioral\\ndisorder of childhood, occurring in', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 4, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='approximately 7% to 8% of children\\nand youth.8,18,28,29 Hence, the number\\nof children with this condition is far\\ngreater than can be managed by the\\nmental health system.4 There is\\nevidence that appropriate diagnosis\\ncan be accomplished in the primary\\ncare setting for children and\\nadolescents.30,31 Note that there is\\ninsufﬁcient evidence to recommend\\ndiagnosis or treatment for children\\nyounger than 4 years (other than\\nparent training in behavior\\nmanagement [PTBM], which does not', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 4, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='require a diagnosis to be applied); in\\ninstances in which ADHD-like\\nsymptoms in children younger than\\n4 years bring substantial impairment,\\nPCCs can consider making a referral\\nfor PTBM.\\nKAS 2\\nTo make a diagnosis of ADHD, the\\nPCC should determine that DSM-5\\ncriteria have been met, including\\ndocumentation of symptoms and\\nimpairment in more than 1 major\\nsetting (ie, social, academic, or\\noccupational), with information\\nobtained primarily from reports from\\nparents or guardians, teachers, other', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 4, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='school personnel, and mental health\\nclinicians who are involved in the\\nchild or adolescent’s care. The PCC\\nshould also rule out any alternative\\ncause (Table 3). (Grade B: strong\\nrecommendation.)\\nThe American Psychiatric Association\\ndeveloped the DSM-5 using expert\\nconsensus and an expanding research\\nfoundation.32 The DSM-5 system is\\nused by professionals in psychiatry,\\npsychology, health care systems, and\\nprimary care; it is also well\\nestablished with third-party payers.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 4, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='PEDIATRICS Volume 144, number 4, October 2019\\n5\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 4, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='The DSM-5 criteria deﬁne 4\\ndimensions of ADHD:\\n1. attention-deﬁcit/hyperactivity\\ndisorder primarily of the\\ninattentive presentation (ADHD/I)\\n(314.00 [F90.0]);\\n2. attention-deﬁcit/hyperactivity\\ndisorder primarily of the\\nhyperactive-impulsive\\npresentation (ADHD/HI) (314.01\\n[F90.1]);\\n3. attention-deﬁcit/hyperactivity\\ndisorder combined presentation\\n(ADHD/C) (314.01 [F90.2]); and\\n4. ADHD other speciﬁed and\\nunspeciﬁed ADHD (314.01\\n[F90.8]).\\nAs with the previous guideline\\nrecommendations, the DSM-5', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 5, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='classiﬁcation criteria are based on\\nthe best available evidence for\\nADHD diagnosis and are the\\nstandard most frequently used by\\nclinicians and researchers to render\\nthe diagnosis and document its\\nappropriateness for a given child.\\nThe use of neuropsychological\\ntesting has not been found to\\nimprove diagnostic accuracy in\\nmost cases, although it may have\\nbeneﬁt in clarifying the child\\nor adolescent’s learning\\nstrengths and weaknesses. (See the', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 5, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='TABLE 1 Summary of KASs for Diagnosing, Evaluating, and Treating ADHD in Children and Adolescents\\nKASs\\nEvidence Quality, Strength of Recommendation\\nKAS 1: The pediatrician or other PCC should initiate an evaluation for ADHD for any child or\\nadolescent age 4 years to the 18th birthday who presents with academic or behavioral\\nproblems and symptoms of inattention, hyperactivity, or impulsivity.\\nGrade B, strong recommendation', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 5, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='KAS 2: To make a diagnosis of ADHD, the PCC should determine that DSM-5 criteria have been\\nmet, including documentation of symptoms and impairment in more than 1 major setting\\n(ie, social, academic, or occupational), with information obtained primarily from reports\\nfrom parents or guardians, teachers, other school personnel, and mental health\\nclinicians who are involved in the child or adolescent’s care. The PCC should also rule out\\nany alternative cause.\\nGrade B, strong recommendation', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 5, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='KAS 3: In the evaluation of a child or adolescent for ADHD, the PCC should include a process\\nto at least screen for comorbid conditions, including emotional or behavioral conditions\\n(eg, anxiety, depression, oppositional deﬁant disorder, conduct disorders, substance use),\\ndevelopmental conditions (eg, learning and language disorders, autism spectrum\\ndisorders), and physical conditions (eg, tics, sleep apnea).\\nGrade B, strong recommendation', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 5, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='KAS 4: ADHD is a chronic condition; therefore, the PCC should manage children and\\nadolescents with ADHD in the same manner that they would children and youth with\\nspecial health care needs, following the principles of the chronic care model and the\\nmedical home.\\nGrade B, strong recommendation\\nKAS 5a: For preschool-aged children (age 4 years to the sixth birthday) with ADHD, the PCC\\nshould prescribe evidence-based PTBM and/or behavioral classroom interventions as the', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 5, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='ﬁrst line of treatment, if available.\\nGrade A, strong recommendation for PTBM\\nMethylphenidate may be considered if these behavioral interventions do not provide\\nsigniﬁcant improvement and there is moderate-to-severe continued disturbance in the\\n4- through 5-year-old child’s functioning. In areas in which evidence-based behavioral\\ntreatments are not available, the clinician needs to weigh the risks of starting\\nmedication before the age of 6 years against the harm of delaying treatment.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 5, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Grade B, strong recommendation for methylphenidate\\nKAS 5b. For elementary and middle school-aged children (age 6 years to the 12th birthday)\\nwith ADHD, the PCC should prescribe FDA-approved medications for ADHD, along with\\nPTBM and/or behavioral classroom intervention (preferably both PTBM and behavioral\\nclassroom interventions). Educational interventions and individualized instructional\\nsupports, including school environment, class placement, instructional placement, and', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 5, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='behavioral supports, are a necessary part of any treatment plan and often include an IEP\\nor a rehabilitation plan (504 plan).\\nGrade A, strong recommendation for medications\\nGrade A, strong recommendation for training and behavioral\\ntreatments for ADHD with family and school\\nKAS 5c. For adolescents (age 12 years to the 18th birthday) with ADHD, the PCC should\\nprescribe FDA-approved medications for ADHD with the adolescent’s assent. The PCC is', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 5, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='encouraged to prescribe evidence-based training interventions and/or behavioral\\ninterventions as treatment of ADHD, if available. Educational interventions and\\nindividualized instructional supports, including school environment, class placement,\\ninstructional placement, and behavioral supports, are a necessary part of any treatment\\nplan and often include an IEP or a rehabilitation plan (504 plan).\\nGrade A, strong recommendation for medications', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 5, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Grade A, strong recommendation for training and behavioral\\ntreatments for ADHD with the family and school\\nKAS 6. The PCC should titrate doses of medication for ADHD to achieve maximum beneﬁt with\\ntolerable side effects.\\nGrade B, strong recommendation\\nKAS 7. The PCC, if trained or experienced in diagnosing comorbid conditions, may initiate\\ntreatment of such conditions or make a referral to an appropriate subspecialist for', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 5, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='treatment. After detecting possible comorbid conditions, if the PCC is not trained or\\nexperienced in making the diagnosis or initiating treatment, the patient should be\\nreferred to an appropriate subspecialist to make the diagnosis and initiate treatment.\\nGrade C, recommendation\\n6\\nFROM THE AMERICAN ACADEMY OF PEDIATRICS\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 5, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='PoCA for more information on\\nimplementing this KAS.)\\nSpecial Circumstances: Preschool-Aged\\nChildren (Age 4 Years to the Sixth\\nBirthday)\\nThere is evidence that the diagnostic\\ncriteria for ADHD can be applied to\\npreschool-aged children.33–39 A\\nreview of the literature, including the\\nmultisite study of the efﬁcacy of\\nmethylphenidate in preschool-aged\\nchildren, found that the DSM-5\\ncriteria could appropriately identify\\nchildren with ADHD.25\\nTo make a diagnosis of ADHD in', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 6, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='preschool-aged children, clinicians\\nshould conduct a clinical interview\\nwith parents, examine and observe\\nthe child, and obtain information\\nfrom parents and teachers through\\nDSM-based ADHD rating scales.40\\nNormative data are available for the\\nDSM-5–based rating scales for ages\\n5 years to the 18th birthday.41 There\\nare, however, minimal changes in the\\nspeciﬁc behaviors from the DSM-IV,\\non which all the other DSM-based\\nADHD rating scales obtained\\nnormative data. Both the ADHD', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 6, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Rating Scale-IV and the Conners\\nRating Scale have preschool-age\\nnormative data based on the DSM-IV.\\nThe speciﬁc behaviors in the DSM-5\\ncriteria for ADHD are the same for all\\nchildren younger than 18 years (ie,\\npreschool-aged children, elementary\\nand middle school–aged children, and\\nadolescents) and are only minimally\\ndifferent from the DSM-IV. Hence, if\\nclinicians do not have the ADHD\\nRating Scale-5 or the ADHD Rating\\nScale-IV Preschool Version,42 any\\nother DSM-based scale can be used to', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 6, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='provide a systematic method for\\ncollecting information from parents\\nand teachers, even in the absence of\\nnormative data.\\nPediatricians and other PCCs should\\nbe aware that determining the\\npresence of key symptoms in this age\\ngroup has its challenges, such as\\nTABLE 2 KAS 1: The pediatrician or other PCC should initiate an evaluation for ADHD for any child or adolescent age 4 years to the 18th birthday who', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 6, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity. (Grade B: strong recommendation.)\\nAggregate evidence\\nquality\\nGrade B\\nBeneﬁts\\nADHD goes undiagnosed in a considerable number of children and adolescents. Primary care clinicians’ more-rigorous identiﬁcation\\nof children with these problems is likely to decrease the rate of undiagnosed and untreated ADHD in children and adolescents.\\nRisks, harm, cost', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 6, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Risks, harm, cost\\nChildren and adolescents in whom ADHD is inappropriately diagnosed may be labeled inappropriately, or another condition may be\\nmissed, and they may receive treatments that will not beneﬁt them.\\nBeneﬁt-harm\\nassessment\\nThe high prevalence of ADHD and limited mental health resources require primary care pediatricians and other PCCs to play\\na signiﬁcant role in the care of patients with ADHD and assist them to receive appropriate diagnosis and treatment. Treatments', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 6, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='available have good evidence of efﬁcacy, and a lack of treatment has the risk of impaired outcomes.\\nIntentional vagueness\\nThere are limits between what a PCC can address and what should be referred to a subspecialist because of varying degrees of skills\\nand comfort levels present among the former.\\nRole of patient\\npreferences\\nSuccess with treatment is dependent on patient and family preference, which need to be taken into account.\\nExclusions\\nNone.\\nStrength\\nStrong recommendation.\\nKey references', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 6, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Key references\\nWolraich et al31; Visser et al28; Thomas et al8; Egger et al30\\nTABLE 3 KAS 2: To make a diagnosis of ADHD, the PCC should determine that DSM-5 criteria have been met, including documentation of symptoms and\\nimpairment in more than 1 major setting (ie, social, academic, or occupational), with information obtained primarily from reports from parents', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 6, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='or guardians, teachers, other school personnel, and mental health clinicians who are involved in the child or adolescent’s care. The PCC should\\nalso rule out any alternative cause. (Grade B: strong recommendation.)\\nAggregate evidence\\nquality\\nGrade B\\nBeneﬁts\\nUse of the DSM-5 criteria has led to more uniform categorization of the condition across professional disciplines. The criteria are', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 6, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='essentially unchanged from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), for children up to\\ntheir 18th birthday, except that DSM-IV required onset prior to age 7 for a diagnosis, while DSM-5 requires onset prior to age 12.\\nRisks, harm, cost\\nThe DSM-5 does not speciﬁcally state that symptoms must be beyond expected levels for developmental (rather than chronologic) age', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 6, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='to qualify for an ADHD diagnosis, which may lead to some misdiagnoses in children with developmental disorders.\\nBeneﬁt-harm\\nassessment\\nThe beneﬁts far outweigh the harm.\\nIntentional vagueness\\nNone.\\nRole of patient\\npreferences\\nAlthough there is some stigma associated with mental disorder diagnoses, resulting in some families preferring other diagnoses, the\\nneed for better clarity in diagnoses outweighs this preference.\\nExclusions\\nNone.\\nStrength\\nStrong recommendation.\\nKey references', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 6, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Key references\\nEvans et al25; McGoey et al42; Young43; Sibley et al46\\nPEDIATRICS Volume 144, number 4, October 2019\\n7\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 6, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='observing symptoms across multiple\\nsettings as required by the DSM-5,\\nparticularly among children who do\\nnot attend a preschool or child care\\nprogram. Here, too, focused checklists\\ncan be used to aid in the diagnostic\\nevaluation.\\nPTBM is the recommended primary\\nintervention for preschool-aged\\nchildren with ADHD as well as\\nchildren with ADHD-like behaviors\\nwhose diagnosis is not yet veriﬁed.\\nThis type of training helps parents\\nlearn age-appropriate developmental\\nexpectations, behaviors that', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 7, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='strengthen the parent-child\\nrelationship, and speciﬁc\\nmanagement skills for problem\\nbehaviors. Clinicians do not need to\\nhave made an ADHD diagnosis before\\nrecommending PTBM because PTBM\\nhas documented effectiveness with\\na wide variety of problem behaviors,\\nregardless of etiology. In addition, the\\nintervention’s results may inform the\\nsubsequent diagnostic evaluation.\\nClinicians are encouraged to\\nrecommend that parents complete\\nPTBM, if available, before assigning\\nan ADHD diagnosis.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 7, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='an ADHD diagnosis.\\nAfter behavioral parent training is\\nimplemented, the clinician can\\nobtain information from parents and\\nteachers through DSM-5–based\\nADHD rating scales. The clinician\\nmay obtain reports about the\\nparents’ ability to manage their\\nchildren and about the child’s core\\nsymptoms and impairments.\\nReferral to an early intervention\\nprogram or enrolling in a PTBM\\nprogram can help provide\\ninformation about the child’s\\nbehavior in other settings or with\\nother observers. The evaluators for', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 7, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='these programs and/or early\\nchildhood special education teachers\\nmay be useful observers, as well.\\nSpecial Circumstances: Adolescents\\n(Age 12 Years to the 18th Birthday)\\nObtaining teacher reports for\\nadolescents is often more challenging\\nthan for younger children because\\nmany adolescents have multiple\\nteachers. Likewise, an adolescent’s\\nparents may have less opportunity to\\nobserve their child’s behaviors than\\nthey did when the child was younger.\\nFurthermore, some problems', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 7, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='experienced by children with ADHD\\nare less obvious in adolescents than\\nin younger children because\\nadolescents are less likely to exhibit\\novert hyperactive behavior. Of note,\\nadolescents’ reports of their own\\nbehaviors often differ from other\\nobservers because they tend to\\nminimize their own problematic\\nbehaviors.43–45\\nDespite these difﬁculties, clinicians\\nneed to try to obtain information\\nfrom at least 2 teachers or other\\nsources, such as coaches, school\\nguidance counselors, or leaders of', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 7, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='community activities in which the\\nadolescent participates.46 For the\\nevaluation to be successful, it is\\nessential that adolescents agree with\\nand participate in the evaluation.\\nVariability in ratings is to be\\nexpected because adolescents’\\nbehavior often varies between\\ndifferent classrooms and with\\ndifferent teachers. Identifying\\nreasons for any variability can\\nprovide valuable clinical insight into\\nthe adolescent’s problems.\\nNote that, unless they previously\\nreceived a diagnosis, to meet DSM-5', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 7, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='criteria for ADHD, adolescents must\\nhave some reported or documented\\nmanifestations of inattention or\\nhyperactivity/impulsivity before age\\n12. Therefore, clinicians must\\nestablish that an adolescent had\\nmanifestations of ADHD before age\\n12 and strongly consider whether\\na mimicking or comorbid condition,\\nsuch as substance use, depression,\\nand/or anxiety, is present.46\\nIn addition, the risks of mood and\\nanxiety disorders and risky sexual\\nbehaviors increase during\\nadolescence, as do the risks of', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 7, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='intentional self-harm and suicidal\\nbehaviors.31 Clinicians should also\\nbe aware that adolescents are at\\ngreater risk for substance use than\\nare younger children.44,45,47 Certain\\nsubstances, such as marijuana, can\\nhave effects that mimic ADHD;\\nadolescent patients may also attempt\\nto obtain stimulant medication to\\nenhance performance (ie, academic,\\nathletic, etc) by feigning symptoms.48\\nTrauma experiences, posttraumatic\\nstress disorder, and toxic stress are\\nadditional comorbidities and risk', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 7, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='factors of concern.\\nSpecial Circumstances: Inattention or\\nHyperactivity/Impulsivity (Problem\\nLevel)\\nTeachers, parents, and child health\\nprofessionals typically encounter\\nchildren who demonstrate behaviors\\nrelating to activity level, impulsivity,\\nand inattention but who do not fully\\nmeet DSM-5 criteria. When assessing\\nthese children, diagnostic criteria\\nshould be closely reviewed, which\\nmay require obtaining more\\ninformation from other settings and\\nsources. Also consider that these', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 7, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='symptoms may suggest other\\nproblems that mimic ADHD.\\nBehavioral interventions, such\\nas PTBM, are often beneﬁcial for\\nchildren with hyperactive/impulsive\\nbehaviors who do not meet full\\ndiagnostic criteria for ADHD.\\nAs noted previously, these programs\\ndo not require a speciﬁc diagnosis\\nto be beneﬁcial to the family. The\\nprevious guideline discussed\\nthe diagnosis of problem-level\\nconcerns on the basis of the\\nDiagnostic and Statistical Manual for\\nPrimary Care (DSM-PC), Child and', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 7, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Adolescent Version,49 and made\\nsuggestions for treatment and care.\\nThe DSM-PC was published in 1995,\\nhowever, and it has not been revised\\nto be compatible with the DSM-5.\\nTherefore, the DSM-PC cannot be\\nused as a deﬁnitive source for\\ndiagnostic codes related to ADHD and\\ncomorbid conditions, although it can\\nbe used conceptually as a resource for\\n8\\nFROM THE AMERICAN ACADEMY OF PEDIATRICS\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 7, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='by guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 7, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='enriching the understanding of\\nproblem-level manifestations.\\nKAS 3\\nIn the evaluation of a child or\\nadolescent for ADHD, the PCC should\\ninclude a process to at least screen\\nfor comorbid conditions, including\\nemotional or behavioral conditions\\n(eg, anxiety, depression, oppositional\\ndeﬁant disorder, conduct disorders,\\nsubstance use), developmental\\nconditions (eg, learning and language\\ndisorders, autism spectrum\\ndisorders), and physical conditions\\n(eg, tics, sleep apnea) (Table 4).', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 8, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='(Grade B: strong recommendation.)\\nThe majority of both boys and girls\\nwith ADHD also meet diagnostic\\ncriteria for another mental\\ndisorder.17,18 A variety of other\\nbehavioral, developmental, and\\nphysical conditions can be comorbid\\nin children and adolescents who are\\nevaluated for ADHD, including\\nemotional or behavioral conditions or\\na history of these problems. These\\ninclude but are not limited to learning\\ndisabilities, language disorder,\\ndisruptive behavior, anxiety, mood', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 8, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='disorders, tic disorders, seizures,\\nautism spectrum disorder,\\ndevelopmental coordination disorder,\\nand sleep disorders.50–66 In some\\ncases, the presence of a comorbid\\ncondition will alter the treatment\\nof ADHD.\\nThe SDBP is developing a clinical\\npractice guideline to support\\nclinicians in the diagnosis of\\ntreatment of “complex ADHD,” which\\nincludes ADHD with comorbid\\ndevelopmental and/or mental health\\nconditions.67\\nSpecial Circumstances: Adolescents\\n(Age 12 Years to the 18th Birthday)', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 8, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='At a minimum, clinicians should\\nassess adolescent patients with newly\\ndiagnosed ADHD for symptoms and\\nsigns of substance use, anxiety,\\ndepression, and learning disabilities.\\nAs noted, all 4 are common comorbid\\nconditions that affect the treatment\\napproach. These comorbidities make\\nit important for the clinician to\\nconsider sequencing psychosocial and\\nmedication treatments to maximize\\nthe impact on areas of greatest risk\\nand impairment while monitoring for\\npossible risks such as stimulant abuse', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 8, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='or suicidal ideation.\\nKAS 4\\nADHD is a chronic condition;\\ntherefore, the PCC should manage\\nchildren and adolescents with ADHD\\nin the same manner that they would\\nchildren and youth with special\\nhealth care needs, following the\\nprinciples of the chronic care model\\nand the medical home (Table 5).\\n(Grade B: strong recommendation.)\\nAs in the 2 previous guidelines, this\\nrecommendation is based on the\\nevidence that for many individuals,\\nADHD causes symptoms and\\ndysfunction over long periods of time,', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 8, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='even into adulthood. Available\\ntreatments address symptoms and\\nfunction but are usually not curative.\\nAlthough the chronic illness model\\nhas not been speciﬁcally studied in\\nchildren and adolescents with ADHD,\\nit has been effective for other chronic\\nconditions, such as asthma.68 In\\naddition, the medical home model has\\nbeen accepted as the preferred\\nstandard of care for children with\\nchronic conditions.69\\nThe medical home and chronic illness\\napproach may be particularly', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 8, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='beneﬁcial for parents who also have\\nADHD themselves. These parents can\\nbeneﬁt from extra support to help\\nthem follow a consistent schedule for\\nmedication and behavioral programs.\\nAuthors of longitudinal studies have\\nfound that ADHD treatments are\\nfrequently not maintained over\\ntime13 and impairments persist into\\nadulthood.70 It is indicated in\\nprospective studies that patients with\\nADHD, whether treated or not, are at\\nincreased risk for early death, suicide,\\nand increased psychiatric', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 8, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='TABLE 4 KAS 3: In the evaluation of a child or adolescent for ADHD, the PCC should include a process to at least screen for comorbid conditions, including\\nemotional or behavioral conditions (eg, anxiety, depression, oppositional deﬁant disorder, conduct disorders, substance use), developmental\\nconditions (eg, learning and language disorders, autism spectrum disorders), and physical conditions (eg, tics, sleep apnea). (Grade B: strong\\nrecommendation.)\\nAggregate evidence\\nquality\\nGrade B\\nBeneﬁts', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 8, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Grade B\\nBeneﬁts\\nIdentifying comorbid conditions is important in developing the most appropriate treatment plan for the child or adolescent with\\nADHD.\\nRisks, harm, cost\\nThe major risk is misdiagnosing the comorbid condition(s) and providing inappropriate care.\\nBeneﬁt-harm\\nassessment\\nThere is a preponderance of beneﬁts over harm.\\nIntentional vagueness\\nNone.\\nRole of patient\\npreferences\\nNone.\\nExclusions\\nNone.\\nStrength\\nStrong recommendation.\\nKey references', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 8, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Key references\\nCuffe et al51; Pastor and Reuben52; Bieiderman et al53; Bieiderman et al54; Bieiderman et al72; Crabtree et al57; LeBourgeois et al58;\\nChan115; Newcorn et al60; Sung et al61; Larson et al66; Mahajan et al65; Antshel et al64; Rothenberger and Roessner63; Froehlich et al62\\nPEDIATRICS Volume 144, number 4, October 2019\\n9\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 8, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='comorbidity, particularly substance\\nuse disorders.71,72 They also have\\nlower educational achievement than\\nthose without ADHD73,74 and\\nincreased rates of incarceration.75–77\\nTreatment discontinuation also\\nplaces individuals with ADHD at\\nhigher risk for catastrophic\\noutcomes, such as motor vehicle\\ncrashes78,79; criminality, including\\ndrug-related crimes77 and violent\\nreoffending76; depression71;\\ninterpersonal issues80; and other\\ninjuries.81,82\\nTo continue providing the best care, it', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 9, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='is important for a treating\\npediatrician or other PCC to engage in\\nbidirectional communication with\\nteachers and other school personnel\\nas well as mental health clinicians\\ninvolved in the child or adolescent’s\\ncare. This communication can be\\ndifﬁcult to achieve and is discussed in\\nboth the PoCA and the section on\\nsystemic barriers to the care of\\nchildren and adolescents with ADHD\\nin the Supplemental Information, as is\\nthe medical home model.69\\nSpecial Circumstances: Inattention', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 9, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='or Hyperactivity/Impulsivity\\n(Problem Level)\\nChildren with inattention or\\nhyperactivity/impulsivity at the\\nproblem level, as well as their\\nfamilies, may also beneﬁt from the\\nchronic illness and medical home\\nprinciples.\\nRecommendations for the Treatment\\nof Children and Adolescents With\\nADHD: KAS 5a, 5b, and 5c\\nRecommendations vary depending on\\nthe patient’s age and are presented\\nfor the following age ranges:\\na. preschool-aged children: age\\n4 years to the sixth birthday;\\nb. elementary and middle', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 9, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='school–aged children: age 6 years\\nto the 12th birthday; and\\nc. adolescents: age 12 years to the\\n18th birthday.\\nThe KASs are presented, followed by\\ninformation on medication,\\npsychosocial treatments, and special\\ncircumstances.\\nKAS 5a\\nFor preschool-aged children (age\\n4 years to the sixth birthday) with\\nADHD, the PCC should prescribe\\nevidence-based behavioral PTBM\\nand/or behavioral classroom\\ninterventions as the ﬁrst line of\\ntreatment, if available (grade A:\\nstrong recommendation).', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 9, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Methylphenidate may be considered\\nif these behavioral interventions do\\nnot provide signiﬁcant improvement\\nand there is moderate-to-severe\\ncontinued disturbance in the 4-\\nthrough 5-year-old child’s\\nfunctioning. In areas in which\\nevidence-based behavioral\\ntreatments are not available, the\\nclinician needs to weigh the risks of\\nstarting medication before the age of\\n6 years against the harm of delaying\\ntreatment (Table 6). (Grade B: strong\\nrecommendation.)\\nA number of special circumstances', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 9, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='support the recommendation to\\ninitiate PTBM as the ﬁrst treatment\\nof preschool-aged children (age\\n4 years to the sixth birthday) with\\nADHD.25,83 Although it was limited to\\nchildren who had moderate-to-\\nsevere dysfunction, the largest\\nmultisite study of methylphenidate\\nuse in preschool-aged children\\nrevealed symptom improvements\\nafter PTBM alone.83 The overall\\nevidence for PTBM among\\npreschoolers is strong.\\nPTBM programs for preschool-aged\\nchildren are typically group programs', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 9, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='and, although they are not always\\npaid for by health insurance, they\\nmay be relatively low cost. One\\nevidence-based PTBM, parent-child\\ninteraction therapy, is a dyadic\\ntherapy for parent and child. The\\nPoCA contains criteria for the\\nclinician’s use to assess the quality of\\nPTBM programs. If the child attends\\npreschool, behavioral classroom\\ninterventions are also recommended.\\nIn addition, preschool programs (such\\nas Head Start) and ADHD-focused\\norganizations (such as CHADD84) can', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 9, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='also provide behavioral supports. The\\nissues related to referral, payment,\\nand communication are discussed in\\nthe section on systemic barriers in\\nthe Supplemental Information.\\nTABLE 5 KAS 4: ADHD is a chronic condition; therefore, the PCC should manage children and adolescents with ADHD in the same manner that they would\\nchildren and youth with special health care needs, following the principles of the chronic care model and the medical home. (Grade B: strong\\nrecommendation.)', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 9, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='recommendation.)\\nAggregate evidence quality\\nGrade B\\nBeneﬁts\\nThe recommendation describes the coordinated services that are most appropriate to manage the condition.\\nRisks, harm, cost\\nProviding these services may be more costly.\\nBeneﬁt-harm assessment\\nThere is a preponderance of beneﬁts over harm.\\nIntentional vagueness\\nNone.\\nRole of patient\\npreferences\\nFamily preference in how these services are provided is an important consideration, because it can increase adherence.\\nExclusions\\nNone\\nStrength', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 9, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='None\\nStrength\\nStrong recommendation.\\nKey references\\nBrito et al69; Biederman et al72; Schefﬂer et al74; Barbaresi et al75; Chang et al71; Chang et al78; Lichtenstein et al77; Harstad and\\nLevy80\\n10\\nFROM THE AMERICAN ACADEMY OF PEDIATRICS\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 9, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='In areas in which evidence-based\\nbehavioral treatments are not\\navailable, the clinician needs to\\nweigh the risks of starting\\nmethylphenidate before the age\\nof 6 years against the harm of\\ndelaying diagnosis and treatment.\\nOther stimulant or nonstimulant\\nmedications have not been\\nadequately studied in children in\\nthis age group with ADHD.\\nKAS 5b\\nFor elementary and middle\\nschool–aged children (age 6 years to\\nthe 12th birthday) with ADHD, the\\nPCC should prescribe US Food and', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 10, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Drug Administration (FDA)–approved\\nmedications for ADHD, along with\\nPTBM and/or behavioral classroom\\nintervention (preferably both PTBM\\nand behavioral classroom interven-\\ntions). Educational interventions\\nand individualized instructional\\nsupports, including school environment,\\nclass placement, instructional\\nplacement, and behavioral supports,\\nare a necessary part of any\\ntreatment plan and often include an\\nIndividualized Education Program\\n(IEP) or a rehabilitation plan (504', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 10, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='plan) (Table 7). (Grade A: strong\\nrecommendation for medications;\\ngrade A: strong recommendation for\\nPTBM training and behavioral\\ntreatments for ADHD implemented\\nwith the family and school.)\\nThe evidence is particularly strong for\\nstimulant medications; it is sufﬁcient,\\nbut not as strong, for atomoxetine,\\nextended-release guanfacine, and\\nextended-release clonidine, in that\\norder (see the Treatment section, and\\nsee the PoCA for more information on\\nimplementation).\\nKAS 5c', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 10, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='KAS 5c\\nFor adolescents (age 12 years to the\\n18th birthday) with ADHD, the PCC\\nshould prescribe FDA-approved\\nmedications for ADHD with the\\nadolescent’s assent (grade A: strong\\nrecommendation). The PCC is\\nencouraged to prescribe evidence-\\nbased training interventions and/or\\nbehavioral interventions as treatment\\nof ADHD, if available. Educational\\ninterventions and individualized\\ninstructional supports, including\\nschool environment, class\\nplacement, instructional placement,', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 10, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='and behavioral supports, are\\na necessary part of any treatment\\nplan and often include an IEP or\\na rehabilitation plan (504 plan)\\n(Table 8). (Grade A: strong\\nrecommendation.)\\nTransition to adult care is an\\nimportant component of the chronic\\ncare model for ADHD. Planning for\\nthe transition to adult care is an\\nongoing process that may culminate\\nafter high school or, perhaps, after\\ncollege. To foster a smooth transition,\\nit is best to introduce components at\\nthe start of high school, at about', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 10, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='14 years of age, and speciﬁcally focus\\nduring the 2 years preceding high\\nschool completion.\\nPsychosocial Treatments\\nSome psychosocial treatments for\\nchildren and adolescents with ADHD\\nhave been demonstrated to be\\neffective for the treatment of ADHD,\\nincluding behavioral therapy and\\ntraining interventions.24–26,85 The\\ndiversity of interventions and\\noutcome measures makes it\\nchallenging to assess a meta-analysis\\nof psychosocial treatment’s effects\\nalone or in association with', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 10, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='medication treatment. As with\\nmedication treatment, the long-term\\npositive effects of psychosocial\\ntreatments have yet to be determined.\\nNonetheless, ongoing adherence\\nto psychosocial treatment is\\na key contributor to its beneﬁcial\\neffects, making implementation of\\na chronic care model for child health\\nimportant to ensure sustained\\nadherence.86\\nBehavioral therapy involves training\\nadults to inﬂuence the contingencies\\nin an environment to improve the\\nbehavior of a child or adolescent in', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 10, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='that setting. It can help parents and\\nschool personnel learn how to\\neffectively prevent and respond to\\nadolescent behaviors such as\\nTABLE 6 KAS 5a: For preschool-aged children (age 4 years to the sixth birthday) with ADHD, the PCC should prescribe evidence-based behavioral PTBM\\nand/or behavioral classroom interventions as the ﬁrst line of treatment, if available (grade A: strong recommendation). Methylphenidate may be', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 10, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='considered if these behavioral interventions do not provide signiﬁcant improvement and there is moderate-to-severe continued disturbance in\\nthe 4- through 5-year-old child’s functioning. In areas in which evidence-based behavioral treatments are not available, the clinician needs to\\nweigh the risks of starting medication before the age of 6 years against the harm of delaying treatment (grade B: strong recommendation).\\nAggregate evidence\\nquality\\nGrade A for PTBM; Grade B for methylphenidate', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 10, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Beneﬁts\\nGiven the risks of untreated ADHD, the beneﬁts outweigh the risks.\\nRisks, harm, cost\\nBoth therapies increase the cost of care; PTBM requires a high level of family involvement, whereas methylphenidate has some\\npotential adverse effects.\\nBeneﬁt-harm\\nassessment\\nBoth PTBM and methylphenidate have relatively low risks; initiating treatment at an early age, before children experience repeated\\nfailure, has additional beneﬁts. Thus, the beneﬁts outweigh the risks.\\nIntentional vagueness\\nNone.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 10, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='None.\\nRole of patient\\npreferences\\nFamily preference is essential in determining the treatment plan.\\nExclusions\\nNone.\\nStrength\\nStrong recommendation.\\nKey references\\nGreenhill et al83; Evans et al25\\nPEDIATRICS Volume 144, number 4, October 2019\\n11\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 10, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='interrupting, aggression, not\\ncompleting tasks, and not complying\\nwith requests. Behavioral parent and\\nclassroom training are well-\\nestablished treatments with\\npreadolescent children.25,87,88 Most\\nstudies comparing behavior therapy\\nto stimulants indicate that stimulants\\nhave a stronger immediate effect on\\nthe 18 core symptoms of ADHD.\\nParents, however, were more satisﬁed\\nwith the effect of behavioral therapy,\\nwhich addresses symptoms and\\nfunctions in addition to ADHD’s core', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 11, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='symptoms. The positive effects of\\nbehavioral therapies tend to persist,\\nbut the positive effects of medication\\ncease when medication stops.\\nOptimal care is likely to occur when\\nboth therapies are used, but the\\ndecision about therapies is heavily\\ndependent on acceptability by, and\\nfeasibility for, the family.\\nTraining interventions target skill\\ndevelopment and involve repeated\\npractice with performance feedback\\nover time, rather than modifying\\nbehavioral contingencies in a speciﬁc', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 11, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='setting. Less research has been\\nconducted on training interventions\\ncompared to behavioral treatments;\\nnonetheless, training interventions\\nare well-established treatments to\\ntarget disorganization of materials\\nand time that are exhibited by\\nmost youth with ADHD; it is likely\\nthat they will beneﬁt younger\\nchildren, as well.25,89 Some training\\ninterventions, including social\\nskills training, have not been shown\\nto be effective for children with\\nADHD.25', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 11, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='ADHD.25\\nTABLE 7 KAS 5b: For elementary and middle school–aged children (age 6 years to the 12th birthday) with ADHD, the PCC should prescribe US Food and\\nDrug Administration (FDA)–approved medications for ADHD, along with PTBM and/or behavioral classroom intervention (preferably both PTBM\\nand behavioral classroom interventions). Educational interventions and individualized instructional supports, including school environment,', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 11, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='class placement, instructional placement, and behavioral supports, are a necessary part of any treatment plan and often include an\\nIndividualized Education Program (IEP) or a rehabilitation plan (504 plan). (Grade A: strong recommendation for medications; grade A: strong\\nrecommendation for PTBM training and behavioral treatments for ADHD implemented with the family and school.)\\nAggregate evidence\\nquality', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 11, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='quality\\nGrade A for Treatment with FDA-Approved Medications; Grade A for Training and Behavioral Treatments for ADHD With the Family and\\nSchool.\\nBeneﬁts\\nBoth behavioral therapy and FDA-approved medications have been shown to reduce behaviors associated with ADHD and to improve\\nfunction.\\nRisks, harm, cost\\nBoth therapies increase the cost of care. Psychosocial therapy requires a high level of family and/or school involvement and may lead', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 11, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='to increased family conﬂict, especially if treatment is not successfully completed. FDA-approved medications may have some\\nadverse effects and discontinuation of medication is common among adolescents.\\nBeneﬁt-harm\\nassessment\\nGiven the risks of untreated ADHD, the beneﬁts outweigh the risks.\\nIntentional vagueness\\nNone.\\nRole of patient\\npreferences\\nFamily preference, including patient preference, is essential in determining the treatment plan and enhancing adherence.\\nExclusions\\nNone.\\nStrength', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 11, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='None.\\nStrength\\nStrong recommendation.\\nKey references\\nEvans et al25; Barbaresi et al73; Jain et al103; Brown and Bishop104; Kambeitz et al105; Bruxel et al106; Kieling et al107; Froehlich et al108;\\nJoensen et al109\\nTABLE 8 KAS 5c: For adolescents (age 12 years to the 18th birthday) with ADHD, the PCC should prescribe FDA-approved medications for ADHD with the\\nadolescent’s assent (grade A: strong recommendation). The PCC is encouraged to prescribe evidence-based training interventions and/or', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 11, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='behavioral interventions as treatment of ADHD, if available. Educational interventions and individualized instructional supports, including school\\nenvironment, class placement, instructional placement, and behavioral supports, are a necessary part of any treatment plan and often include\\nan IEP or a rehabilitation plan (504 plan). (Grade A: strong recommendation.)\\nAggregate evidence\\nquality\\nGrade A for Medications; Grade A for Training and Behavioral Therapy\\nBeneﬁts', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 11, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Beneﬁts\\nTraining interventions, behavioral therapy, and FDA-approved medications have been demonstrated to reduce behaviors associated\\nwith ADHD and to improve function.\\nRisks, harm, cost\\nBoth therapies increase the cost of care. Psychosocial therapy requires a high level of family and/or school involvement and may lead\\nto unintended increased family conﬂict, especially if treatment is not successfully completed. FDA-approved medications may have', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 11, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='some adverse effects, and discontinuation of medication is common among adolescents.\\nBeneﬁt-harm\\nassessment\\nGiven the risks of untreated ADHD, the beneﬁts outweigh the risks.\\nIntentional vagueness\\nNone.\\nRole of patient\\npreferences\\nFamily preference, including patient preference, is likely to predict engagement and persistence with a treatment.\\nExclusions\\nNone.\\nStrength\\nStrong recommendation.\\nKey references', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 11, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Key references\\nEvans et al25; Webster-Stratton et al87; Evans et al95; Fabiano et al93; Sibley and Graziano et al94; Langberg et al96; Schultz et al97; Brown\\nand Bishop104; Kambeitz et al105; Bruxel et al106; Froehlich et al108; Joensen et al109\\n12\\nFROM THE AMERICAN ACADEMY OF PEDIATRICS\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 11, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Some nonmedication treatments for\\nADHD-related problems have either\\ntoo little evidence to recommend them\\nor have been found to have little or no\\nbeneﬁt. These include mindfulness,\\ncognitive training, diet modiﬁcation,\\nEEG biofeedback, and supportive\\ncounseling. The suggestion that\\ncannabidiol oil has any effect on ADHD\\nis anecdotal and has not been\\nsubjected to rigorous study. Although\\nit is FDA approved, the efﬁcacy for\\nexternal trigeminal nerve stimulation\\n(eTNS) is documented by one 5-week', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 12, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='randomized controlled trial with just\\n30 participants receiving eTNS.90 To\\ndate, there is no long-term safety and\\nefﬁcacy evidence for eTNS. Overall, the\\ncurrent evidence supporting\\ntreatment of ADHD with eTNS is\\nsparse and in no way approaches the\\nrobust strength of evidence\\ndocumented for established\\nmedication and behavioral treatments\\nfor ADHD; therefore, it cannot be\\nrecommended as a treatment of ADHD\\nwithout considerably more extensive\\nstudy on its efﬁcacy and safety.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 12, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Special Circumstances: Adolescents\\nMuch less research has been\\npublished on psychosocial treatments\\nwith adolescents than with younger\\nchildren. PTBM has been modiﬁed to\\ninclude the parents and adolescents\\nin sessions together to develop\\na behavioral contract and improve\\nparent-adolescent communication\\nand problem-solving (see above).91\\nSome training programs also include\\nmotivational interviewing\\napproaches. The evidence for this\\nbehavioral family approach is mixed', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 12, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='and less strong than PTBM with pre-\\nadolescent children.92–94 Adolescents’\\nresponses to behavioral contingencies\\nare more varied than those of\\nyounger children because they can\\noften effectively obstruct behavioral\\ncontracts, increasing parent-\\nadolescent conﬂict.\\nTraining approaches that are focused\\non school functioning skills have\\nconsistently revealed beneﬁts for\\nadolescents.95–97 The greatest\\nbeneﬁts from training interventions\\noccur when treatment is continued', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 12, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='over an extended period of time,\\nperformance feedback is constructive\\nand frequent, and the target\\nbehaviors are directly applicable to\\nthe adolescent’s daily functioning.\\nOverall, behavioral family approaches\\nmay be helpful to some adolescents\\nand their families, and school-based\\ntraining interventions are well\\nestablished.25,94 Meaningful\\nimprovements in functioning have\\nnot been reported from cognitive\\nbehavioral approaches.\\nMedication for ADHD\\nPreschool-aged children may', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 12, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='experience increased mood lability\\nand dysphoria with stimulant\\nmedications.83 None of the\\nnonstimulants have FDA approval for\\nuse in preschool-aged children. For\\nelementary school–aged students, the\\nevidence is particularly strong for\\nstimulant medications and is\\nsufﬁcient, but less strong, for\\natomoxetine, extended-release\\nguanfacine, and extended-release\\nclonidine (in that order). The effect\\nsize for stimulants is 1.0 and for\\nnonstimulants is 0.7. An individual’s', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 12, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='response to methylphenidate verses\\namphetamine is idiosyncratic, with\\napproximately 40% responding to\\nboth and about 40% responding to\\nonly 1. The subtype of ADHD does not\\nappear to be a predictor of response\\nto a speciﬁc agent. For most\\nadolescents, stimulant medications\\nare highly effective in reducing\\nADHD’s core symptoms.73\\nStimulant medications have an effect\\nsize of around 1.0 (effect size =\\n[treatment M 2 control M)/control\\nSD]) for the treatment of ADHD.98', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 12, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Among nonstimulant medications, 1\\nselective norepinephrine reuptake\\ninhibitor, atomoxetine,99,100 and 2\\nselective a-2 adrenergic agonists,\\nextended-release guanfacine101,102\\nand extended-release clonidine,103\\nhave also demonstrated efﬁcacy in\\nreducing core symptoms among\\nschool-aged children and adolescents,\\nalthough their effect sizes, —around\\n0.7 for all 3, are less robust than that\\nof stimulant medications.\\nNorepinephrine reuptake inhibitors\\nand a-2 adrenergic agonists are', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 12, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='newer medications, so, in general, the\\nevidence base supporting them is\\nconsiderably less than that for\\nstimulants, although it was adequate\\nfor FDA approval.\\nA free list of the currently available,\\nFDA-approved medications for ADHD\\nis available online at www.\\nADHDMedicationGuide.com. Each\\nmedication’s characteristics are\\nprovided to help guide the clinician’s\\nprescription choice. With the\\nexpanded list of medications, it is less\\nlikely that PCCs need to consider the', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 12, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='off-label use of other medications.\\nThe section on systemic barriers in\\nthe Supplemental Information\\nprovides suggestions for fostering\\nmore realistic and effective payment\\nand communication systems.\\nBecause of the large variability in\\npatients’ response to ADHD\\nmedication, there is great interest in\\npharmacogenetic tools that can help\\nclinicians predict the best medication\\nand dose for each child or adolescent.\\nAt this time, however, the available\\nscientiﬁc literature does not provide', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 12, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='sufﬁcient evidence to support their\\nclinical utility given that the genetic\\nvariants assayed by these tools have\\ngenerally not been fully studied with\\nrespect to medication effects on\\nADHD-related symptoms and/or\\nimpairment, study ﬁndings are\\ninconsistent, or effect sizes are not of\\nsufﬁcient size to ensure clinical\\nutility.104–109 For that reason, these\\npharmacogenetics tools are not\\nrecommended. In addition, these tests\\nmay cost thousands of dollars and are\\ntypically not covered by insurance.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 12, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='For a pharmacogenetics tool to be\\nrecommended for clinical use, studies\\nwould need to reveal (1) the genetic\\nvariants assayed have consistent,\\nreplicated associations with\\nPEDIATRICS Volume 144, number 4, October 2019\\n13\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 12, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='medication response; (2) knowledge\\nabout a patient’s genetic proﬁle\\nwould change clinical decision-\\nmaking, improve outcomes and/or\\nreduce costs or burden; and (3) the\\nacceptability of the test’s operating\\ncharacteristics has been\\ndemonstrated (eg, sensitivity,\\nspeciﬁcity, and reliability).\\nSide Effects\\nStimulants’ most common short-term\\nadverse effects are appetite loss,\\nabdominal pain, headaches, and\\nsleep disturbance. The Multimodal\\nTreatment of Attention Deﬁcit', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 13, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Hyperactivity Disorder (MTA) study\\nresults identiﬁed stimulants as having\\na more persistent effect on decreasing\\ngrowth velocity compared to most\\nprevious studies.110 Diminished\\ngrowth was in the range of 1 to 2 cm\\nfrom predicted adult height. The\\nresults of the MTA study were\\nparticularly noted among children\\nwho were on higher and more\\nconsistently administered doses of\\nstimulants.110 The effects diminished\\nby the third year of treatment, but no\\ncompensatory rebound growth was', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 13, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='observed.110 An uncommon signiﬁcant\\nadverse effect of stimulants is the\\noccurrence of hallucinations and other\\npsychotic symptoms.111\\nStimulant medications, on average,\\nincrease patient heart rate (HR) and\\nblood pressure (BP) to a mild and\\nclinically insigniﬁcant degree (average\\nincreases: 1–2 beats per minute for HR\\nand 1–4 mm Hg for systolic and\\ndiastolic BP).112 However, because\\nstimulants have been linked to more\\nsubstantial increases in HR and BP in\\na subset of individuals (5%–15%),', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 13, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='clinicians are encouraged to monitor\\nthese vital signs in patients receiving\\nstimulant treatment.112 Although\\nconcerns have been raised about\\nsudden cardiac death among children\\nand adolescents using stimulant and\\nmedications,113 it is an extremely rare\\noccurrence. In fact, stimulant\\nmedications have not been shown to\\nincrease the risk of sudden death\\nbeyond that observed in children who\\nare not receiving stimulants.114–118\\nNevertheless, before initiating therapy', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 13, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='with stimulant medications, it is\\nimportant to obtain the child or\\nadolescent’s history of speciﬁc cardiac\\nsymptoms in addition to the family\\nhistory of sudden death,\\ncardiovascular symptoms, Wolff-\\nParkinson-White syndrome,\\nhypertrophic cardiomyopathy, and\\nlong QT syndrome. If any of these risk\\nfactors are present, clinicians should\\nobtain additional evaluation to\\nascertain and address potential safety\\nconcerns of stimulant medication use\\nby the child or adolescent.112,114', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 13, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Among nonstimulants, the risk of\\nserious cardiovascular events is\\nextremely low, as it is for stimulants.\\nThe 3 nonstimulant medications that\\nare FDA approved to treat ADHD (ie,\\natomoxetine, guanfacine, and\\nclonidine) may be associated with\\nchanges in cardiovascular parameters\\nor other serious cardiovascular events.\\nThese events could include increased\\nHR and BP for atomoxetine and\\ndecreased HR and BP for guanfacine\\nand clonidine. Clinicians are\\nrecommended to not only obtain the', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 13, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='personal and family cardiac history, as\\ndetailed above, but also to perform\\nadditional evaluation if risk factors are\\npresent before starting nonstimulant\\nmedications (ie, perform an\\nelectrocardiogram [ECG] and possibly\\nrefer to a pediatric cardiologist if the\\nECG is not normal).112\\nAdditional adverse effects of\\natomoxetine include initial\\nsomnolence and gastrointestinal tract\\nsymptoms, particularly if the dosage is\\nincreased too rapidly, and decreased\\nappetite.119–122 Less commonly, an', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 13, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='increase in suicidal thoughts has been\\nfound; this is noted by an FDA black\\nbox warning. Extremely rarely,\\nhepatitis has been associated with\\natomoxetine. Atomoxetine has also\\nbeen linked to growth delays\\ncompared to expected trajectories in\\nthe ﬁrst 1 to 2 years of treatment, with\\na return to expected measurements\\nafter 2 to 3 years of treatment, on\\naverage. Decreases were observed\\namong those who were taller or\\nheavier than average before\\ntreatment.123\\nFor extended-release guanfacine and', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 13, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='extended-release clonidine, adverse\\neffects include somnolence, dry\\nmouth, dizziness, irritability,\\nheadache, bradycardia, hypotension,\\nand abdominal pain.30,124,125 Because\\nrebound hypertension after abrupt\\nguanfacine and clonidine\\ndiscontinuation has been\\nobserved,126 these medications\\nshould be tapered off rather than\\nsuddenly discontinued.\\nAdjunctive Therapy\\nAdjunctive therapies may be\\nconsidered if stimulant therapy is not\\nfully effective or limited by side\\neffects. Only extended-release', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 13, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='guanfacine and extended-release\\nclonidine have evidence supporting\\ntheir use as adjunctive therapy with\\nstimulant medications sufﬁcient to\\nhave achieved FDA approval.127 Other\\nmedications have been used in\\ncombination on an off-label basis,\\nwith some limited evidence available\\nto support the efﬁcacy and safety of\\nusing atomoxetine in combination\\nwith stimulant medications to\\naugment treatment of ADHD.128\\nSpecial Circumstances: Preschool-Aged\\nChildren (Age 4 Years to the Sixth\\nBirthday)', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 13, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Birthday)\\nIf children do not experience\\nadequate symptom improvement\\nwith PTBM, medication can be\\nprescribed for those with moderate-\\nto-severe ADHD. Many young children\\nwith ADHD may require medication\\nto achieve maximum improvement;\\nmethylphenidate is the recommended\\nﬁrst-line pharmacologic treatment of\\npreschool children because of the lack\\nof sufﬁcient rigorous study in the\\npreschool-aged population for\\nnonstimulant ADHD medications and\\ndextroamphetamine. Although', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 13, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='amphetamine is the only medication\\n14\\nFROM THE AMERICAN ACADEMY OF PEDIATRICS\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 13, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='with FDA approval for use in children\\nyounger than 6 years, this authorization\\nwas issued at a time when approval\\ncriteria were less stringent than current\\nrequirements. Hence, the available\\nevidence regarding dextroampheta-\\nmine’s use in preschool-aged children\\nwith ADHD is not adequate to\\nrecommend it as an initial ADHD\\nmedication treatment at this time.80\\nNo nonstimulant medication has\\nreceived sufﬁcient rigorous study in\\nthe preschool-aged population to be\\nrecommended for treatment of ADHD', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 14, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='of children 4 through 5 years of age.\\nAlthough methylphenidate is the\\nADHD medication with the strongest\\nevidence for safety and efﬁcacy in\\npreschool-aged children, it should be\\nnoted that the evidence has not yet\\nmet the level needed for FDA\\napproval. Evidence for the use of\\nmethylphenidate consists of 1\\nmultisite study of 165 children83 and\\n10 other smaller, single-site studies\\nranging from 11 to 59 children, for\\na total of 269 children.129 Seven of the\\n10 single-site studies revealed efﬁcacy', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 14, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='for methylphenidate in preschoolers.\\nTherefore, although there is moderate\\nevidence that methylphenidate is safe\\nand effective in preschool-aged\\nchildren, its use in this age group\\nremains on an “off-label” basis.\\nWith these caveats in mind, before\\ninitiating treatment with medication,\\nthe clinician should assess the severity\\nof the child’s ADHD. Given current\\ndata, only preschool-aged children\\nwith ADHD and moderate-to-severe\\ndysfunction should be considered for', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 14, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='medication. Severity criteria are\\nsymptoms that have persisted for at\\nleast 9 months; dysfunction that is\\nmanifested in both home and other\\nsettings, such as preschool or child\\ncare; and dysfunction that has not\\nresponded adequately to PTBM.83\\nThe decision to consider initiating\\nmedication at this age depends, in\\npart, on the clinician’s assessment\\nof the estimated developmental\\nimpairment, safety risks, and potential\\nconsequences if medications are not\\ninitiated. Other considerations affecting', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 14, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='the treatment of preschool-aged\\nchildren with stimulant medications\\ninclude the lack of information and\\nexperience about their longer-term\\neffects on growth and brain\\ndevelopment, as well as the potential\\nfor other adverse effects in this\\npopulation. It may be helpful to obtain\\nconsultation from a mental health\\nspecialist with speciﬁc experience with\\npreschool-aged children, if possible.\\nEvidence suggests that the rate of\\nmetabolizing methylphenidate is\\nslower in children 4 through 5 years of', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 14, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='age, so they should be given a low dose\\nto start; the dose can be increased in\\nsmaller increments. Maximum doses\\nhave not been adequately studied in\\npreschool-aged children.83\\nSpecial Circumstances: Adolescents\\n(Age 12 Years to the 18th Birthday)\\nAs noted, before beginning\\nmedication treatment of adolescents\\nwith newly diagnosed ADHD,\\nclinicians should assess the patient\\nfor symptoms of substance use. If\\nactive substance use is identiﬁed, the\\nclinician should refer the patient to', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 14, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='a subspecialist for consultative\\nsupport and guidance.2,1302134\\nIn addition, diversion of ADHD\\nmedication (ie, its use for something\\nother than its intended medical\\npurposes) is a special concern among\\nadolescents.135 Clinicians should\\nmonitor the adolescent’s symptoms and\\nprescription reﬁll requests for signs of\\nmisuse or diversion of ADHD\\nmedication, including by parents,\\nclassmates, or other acquaintances of\\nthe adolescent. The majority of states\\nnow require prescriber participation in', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 14, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='prescription drug monitoring programs,\\nwhich can be helpful in identifying and\\npreventing diversion activities. They\\nmay consider prescribing nonstimulant\\nmedications that minimize abuse\\npotential, such as atomoxetine and\\nextended-release guanfacine or\\nextended-release clonidine.\\nGiven the risks of driving for\\nadolescents with ADHD, including\\ncrashes and motor vehicle violations,\\nspecial concern should be taken to\\nprovide medication coverage for\\nsymptom control while', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 14, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='driving.79,136,137 Longer-acting or late-\\nafternoon, short-acting medications\\nmay be helpful in this regard.138\\nSpecial Circumstances: Inattention\\nor Hyperactivity/Impulsivity (Problem\\nLevel)\\nMedication is not appropriate for\\nchildren whose symptoms do not\\nmeet DSM-5 criteria for ADHD.\\nPsychosocial treatments may be\\nappropriate for these children and\\nadolescents. As noted, psychosocial\\ntreatments do not require a speciﬁc\\ndiagnosis of ADHD, and many of the\\nstudies on the efﬁcacy of PTBM', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 14, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='included children who did not have\\na speciﬁc psychiatric or ADHD\\ndiagnosis.\\nCombination Treatments\\nStudies indicate that behavioral\\ntherapy has positive effects when it is\\ncombined with medication for pre-\\nadolescent children.139 (The\\ncombined effects of training\\ninterventions and medication have\\nnot been studied.)\\nIn the MTA study, researchers found\\nthat although the combination of\\nbehavioral therapy and stimulant\\nmedication was not signiﬁcantly more\\neffective than treatment with', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 14, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='medication alone for ADHD’s core\\nsymptoms, after correcting for\\nmultiple tests in the primary\\nanalysis,139 a secondary analysis of\\na combined measure of parent and\\nteacher ratings of ADHD symptoms\\ndid ﬁnd a signiﬁcant advantage for\\nthe combination, with a small effect of\\nd = 0.28.140 The combined treatment\\nalso offered greater improvements on\\nacademic and conduct measures,\\ncompared to medication alone, when\\nthe ADHD was comorbid with anxiety\\nand the child or adolescent lived in', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 14, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='a lower socioeconomic environment.\\nPEDIATRICS Volume 144, number 4, October 2019\\n15\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 14, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='In addition, parents and teachers of\\nchildren who received combined\\ntherapy reported that they were\\nsigniﬁcantly more satisﬁed with the\\ntreatment plan. Finally, the combination\\nof medication management and\\nbehavioral therapy allowed for the use\\nof lower stimulant dosages, possibly\\nreducing the risk of adverse effects.141\\nSchool Programming and Supports\\nEncouraging strong family-school\\npartnerships helps the ADHD\\nmanagement process.142 Psychosocial\\ntreatments that include coordinating', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 15, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='efforts at school and home may\\nenhance the effects.\\nChildren and adolescents with ADHD\\nmay be eligible for services as part of\\na 504 Rehabilitation Act Plan (504\\nplan) or special education IEP under\\nthe “other health impairment”\\ndesignation in the Individuals with\\nDisability Education Act (IDEA).143\\n(ADHD qualiﬁes as a disability under\\na 504 plan. It does not qualify under\\nan IEP unless its severity impairs the\\nchild’s ability to learn. See the PoCA\\nfor more details.) It is helpful for', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 15, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='clinicians to be aware of the eligibility\\ncriteria in their states and school\\ndistricts to advise families of their\\noptions. Eligibility decisions can vary\\nconsiderably between school\\ndistricts, and school professionals’\\nindependent determinations might\\nnot agree with the recommendations\\nof outside clinicians.\\nThere are essentially 2 categories of\\nschool-based services for students\\nwith ADHD. The ﬁrst category\\nincludes interventions that are\\nintended to help the student', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 15, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='independently meet age-appropriate\\nacademic and behavioral\\nexpectations. Examples of these\\ninterventions include daily report\\ncards, training interventions, point\\nsystems, and academic remediation of\\nskills. If successful, the student’s\\nimpairment will resolve, and the\\nstudent will no longer need services.\\nThe second category is intended to\\nprovide changes in the student’s\\nprogram so his or her ADHD-related\\nproblems no longer result in failure and\\ncause distress to parents, teachers, and', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 15, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='the student.144 These services are\\nreferred to as “accommodations” and\\ninclude extended time to complete tests\\nand assignments, reduced homework\\ndemands, the ability to keep study\\nmaterials in class, and provision of the\\nteacher’s notes to the student. These\\nservices are intended to allow the\\nstudent to accomplish his work\\nsuccessfully and communicate that the\\nstudent’s impairment is acceptable.\\nAccommodations make the student’s\\nimpairment acceptable and are separate', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 15, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='from interventions aimed at improving\\nthe students’ skills or behaviors. In the\\nabsence of such interventions, long-\\nterm accommodations may lead to\\nreduced expectations and can lead to\\nthe need for accommodations to be\\nmaintained throughout the student’s\\neducation.\\nEncouraging strong family-school\\npartnerships helps the ADHD\\nmanagement process, and addressing\\nsocial determinants of health is\\nessential to these partnerships.145,146\\nPsychosocial treatments that include', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 15, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='coordinating efforts at school and\\nhome may enhance the effects.\\nKAS 6\\nThe PCC should titrate doses of\\nmedication for ADHD to achieve\\nmaximum beneﬁt with tolerable side\\neffects (Table 9). (Grade B: strong\\nrecommendation.)\\nThe MTA study is the landmark study\\ncomparing effects of methylphenidate\\nand behavioral treatments in children\\nwith ADHD. Investigators compared\\ntreatment effects in 4 groups of\\nchildren who received optimal\\nmedication management, optimal\\nbehavioral management, combined', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 15, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='medication and behavioral\\nmanagement, or community treatment.\\nChildren in the optimal medication\\nmanagement and combined medication\\nand behavioral management groups\\nunderwent a systematic trial with 4\\ndifferent doses of methylphenidate, with\\nresults suggesting that when this full\\nrange of doses is administered, more\\nthan 70% of children and adolescents\\nwith ADHD are methylphenidate\\nresponders.140\\nAuthors of other reports suggest that\\nmore than 90% of patients will have', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 15, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='a beneﬁcial response to 1 of the\\npsychostimulants if a range of\\nmedications from both the\\nmethylphenidate and amphetamine\\nand/or dextroamphetamine classes\\nTABLE 9 KAS 6: The PCC should titrate doses of medication for ADHD to achieve maximum beneﬁt with tolerable side effects. (Grade B: strong\\nrecommendation.)\\nAggregate evidence\\nquality\\nGrade B\\nBeneﬁts\\nThe optimal dose of medication is required to reduce core symptoms to, or close to, the levels of children without ADHD.\\nRisks, harm, cost', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 15, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Risks, harm, cost\\nHigher levels of medication increase the chances of side effects.\\nBeneﬁt-harm\\nassessment\\nThe importance of adequately treating ADHD outweighs the risk of adverse effects.\\nIntentional vagueness\\nNone.\\nRole of patient\\npreferences\\nThe families’ preferences and comfort need to be taken into consideration in developing a titration plan, as they are likely to predict\\nengagement and persistence with a treatment.\\nExclusions\\nNone\\nStrength\\nStrong recommendation\\nKey references', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 15, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Key references\\nJensen et al140; Solanto147; Brinkman et al149\\n16\\nFROM THE AMERICAN ACADEMY OF PEDIATRICS\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 15, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='are tried.147 Of note, children in the\\nMTA study who received care in the\\ncommunity as usual, either from\\na clinician they chose or to whom\\ntheir family had access, showed less\\nbeneﬁcial results compared with\\nchildren who received optimal\\nmedication management. The\\nexplanation offered by the study\\ninvestigators was that the community\\ntreatment group received lower\\nmedication doses and less frequent\\nmonitoring than the optimal\\nmedication management group.\\nA child’s response to stimulants is', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 16, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='variable and unpredictable. For this\\nreason, it is recommended to titrate\\nfrom a low dose to one that achieves\\na maximum, optimal effect in controlling\\nsymptoms without adverse effects.\\nCalculating the dose on the basis of\\nmilligrams per kilogram has not usually\\nbeen helpful because variations in dose\\nhave not been found to be related to\\nheight or weight. In addition, because\\nstimulant medication effects are seen\\nrapidly, titration can be accomplished in', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 16, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='a relatively short time period. Stimulant\\nmedications can be effectively titrated\\non a 7-day basis, but in urgent\\nsituations, they may be effectively\\ntitrated in as few as 3 days.140\\nParent and child and adolescent\\neducation is an important component\\nin the chronic illness model to ensure\\ncooperation in efforts to achieve\\nappropriate titration, remembering\\nthat the parents themselves may be\\nsigniﬁcantly challenged by\\nADHD.148,149 The PCC should alert\\nparents and children that changing', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 16, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='medication dose and occasionally\\nchanging a medication may be\\nnecessary for optimal medication\\nmanagement, may require a few\\nmonths to achieve optimal success,\\nand that medication efﬁcacy should\\nbe monitored at regular intervals.\\nBy the 3-year (ie, 36-month) follow-up\\nto the MTA interventions, there were\\nno differences among the 4 groups (ie,\\noptimal medications management,\\noptimal behavioral management,\\na combination of medication and\\nbehavioral management, and\\ncommunity treatment). This', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 16, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='equivalence in poststudy outcomes\\nmay, however, have been attributable\\nto convergence in ongoing treatments\\nreceived for the 4 groups. After the\\ninitial 14-month intervention, the\\nchildren no longer received the careful\\nmonthly monitoring provided by the\\nstudy and went back to receiving care\\nfrom their community providers;\\ntherefore, they all effectively received\\na level of ongoing care consistent with\\nthe “community treatment” study arm\\nof the study. After leaving the MTA', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 16, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='trial, medications and doses varied for\\nthe children who had been in the\\noptimal medication management or\\ncombined medication and behavioral\\nmanagement groups, and a number\\nstopped taking ADHD medication. On\\nthe other hand, some children who\\nhad been in the optimal behavioral\\nmanagement group started taking\\nmedication after leaving the trial. The\\nresults further emphasize the need to\\ntreat ADHD as a chronic illness and\\nprovide continuity of care and, where\\npossible, provide a medical home.140', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 16, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='See the PoCA for more on\\nimplementation of this KAS.\\nKAS 7\\nThe PCC, if trained or experienced in\\ndiagnosing comorbid conditions, may\\ninitiate treatment of such conditions\\nor make a referral to an appropriate\\nsubspecialist for treatment. After\\ndetecting possible comorbid\\nconditions, if the PCC is not trained or\\nexperienced in making the diagnosis\\nor initiating treatment, the patient\\nshould be referred to an appropriate\\nsubspecialist to make the diagnosis\\nand initiate treatment (Table 10).', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 16, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='(Grade C: recommendation.)\\nThe effect of comorbid conditions on\\nADHD treatment is variable. In some\\ncases, treatment of the ADHD may\\nresolve the comorbid condition. For\\nexample, treatment of ADHD may\\nlead to improvement in coexisting\\naggression and/or oppositional\\ndeﬁant, depressive, or anxiety\\nsymptoms.150,151\\nSometimes, however, the comorbid\\ncondition may require treatment in\\naddition to the ADHD treatment. If the\\nPCC is conﬁdent of his or her ability to\\ndiagnose and treat certain comorbid', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 16, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='conditions, the PCC may do so. The\\nPCC may beneﬁt from additional\\nconsultative support and guidance\\nfrom a mental health subspecialist or\\nmay need to refer a child with ADHD\\nand comorbid conditions, such as\\nsevere mood or anxiety disorders, to\\nsubspecialists for assessment and\\nmanagement. The subspecialists could\\ninclude child and adolescent\\npsychiatrists, clinical child\\npsychologists, developmental-\\nbehavioral pediatricians,\\nneurodevelopmental disability\\nphysicians, child neurologists, or', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 16, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='child- or school-based evaluation\\nteams.\\nIMPLEMENTATION: PREPARING THE\\nPRACTICE\\nIt is generally the role of the primary\\ncare pediatrician to manage mild-to-\\nmoderate ADHD, anxiety, depression,\\nand substance use. The AAP\\nstatement “The Future of Pediatrics:\\nMental Health Competencies for\\nPediatric Primary Care” describes the\\ncompetencies needed in both\\npediatric primary and specialty care\\nto address the social-emotional and\\nmental health needs of children and\\nfamilies.152 Broadly, these include', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 16, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='incorporating mental health content\\nand tools into health promotion,\\nprevention, and primary care\\nintervention, becoming\\nknowledgeable about use of\\nevidence-based treatments, and\\nparticipating as a team member and\\ncomanaging with pediatric and\\nmental health specialists.\\nThe recommendations made in this\\nguideline are intended to be integrated\\nwith the broader mental health\\nalgorithm developed as part of the AAP\\nMental Health Initiatives.2,133,153\\nPediatricians have unique opportunities', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 16, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='PEDIATRICS Volume 144, number 4, October 2019\\n17\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 16, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='to identify conditions, including ADHD,\\nintervene early, and partner with both\\nfamilies and specialists for the beneﬁt\\nof children’s health. A wealth of useful\\ninformation is available at the AAP\\nMental Health Initiatives Web site\\n(https://www.aap.org/en-us/advocacy-\\nand-policy/aap-health-initiatives/\\nMental-Health/Pages/Tips-For-\\nPediatricians.aspx).\\nIt is also important for PCCs to be\\naware of health disparities and social\\ndeterminants that may impact patient\\noutcomes and strive to provide', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 17, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='culturally appropriate care to all\\nchildren and adolescents in their\\npractice.145,146,154,155\\nThe accompanying PoCA provides\\nsupplemental information to support\\nPCCs as they implement this\\nguideline’s recommendations. In\\nparticular, the PoCA describes steps\\nfor preparing the practice that provide\\nuseful recommendations to clinicians.\\nFor example, the PoCA includes\\ninformation about using standardized\\nrating scales to diagnose ADHD,\\nassessing for comorbid conditions,', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 17, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='documenting all aspects of the\\ndiagnostic and treatment procedures\\nin the patient’s records, monitoring\\nthe patient’s treatment and outcomes,\\nand providing families with written\\nmanagement plans.\\nThe AAP acknowledges that some\\nPCCs may not have the training,\\nexperience, or resources to diagnose\\nand treat children and adolescents\\nwith ADHD, especially if severity or\\ncomorbid conditions make these\\npatients complex to manage. In these\\nsituations, comanagement with', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 17, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='specialty clinicians is recommended.\\nThe SDBP is developing a guideline to\\naddress such complex cases and aid\\npediatricians and other PCCs to\\nmanage these cases; the SDBP\\ncurrently expects to publish this\\ndocument in 2019.67\\nAREAS FOR FUTURE RESEARCH\\nThere is a need to conduct research\\non topics pertinent to the diagnosis\\nand treatment of ADHD,\\ndevelopmental variations, and\\nproblems in children and adolescents\\nin primary care. These research\\nopportunities include the following:', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 17, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='• assessment of ADHD and its\\ncommon comorbidities: anxiety,\\ndepression, learning disabilities,\\nand autism spectrum disorder;\\n• identiﬁcation and/or development\\nof reliable instruments suitable for\\nuse in primary care to assess the\\nnature or degree of functional\\nimpairment in children and\\nadolescents with ADHD and to\\nmonitor improvement over time;\\n• reﬁnement of developmentally\\ninformed assessment procedures\\nfor evaluating ADHD in\\npreschoolers;\\n• study of medications and other', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 17, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='therapies used clinically but not\\nFDA approved for ADHD;\\n• determination of the optimal\\nschedule for monitoring children\\nand adolescents with ADHD,\\nincluding factors for adjusting\\nthat schedule according to age,\\nsymptom severity, and progress\\nreports;\\n• evaluation of the effectiveness and\\nadverse effects of medications used\\nin combination, such as a stimulant\\nwith an a-adrenergic agent,\\nselective serotonin reuptake\\ninhibitor, or atomoxetine;\\n• evaluation of processes of care to', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 17, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='assist PCCs to identify and treat\\ncomorbid conditions;\\n• evaluation of the effectiveness of\\nvarious school-based interventions;\\n• comparisons of medication use\\nand effectiveness in different\\nages, including both harms and\\nbeneﬁts;\\n• development of methods to involve\\nparents, children, and adolescents\\nin their own care and improve\\nadherence to both psychosocial and\\nmedication treatments;\\n• conducting research into\\npsychosocial treatments, such as\\ncognitive behavioral therapy and', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 17, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='cognitive training, among others;\\nTABLE 10 KAS 7: The PCC, if trained or experienced in diagnosing comorbid conditions, may initiate treatment of such conditions or make a referral to an\\nappropriate subspecialist for treatment. After detecting possible comorbid conditions, if the PCC is not trained or experienced in making the\\ndiagnosis or initiating treatment, the patient should be referred to an appropriate subspecialist to make the diagnosis and initiate treatment.\\n(Grade C: recommendation.)', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 17, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Aggregate evidence\\nquality\\nGrade C\\nBeneﬁts\\nClinicians are most effective when they know the limits of their practice to diagnose comorbid conditions and are aware of resources\\nin their community.\\nRisks, harm, cost\\nUnder-identiﬁcation or inappropriate identiﬁcation of comorbidities can lead to inadequate or inappropriate treatments.\\nBeneﬁt-harm\\nassessment\\nThe importance of adequately identifying and addressing comorbidities outweighs the risk of inappropriate referrals or treatments.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 17, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Intentional vagueness\\nNone.\\nRole of patient\\npreferences\\nThe families’ preferences and comfort need to be taken into consideration in identifying and treating or referring their patients with\\ncomorbidities, as they are likely to predict engagement and persistence with a treatment.\\nExclusions\\nNone.\\nStrength\\nRecommendation.\\nKey references\\nPliszka et al150; Pringsheim et al151\\n18\\nFROM THE AMERICAN ACADEMY OF PEDIATRICS', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 17, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Downloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 17, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='• development of standardized and\\ndocumented tools to help primary\\ncare providers identify comorbid\\nconditions;\\n• development of effective electronic\\nand Web-based systems to help\\ngather information to diagnose and\\nmonitor children and adolescents\\nwith ADHD;\\n• improvements to systems for\\ncommunicating with schools,\\nmental health professionals, and\\nother community agencies to\\nprovide effective collaborative care;\\n• development of more objective\\nmeasures of performance to more', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 18, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='objectively monitor aspects of\\nseverity, disability, or impairment;\\n• assessment of long-term outcomes\\nfor children in whom ADHD was\\nﬁrst diagnosed at preschool ages;\\nand\\n• identiﬁcation and implementation\\nof ideas to address the barriers\\nthat hamper the implementation\\nof these guidelines and the\\nPoCA.\\nCONCLUSIONS\\nEvidence is clear with regard to the\\nlegitimacy of the diagnosis of ADHD\\nand the appropriate diagnostic\\ncriteria and procedures required to\\nestablish a diagnosis, identify', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 18, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='comorbid conditions, and effectively\\ntreat with both psychosocial and\\npharmacologic interventions. The\\nsteps required to sustain appropriate\\ntreatments and achieve successful\\nlong-term outcomes remain\\nchallenging, however.\\nAs noted, this clinical practice\\nguideline is supported by 2\\naccompanying documents available in\\nthe Supplemental Information: the\\nPoCA and the article on systemic\\nbarriers to the car of children and\\nadolescents with ADHD. Full\\nimplementation of the guideline’s', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 18, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='KASs, the PoCA, and the\\nrecommendations to address barriers\\nto care may require changes in ofﬁce\\nprocedures and the identiﬁcation of\\ncommunity resources. Fully\\naddressing systemic barriers requires\\nidentifying local, state, and national\\nentities with which to partner to\\nadvance solutions and manifest\\nchange.156\\nSUBCOMMITTEE ON CHILDREN AND\\nADOLESCENTS WITH ADHD (OVERSIGHT BY\\nTHE COUNCIL ON QUALITY IMPROVEMENT\\nAND PATIENT SAFETY)\\nMark L. Wolraich, MD, FAAP, Chairperson,', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 18, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Section on Developmental Behavioral\\nPediatrics\\nJoseph F. Hagan Jr, MD, FAAP, Vice\\nChairperson, Section on Developmental\\nBehavioral Pediatrics\\nCarla Allan, PhD, Society of Pediatric\\nPsychology\\nEugenia Chan, MD, MPH, FAAP,\\nImplementation Scientist\\nDale Davison, MSpEd, PCC, Parent Advocate,\\nChildren and Adolescents with Attention-\\nDeﬁcit/Hyperactivity Disorder\\nMarian Earls, MD, MTS, FAAP, Mental Health\\nLeadership Work Group\\nSteven W. Evans, PhD, Clinical Psychologist', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 18, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Tanya Froehlich, MD, FAAP, Section on\\nDevelopmental Behavioral Pediatrics/Society\\nfor Developmental and Behavioral Pediatrics\\nJennifer Frost, MD, FAAFP, American\\nAcademy of Family Physicians\\nJoseph R. Holbrook, PhD, MPH,\\nEpidemiologist, Centers for Disease Control\\nand Prevention\\nHerschel Robert Lessin, MD, FAAP, Section\\non Administration and Practice Management\\nKaren L. Pierce, MD, DFAACAP, American\\nAcademy of Child and Adolescent Psychiatry\\nChristoph Ulrich Lehmann, MD, FAAP,', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 18, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Partnership for Policy Implementation\\nJonathan D. Winner, MD, FAAP, Committee\\non Practice and Ambulatory Medicine\\nWilliam Zurhellen, MD, FAAP, Section on\\nAdministration and Practice Management\\nSTAFF\\nKymika Okechukwu, MPA, Senior Manager,\\nEvidence-Based Medicine Initiatives\\nJeremiah Salmon, MPH, Program Manager,\\nPolicy Dissemination and Implementation\\nCONSULTANT\\nSusan K. Flinn, MA, Medical Editor\\nABBREVIATIONS\\nAAP: American Academy of Pediatrics\\nADHD: attention-deﬁcit/\\nhyperactivity disorder', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 18, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='ADHD/C: attention-deﬁcit/\\nhyperactivity disorder\\ncombined presentation\\nADHD/HI: attention-deﬁcit/\\nhyperactivity disorder\\nprimarily of the\\nhyperactive-impulsive\\npresentation\\nADHD/I: attention-deﬁcit/\\nhyperactivity disorder\\nprimarily of the\\ninattentive presentation\\nAHRQ: Agency for Healthcare\\nResearch and Quality\\nBP: blood pressure\\nCHADD: Children and Adults with\\nAttention-Deﬁcit/\\nHyperactivity Disorder\\nDSM-5: Diagnostic and Statistical\\nManual of Mental Disorders,\\nFifth Edition', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 18, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Fifth Edition\\nDSM-IV: Diagnostic and Statistical\\nManual of Mental Disorders\\nFourth Edition\\nDSM-PC: Diagnostic and Statistical\\nManual for Primary Care\\nECG: electrocardiogram\\neTNS: external trigeminal nerve\\nstimulation\\nFDA: US Food and Drug\\nAdministration\\nHR: heart rate\\nIDEA: Individuals with Disability\\nEducation Act\\nIEP: Individualized Education\\nProgram\\nKAS: key action statement\\nMTA: The Multimodal Treatment\\nof Attention Deﬁcit\\nHyperactivity Disorder\\nPCC: primary care clinician', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 18, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='PoCA: process of care algorithm\\nPTBM: parent training in behavior\\nmanagement\\nSDBP: Society for Developmental\\nand Behavioral Pediatrics\\nPEDIATRICS Volume 144, number 4, October 2019\\n19\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 18, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='vAmerican Academy of Pediatrics, Itasca, Illinois; wAmerican Academy of Child and Adolescent Psychiatry, Washington, District of Columbia; xFeinberg School of\\nMedicine, Northwestern University, Chicago, Illinois; yAtlanta, Georgia; and zHolderness, New Hampshire\\nThe guidance in this report does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual\\ncircumstances, may be appropriate.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 19, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='All clinical practice guidelines from the American Academy of Pediatrics automatically expire 5 years after publication unless reafﬁrmed, revised, or retired at or\\nbefore that time.\\nThe ﬁndings and conclusions in this report are those of the authors and do not necessarily represent the ofﬁcial position of the Centers for Disease Control and\\nPrevention. Dr Holbrook was not an author of the accompanying supplemental section on barriers to care.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 19, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have ﬁled conﬂict of interest statements\\nwith the American Academy of Pediatrics. Any conﬂicts have been resolved through a process approved by the Board of Directors. The American Academy of\\nPediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.\\nDOI: https://doi.org/10.1542/peds.2019-2528', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 19, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Address correspondence to Mark L. Wolraich, MD, FAAP. Email: mark-wolraich@ouhsc.edu\\nPEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).\\nCopyright © 2019 by the American Academy of Pediatrics\\nFINANCIAL DISCLOSURE: The authors have indicated they have no ﬁnancial relationships relevant to this article to disclose.\\nFUNDING: No external funding.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 19, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='POTENTIAL CONFLICT OF INTEREST: All authors have ﬁled conﬂict of interest statements with the American Academy of Pediatrics. Any conﬂicts have been resolved\\nthrough a process approved by the American Academy of Pediatrics board of directors. Dr Allan reports a relationship with ADDitude Magazine; Dr Chan reports\\nrelationships with TriVox Health and Wolters Kluwer; Dr Lehmann reports relationships with International Medical Informatics Association, Springer Publishing, and', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 19, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Thieme Publishing Group; Dr Wolraich reports a Continuing Medical Education trainings relationship with the Resource for Advancing Children’s Health Institute; the\\nother authors have indicated they have no potential conﬂicts of interest to disclose.\\nREFERENCES\\n1. American Academy of Pediatrics.\\nSubcommittee on Attention-Deﬁcit/\\nHyperactivity Disorder, Steering\\nCommittee on Quality Improvement and\\nManagement. ADHD: Clinical guideline for\\nthe diagnosis, evaluation, and treatment', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 19, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='of attention-deﬁcit/hyperactivity disorder\\nin children and adolescents. Pediatrics.\\n2011;128(5):1007–1022\\n2. American Academy of Pediatrics Task\\nForce on Mental Health. Addressing\\nMental Health Concerns in Primary\\nCare: A Clinician’s Toolkit [CD-ROM]. Elk\\nGrove Village, IL: American Academy of\\nPediatrics; 2010\\n3. Pastor PN, Reuben CA. Racial and\\nethnic differences in ADHD and LD in\\nyoung school-age children: parental\\nreports in the National Health\\nInterview Survey. Public Health Rep.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 19, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='2005;120(4):383–392\\n4. US Department of Health and Human\\nServices; Health Resources and\\nServices Administration. Designated\\nhealth professional shortage areas\\nstatistics: designated HPSA quarterly\\nsummary. Rockville, MD: Health\\nResources and Services\\nAdministration; 2018\\n5. Pelech D, Hayford T. Medicare\\nadvantage and commercial prices for\\nmental health services. Health Aff\\n(Millwood). 2019;38(2):262–267\\n6. Melek SP, Perlman D, Davenport S.\\nDifferential Reimbursement of', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 19, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Psychiatric Services by Psychiatrists\\nand Other Medical Providers. Seattle,\\nWA: Milliman;2017\\n7. Holbrook JR, Bitsko RH, Danielson ML,\\nVisser SN. Interpreting the prevalence\\nof mental disorders in children:\\ntribulation and triangulation. Health\\nPromot Pract. 2017;18(1):5–7\\n8. Thomas R, Sanders S, Doust J, Beller E,\\nGlasziou P. Prevalence of attention-\\ndeﬁcit/hyperactivity disorder:\\na systematic review and meta-\\nanalysis. Pediatrics. 2015;135(4).\\nAvailable at: www.pediatrics.org/cgi/', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 19, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='content/full/135/4/e994\\n9. Wolraich ML, McKeown RE, Visser SN,\\net al. The prevalence of ADHD: its\\ndiagnosis and treatment in four\\nschool districts across two states.\\nJ Atten Disord. 2014;18(7):563–575\\n10. Rowland AS, Skipper BJ, Umbach DM,\\net al. The prevalence of ADHD in\\na population-based sample. J Atten\\nDisord. 2015;19(9):741–754\\n11. Danielson ML, Bitsko RH, Ghandour RM,\\nHolbrook JR, Kogan MD, Blumberg SJ.\\nPrevalence of parent-reported ADHD\\ndiagnosis and associated treatment', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 19, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='among U.S. children and adolescents,\\n2016. J Clin Child Adolesc Psychol. 2018;\\n47(2):199–212\\n12. Visser SN, Zablotsky B, Holbrook JR,\\net al. National Health Statistics Reports,\\nNo 81: Diagnostic Experiences of Children\\nwith Attention-Deﬁcit/Hyperactivity\\nDisorder. Hyattsville, MD: National Center\\nfor Health Statistics; 2015\\n13. Molina BS, Hinshaw SP, Swanson JM,\\net al; MTA Cooperative Group. The MTA\\nat 8 years: prospective follow-up of\\nchildren treated for combined-type ADHD', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 19, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='in a multisite study. J Am Acad Child\\nAdolesc Psychiatry. 2009;48(5):484–500\\n14. Holbrook JR, Cuffe SP, Cai B, et al.\\nPersistence of parent-reported ADHD\\nsymptoms from childhood through\\nadolescence in a community sample.\\nJ Atten Disord. 2016;20(1):11–20\\n20\\nFROM THE AMERICAN ACADEMY OF PEDIATRICS\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 19, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='15. Mueller KL, Tomblin JB. Examining the\\ncomorbidity of language disorders and\\nADHD. Top Lang Disord. 2012;32(3):\\n228–246\\n16. Pastor PN, Reuben CA, Duran CR,\\nHawkins LD. Association Between\\nDiagnosed ADHD and Selected\\nCharacteristics Among Children Aged\\n4–17 Years: United States, 2011–2013.\\nNCHS Data Brief, No. 201. Hyattsville,\\nMD: National Center for Health\\nStatistics; 2015\\n17. Elia J, Ambrosini P, Berrettini W. ADHD\\ncharacteristics: I. Concurrent co-\\nmorbidity patterns in children &', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 20, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='adolescents. Child Adolesc Psychiatry\\nMent Health. 2008;2(1):15\\n18. Centers for Disease Control and\\nPrevention (CDC). Mental health in the\\nUnited States. Prevalence of diagnosis\\nand medication treatment for attention-\\ndeﬁcit/hyperactivity disorder--United\\nStates, 2003. MMWR Morb Mortal Wkly\\nRep. 2005;54(34):842–847\\n19. Cuffe SP, Visser SN, Holbrook JR, et al.\\nADHD and psychiatric comorbidity:\\nfunctional outcomes in a school-based\\nsample of children [published online', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 20, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='ahead of print November 25, 2015].\\nJ Atten Disord. doi:10.1177/\\n1087054715613437\\n20. Gaub M, Carlson CL. Gender differences\\nin ADHD: a meta-analysis and critical\\nreview. J Am Acad Child Adolesc\\nPsychiatry. 1997;36(8):1036–1045\\n21. Tung I, Li JJ, Meza JI, et al. Patterns of\\ncomorbidity among girls with ADHD:\\na meta-analysis. Pediatrics. 2016;138(4):\\ne20160430\\n22. Layton TJ, Barnett ML, Hicks TR, Jena\\nAB. Attention deﬁcit-hyperactivity\\ndisorder and month of school', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 20, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='enrollment. N Engl J Med. 2018;379(22):\\n2122–2130\\n23. Kemper AR, Maslow GR, Hill S, et al.\\nAttention Deﬁcit Hyperactivity Disorder:\\nDiagnosis and Treatment in Children\\nand Adolescents. Comparative\\nEffectiveness Reviews, No. 203.\\nRockville, MD: Agency for Healthcare\\nResearch and Quality; 2018\\n24. Pelham WE Jr, Wheeler T, Chronis A.\\nEmpirically supported psychosocial\\ntreatments for attention deﬁcit\\nhyperactivity disorder. J Clin Child\\nPsychol. 1998;27(2):190–205', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 20, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='25. Evans SW, Owens JS, Wymbs BT, Ray AR.\\nEvidence-based psychosocial\\ntreatments for children and\\nadolescents with attention deﬁcit/\\nhyperactivity disorder. J Clin Child\\nAdolesc Psychol. 2018;47(2):157–198\\n26. Pelham WE Jr, Fabiano GA. Evidence-\\nbased psychosocial treatments for\\nattention-deﬁcit/hyperactivity disorder.\\nJ Clin Child Adolesc Psychol. 2008;37(1):\\n184–214\\n27. American Academy of Pediatrics\\nSteering Committee on Quality\\nImprovement and Management.\\nClassifying recommendations for', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 20, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='clinical practice guidelines. Pediatrics.\\n2004;114(3):874–877\\n28. Visser SN, Lesesne CA, Perou R. National\\nestimates and factors associated with\\nmedication treatment for childhood\\nattention-deﬁcit/hyperactivity disorder.\\nPediatrics. 2007;119(suppl 1):S99–S106\\n29. Centers for Disease Control and\\nPrevention (CDC). Increasing\\nprevalence of parent-reported\\nattention-deﬁcit/hyperactivity disorder\\namong children–United States, 2003\\nand 2007. MMWR Morb Mortal Wkly\\nRep. 2010;59(44):1439–1443', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 20, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='30. Egger HL, Kondo D, Angold A. The\\nepidemiology and diagnostic issues in\\npreschool attention-deﬁcit/hyperactivity\\ndisorder: a review. Infants Young Child.\\n2006;19(2):109–122\\n31. Wolraich ML, Wibbelsman CJ, Brown TE,\\net al. Attention-deﬁcit/hyperactivity\\ndisorder among adolescents: a review\\nof the diagnosis, treatment, and clinical\\nimplications. Pediatrics. 2005;115(6):\\n1734–1746\\n32. American Psychiatric Association.\\nDiagnostic and Statistical Manual of\\nMental Disorders (DSM-5). 5th ed.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 20, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Arlington, VA: American Psychiatric\\nAssociation; 2013\\n33. Lahey BB, Pelham WE, Stein MA, et al.\\nValidity of DSM-IV attention-deﬁcit/\\nhyperactivity disorder for younger\\nchildren. J Am Acad Child Adolesc\\nPsychiatry. 1998;37(7):695–702\\n34. Pavuluri MN, Luk SL, McGee R. Parent\\nreported preschool attention deﬁcit\\nhyperactivity: measurement and\\nvalidity. Eur Child Adolesc Psychiatry.\\n1999;8(2):126–133\\n35. Harvey EA, Youngwirth SD, Thakar DA,\\nErrazuriz PA. Predicting attention-', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 20, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='deﬁcit/hyperactivity disorder and\\noppositional deﬁant disorder from\\npreschool diagnostic assessments.\\nJ Consult Clin Psychol. 2009;77(2):\\n349–354\\n36. Keenan K, Wakschlag LS. More than the\\nterrible twos: the nature and severity of\\nbehavior problems in clinic-referred\\npreschool children. J Abnorm Child\\nPsychol. 2000;28(1):33–46\\n37. Gadow KD, Nolan EE, Litcher L, et al.\\nComparison of attention-deﬁcit/\\nhyperactivity disorder symptom\\nsubtypes in Ukrainian schoolchildren.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 20, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='J Am Acad Child Adolesc Psychiatry.\\n2000;39(12):1520–1527\\n38. Sprafkin J, Volpe RJ, Gadow KD, Nolan\\nEE, Kelly K. A DSM-IV-referenced\\nscreening instrument for preschool\\nchildren: the Early Childhood Inventory-\\n4. J Am Acad Child Adolesc Psychiatry.\\n2002;41(5):604–612\\n39. Poblano A, Romero E. ECI-4 screening of\\nattention deﬁcit-hyperactivity disorder\\nand co-morbidity in Mexican preschool\\nchildren: preliminary results. Arq\\nNeuropsiquiatr. 2006;64(4):932–936\\n40. American Academy of Pediatrics.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 20, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Mental Health Screening and\\nAssessment Tools for Primary Care. Elk\\nGrove Village, IL: American Academy of\\nPediatrics; 2012. Available at: https://\\nwww.aap.org/en-us/advocacy-and-\\npolicy/aap-health-initiatives/Mental-\\nHealth/Documents/MH_ScreeningChart.\\npdf. Accessed September 8, 2019\\n41. DuPaul GJ, Power TJ, Anastopoulos AD,\\nReid R. ADHD Rating Scale – 5 for\\nChildren and Adolescents: Checklists,\\nNorms, and Clinical Interpretation. 2nd\\ned. New York, NY: Guilford Press; 2016', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 20, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='42. McGoey KE, DuPaul GJ, Haley E, Shelton\\nTL. Parent and teacher ratings of\\nattention-deﬁcit/hyperactivity disorder\\nin preschool: the ADHD rating scale-IV\\npreschool version. J Psychopathol\\nBehav Assess. 2007;29(4):269–276\\n43. Young J. Common comorbidities seen in\\nadolescents with attention-deﬁcit/\\nhyperactivity disorder. Adolesc Med\\nState Art Rev. 2008;19(2):216–228, vii\\n44. Freeman RD; Tourette Syndrome\\nInternational Database Consortium. Tic\\ndisorders and ADHD: answers from', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 20, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='PEDIATRICS Volume 144, number 4, October 2019\\n21\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 20, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='a world-wide clinical dataset on\\nTourette syndrome. Eur Child Adolesc\\nPsychiatry. 2007;16(suppl 1):15–23\\n45. Riggs PD. Clinical approach to\\ntreatment of ADHD in adolescents with\\nsubstance use disorders and conduct\\ndisorder. J Am Acad Child Adolesc\\nPsychiatry. 1998;37(3):331–332\\n46. Sibley MH, Pelham WE, Molina BSG,\\net al. Diagnosing ADHD in adolescence.\\nJ Consult Clin Psychol. 2012;80(1):\\n139–150\\n47. Kratochvil CJ, Vaughan BS, Stoner JA,\\net al. A double-blind, placebo-controlled', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 21, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='study of atomoxetine in young children\\nwith ADHD. Pediatrics. 2011;127(4).\\nAvailable at: www.pediatrics.org/cgi/\\ncontent/full/127/4/e862\\n48. Harrison AG, Edwards MJ, Parker KC.\\nIdentifying students faking ADHD:\\npreliminary ﬁndings and strategies for\\ndetection. Arch Clin Neuropsychol. 2007;\\n22(5):577–588\\n49. Wolraich ML, Felice ME, Drotar DD. The\\nClassiﬁcation of Child and Adolescent\\nMental Conditions in Primary Care:\\nDiagnostic and Statistical Manual for\\nPrimary Care (DSM-PC), Child and', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 21, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Adolescent Version. Elk Grove Village, IL:\\nAmerican Academy of Pediatrics; 1996\\n50. Rowland AS, Lesesne CA, Abramowitz\\nAJ. The epidemiology of attention-\\ndeﬁcit/hyperactivity disorder (ADHD):\\na public health view. Ment Retard Dev\\nDisabil Res Rev. 2002;8(3):162–170\\n51. Cuffe SP, Moore CG, McKeown RE.\\nPrevalence and correlates of ADHD\\nsymptoms in the national health\\ninterview survey. J Atten Disord. 2005;\\n9(2):392–401\\n52. Pastor PN, Reuben CA. Diagnosed\\nattention deﬁcit hyperactivity disorder', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 21, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='and learning disability: United States,\\n2004-2006. Vital Health Stat 10. 2008;\\n10(237):1–14\\n53. Biederman J, Faraone SV, Wozniak J,\\nMick E, Kwon A, Aleardi M. Further\\nevidence of unique developmental\\nphenotypic correlates of pediatric\\nbipolar disorder: ﬁndings from a large\\nsample of clinically referred\\npreadolescent children assessed over\\nthe last 7 years. J Affect Disord. 2004;\\n82(suppl 1):S45–S58\\n54. Biederman J, Kwon A, Aleardi M, et al.\\nAbsence of gender effects on attention', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 21, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='deﬁcit hyperactivity disorder: ﬁndings\\nin nonreferred subjects. Am\\nJ Psychiatry. 2005;162(6):1083–1089\\n55. Biederman J, Ball SW, Monuteaux MC,\\net al. New insights into the comorbidity\\nbetween ADHD and major depression in\\nadolescent and young adult females.\\nJ Am Acad Child Adolesc Psychiatry.\\n2008;47(4):426–434\\n56. Biederman J, Melmed RD, Patel A,\\nMcBurnett K, Donahue J, Lyne A. Long-\\nterm, open-label extension study of\\nguanfacine extended release in\\nchildren and adolescents with ADHD.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 21, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='CNS Spectr. 2008;13(12):1047–1055\\n57. Crabtree VM, Ivanenko A, Gozal D.\\nClinical and parental assessment of\\nsleep in children with attention-deﬁcit/\\nhyperactivity disorder referred to\\na pediatric sleep medicine center. Clin\\nPediatr (Phila). 2003;42(9):807–813\\n58. LeBourgeois MK, Avis K, Mixon M, Olmi J,\\nHarsh J. Snoring, sleep quality, and\\nsleepiness across attention-deﬁcit/\\nhyperactivity disorder subtypes. Sleep.\\n2004;27(3):520–525\\n59. Chan E, Zhan C, Homer CJ. Health care', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 21, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='use and costs for children with\\nattention-deﬁcit/hyperactivity disorder:\\nnational estimates from the Medical\\nExpenditure Panel Survey. Arch Pediatr\\nAdolesc Med. 2002;156(5):504–511\\n60. Newcorn JH, Miller SR, Ivanova I, et al.\\nAdolescent outcome of ADHD: impact of\\nchildhood conduct and anxiety\\ndisorders. CNS Spectr. 2004;9(9):\\n668–678\\n61. Sung V, Hiscock H, Sciberras E, Efron D.\\nSleep problems in children with\\nattention-deﬁcit/hyperactivity disorder:\\nprevalence and the effect on the child', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 21, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='and family. Arch Pediatr Adolesc Med.\\n2008;162(4):336–342\\n62. Froehlich TE, Fogler J, Barbaresi WJ,\\nElsayed NA, Evans SW, Chan E. Using\\nADHD medications to treat coexisting\\nADHD and reading disorders:\\na systematic review. Clin Pharmacol\\nTher. 2018;104(4):619–637\\n63. Rothenberger A, Roessner V. The\\nphenomenology of attention-deﬁcit/\\nhyperactivity disorder in tourette\\nsyndrome. In: Martino D, Leckman JF,\\neds. Tourette Syndrome. New York, NY:\\nOxford University Press; 2013:26–49', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 21, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='64. Antshel KM, Zhang-James Y, Faraone SV.\\nThe comorbidity of ADHD and autism\\nspectrum disorder. Expert Rev\\nNeurother. 2013;13(10):1117–1128\\n65. Mahajan R, Bernal MP, Panzer R, et al;\\nAutism Speaks Autism Treatment\\nNetwork Psychopharmacology\\nCommittee. Clinical practice pathways\\nfor evaluation and medication choice\\nfor attention-deﬁcit/hyperactivity\\ndisorder symptoms in autism spectrum\\ndisorders. Pediatrics. 2012;130(suppl\\n2):S125–S138\\n66. Larson K, Russ SA, Kahn RS, Halfon N.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 21, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Patterns of comorbidity, functioning,\\nand service use for US children with\\nADHD, 2007. Pediatrics. 2011;127(3):\\n462–470\\n67. Society for Developmental and\\nBehavioral Pediatrics. ADHD special\\ninterest group. Available at: www.sdbp.\\norg/committees/sig-adhd.cfm. Accessed\\nSeptember 8, 2019\\n68. Medical Home Initiatives for Children\\nWith Special Needs Project Advisory\\nCommittee. American Academy of\\nPediatrics. The medical home.\\nPediatrics. 2002;110(1 pt 1):184–186', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 21, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='69. Brito A, Grant R, Overholt S, et al. The\\nenhanced medical home: the pediatric\\nstandard of care for medically\\nunderserved children. Adv Pediatr.\\n2008;55:9–28\\n70. Sibley MH, Swanson JM, Arnold LE, et al;\\nMTA Cooperative Group. Deﬁning ADHD\\nsymptom persistence in adulthood:\\noptimizing sensitivity and speciﬁcity.\\nJ Child Psychol Psychiatry. 2017;58(6):\\n655–662\\n71. Chang Z, D’Onofrio BM, Quinn PD,\\nLichtenstein P, Larsson H. Medication\\nfor attention-deﬁcit/hyperactivity', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 21, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='disorder and risk for depression:\\na nationwide longitudinal cohort study.\\nBiol Psychiatry. 2016;80(12):916–922\\n72. Biederman J, Monuteaux MC, Spencer T,\\nWilens TE, Faraone SV. Do stimulants\\nprotect against psychiatric disorders in\\nyouth with ADHD? A 10-year follow-up\\nstudy. Pediatrics. 2009;124(1):71–\\n78\\n73. Barbaresi WJ, Katusic SK, Colligan RC,\\nWeaver AL, Jacobsen SJ. Modiﬁers of\\nlong-term school outcomes for children\\nwith attention-deﬁcit/hyperactivity\\ndisorder: does treatment with\\n22', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 21, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='22\\nFROM THE AMERICAN ACADEMY OF PEDIATRICS\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 21, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='stimulant medication make\\na difference? Results from a population-\\nbased study. J Dev Behav Pediatr. 2007;\\n28(4):274–287\\n74. Schefﬂer RM, Brown TT, Fulton BD,\\nHinshaw SP, Levine P, Stone S. Positive\\nassociation between attention-deﬁcit/\\nhyperactivity disorder medication use\\nand academic achievement during\\nelementary school. Pediatrics. 2009;\\n123(5):1273–1279\\n75. Barbaresi WJ, Colligan RC, Weaver AL,\\nVoigt RG, Killian JM, Katusic SK.\\nMortality, ADHD, and psychosocial', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 22, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='adversity in adults with childhood\\nADHD: a prospective study. Pediatrics.\\n2013;131(4):637–644\\n76. Chang Z, Lichtenstein P, Långström N,\\nLarsson H, Fazel S. Association between\\nprescription of major psychotropic\\nmedications and violent reoffending\\nafter prison release. JAMA. 2016;\\n316(17):1798–1807\\n77. Lichtenstein P, Halldner L, Zetterqvist J,\\net al. Medication for attention deﬁcit-\\nhyperactivity disorder and criminality.\\nN Engl J Med. 2012;367(21):2006–2014\\n78. Chang Z, Quinn PD, Hur K, et al.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 22, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Association between medication use for\\nattention-deﬁcit/hyperactivity disorder\\nand risk of motor vehicle crashes.\\nJAMA Psychiatry. 2017;74(6):597–603\\n79. Chang Z, Lichtenstein P, D’Onofrio BM,\\nSjölander A, Larsson H. Serious\\ntransport accidents in adults with\\nattention-deﬁcit/hyperactivity disorder\\nand the effect of medication:\\na population-based study. JAMA\\nPsychiatry. 2014;71(3):319–325\\n80. Harstad E, Levy S; Committee on\\nSubstance Abuse. Attention-deﬁcit/\\nhyperactivity disorder and substance', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 22, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='abuse. Pediatrics. 2014;134(1). Available\\nat: www.pediatrics.org/cgi/content/\\nfull/134/1/e293\\n81. Dalsgaard S, Leckman JF, Mortensen\\nPB, Nielsen HS, Simonsen M. Effect of\\ndrugs on the risk of injuries in children\\nwith attention deﬁcit hyperactivity\\ndisorder: a prospective cohort study.\\nLancet Psychiatry. 2015;2(8):702–709\\n82. Raman SR, Marshall SW, Haynes K,\\nGaynes BN, Naftel AJ, Stürmer T.\\nStimulant treatment and injury among\\nchildren with attention deﬁcit', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 22, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='hyperactivity disorder: an application of\\nthe self-controlled case series study\\ndesign. Inj Prev. 2013;19(3):164–170\\n83. Greenhill L, Kollins S, Abikoff H, et al.\\nEfﬁcacy and safety of immediate-\\nrelease methylphenidate treatment for\\npreschoolers with ADHD. J Am Acad\\nChild Adolesc Psychiatry. 2006;45(11):\\n1284–1293\\n84. Children and Adults with Attention-\\nDeﬁcit/Hyperactivity Disorder. CHADD.\\nAvailable at: www.chadd.org. Accessed\\nSeptember 8, 2019\\n85. Sonuga-Barke EJ, Daley D, Thompson M,', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 22, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Laver-Bradbury C, Weeks A. Parent-\\nbased therapies for preschool\\nattention-deﬁcit/hyperactivity disorder:\\na randomized, controlled trial with\\na community sample. J Am Acad Child\\nAdolesc Psychiatry. 2001;40(4):402–408\\n86. Van Cleave J, Leslie LK. Approaching\\nADHD as a chronic condition:\\nimplications for long-term adherence.\\nJ Psychosoc Nurs Ment Health Serv.\\n2008;46(8):28–37\\n87. Webster-Stratton CH, Reid MJ,\\nBeauchaine T. Combining parent and\\nchild training for young children with', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 22, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='ADHD. J Clin Child Adolesc Psychol.\\n2011;40(2):191–203\\n88. Shepard SA, Dickstein S. Preventive\\nintervention for early childhood\\nbehavioral problems: an ecological\\nperspective. Child Adolesc Psychiatr\\nClin N Am. 2009;18(3):687–706\\n89. Evans SW, Langberg JM, Egan T, Molitor\\nSJ. Middle school-based and high\\nschool-based interventions for\\nadolescents with ADHD. Child Adolesc\\nPsychiatr Clin N Am. 2014;23(4):699–715\\n90. McGough JJ, Sturm A, Cowen J, et al.\\nDouble-blind, sham-controlled, pilot', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 22, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='study of trigeminal nerve stimulation\\nfor attention-deﬁcit/hyperactivity\\ndisorder. J Am Acad Child Adolesc\\nPsychiatry. 2019;58(4):403–411.e3\\n91. Robin AL, Foster SL. The Guilford Family\\nTherapy Series. Negotiating\\nParent–Adolescent Conﬂict: A\\nBehavioral–Family Systems Approach.\\nNew York, NY: Guilford Press; 1989\\n92. Barkley RA, Guevremont DC,\\nAnastopoulos AD, Fletcher KE. A\\ncomparison of three family therapy\\nprograms for treating family conﬂicts\\nin adolescents with attention-deﬁcit', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 22, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='hyperactivity disorder. J Consult Clin\\nPsychol. 1992;60(3):450–462\\n93. Fabiano GA, Schatz NK, Morris KL, et al.\\nEfﬁcacy of a family-focused intervention\\nfor young drivers with attention-deﬁcit\\nhyperactivity disorder. J Consult Clin\\nPsychol. 2016;84(12):1078–1093\\n94. Sibley MH, Graziano PA, Kuriyan AB,\\net al. Parent-teen behavior therapy 1\\nmotivational interviewing for\\nadolescents with ADHD. J Consult Clin\\nPsychol. 2016;84(8):699–712\\n95. Evans SW, Langberg JM, Schultz BK,', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 22, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='et al. Evaluation of a school-based\\ntreatment program for young\\nadolescents with ADHD. J Consult Clin\\nPsychol. 2016;84(1):15–30\\n96. Langberg JM, Dvorsky MR, Molitor SJ,\\net al. Overcoming the research-to-\\npractice gap: a randomized trial with\\ntwo brief homework and organization\\ninterventions for students with ADHD as\\nimplemented by school mental health\\nproviders. J Consult Clin Psychol. 2018;\\n86(1):39–55\\n97. Schultz BK, Evans SW, Langberg JM,\\nSchoemann AM. Outcomes for', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 22, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='adolescents who comply with long-term\\npsychosocial treatment for ADHD.\\nJ Consult Clin Psychol. 2017;85(3):\\n250–261\\n98. Newcorn JH, Kratochvil CJ, Allen AJ,\\net al; Atomoxetine/Methylphenidate\\nComparative Study Group. Atomoxetine\\nand osmotically released\\nmethylphenidate for the treatment of\\nattention deﬁcit hyperactivity disorder:\\nacute comparison and differential\\nresponse. Am J Psychiatry. 2008;165(6):\\n721–730\\n99. Cheng JY, Chen RY, Ko JS, Ng EM.\\nEfﬁcacy and safety of atomoxetine for', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 22, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='attention-deﬁcit/hyperactivity disorder\\nin children and adolescents-meta-\\nanalysis and meta-regression analysis.\\nPsychopharmacology (Berl). 2007;\\n194(2):197–209\\n100. Michelson D, Allen AJ, Busner J, et al.\\nOnce-daily atomoxetine treatment for\\nchildren and adolescents with attention\\ndeﬁcit hyperactivity disorder:\\na randomized, placebo-controlled study.\\nAm J Psychiatry. 2002;159(11):\\n1896–1901\\n101. Biederman J, Melmed RD, Patel A, et al;\\nSPD503 Study Group. A randomized,', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 22, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='PEDIATRICS Volume 144, number 4, October 2019\\n23\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 22, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='double-blind, placebo-controlled study\\nof guanfacine extended release in\\nchildren and adolescents with\\nattention-deﬁcit/hyperactivity disorder.\\nPediatrics. 2008;121(1). Available at:\\nwww.pediatrics.org/cgi/content/\\nfull/121/1/e73\\n102. Sallee FR, Lyne A, Wigal T, McGough JJ.\\nLong-term safety and efﬁcacy of\\nguanfacine extended release in\\nchildren and adolescents with\\nattention-deﬁcit/hyperactivity disorder.\\nJ Child Adolesc Psychopharmacol. 2009;\\n19(3):215–226', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 23, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='19(3):215–226\\n103. Jain R, Segal S, Kollins SH, Khayrallah\\nM. Clonidine extended-release tablets\\nfor pediatric patients with attention-\\ndeﬁcit/hyperactivity disorder. J Am\\nAcad Child Adolesc Psychiatry. 2011;\\n50(2):171–179\\n104. Brown JT, Bishop JR. Atomoxetine\\npharmacogenetics: associations with\\npharmacokinetics, treatment response\\nand tolerability. Pharmacogenomics.\\n2015;16(13):1513–1520\\n105. Kambeitz J, Romanos M, Ettinger U.\\nMeta-analysis of the association\\nbetween dopamine transporter', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 23, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='genotype and response to\\nmethylphenidate treatment in ADHD.\\nPharmacogenomics J. 2014;14(1):77–84\\n106. Bruxel EM, Akutagava-Martins GC,\\nSalatino-Oliveira A, et al. ADHD\\npharmacogenetics across the life cycle:\\nnew ﬁndings and perspectives. Am\\nJ Med Genet B Neuropsychiatr Genet.\\n2014;165B(4):263–282\\n107. Kieling C, Genro JP, Hutz MH, Rohde LA.\\nA current update on ADHD\\npharmacogenomics.\\nPharmacogenomics. 2010;11(3):\\n407–419\\n108. Froehlich TE, McGough JJ, Stein MA.\\nProgress and promise of attention-', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 23, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='deﬁcit hyperactivity disorder\\npharmacogenetics. CNS Drugs. 2010;\\n24(2):99–117\\n109. Joensen B, Meyer M, Aagaard L. Speciﬁc\\ngenes associated with adverse events\\nof methylphenidate use in the pediatric\\npopulation: a systematic literature\\nreview. J Res Pharm Pract. 2017;6(2):\\n65–72\\n110. Swanson JM, Elliott GR, Greenhill LL,\\net al. Effects of stimulant medication on\\ngrowth rates across 3 years in the MTA\\nfollow-up. J Am Acad Child Adolesc\\nPsychiatry. 2007;46(8):1015–1027', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 23, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='111. Mosholder AD, Gelperin K, Hammad TA,\\nPhelan K, Johann-Liang R.\\nHallucinations and other psychotic\\nsymptoms associated with the use of\\nattention-deﬁcit/hyperactivity disorder\\ndrugs in children. Pediatrics. 2009;\\n123(2):611–616\\n112. Cortese S, Holtmann M, Banaschewski\\nT, et al; European ADHD Guidelines\\nGroup. Practitioner review: current best\\npractice in the management of adverse\\nevents during treatment with ADHD\\nmedications in children and\\nadolescents. J Child Psychol Psychiatry.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 23, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='2013;54(3):227–246\\n113. Avigan M. Review of AERS Data From\\nMarketed Safety Experience During\\nStimulant Therapy: Death, Sudden\\nDeath, Cardiovascular SAEs (Including\\nStroke). Report No. D030403. Silver\\nSpring, MD: Food and Drug\\nAdministration, Center for Drug\\nEvaluation and Research; 2004\\n114. Perrin JM, Friedman RA, Knilans TK;\\nBlack Box Working Group; Section on\\nCardiology and Cardiac Surgery.\\nCardiovascular monitoring and\\nstimulant drugs for attention-deﬁcit/', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 23, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='hyperactivity disorder. Pediatrics. 2008;\\n122(2):451–453\\n115. McCarthy S, Cranswick N, Potts L, Taylor\\nE, Wong IC. Mortality associated with\\nattention-deﬁcit hyperactivity disorder\\n(ADHD) drug treatment: a retrospective\\ncohort study of children, adolescents\\nand young adults using the general\\npractice research database. Drug Saf.\\n2009;32(11):1089–1096\\n116. Gould MS, Walsh BT, Munfakh JL, et al.\\nSudden death and use of stimulant\\nmedications in youths. Am J Psychiatry.\\n2009;166(9):992–1001', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 23, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='117. Cooper WO, Habel LA, Sox CM, et al.\\nADHD drugs and serious cardiovascular\\nevents in children and young adults.\\nN Engl J Med. 2011;365(20):1896–1904\\n118. Schelleman H, Bilker WB, Strom BL,\\net al. Cardiovascular events and death\\nin children exposed and unexposed to\\nADHD agents. Pediatrics. 2011;127(6):\\n1102–1110\\n119. Garnock-Jones KP, Keating GM.\\nAtomoxetine: a review of its use in\\nattention-deﬁcit hyperactivity disorder\\nin children and adolescents. Paediatr\\nDrugs. 2009;11(3):203–226', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 23, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='120. Reed VA, Buitelaar JK, Anand E, et al.\\nThe safety of atomoxetine for the\\ntreatment of children and adolescents\\nwith attention-deﬁcit/hyperactivity\\ndisorder: a comprehensive review of\\nover a decade of research. CNS Drugs.\\n2016;30(7):603–628\\n121. Bangs ME, Tauscher-Wisniewski S,\\nPolzer J, et al. Meta-analysis of suicide-\\nrelated behavior events in patients\\ntreated with atomoxetine. J Am Acad\\nChild Adolesc Psychiatry. 2008;47(2):\\n209–218\\n122. Bangs ME, Jin L, Zhang S, et al. Hepatic', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 23, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='events associated with atomoxetine\\ntreatment for attention-deﬁcit\\nhyperactivity disorder. Drug Saf. 2008;\\n31(4):345–354\\n123. Spencer TJ, Kratochvil CJ, Sangal RB,\\net al. Effects of atomoxetine on growth\\nin children with attention-deﬁcit/\\nhyperactivity disorder following up to\\nﬁve years of treatment. J Child Adolesc\\nPsychopharmacol. 2007;17(5):689–700\\n124. Elbe D, Reddy D. Focus on guanfacine\\nextended-release: a review of its use in\\nchild and adolescent psychiatry. J Can', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 23, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Acad Child Adolesc Psychiatry. 2014;\\n23(1):48–60\\n125. Croxtall JD. Clonidine extended-release:\\nin attention-deﬁcit hyperactivity\\ndisorder. Paediatr Drugs. 2011;13(5):\\n329–336\\n126. Vaughan B, Kratochvil CJ.\\nPharmacotherapy of pediatric\\nattention-deﬁcit/hyperactivity disorder.\\nChild Adolesc Psychiatr Clin N Am. 2012;\\n21(4):941–955\\n127. Hirota T, Schwartz S, Correll CU. Alpha-2\\nagonists for attention-deﬁcit/\\nhyperactivity disorder in youth:\\na systematic review and meta-analysis', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 23, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='of monotherapy and add-on trials to\\nstimulant therapy. J Am Acad Child\\nAdolesc Psychiatry. 2014;53(2):153–173\\n128. Treuer T, Gau SS, Méndez L, et al. A\\nsystematic review of combination\\ntherapy with stimulants and\\natomoxetine for attention-deﬁcit/\\nhyperactivity disorder, including patient\\ncharacteristics, treatment strategies,\\neffectiveness, and tolerability. J Child\\nAdolesc Psychopharmacol. 2013;23(3):\\n179–193\\n24\\nFROM THE AMERICAN ACADEMY OF PEDIATRICS', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 23, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Downloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 23, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='129. Greenhill LL, Posner K, Vaughan BS,\\nKratochvil CJ. Attention deﬁcit\\nhyperactivity disorder in preschool\\nchildren. Child Adolesc Psychiatr Clin N\\nAm. 2008;17(2):347–366, ix\\n130. Wilens TE, Spencer TJ. Understanding\\nattention-deﬁcit/hyperactivity disorder\\nfrom childhood to adulthood. Postgrad\\nMed. 2010;122(5):97–109\\n131. Foy JM, ed. Psychotropic medications in\\nprimary care. In: Mental Health Care of\\nChildren and Adolescents: A Guide for\\nPrimary Care Clinicians. Itasca, IL:', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 24, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='American Academy of Pediatrics; 2018:\\n315–374\\n132. Wilens TE, Adler LA, Adams J, et al.\\nMisuse and diversion of stimulants\\nprescribed for ADHD: a systematic\\nreview of the literature. J Am Acad\\nChild Adolesc Psychiatry. 2008;47(1):\\n21–31\\n133. American Academy of Pediatrics.\\nMental health initiatives. Available at:\\nhttps://www.aap.org/en-us/advocacy-\\nand-policy/aap-health-initiatives/\\nMental-Health/Pages/default.aspx.\\nAccessed September 8, 2019\\n134. Levy S, Campbell MD, Shea CL, DuPont R.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 24, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Trends in abstaining from substance\\nuse in adolescents: 1975-2014.\\nPediatrics. 2018;142(2):e20173498\\n135. Graff Low K, Gendaszek AE. Illicit use of\\npsychostimulants among college\\nstudents: a preliminary study. Psychol\\nHealth Med. 2002;7(3):283–287\\n136. Barkley RA, Cox D. A review of driving\\nrisks and impairments associated with\\nattention-deﬁcit/hyperactivity disorder\\nand the effects of stimulant medication\\non driving performance. J Safety Res.\\n2007;38(1):113–128', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 24, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='2007;38(1):113–128\\n137. Jerome L, Habinski L, Segal A. Attention-\\ndeﬁcit/hyperactivity disorder (ADHD)\\nand driving risk: a review of the\\nliterature and a methodological\\ncritique. Curr Psychiatry Rep. 2006;8(5):\\n416–426\\n138. Cox DJ, Merkel RL, Moore M, Thorndike\\nF, Muller C, Kovatchev B. Relative\\nbeneﬁts of stimulant therapy with OROS\\nmethylphenidate versus mixed\\namphetamine salts extended release in\\nimproving the driving performance of\\nadolescent drivers with attention-', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 24, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='deﬁcit/hyperactivity disorder.\\nPediatrics. 2006;118(3). Available at:\\nwww.pediatrics.org/cgi/content/\\nfull/118/3/e704\\n139. The MTA Cooperative Group; Multimodal\\nTreatment Study of Children with ADHD.\\nA 14-month randomized clinical trial of\\ntreatment strategies for attention-\\ndeﬁcit/hyperactivity disorder. Arch Gen\\nPsychiatry. 1999;56(12):1073–1086\\n140. Jensen PS, Hinshaw SP, Swanson JM,\\net al. Findings from the NIMH\\nMultimodal Treatment Study of ADHD\\n(MTA): implications and applications for', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 24, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='primary care providers. J Dev Behav\\nPediatr. 2001;22(1):60–73\\n141. Pelham WE Jr, Gnagy EM. Psychosocial\\nand combined treatments for ADHD.\\nMent Retard Dev Disabil Res Rev. 1999;\\n5(3):225–236\\n142. Homer CJ, Klatka K, Romm D, et al. A\\nreview of the evidence for the medical\\nhome for children with special health\\ncare needs. Pediatrics. 2008;122(4).\\nAvailable at: www.pediatrics.org/cgi/\\ncontent/full/122/4/e922\\n143. Davila RR, Williams ML, MacDonald JT.\\nMemorandum on clariﬁcation of policy', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 24, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='to address the needs of children with\\nattention deﬁcit disorders within\\ngeneral and/or special education. In:\\nParker HC, ed. The ADD Hyperactivity\\nHandbook for Schools. Plantation, FL:\\nImpact Publications Inc; 1991:261–268\\n144. Harrison JR, Bunford N, Evans SW,\\nOwens JS. Educational accommodations\\nfor students with behavioral\\nchallenges: a systematic review of the\\nliterature. Rev Educ Res. 2013;83(4):\\n551–597\\n145. Committee on Pediatric Workforce.\\nEnhancing pediatric workforce diversity', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 24, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='and providing culturally effective\\npediatric care: implications for\\npractice, education, and policy making.\\nPediatrics. 2013;132(4). Available at:\\nwww.pediatrics.org/cgi/content/\\nfull/132/4/e1105\\n146. Berman RS, Patel MR, Belamarich PF,\\nGross RS. Screening for poverty and\\npoverty-related social determinants of\\nhealth. Pediatr Rev. 2018;39(5):235–246\\n147. Solanto MV.\\nNeuropsychopharmacological\\nmechanisms of stimulant drug action in\\nattention-deﬁcit hyperactivity disorder:', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 24, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='a review and integration. Behav Brain\\nRes. 1998;94(1):127–152\\n148. Wagner E. Chronic disease\\nmanagement: what will it take to\\nimprove care for chronic illness? Effect\\nClin Pract. 1998;1(1):2–4\\n149. Brinkman WB, Sucharew H, Majcher JH,\\nEpstein JN. Predictors of medication\\ncontinuity in children with ADHD.\\nPediatrics. 2018;141(6):e20172580\\n150. Pliszka SR, Crismon ML, Hughes CW,\\net al; Texas Consensus Conference\\nPanel on Pharmacotherapy of\\nChildhood Attention Deﬁcit Hyperactivity', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 24, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Disorder. The Texas Children’s\\nMedication Algorithm Project: revision\\nof the algorithm for pharmacotherapy\\nof attention-deﬁcit/hyperactivity\\ndisorder. J Am Acad Child Adolesc\\nPsychiatry. 2006;45(6):642–657\\n151. Pringsheim T, Hirsch L, Gardner D,\\nGorman DA. The pharmacological\\nmanagement of oppositional behaviour,\\nconduct problems, and aggression in\\nchildren and adolescents with\\nattention-deﬁcit hyperactivity disorder,\\noppositional deﬁant disorder, and\\nconduct disorder: a systematic review', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 24, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='and meta-analysis. Part 1:\\npsychostimulants, alpha-2 agonists, and\\natomoxetine. Can J Psychiatry. 2015;\\n60(2):42–51\\n152. Committee on Psychosocial Aspects of\\nChild and Family Health and Task Force\\non Mental Health. Policy statement--The\\nfuture of pediatrics: mental health\\ncompetencies for pediatric primary\\ncare. Pediatrics. 2009;124(1):410–421\\n153. Foy JM, ed. Algorithm: a process for\\nintegrating mental health care into\\npediatric practice. In: Mental Health\\nCare of Children and Adolescents: A', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 24, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Guide for Primary Care Clinicians.\\nItasca, IL: American Academy of\\nPediatrics; 2018:815\\n154. Cheng TL, Emmanuel MA, Levy DJ,\\nJenkins RR. Child health disparities:\\nwhat can a clinician do? Pediatrics.\\n2015;136(5):961–968\\n155. Stein F, Remley K, Laraque-Arena D,\\nPursley DM. New resources and\\nstrategies to advance the AAP’s values\\nof diversity, inclusion, and health equity.\\nPediatrics. 2018;141(4):e20180177\\n156. American Academy of Pediatrics,\\nCommittee on Child Health Financing.', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 24, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''}),\n",
       " Document(page_content='Scope of health care beneﬁts for\\nchildren from birth through age 26.\\nPediatrics. 2012;129(1):185–189\\nPEDIATRICS Volume 144, number 4, October 2019\\n25\\nDownloaded from http://publications.aap.org/pediatrics/article-pdf/144/4/e20192528/1443490/peds_20192528.pdf\\nby guest', metadata={'source': 'dataSet\\\\peds_20192528.pdf', 'file_path': 'dataSet\\\\peds_20192528.pdf', 'page': 24, 'total_pages': 25, 'format': 'PDF 1.4', 'title': 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Arbortext Advanced Print Publisher 9.1.510/W Unicode', 'producer': 'Acrobat Distiller 10.0.0 (Windows); modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20191223143829+05'30'\", 'modDate': \"D:20240323130638+00'00'\", 'trapped': ''})]"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "textChunks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "#downloading embedding model\n",
    "def downloadHuggingFaceEmbeddings():\n",
    "    embeddings=HuggingFaceEmbeddings(model_name=\"sentence-transformers/all-MiniLM-L6-v2\")\n",
    "    return embeddings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "embeddings=downloadHuggingFaceEmbeddings()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "HuggingFaceEmbeddings(client=SentenceTransformer(\n",
       "  (0): Transformer({'max_seq_length': 256, 'do_lower_case': False}) with Transformer model: BertModel \n",
       "  (1): Pooling({'word_embedding_dimension': 384, 'pooling_mode_cls_token': False, 'pooling_mode_mean_tokens': True, 'pooling_mode_max_tokens': False, 'pooling_mode_mean_sqrt_len_tokens': False})\n",
       "  (2): Normalize()\n",
       "), model_name='sentence-transformers/all-MiniLM-L6-v2', cache_folder=None, model_kwargs={}, encode_kwargs={})"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "embeddings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[-0.09151122719049454,\n",
       " 0.02514779008924961,\n",
       " 0.002047134330496192,\n",
       " 0.005181116051971912,\n",
       " -0.015277020633220673,\n",
       " -0.05271577835083008,\n",
       " 0.016557365655899048,\n",
       " 0.0423915795981884,\n",
       " -0.029215754941105843,\n",
       " 0.0068251099437475204,\n",
       " -0.02768445573747158,\n",
       " 0.007252746261656284,\n",
       " -0.01055943313986063,\n",
       " -0.04191434755921364,\n",
       " 0.03230905532836914,\n",
       " 0.03700309991836548,\n",
       " -0.05315249040722847,\n",
       " -0.00993194617331028,\n",
       " -0.10471194982528687,\n",
       " -0.039068449288606644,\n",
       " 0.03552796319127083,\n",
       " 0.07589998096227646,\n",
       " -0.10407808423042297,\n",
       " 0.04460618272423744,\n",
       " -0.02690213918685913,\n",
       " -0.0319899246096611,\n",
       " -0.006866826210170984,\n",
       " 0.06416881829500198,\n",
       " -0.0711832121014595,\n",
       " -0.017583850771188736,\n",
       " 0.012554123066365719,\n",
       " 0.12845946848392487,\n",
       " -0.022762032225728035,\n",
       " 0.05372186005115509,\n",
       " 0.029169755056500435,\n",
       " 0.048878032714128494,\n",
       " -0.04694395512342453,\n",
       " -0.07912524789571762,\n",
       " 0.0451648011803627,\n",
       " 0.02378946915268898,\n",
       " -0.011888740584254265,\n",
       " 0.011806312017142773,\n",
       " -0.0173427052795887,\n",
       " 0.03931812942028046,\n",
       " 0.053550127893686295,\n",
       " -0.07429260015487671,\n",
       " 0.025027206167578697,\n",
       " -0.08755501359701157,\n",
       " 0.027243463322520256,\n",
       " 0.07727691531181335,\n",
       " -0.047840043902397156,\n",
       " -0.005763424560427666,\n",
       " -0.054666925221681595,\n",
       " -0.05343819782137871,\n",
       " 0.0860077515244484,\n",
       " 0.007336646784096956,\n",
       " 0.009187474846839905,\n",
       " -0.0990699753165245,\n",
       " 0.05315794050693512,\n",
       " -0.06462105363607407,\n",
       " -0.09006987512111664,\n",
       " 0.04465141147375107,\n",
       " -0.11563209444284439,\n",
       " -0.021690094843506813,\n",
       " 0.01754831150174141,\n",
       " -0.03665591776371002,\n",
       " -0.03430086746811867,\n",
       " -0.05340960994362831,\n",
       " -0.0506414994597435,\n",
       " -0.08569804579019547,\n",
       " -0.00952941831201315,\n",
       " 0.02503645420074463,\n",
       " 0.03245273604989052,\n",
       " 0.05344977602362633,\n",
       " -0.013130972161889076,\n",
       " -0.08975651115179062,\n",
       " 0.05662137642502785,\n",
       " 0.001969901379197836,\n",
       " 0.030657317489385605,\n",
       " 0.0064316694624722,\n",
       " 0.07051170617341995,\n",
       " -0.048392727971076965,\n",
       " 0.015184343792498112,\n",
       " -0.027121322229504585,\n",
       " -0.009402972646057606,\n",
       " -0.0502878837287426,\n",
       " 0.05843989551067352,\n",
       " 0.002062082989141345,\n",
       " -0.028014158830046654,\n",
       " -0.033932216465473175,\n",
       " -0.11036336421966553,\n",
       " 0.07281821221113205,\n",
       " -0.0274397861212492,\n",
       " 0.0014599522110074759,\n",
       " -0.05286683887243271,\n",
       " -0.10202642530202866,\n",
       " 0.09397844225168228,\n",
       " 0.04555303603410721,\n",
       " -0.12457722425460815,\n",
       " 0.15514765679836273,\n",
       " 0.03557372838258743,\n",
       " 0.03785540908575058,\n",
       " 0.025922566652297974,\n",
       " 0.04260682687163353,\n",
       " -0.05040375515818596,\n",
       " 0.06678261607885361,\n",
       " -0.05466315150260925,\n",
       " 0.08857452869415283,\n",
       " -0.02877749875187874,\n",
       " -0.0115989213809371,\n",
       " 0.02344677597284317,\n",
       " -0.012094800360500813,\n",
       " 0.04150662571191788,\n",
       " 0.04544734209775925,\n",
       " 0.08052344620227814,\n",
       " 0.056352175772190094,\n",
       " 0.047780174762010574,\n",
       " 0.030067414045333862,\n",
       " 0.13186819851398468,\n",
       " -0.06568571925163269,\n",
       " 0.004145560320466757,\n",
       " -0.049214448779821396,\n",
       " -0.019922731444239616,\n",
       " -0.02834707498550415,\n",
       " 0.011700741946697235,\n",
       " -0.02401086315512657,\n",
       " -0.03260244429111481,\n",
       " -1.9912642877479232e-33,\n",
       " 0.062299229204654694,\n",
       " -0.00987206306308508,\n",
       " 0.03463204205036163,\n",
       " 0.04109497368335724,\n",
       " -0.044450320303440094,\n",
       " -0.024610739201307297,\n",
       " -0.07881556451320648,\n",
       " -0.020856836810708046,\n",
       " 0.0049642277881503105,\n",
       " 0.0049084569327533245,\n",
       " -0.03617074340581894,\n",
       " -0.04287095367908478,\n",
       " -0.07707691192626953,\n",
       " 0.039736464619636536,\n",
       " -0.00028871148242615163,\n",
       " 0.07861847430467606,\n",
       " 0.012634583748877048,\n",
       " -0.010675984434783459,\n",
       " 0.030558817088603973,\n",
       " 0.031039398163557053,\n",
       " -0.032372795045375824,\n",
       " -0.014470446854829788,\n",
       " 0.02795693464577198,\n",
       " 0.027509350329637527,\n",
       " -0.013136283494532108,\n",
       " -0.00721008563414216,\n",
       " 0.07515053451061249,\n",
       " -0.12660902738571167,\n",
       " 0.05345912650227547,\n",
       " 0.08321762830018997,\n",
       " -0.015919368714094162,\n",
       " 0.01824548840522766,\n",
       " -0.016796590760350227,\n",
       " 0.038190945982933044,\n",
       " -0.062018442898988724,\n",
       " -0.03644636273384094,\n",
       " -0.011948040686547756,\n",
       " -0.04613084718585014,\n",
       " -0.049725066870450974,\n",
       " 0.05344916135072708,\n",
       " 0.02340271696448326,\n",
       " 0.005951441824436188,\n",
       " 0.06029917672276497,\n",
       " -0.03883714601397514,\n",
       " 0.011735574342310429,\n",
       " -0.00055740587413311,\n",
       " 0.07979860156774521,\n",
       " 0.031749919056892395,\n",
       " 0.07367044687271118,\n",
       " -0.005358579568564892,\n",
       " -0.11065541952848434,\n",
       " -0.007001211866736412,\n",
       " -0.049186307936906815,\n",
       " 0.023270098492503166,\n",
       " -0.0637497678399086,\n",
       " -0.012503075413405895,\n",
       " 0.012850173749029636,\n",
       " -0.028148949146270752,\n",
       " 0.061736755073070526,\n",
       " 0.026269420981407166,\n",
       " 0.0768682211637497,\n",
       " 0.09612704068422318,\n",
       " -0.053449597209692,\n",
       " -0.05697272717952728,\n",
       " -0.0962376818060875,\n",
       " -0.008492652326822281,\n",
       " 0.06619138270616531,\n",
       " -0.014823435805737972,\n",
       " 0.053441066294908524,\n",
       " 0.0024223043583333492,\n",
       " 0.0054548983462154865,\n",
       " 0.008450223132967949,\n",
       " 0.004888226743787527,\n",
       " 0.0025905666407197714,\n",
       " 0.0009861045982688665,\n",
       " 0.03382910043001175,\n",
       " 0.01698143035173416,\n",
       " -0.011704957112669945,\n",
       " -0.0050368281081318855,\n",
       " -0.04812739044427872,\n",
       " -0.002070201560854912,\n",
       " -0.006697007920593023,\n",
       " -0.070664182305336,\n",
       " -0.022107912227511406,\n",
       " 0.009296414442360401,\n",
       " -0.07361125200986862,\n",
       " -0.002948026405647397,\n",
       " -0.0992271676659584,\n",
       " -0.1464570164680481,\n",
       " -0.008813535794615746,\n",
       " 0.01688300631940365,\n",
       " 0.05612265691161156,\n",
       " 0.09880466014146805,\n",
       " -0.03989925608038902,\n",
       " -0.009538096375763416,\n",
       " 1.0215195600504416e-33,\n",
       " 0.1457991749048233,\n",
       " 0.00996050238609314,\n",
       " -0.02433600276708603,\n",
       " -0.025420673191547394,\n",
       " 0.03425239399075508,\n",
       " -0.0026528157759457827,\n",
       " 0.004149414133280516,\n",
       " 0.059019602835178375,\n",
       " -0.06796855479478836,\n",
       " 0.028607631102204323,\n",
       " 0.004740015137940645,\n",
       " 0.015115910209715366,\n",
       " 0.05504804849624634,\n",
       " -0.019880706444382668,\n",
       " 0.04234760254621506,\n",
       " 0.0874376967549324,\n",
       " 0.026790838688611984,\n",
       " 0.040324486792087555,\n",
       " -0.03888397291302681,\n",
       " 0.02790353260934353,\n",
       " -0.08030318468809128,\n",
       " -0.03400102257728577,\n",
       " -0.006011088378727436,\n",
       " -0.0621599443256855,\n",
       " 0.04875313490629196,\n",
       " -0.0024327668361365795,\n",
       " 0.07537814229726791,\n",
       " 0.05105171352624893,\n",
       " -0.10411727428436279,\n",
       " -0.011104974895715714,\n",
       " 0.002903213957324624,\n",
       " 0.057382985949516296,\n",
       " -0.027404850348830223,\n",
       " -0.0053303358145058155,\n",
       " 0.04306602105498314,\n",
       " 0.00913508515805006,\n",
       " 0.011325023137032986,\n",
       " -0.03752729296684265,\n",
       " 0.016563057899475098,\n",
       " -0.03738570585846901,\n",
       " -0.022031145170331,\n",
       " 0.001476898672990501,\n",
       " 0.007139078341424465,\n",
       " 0.06618741154670715,\n",
       " -0.04125579819083214,\n",
       " -0.0056039500050246716,\n",
       " 0.05445297062397003,\n",
       " -0.025300893932580948,\n",
       " -0.047180626541376114,\n",
       " 0.015727903693914413,\n",
       " -0.08216183632612228,\n",
       " -0.06643764674663544,\n",
       " 0.04537379369139671,\n",
       " 0.00787401758134365,\n",
       " -0.034523069858551025,\n",
       " 0.09003133326768875,\n",
       " 0.0625593513250351,\n",
       " 0.01990691013634205,\n",
       " 0.08142149448394775,\n",
       " -0.01210628729313612,\n",
       " 0.03163385018706322,\n",
       " 0.055270664393901825,\n",
       " 0.022233514115214348,\n",
       " 0.11265015602111816,\n",
       " 0.028902482241392136,\n",
       " 0.036018356680870056,\n",
       " -0.056327637284994125,\n",
       " -0.059204500168561935,\n",
       " -0.031945955008268356,\n",
       " -0.018858300521969795,\n",
       " 0.034312039613723755,\n",
       " -0.020330246537923813,\n",
       " 0.07562768459320068,\n",
       " -0.008240415714681149,\n",
       " 0.00997002050280571,\n",
       " -0.0059747216291725636,\n",
       " 0.057787299156188965,\n",
       " 0.050278712064027786,\n",
       " 0.015793487429618835,\n",
       " 0.035391997545957565,\n",
       " 0.01492551900446415,\n",
       " -0.008465591818094254,\n",
       " 0.028696345165371895,\n",
       " 0.02533898875117302,\n",
       " 0.00621158629655838,\n",
       " 0.031197598204016685,\n",
       " 0.06677699834108353,\n",
       " 0.04585810378193855,\n",
       " 0.014167707413434982,\n",
       " -0.06819607317447662,\n",
       " 0.03385995328426361,\n",
       " 0.06280353665351868,\n",
       " 0.017528211697936058,\n",
       " 0.01406088937073946,\n",
       " 0.03421974182128906,\n",
       " -1.7425245246727172e-08,\n",
       " 0.025908971205353737,\n",
       " -0.0015170369297266006,\n",
       " 0.13716058433055878,\n",
       " 0.04528225585818291,\n",
       " 0.048668332397937775,\n",
       " 0.04849410429596901,\n",
       " -0.02631830796599388,\n",
       " -0.05913401022553444,\n",
       " -0.04150428995490074,\n",
       " -0.012950257398188114,\n",
       " 0.04486389085650444,\n",
       " 0.06018153578042984,\n",
       " -0.0809069350361824,\n",
       " -0.02298896759748459,\n",
       " 0.07353052496910095,\n",
       " 0.008819207549095154,\n",
       " -0.004131743684411049,\n",
       " 0.06105373799800873,\n",
       " -0.05855998769402504,\n",
       " -0.07941022515296936,\n",
       " 0.006867972668260336,\n",
       " 0.07912299782037735,\n",
       " -0.004490411374717951,\n",
       " -0.07611899077892303,\n",
       " 0.022105418145656586,\n",
       " -0.024886438623070717,\n",
       " -0.01300166454166174,\n",
       " -0.02404768578708172,\n",
       " -0.0633823424577713,\n",
       " -0.022534005343914032,\n",
       " -0.005545997526496649,\n",
       " 0.13573870062828064,\n",
       " -0.031814415007829666,\n",
       " 0.004699897952377796,\n",
       " -0.01683567650616169,\n",
       " -0.004079774487763643,\n",
       " -0.04844221845269203,\n",
       " -0.006069817114621401,\n",
       " 0.05689242482185364,\n",
       " -0.09979326277971268,\n",
       " -0.0575115792453289,\n",
       " -0.10030486434698105,\n",
       " -0.009373207576572895,\n",
       " -0.06461706012487411,\n",
       " -0.008519764058291912,\n",
       " 0.040548406541347504,\n",
       " 0.019014941528439522,\n",
       " -0.04364655166864395,\n",
       " 0.022501617670059204,\n",
       " -0.11012446135282516,\n",
       " -0.011613869108259678,\n",
       " 0.0023826598189771175,\n",
       " 0.06422434002161026,\n",
       " 0.05645544454455376,\n",
       " 0.05996238440275192,\n",
       " 0.053531091660261154,\n",
       " 0.031024063006043434,\n",
       " -0.0038782423362135887,\n",
       " -0.06688221544027328,\n",
       " 0.008501110598444939,\n",
       " 0.1107160896062851,\n",
       " 0.027430666610598564,\n",
       " 0.03734198585152626,\n",
       " 0.03842877969145775]"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "queryResult=embeddings.embed_query(\"Hi there!\")\n",
    "queryResult"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.vectorstores import FAISS"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: faiss-cpu in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (1.8.0)\n",
      "Requirement already satisfied: numpy in c:\\users\\asus\\anaconda3\\envs\\adhdchatbot\\lib\\site-packages (from faiss-cpu) (1.26.4)\n",
      "Note: you may need to restart the kernel to use updated packages.\n"
     ]
    }
   ],
   "source": [
    "pip install faiss-cpu"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "llm=CTransformers(model=\"model/llama-2-7b-chat.ggmlv3.q4_0.bin\",model_type=\"llama\",config={'max_new_tokens':512,'temperature':0.8})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "vectorstore=FAISS.from_texts(texts= [doc.page_content for doc in textChunks],embedding=embeddings)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.memory import ConversationBufferMemory\n",
    "from langchain.chains import ConversationalRetrievalChain\n",
    "def getConversationChain(vectorstore):\n",
    "    memory=ConversationBufferMemory(memory_keys='chat_history',return_messages=True)\n",
    "    conversationchain=ConversationalRetrievalChain.from_llm(\n",
    "        llm=llm,\n",
    "        retriever=vectorstore.as_retriever(),\n",
    "        memory=memory\n",
    "    )\n",
    "    return conversationchain"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Conversation Chain\n",
    "conversation=getConversationChain(vectorstore)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "prompt_tempate=\"\"\"\n",
    "Use the following pieces of information to aswer the user's question.\n",
    "If you don't know the answer,just say you don't know,don't try to make up an answer.\n",
    "\n",
    "Context: {context}\n",
    "Question: {question}\n",
    "\n",
    "Only return the helpful answer below and nothing else.\n",
    "Helpful answer:\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "prompt=PromptTemplate(template=prompt_tempate,input_variables=[\"context\",\"question\"])\n",
    "chain_type_kwargs={\"prompt\":prompt}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [],
   "source": [
    "def generate_response_with_llma(prompt, chain_type_kwargs={}):\n",
    "  \"\"\"\n",
    "  Generates a response using LLaMA with the provided prompt and chain arguments.\n",
    "\n",
    "  Args:\n",
    "      prompt: The prompt string for LLaMA.\n",
    "      chain_type_kwargs: Optional keyword arguments for specific chain types (if used).\n",
    "\n",
    "  Returns:\n",
    "      The generated response from LLaMA as a dictionary.\n",
    "  \"\"\"\n",
    "\n",
    "  # Execute the prompt on LLaMA\n",
    "  response = llm.(prompt, **chain_type_kwargs)\n",
    "  return response"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [],
   "source": [
    "def handle_conversation(context, question):\n",
    "  \"\"\"\n",
    "  Takes user input (context and question) and generates a response using LLaMA.\n",
    "\n",
    "  Args:\n",
    "      context: String containing relevant background information.\n",
    "      question: User's question.\n",
    "\n",
    "  Returns:\n",
    "      A dictionary containing the generated response or an indication of no answer found.\n",
    "  \"\"\"\n",
    "  prompt_tempate=\"\"\"\n",
    "    Use the following pieces of information to aswer the user's question.\n",
    "    If you don't know the answer,just say you don't know,don't try to make up an answer.\n",
    "\n",
    "    Context: {context}\n",
    "    Question: {question}\n",
    "\n",
    "    Only return the helpful answer below and nothing else.\n",
    "    Helpful answer:\n",
    "    \"\"\"\n",
    "  prompt =   prompt = f\"\"\"\n",
    "  Use the following pieces of information to answer the user's question.\n",
    "  If you don't know the answer, just say you don't know, don't try to make up an answer.\n",
    "\n",
    "  Context: {context}\n",
    "  Question: {question}\n",
    "\n",
    "  Only return the helpful answer below and nothing else.\n",
    "  Helpful answer:\n",
    "  \"\"\"\n",
    "  chain_type_kwargs={\"prompt\":prompt}\n",
    "  # Assuming you have a function to generate response using LLaMA with the prompt\n",
    "  response = generate_response_with_llma(prompt, chain_type_kwargs)\n",
    "\n",
    "  # Check if LLaMA generated a helpful answer\n",
    "  if \"helpful answer\" in response:\n",
    "    return {\"answer\": response[\"helpful answer\"]}\n",
    "  else:\n",
    "    return {\"answer\": \"I don't know the answer to that question yet.\"}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "ename": "ValueError",
     "evalue": "Argument 'prompts' is expected to be of type List[str], received argument of type <class 'str'>.",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mValueError\u001b[0m                                Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[49], line 4\u001b[0m\n\u001b[0;32m      1\u001b[0m context \u001b[38;5;241m=\u001b[39m \u001b[38;5;28minput\u001b[39m(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mProvide some context (e.g., what were we talking about?): \u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[0;32m      2\u001b[0m question \u001b[38;5;241m=\u001b[39m \u001b[38;5;28minput\u001b[39m(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mAsk your question: \u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m----> 4\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[43mhandle_conversation\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcontext\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mquestion\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m      5\u001b[0m \u001b[38;5;28mprint\u001b[39m(response)\n",
      "Cell \u001b[1;32mIn[48], line 34\u001b[0m, in \u001b[0;36mhandle_conversation\u001b[1;34m(context, question)\u001b[0m\n\u001b[0;32m     32\u001b[0m chain_type_kwargs\u001b[38;5;241m=\u001b[39m{\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mprompt\u001b[39m\u001b[38;5;124m\"\u001b[39m:prompt}\n\u001b[0;32m     33\u001b[0m \u001b[38;5;66;03m# Assuming you have a function to generate response using LLaMA with the prompt\u001b[39;00m\n\u001b[1;32m---> 34\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[43mgenerate_response_with_llma\u001b[49m\u001b[43m(\u001b[49m\u001b[43mprompt\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mchain_type_kwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     36\u001b[0m \u001b[38;5;66;03m# Check if LLaMA generated a helpful answer\u001b[39;00m\n\u001b[0;32m     37\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mhelpful answer\u001b[39m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;129;01min\u001b[39;00m response:\n",
      "Cell \u001b[1;32mIn[47], line 14\u001b[0m, in \u001b[0;36mgenerate_response_with_llma\u001b[1;34m(prompt, chain_type_kwargs)\u001b[0m\n\u001b[0;32m      2\u001b[0m \u001b[38;5;250m\u001b[39m\u001b[38;5;124;03m\"\"\"\u001b[39;00m\n\u001b[0;32m      3\u001b[0m \u001b[38;5;124;03mGenerates a response using LLaMA with the provided prompt and chain arguments.\u001b[39;00m\n\u001b[0;32m      4\u001b[0m \n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m     10\u001b[0m \u001b[38;5;124;03m    The generated response from LLaMA as a dictionary.\u001b[39;00m\n\u001b[0;32m     11\u001b[0m \u001b[38;5;124;03m\"\"\"\u001b[39;00m\n\u001b[0;32m     13\u001b[0m \u001b[38;5;66;03m# Execute the prompt on LLaMA\u001b[39;00m\n\u001b[1;32m---> 14\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[43mllm\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mgenerate\u001b[49m\u001b[43m(\u001b[49m\u001b[43mprompt\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mchain_type_kwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     15\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m response\n",
      "File \u001b[1;32mc:\\Users\\ASUS\\anaconda3\\envs\\adhdchatBot\\Lib\\site-packages\\langchain\\llms\\base.py:200\u001b[0m, in \u001b[0;36mBaseLLM.generate\u001b[1;34m(self, prompts, stop, callbacks, tags, metadata, **kwargs)\u001b[0m\n\u001b[0;32m    198\u001b[0m \u001b[38;5;250m\u001b[39m\u001b[38;5;124;03m\"\"\"Run the LLM on the given prompt and input.\"\"\"\u001b[39;00m\n\u001b[0;32m    199\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(prompts, \u001b[38;5;28mlist\u001b[39m):\n\u001b[1;32m--> 200\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\n\u001b[0;32m    201\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mArgument \u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mprompts\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124m is expected to be of type List[str], received\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    202\u001b[0m         \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m argument of type \u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[38;5;28mtype\u001b[39m(prompts)\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m.\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    203\u001b[0m     )\n\u001b[0;32m    204\u001b[0m params \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mdict()\n\u001b[0;32m    205\u001b[0m params[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mstop\u001b[39m\u001b[38;5;124m\"\u001b[39m] \u001b[38;5;241m=\u001b[39m stop\n",
      "\u001b[1;31mValueError\u001b[0m: Argument 'prompts' is expected to be of type List[str], received argument of type <class 'str'>."
     ]
    }
   ],
   "source": [
    "context = input(\"Provide some context (e.g., what were we talking about?): \")\n",
    "question = input(\"Ask your question: \")\n",
    "\n",
    "response = handle_conversation(context, question)\n",
    "print(response)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [],
   "source": [
    "prompt=input()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'diagnostic process?\\nThe treatment questions were as\\nfollows:\\n1. What are the comparative safety\\nand effectiveness of pharmacologic\\nand/or nonpharmacologic\\ntreatments of ADHD in improving\\noutcomes associated with ADHD?\\n2. What is the risk of diversion of\\npharmacologic treatment?\\n3. What are the comparative safety\\nand effectiveness of different\\nmonitoring strategies to evaluate\\nthe effectiveness of treatment or\\nchanges in ADHD status (eg,\\nworsening or resolving\\nsymptoms)?'"
      ]
     },
     "execution_count": 53,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "query_answer=vectorstore.similarity_search(prompt)\n",
    "query_answer[0].page_content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "ename": "AttributeError",
     "evalue": "'RetrievalQA' object has no attribute 'invoke'",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mAttributeError\u001b[0m                            Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[91], line 4\u001b[0m\n\u001b[0;32m      2\u001b[0m qa\u001b[38;5;241m=\u001b[39mRetrievalQA\u001b[38;5;241m.\u001b[39mfrom_chain_type(llm\u001b[38;5;241m=\u001b[39mllm,chain_type\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mstuff\u001b[39m\u001b[38;5;124m\"\u001b[39m,retriever\u001b[38;5;241m=\u001b[39mretriever)\n\u001b[0;32m      3\u001b[0m query\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mWhat is adhd ?\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m----> 4\u001b[0m results\u001b[38;5;241m=\u001b[39m\u001b[43mqa\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43minvoke\u001b[49m(query)\n\u001b[0;32m      5\u001b[0m results\n",
      "\u001b[1;31mAttributeError\u001b[0m: 'RetrievalQA' object has no attribute 'invoke'"
     ]
    }
   ],
   "source": [
    "retriever=vectorstore.as_retriever()\n",
    "qa=RetrievalQA.from_chain_type(llm=llm,chain_type=\"stuff\",retriever=retriever)\n",
    "query=\"What is adhd ?\"\n",
    "results=qa.invoke(query)\n",
    "results"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "adhdchatBot",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
